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International research has demonstrated the effectiveness of treatment for heroin 
abuse, yet many treatment-seekers fail to enter treatment when a place becomes 
available. Understanding the factors that encourage, or impede, treatment access 
and utilisation may help to attract more users into treatment.  The waiting period 
prior to treatment entry is often listed among the most common barriers for those 
seeking treatment, yet little research has examined the motivation of substance 
users awaiting treatment entry or the patterns of substance use during this time.  
 
This research programme investigated the associations between treatment waiting 
times and motivation to change heroin use through two empirical studies. The 
first study examined the use of a measure of motivation – the SOCRATES - to 
assess changes in motivation in a sample of heroin users starting a new treatment 
episode. The results indicated that the measure was capable of detecting changes 
in motivation over a three-month period.  
 
In the second study, the SOCRATES examined changes in motivation among a 
sample of heroin users randomly allocated to short or prolonged waiting periods 
prior to treatment entry. The study found reductions in motivation over shorter 
waiting periods but no changes over more prolonged waits. Longer waiting 
periods were also associated with improvements in heroin use. Successful 
treatment entry was associated with motivation but not with the length of the 
waiting period. 
 
The research programme found motivation is subject to change over the waiting 
period, with many reporting reductions in their motivation, regardless of the 
duration of delay. These findings suggest that the waiting period represents a 
missed opportunity for intervention, many treatment-seekers may lose motivation 
for change and continue to be exposed to the risks associated with drug use at a 
time when they express a desire for change. With a better understanding of the 
waiting experience strategies such as motivational enhancements or support 
during the waiting period can be implemented to help encourage treatment 
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CHAPTER 1:      INTRODUCTION AND LITERATURE REVIEW    
 
 
1.1      OVERALL RATIONALE 
 
The purpose of this research programme was to determine the extent and nature of the 
relationship between waiting times to enter drug abuse treatment and  patients’ 
motivation to change their drug use and how this relationship impacts on treatment 
entry and substance use. Untreated drug and alcohol abuse inflicts a considerable 
burden on individuals and on society in terms of medical, social and economic 
problems. Substance abuse treatment can play an important role in reducing the 
incidence of many of these problems. However, only a small proportion of individuals 
who might benefit from treatment actually receive it. There is an increasing recognition 
that certain factors in the treatment environment may inhibit treatment seeking and 
entry. 
 
Waiting times are a common and enduring feature of many drug and alcohol treatment 
programmes in the UK. While a number of studies have shown that the longer the user 
has to wait for treatment the less likely they are to enter treatment, little research has 
examined what factors may mediate this relationship. Motivation during treatment has 
been found to be related to outcomes such as reductions in substance use and successful 
completion of treatment, yet its role during the waiting period has not been previously 
examined. 
 
The thesis proposes that the relationship between outcomes (e.g. treatment entry) and 
the amount of time spent waiting for treatment is mediated by drug users’ motivation 
for change. The research programme will assess changes in the motivation of heroin 
users over the waiting period and assess how the length of the waiting period is related 
to these changes. It will also examine how waiting times and motivation are related to 
key treatment events such as treatment entry and patterns of substance use during the 
waiting period. With a better understanding of the waiting experience and how it may 
impact on motivation to change, treatment can be modified to help attract and engage 
more users into treatment. If motivation to change heroin use is associated with the 





patient motivation, lead to increased participation rates and reduce the harms associated 
with not receiving treatment.  
 
1.2      OVERVIEW AND STRUCTURE OF CHAPTER ONE 
 
This chapter provides a review of the research evidence on waiting times in substance 
abuse treatment services.  It will also examine the role of patient motivation in treatment 
and will draw attention to the gaps in the current evidence base regarding the 
relationship between motivation and treatment waiting times. The chapter will conclude 
with the presentation of the conceptual framework to be used for examining the 
relationships specified within the current research programme and provide an outline of 
the overall structure of the thesis. 
 
The literature is reviewed in three sections. The first section provides a brief description 
of the prevalence of substance abuse in the UK, the harms associated with substance 
abuse and the role of substance abuse treatment. This is followed by a review of the 
literature concerning the potential impediments to accessing substance abuse treatment, 
focusing on a specific treatment factor - waiting lists. The last section of the review will 
focus on the role of patient motivation in substance use treatment, and will make 
suggestions about the potential relationships between patient motivation, waiting times 
and treatment entry.   
 
A literature review was carried out to identify relevant studies using the following data 
sources: PsychINFO, PubMed, ScienceDirect, Cochrane Library, Department of Health 
publications, in addition to manual searching and internet sources. The search was 
limited to documents available in the English language. Search terms included 
‘substance use’, ’substance abuse’, ‘drug dependent’, ’alcohol dependent’ ‘treatment 
access’, ’treatment availability’, treatment entry’, ’waiting times’, ’waiting lists’,            
’treatment delay’, ‘treatment barriers’, ‘motivation’, ‘motivation  to change’, ‘readiness 
to change’. This review will draw from the literature of both drug and alcohol use from 
the UK and international literature. 
 
The development of the research programme was designed specifically to address the 





literature review has been regularly updated since the initiation of the thesis and while 
the findings of the most recent studies will be discussed in the review, they were not 
used to alter the design or content of the studies carried out. Since the completion of the 
data collection for this thesis there have been major changes in the management of 
waiting times in substance abuse treatment services in the UK. Government initiatives 
and expenditure have been put in place to address some of the problems associated with 
drug abuse treatment entry. These changes and the implications for treatment will be 
reviewed in Chapter 5. 
 
1.3     BACKGROUND 
 
1.3.1      Defining substance abuse 
 
Substance abuse is characterised by a pattern of excessive use of a substance, especially 
alcohol or a drug, which results in repeated adverse social consequences related to the 
substance use. This can include legal problems, failures to meet family, employment 
and social obligations and interpersonal conflicts.  Rassool (2002) noted that whether 
substance use is classified as abuse or not depends on the socio-cultural conventions, 
the pattern and mode of consumption and the perception of the observer. The two main 
classification systems for psychiatric disorders, the World Health Organization’s 
International Classification of Diseases (ICD-10, WHO, 1992) and the American 
Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM-
IV-TR, APA, 2000) adopt a multi-axial classification, recognising both the behavioural 
and physiological factors in diagnosis.  
 
The DSM-IV-TR makes the distinction between substance abuse and substance 
dependence. Substance abuse is a term commonly used to describe the use of a 
substance for a purpose not consistent with legal or medical guidelines, such as the non-
medical use of prescription medications with sedative or stimulant properties. Abuse, 
according to this classification, refers to the recurrent use of a substance without 
physiological dependence. Substance dependence, on the other hand, includes patterns 
of compulsive use, physical and psychological dependence and withdrawal. There are 
long-standing debates as to the exact distinctions between substance abuse, substance 
dependence, substance misuse, between alcoholism, alcohol abuse and alcohol 





purpose of this thesis the terms substance use and substance abuse will be used. In this 
context substance use refers to the taking of alcohol or illicit drugs, and substance abuse 
refers to the excessive use of alcohol or illicit drugs that are detrimental to the 
individual's physical and mental health or the welfare of others.           
 
1.3.2      Prevalence of substance use in the UK 
 
 
Alcohol and illicit drug consumption are widespread. There are several surveys 
conducted in the UK which seek to estimate the prevalence of alcohol and illicit drug 
use among the general population (e.g. British Crime Survey, Smith and Flatley, 2011; 
General Lifestyle Survey, Office for National Statistics, 2011), and among specific 
groups such as young people (Fuller, 2009). The 2010/11 British Crime Survey 
estimated that approximately 12 million people aged between 16 and 59 have used one 
or more illicit drugs in their lifetime and approximately 2.9 million people are estimated 
to have used illicit drugs in the last year (Smith and Flatley, 2011).   
 
Alcohol consumption represents an integral part of modern culture. The vast majority of 
individuals in the UK who consume alcohol do so in moderation. Analysis of the 
patterns of alcohol consumption, however, reveals that a significant proportion of 
individuals are drinking above the UK recommended guidelines. The General Lifestyle 
Survey (ONS, 2011) found that 37 per cent of men and 29 per cent of women in Britain 
exceeded the recommended daily alcohol consumption guidelines (4 units per day for 
men and 3 units per day for women) on at least one day in the previous week. The 
proportion of men who drank heavily (8 or more units per day for men and 6 or more 
units per day for women) on at least one day during the previous week was 20 per cent 
compared to 12 per cent of women.  
 
It is acknowledged that accurate information concerning the prevalence of substance use 
is difficult to obtain and that these surveys may underestimate the prevalence of 
substance use because of sampling biases and non-responses. The British Crime Survey, 
which samples adults living in private households in England and Wales, acknowledges 
that certain sub-groups of substance users are less likely to respond to population 





prisons. Such groups, including the homeless, may have higher rates of drug use than 
those groups who are more likely to be surveyed (British Crime Survey, 2008).  
 
1.3.3     Prevalence of substance abuse in the UK 
 
Population surveys often fail to differentiate between occasional substance users and 
substance abusers. The identification of substance abusers is usually achieved when an 
individual comes into contact with a monitoring system such as the health or social 
system via general practitioners, substance use treatment centres and social workers, or 
the legal system via the police and courts or drug death and/or HIV registers. Estimates 
of the number of substance abusers who are not in contact with such systems are 
generally uncertain given the hidden nature of the behaviour (Griffiths et al, 2006). 
Results published by survey organisations are often extrapolations based on relatively 
small quantities of information from the available data sources. Bearing these problems 
in mind, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
estimated the number of drug abusers in the UK to be 398,845 in 2004-7 using data 
from recent studies (based on different time periods and definitions of problem drug 
use). This is a rate of 10.1 per 1,000 of the population aged between 15-64 years 
(EMCDDA, 2011).  
 
The Alcohol Needs Assessment Research Project conducted in 2004 found 26% of the 
population aged between 16 and 64 years have an alcohol use problem which is 
equivalent to approximately 8.2 million people in England and a further 1.1 million 
people with alcohol dependence nationally (Drummond et al, 2005). However, under-
diagnosis of alcohol abuse is common (Myrick and Wright, 2008; Truman, 2006) so the 
accuracy of such figures is uncertain. 
 
1.3.4      The impact of substance abuse 
 
Untreated drug and alcohol abuse inflict a considerable burden on individuals and on 
society as a whole.  In recent years, mounting evidence has confirmed that heavy drug 
and alcohol consumption are linked to a host of medical and social problems affecting 
many levels of society. In the UK most of the widespread drug-related health and social 





most immediate and long-lasting problems caused by these drugs are often medical in 
nature. Among the more recent health issues related to drug abuse is the spread of drug- 
related infectious diseases including viral hepatitis and HIV/AIDS through needle and 
paraphernalia sharing, unsafe sexual practices or from mother to child (DeGennaro and 
Zeitz, 2009; Chen and Lin, 2009). Intravenous heroin use can also cause collapsed 
veins, bacterial infections of the blood vessels and heart valves, abscesses and other 
soft-tissue infections as well as liver and kidney disease (Licata et al, 2010; Buckland et 
al, 2008). Many of the additives in street heroin may include substances that result in 
the clogging of the blood vessels that lead to the lungs, liver, kidneys, or brain 
(Hoffman et al, 2008).  
 
The death rate among drug users is higher than that expected in the general population. 
A meta-analysis using data from a variety of sources estimated the mortality associated 
with illicit opiate use to be over 13 times higher than that of the general age- and 
gender-matched population (Hulse et al, 1999). The Office for National Statistics 
reported a total of 2,747 deaths related to drug misuse in the England and Wales in 2010 
(ONS, 2011). Drug users are also more likely to be involved in incidents of violence 
which may result in death (Moore et al, 2011; Darke et al, 2010).  
 
Alcohol consumption has been shown to be causally related to over sixty different 
medical conditions and is a significant cause of morbidity and premature death 
worldwide. In the majority of cases there is a dose-response relationship, with risk 
increasing with the amount of alcohol consumed (Monforte et al, 1995). The alcohol-
related death rate in the UK was reported at 13.6 deaths per 100,000 of the population in 
2008, approximately 9,031 individuals (Office for National Statistics, 2010). Heavy 
drinking is linked to suicide (Borges and Loera, 2010; Landberg, 2009), incidents of 
violence (Laslett et al, 2011; Duke et al, 2011), fatal accidents and many fatal diseases.  
Drinking excessively over time has been associated with hepatitis and alcoholic liver 
disease (Jackson et al, 2010; Mueller et al, 2009), gastritis or pancreatitis (Franke et al, 
2005), high blood pressure and stroke (Brummett et al, 2011; Parry et al, 2011). It has 
also been related to certain types of cancer, including breast, mouth and throat cancer 
(Boffetta et al, 2006; Su and Arab, 2004), damage to the brain (Jauhar and Smith, 
2009), and cardiovascular disease (Room and Rehm, 2011; Ruidavets et al, 2010). Long 





2012; Barnett et al, 2007). Psychiatric disorders are common in alcohol abusers, 
especially anxiety and depression disorders, with as many as 25% of abusers presenting 
to treatment services with severe psychiatric disturbances (Grant et al, 2005). 
 
Social problems related to the use of drugs fall into several categories, including 
economic factors, crime and disorder, and impact on families and communities. Illegal 
drug use imposes a vast financial cost on UK society through the increased costs of 
policing, incarceration, and healthcare utilisation to stem the flow of illegal drugs and to 
counter the associated negative consequences of drug use. It has been estimated that the 
national costs associated with illegal drug use in the UK is between £12 and £18 billion 
per year with drug-related crime accounting for 90 per cent of these costs (Gordon et al, 
2006).  
 
Societal, economic, family and personal costs are also associated with excessive 
drinking.  Alcohol use significantly impacts on family life and is a significant 
contributory factor in incidents of domestic violence and neglect (Orford et al, 2005; 
Finney, 2003).  The economic impact of excessive alcohol consumption is significant 
with estimates that alcohol-related crime and disorder costs up to £7.3 billion a year in 
the UK (Home Office, 2006).  Reduced productivity and increased absenteeism from 
work due to either drug or alcohol use, and their associated ill-health, also contributes to 
the financial impact of substance use (McFarlin and Fals-Stewart, 2002).  
 
1.3.5     The treatment of substance abuse 
 
Substance abuse treatment can play an important role in reducing the incidence of many 
of the problems associated with substance abuse. Methods of treatment for substance 
abuse vary widely according to the types of substances used, the setting, the treatment 
philosophy, and the needs of the individual. The primary purpose of treatment is to 
minimise the risks associated with substance abuse by avoiding its psychological, legal, 
social and physical consequences (Gerstein and Harwood, 1990). Over the last three 
decades the treatment of drug abuse has taken on even greater importance. A large part 
of this is due to the pivotal role that intravenous drug use plays in HIV transmission and 






Pharmacotherapies have come to play an important role in the treatment of substance 
abuse. Methadone-based treatments for opiate addiction are the most widely used 
pharmacotherapy worldwide (Kreek and Vocci, 2002) and the most evaluated. 
Therapeutically prescribed doses of methadone relieve withdrawal symptoms, alleviate 
opiate cravings and allow normal functioning (Gerra et al, 2003). Other 
pharmacotherapies, such as buprenorphine, have also been used in more recent years to 
treat opiate problems (Carrieri et al, 2006; De Wet et al, 2005). These 
pharmacotherapies are often used in tandem with psychological therapies to understand 
the source of substance abuse problems and prevent relapse (Ball and Ross, 1991; 
Gronbladh and Gunne, 1989).  
 
The types of programmes typically used to treat opiate abusers in the UK include 
methadone maintenance, methadone reduction, residential rehabilitation and in-patient 
programmes (Stewart et al, 2000). Methadone maintenance and methadone reduction 
treatments are typically delivered through drug dependence clinics or through general 
practitioners. Methadone maintenance treatment involves stable doses of methadone 
delivered over many years. Methadone reduction programmes provide methadone in 
progressively diminishing amounts to maximise withdrawal comfort with a goal of 
eventual abstinence. These substitution regimes are often delivered in conjunction with 
individual counselling (Hubbard et al, 1989). Residential rehabilitation programmes 
provide care 24-hours a day, generally in non-hospital settings, and are often effective 
for those with more severe problems. They are highly structured programmes, often 
committed to abstinence, where patients remain in residence for up to 12 months. They 
include therapeutic communities and Twelve-Step programmes (Miller, 1998; Stevens 
and Glider, 1994). In-patient programmes provide medically supervised detoxifications 
in conjunction with counselling. Different programmes have been found to differ in 
their effectiveness. For example, methadone maintenance treatment has been found to 
have substantially higher retention rates compared to out-patient counselling without 
methadone or residential programmes without methadone (Hubbard et al, 1989).  Other 
studies have found poorer outcomes for patients treated with detoxification regimes 
compared to maintenance regimes (Gossop et al, 2001). Voluntary self-help groups such 
as Narcotics Anonymous (NA) exist which promote contact between drug users who 
share a desire to stop using drugs and members are encouraged to share their personal 





The National Treatment Agency for Substance Misuse (NTA) monitors the performance 
of the drug treatment sector through the National Drug Treatment Monitoring System 
(NDTMS) and information on individuals in treatment is collected on a monthly basis. 
The results, collated by Manchester University, identified 206,889 people aged 18 and 
over in contact with specialist, structured drug treatment in England during 2009/10. Of 
these patients 153,632 were receiving substitute prescribing (NDTMS, 2010).  
  
Most treatments for alcohol abuse focus on helping the individual reduce and 
discontinue their alcohol intake, followed up with life skills training and/or social 
support in order to help them resist a return to alcohol use. The types of treatment 
available can be categorised into three groups – pharmacotherapies, psychosocial 
treatment and non-alcohol-focused specialist treatment. Pharmacotherapies treat alcohol 
problems with drugs for detoxification to prevent alcohol withdrawal  (Mayo-Smith, 
1997; Anton and Becker, 1995),  relapse-prevention medications such as Antabuse 
(disulfiram) which causes severe discomfort when alcohol is ingested (Krampe et al, 
2006) and  Naltrexone which decreases cravings for alcohol and encourages abstinence 
(O’Malley et al, 1992). After detoxification, various forms of psychosocial intervention 
can be used to deal with underlying psychological issues related to alcohol abuse, as 
well as provide relapse prevention skills. These include Alcoholics Anonymous or 
Twelve-Step programmes which provide mutual-help group counselling.  Non-alcohol-
focused specialist treatments include coping skills, counselling, family work and 
complementary therapies.  
 
Statistics from the National Alcohol Treatment Monitoring System  (NATMS) reported 
that there were 111,381 patients in contact with structured treatment over the age 18 
who cited alcohol as their primary problematic substance in 2009/10 and  a further 
31,733 patients who cited alcohol abuse as an adjunctive problem to a range of other 











1.3.6      The benefits of substance abuse treatment 
 
National evaluation studies conducted over the last three decades have yielded 
consistent evidence that treatment for drug abuse is effective for a significant number of 
patients who enter treatment. Major reviews of the effectiveness of different treatment 
modalities including the Drug Treatment Outcomes Research Study (DTORS; Jones et 
al, 2009), the Drug Abuse Treatment Outcome Study (DATOS; Fletcher and Battjes, 
1999), the National Treatment Outcome Research Study (NTORS; Gossop et al, 1998), 
 The Drug Abuse Reporting Programme (DARP; Simpson and Sells, 1982), and the 
Treatment Outcome Prospective Study (TOPS; Hubbard et al, 1989). Many of these 
studies have found considerable evidence to suggest that drug substitution treatment can 
help opiate users in a number of important domains. 
 
These and other studies have reported substantial reductions in the rates of heroin use 
and abstinence from illicit opiates in patients enrolled in methadone maintenance 
programmes (Connock et al, 2007; Teesson et al, 2006; Gossop et al, 2005). The most 
enduring reductions in heroin use have been found over long periods among patients 
who receive continuous treatment (Condelli and Dunteman, 1993; Hser et al, 1988). The 
research findings are mixed with regard to methadone maintenance treatment’s effect on 
non-opioid drugs, although a number of studies have shown that when people enter 
treatment the use of other drugs often declines (Fletcher and Battjes, 1999). 
Effective treatment of opioid dependence has also been shown to markedly reduce rates 
of criminal activity (Jones et al, 2009; Gossop et al, 2005). 
 
Methadone maintenance treatment is effective in supporting improvements in many 
domains of physical health, mental health and social functioning. These include 
improvements in health status with access to medical care (Connock et al, 2007; 
Teesson et al, 2006), reductions in sharing drug injecting equipment among intravenous 
drug users and lower rates of HIV infection (Gowing et al, 2011; Connock et al, 2007). 
Lower death rates have been reported among individuals receiving methadone treatment 
relative to those dependent on opioids but not receiving treatment (Kimber et al, 2010; 
Mattick et al, 2009). Treatment has also been found to significantly increase the 
likelihood of being employed full-time (Anglin et al, 2009; Hubbard et al, 2003).  





commonly relapse and require numerous treatment episodes (O’Brien and McLellan, 
1996). Gerstein and Harwood (1990) suggested that approximately twenty-five per cent 
of patients treated in methadone programmes will not respond well to treatment. Some 
have suggested that variability in outcomes may be associated with treatment variables 
such as methadone dose (Fareed et al, 2010; Strain et al, 1999) and the range of 
treatment services delivered (McLellan et al, 1994; Ball and Ross, 1991), factors which 
vary between and within different programmes (Stewart et al, 2000).  
 
The evidence base for the effectiveness of the interventions for alcohol abuse is also 
strong and has been reported in several systematic reviews (Slattery et al, 2003; 
Berglund et al, 2003; Shand et al, 2003) and research trials (UKATT Research Team, 
2005; Project MATCH Research Group, 1997). Improvements in alcohol consumption, 
alcohol dependence, alcohol-related problems and aspects of general functioning have 
been found in a number of studies, although trials have failed to demonstrate the 
superiority of any one widely practiced treatment modality over another (Raistrick et al, 
2006).  
 
1.3.7      Substance users in need of help 
 
Despite the documented benefits of treatment for substance use, the literature suggests 
that only a small proportion of individuals who might benefit from treatment actually 
receive it (Drummond et al, 2005). Many substance users are unable to enter treatment 
or do not feel the need for treatment (Kaplan and Johri, 2000; Grant, 1997). In the US 
observers have reported that approximately 15-40% of drug users are engaged in some 
form of treatment for their drug abuse at any one time (Metzger and Navaline, 2003; 
Booth et al, 2001). Estimates of the ratio of treated to untreated individuals needing 
treatment for alcohol problems in the US ranges from 1:3 to 1:14 (Cunningham and 
Breslin, 2004; Kessler et al, 1999). In the UK, the Alcohol Needs Assessment Report 
Project found that only a third of alcohol dependent individuals referred to treatment 
actually access treatment (Drummond et al, 2005). It must be noted that comparisons 
between different substances or different countries should be made cautiously. Alcohol 
and drug use vary in many ways (e.g. drug use is illegal, alcohol use is not) and 
countries vary in their drug policies, legislation, and practical approaches to delivering 





Of those substance users who seek treatment, there is often a time lag of many years 
between the onset of the problem and treatment seeking (Wang et al, 2007; Dennis et al, 
2005). Early-onset users have been found to have higher rates of treatment seeking than 
older-onset users (Hingson et al, 2006; Kessler et al, 2001), and treatment seekers have 
more symptoms of dependence than those who do not seek treatment (Kessler et al, 
2001).  
 
1.4    TREATMENT ACCESS 
 
The National Treatment Agency for Substance Misuse (NTA) was established by the 
government in 2001 to  manage the  expansion of drug treatment services as 
recommended by The Advisory Council on the Misuse of Drugs (1993) and the 
government's strategies, Tackling Drugs Together (Home Office, Department for Health 
and Department for Education, 1995) and Tackling Drugs to Build a Better Britain 
(President of the Council, 1998). The NTA aimed to increase the participation of 
problem drug users, and the availability, capacity and effectiveness of treatment for 
drug abuse in England in order to minimise the harms associated with drug use (NTA, 
2002). However, this objective assumed that all individuals who needed treatment could 
receive treatment. Universal eligibility and the removal of financial barriers to health 
care were among the founding principles of the National Health Service in the UK. 
However, problems of access to treatment of any form have been a serious problem in 
the Health Service for many years (National Audit Office, 2001) and specifically for 
substance abuse treatment.  In 2001 the UK government proposed that ‘patients will get 
fair access to consistently high quality, prompt and accessible services right across the 
country’ (NHS Executive, 2001). However, to achieve this ‘fair access’ it is important 
to understand why some people access treatment while others do not. 
 
1.4.1      Barriers to treatment access  
 
Research into the factors impeding treatment seeking and utilisation is critical to 
understanding why a greater number of people do not seek or receive treatment for their 
substance abuse problems.  Discussions of help-seeking and service utilisation 
frequently focus on the influence of barriers to treatment. The term ‘barriers’ is used to 





serve as obstacles to the person receiving health care. Schober and Annis (1996) defined 
barriers as “the reasons people have for not utilising specialised addiction services or 
not modifying the target problem behaviour”. Similar definitions have been used by 
other investigators (Tsogia et al, 2001; Cunningham et al, 1993).   
 
Many studies on help-seeking behaviours and barriers have focused on medical and 
mental health care utilisation (Anderson, 1995; Beckman and Amaro, 1986). While 
these studies are useful in explaining behaviour, generalisations from medical and 
mental health settings to substance abuse settings are difficult as drug use is illegal and 
treatment utilisation is highly stigmatised (Hser et al, 1998). Factors that influence or 
impede substance misuse treatment access and utilisation may therefore be different 
from those factors that influence different types of medical and mental health service 
utilisation.  
 
Barriers to seeking substance use treatment or entering treatment have been examined 
with different populations of substance users to better understand treatment utilisation. 
These populations have included both alcohol- and drug-using patients engaged in 
treatment (Cunningham et al, 1993; George and Tucker, 1996) former treatment patients 
(Neale et al, 2007), substance users seeking referral to treatment (Hser et al, 1998), 
untreated substance users identified from population surveys or through media 
solicitation (Grant, 1997; George and Tucker, 1996) and substance users who solved 
their problems without treatment (Cunningham et al, 1993; Biernacki, 1986). Although 
many of these studies are descriptive accounts, they have identified a variety of factors 
believed to deter or encourage access to treatment (Kaskutas et al, 1997; Finney and 
Moos, 1995).   
 
Barriers to substance use treatment have generally been conceptualised along internal 
and external dimensions (Hser et al, 1998; Melnyk, 1990). Allen (1994), for example, 
defined internal treatment barriers as “subjective phenomena - beliefs or perceptions 
arising from within the person” and external barriers as “health care system, structural 
characteristics of a programme, and socio-cultural-environmental factors.” Neale et al’s 
(2007) review of the literature found barriers relating to individual factors were divided 
into (1) demographic characteristics and personal circumstances, and (2) psychological 





personal attributes, social and material resources, provider characteristics and 
convenience in accessing services, from interviews with out-of-treatment drug users. 
For the purpose of this review, barriers to treatment will be presented under the broad 
categories of patient barriers and treatment barriers (Schober and Annis, 1996; Thom, 
1984).  
 
1.4.2     Patient barriers       
 
The literature on barriers has examined a broad range of patient factors that may 
interfere with treatment entry among alcohol and drug users. A number of studies have 
shown that ethnic differences in health beliefs, perceptions about substance use 
problems, and treatment system biases such as cultural and ethnic differences between 
patients and providers, may hamper treatment access (Dana, 2002; Farabee et al, 1998; 
Kaskutas et al, 1997).  Other studies have failed to find a relationship between ethnicity 
and treatment entry (Hser et al 1998; Riley et al, 1997). 
 
Research into the influence of age has found the likelihood of seeking treatment 
increases with age up to the mid-30s and then declines (Pfeiffer et al, 1991), therefore 
younger and older people may be experiencing significant obstacles in accessing 
treatment (Hajema et al, 1999). Grant (1997) found that certain barriers such as 
transportation for older people and time constraints for younger people may serve as 
age-specific barriers to treatment entry. Other studies have failed to demonstrate age as 
a barrier to successful treatment entry (Hser et al, 1998; Tucker, 1995).   
 
A number of studies have shown that women are more likely than men to encounter 
barriers that prevent them from seeking or following through with treatment (Brady and 
Ashley, 2005). Women are more likely to experience economic barriers to treatment 
(Brady and Ashley, 2005). This is particularly relevant in American populations where 
health care is heavily dependent on private health insurance financing. Other studies 
have failed to find an association between treatment entry and gender (Grant, 1997; 
Zule et al, 1997).  
 
It has been suggested that characteristics such as age, gender and ethnicity are not actual 





with other factors (Rapp et al, 2006). Examples of this include the lack of childcare 
facilities in many treatment services which may restrict women’s ability to utilise 
services (Smith, 1992; Beckman and Kocel, 1982). Grant (1997) also found that female 
problem drinkers often reported that they did not know where to seek help, which may 
suggest that females may be more likely to access treatment through less conventional 
routes such as through family and friends. 
 
Substance use factors have frequently been identified as barriers to treatment. Greater 
severity, and higher levels, of substance use have been shown to be associated with 
treatment utilisation (Hser et al, 1998; Allen, 1994; Price et al, 1990). This may be 
partly accounted for by reports that substance users delay accessing treatment until their 
problems become acute or unmanageable (Drumm et al, 2003). The relationship 
between the severity and the level of substance use and treatment utilisation has not 
been found in all studies (Carroll and Rounsaville, 1992; Hartnoll and Power, 1989). 
History of prior substance abuse treatment has also been found to be an impediment to 
treatment access (Zule et al, 1997; Messer et al, 1996).  In many studies this was related 
to the amount of success the patients had experienced during previous treatment 
episodes.  
 
Substance-related psychosocial variables may also serve as barriers to treatment entry 
(George and Tucker, 1996; Thom, 1987). Problem recognition has been found to be 
important for treatment access in a number of studies with substance users delaying, or 
not seeking, treatment because they felt that their substance use was not serious enough 
to warrant attention (Finney and Moos, 1995; Cunningham et al, 1993). Fear of 
stigmatization (Grant, 1997; Cunningham et al, 1993), belief in solving one’s own 
problems (Williamson and Fast, 1998; George and Tucker, 1996), and anxieties about 
treatment (MacMaster, 2005; Appel et al, 2004) may influence whether a person 
accesses treatment or not. Higher levels of psychiatric distress (Smith, 1992), symptoms 
of depression and low self-esteem (Finney and Moos, 1995) have been demonstrated as 
predictors of treatment entry, although a number of studies contradict these findings 
(Hser et al, 1998). Feelings of guilt, embarrassment and fears of failing treatment have 
also been cited amongst the reasons for not seeking or entering treatment (Cunningham 






Despite the large number of patient barriers which have been associated with treatment 
entry and utilisation, studies have failed to provide any conclusive evidence as to why 
some substance users choose to enter treatment while others choose not to (Tsogia et al, 
2001; Hser et al, 1998). Few studies have examined the complexity of barriers to 
treatment or the interactive effects, or interdependence, of different factors (Rapp et al, 
2006; Tsogia et al, 2001). Anderson (1995) noted that barriers which influence health 
care utilisation are “dynamic and recursive” and do not exist independently, possibly 
explaining why one individual determinant of treatment access has not been consistently 
identified in research studies. A number of methodological weaknesses in the body of 
research into barriers to treatment access have been cited. These include the over-
reliance on quantitative designs and retrospective data collection, the latter which may 
interfere with the perception of events influencing help-seeking (O’Doherty and Davies, 
1987). Many studies have failed to report on the timing of data collection and the type 
of treatment programmes entered, which has led some to question the generalisability of 
the findings (George and Tucker, 1996; Weisner, 1990). While the majority of the 
barriers to substance abuse treatment research have been conducted in North America it 
cannot be assumed that patterns of help-seeking, service policies and provision can be 
applied to the British situation (Neale et al, 2007).  
 
1.4.3     Treatment barriers 
 
Previous research has suggested that the availability and characteristics of services are, 
in part, responsible for determining patterns of health care utilisation. Anderson’s 
conceptualisation of health care utilisation (Anderson, 1995; Anderson and Newman, 
1973) stresses that although individual determinants may act as enabling or inhibiting 
factors, the characteristics of the health care system may interact to influence health care 
access and utilisation. Although few studies have examined the characteristics of 
substance use treatment services (Schober and Annis, 1996; Allen and Dixon, 1994), 
those which do exist have shown the importance of a number of characteristics that may 
impede treatment entry. These include characteristics of individual treatment 
programmes, such as personnel and programme components (Leigh et al, 1984; 
Baekeland and Lundwall, 1975), operating aspects such as opening times or the absence 





treatment availability and admission difficulties (Rapp et al, 2006; Wenger and 
Rosenbaum, 1994).  
 
Hser et al (1998) studied 105 drug users who did not enter drug treatment in the US 
after the referral process. The patients were allowed to give multiple reasons for not 
participating in the programme. Fifty-nine per cent of the drug users interviewed cited 
service barriers as reasons for not entering treatment. These included programme 
admission eligibility problems, financial difficulties, not wanting to be on a waiting list 
or being on a waiting list too long, problems with transportation, and scheduling 
conflicts. The remaining reasons were largely attributable to the patient and included 
difficulties making arrangements to enter treatment, arrest or incarceration, ill health or 
deciding to stop using drugs on their own.  
 
Similar service barriers have been cited in other studies (Neale et al, 2007; Donmall et 
al, 2005; Appel et al, 2004). Farabee and colleagues (1998), for example, gathered data 
from 2613 street drug users in North and South America who reported having tried 
unsuccessfully to enter drug abuse treatment over the previous year.  Excluding 
participants who cited both individual-based and programme-based reasons for not 
entering treatment, 72.1% attributed their failure to enter drug treatment to programme-
based reasons, with the most commonly cited reason being that the programme did not 
have room. The cost of treatment and the strict admission criteria were also cited. Only 
14.5% of the drug users cited solely individual-based reasons (e.g. failed to attend a 
scheduled appointment). 
 
1.4.4      Treatment availability 
 
While participation in substance abuse treatment has frequently been associated with 
positive outcomes, to achieve these benefits substance users must be able to enter 
treatment after they have made the decision to seek help.  Joseph and Poyner (1982) 
stated that unless services are ‘available’, there can be no consideration of the factors 
that differentially influence or impede access of individuals to services. The treatment 
utilisation models proposed by Aday and Anderson (1974) and Rosenberg and Hanlon 





understanding treatment access. Treatment availability is typically measured in terms of 
treatment slots, hours of operation and waiting times.  
 
1.5     WAITING TIMES 
 
The following section will review the literature on the existence and consequences of 
waiting lists imposed in many substance abuse treatment services. Research will be 
presented on the effects of being placed on a waiting list in terms of the risks and harms 
associated with delays to enter treatment and the likelihood of entering treatment when 
a place becomes available. The review will draw upon literature from both drug and 
alcohol abuse populations and treatment services, although it is acknowledged that 
differences between these two populations and types of services exist.  
 
At the beginning of this research programme there were concerns surrounding the 
existence of extensive waiting times in drug treatment services. An increase in the 
number of heroin users over the previous three decades and the associated risks of HIV 
infection led to a major expansion of drug abuse treatment. However, this level of 
demand led to an insufficient capacity of many publicly-funded treatment facilities to 
provide help to all individuals who requested treatment (Guydish and Muck, 1999). As 
a result of this insufficient capacity many services imposed waiting lists. A waiting list 
is defined as a ‘list of persons who have applied for treatment but for whom a treatment 
position is not presently available’ (Yancovitz et al, 1991). Until recent years the 
definition of waiting times was not standardised. Some treatment programmes included 
an applicant on a waiting list after an initial telephone or face-to-face contact, others 
after referral from another source had been received and others after an initial 
assessment had been conducted. 
 
There are an undetermined number of substance users on treatment waiting lists and an 
unmeasured number of substance users who desire treatment but who do not apply for 
treatment. A number of studies have examined the prevalence of waiting lists in drug 
treatment services and the length of time drug users are required to wait for treatment. 
Stewart et al’s (2000) examination of 54 drug treatment programmes representative of 
the main treatment modalities in the UK, found 67% of methadone reduction 





facilities operated waiting lists. Average waiting times were over six and a half weeks 
for methadone maintenance and reduction programmes, and over 12 weeks for inpatient 
services. Luty (2002) reported the widespread use of waiting lists across England and 
Wales for community/out-patient drug treatment. The mean waiting time for assessment 
of any drug problem was 7.2 weeks.  The average time from referral to receiving 
medication was 10.6 weeks. Donmall et al’s (2005) national survey of drug services in 
England also reported the widespread use of waiting lists in substitute prescribing and 
in-patient services with average waiting times from referral to treatment entry of 12 
weeks, with a quarter of treatment-seekers waiting for 16 weeks or more. The Alcohol 
Needs Assessment Research Project found the average waiting time for assessment at 
an alcohol treatment service in 2004 was 4.6 weeks (4.1 weeks for community agencies 
and 5.5 for residential agencies) with mean waiting times in excess of 6 weeks in some 
regions (Drummond et al, 2005). 
 
Tackling excessive waiting times for drug users to access treatment was highlighted as a 
priority when the NTA was established (Department of Health, 2001). The Updated 
Drug Strategy of 2002 called for "maximum waiting times from referral to receipt of 
treatment should be no more than two weeks for in-patient detoxification and G.P. 
prescribing and three weeks for all other types of treatment” (Home Office, 2002). 
Providing treatment for drug users is a government priority, yet at the commencement 
of the research programme there was comparatively little provision of treatment for 
alcohol-related problems despite the number of problem alcohol users exceeding the 
number of problem drug users by several million (Drummond et al, 2005). The Alcohol 
Harm Reduction Strategy for England noted an insufficient focus on alcohol treatments 
and limited information on the extent to which existing levels of service provision meet 
demand (Prime Minister’s Strategy Unit, 2004).  A Needs Assessment conducted for the 
Department of Health (Drummond et al, 2005) found an extensive gap between the need 
for alcohol treatment and access to treatment with only approximately 1 in 18 (5.6%) 
alcohol dependent individuals accessing specialist alcohol treatment nationally per 
annum. It also found the absence of dedicated funding and no targeted waiting time 
limits for alcohol treatment. The reasons for these findings are unclear but may be a 
result of the government’s focus on reducing the rates of acquisitive crimes committed 
by drug users by encouraging treatment participation. Alternatively it may be due to the 





and has less stigma attached to it than illicit drug use and so may be deemed as less of a 
problem. 
  
1.5.1     The relationship between waiting times and treatment processes   
 
The waiting period is one of the first events a treatment-seeking substance user will 
experience of a specific treatment episode, yet little is known about the effects of being 
placed on a waiting list, or of the relationship between the waiting experience and 
subsequent patient experience in  treatment. As Brown et al (1989) states  
 
      “ in spite of the increasing reports of the need to employ waiting lists, and their    
      significance for the users and the treatment program, there is a virtual absence of  
      research in this area, with the exception of those studies using waiting list controls”.  
 
The waiting period is often listed among the most common barriers for those seeking 
treatment in both qualitative (Stevens et al, 2008; Redko et al, 2006; Neale et al, 2007) 
and quantitative studies of substance users (Rapp et al, 2006; Appel et al, 2004). 
Porter’s (1999) study on Puerto Rican long-term heroin injectors found the waiting 
period to get into treatment initially and then between detoxifications and “rehabs” was 
described as a major structural barrier that affected all heroin injectors. Similar reports 
were found in other studies of heroin users seeking methadone maintenance treatment 
(Wenger and Rosenbaum, 1994) and among crack-cocaine users in the US who reported 
having tried unsuccessfully to enter substance use treatment over the previous year 
(Farabee, et al, 1998). Interviews with out-of-treatment drug users in the UK revealed 
that the ease or convenience of getting services and the level of convenience of moving 
through the treatment system was a priority (Drumm et al, 2003). 
 
Research into patient waiting times has not been extensive. Yancovitz et al (1991) 
attempted to perform a series of meta-analyses on the scientific data on waiting lists but 
were unable to due to the lack of published data. The literature examining treatment 
waiting times can be divided into three main areas: (1) treatment entry, (2) treatment 







1.5.2     Treatment entry  
 
A large number of studies have found that many substance users seeking treatment for 
their substance abuse problems fail to enter treatment once a treatment place becomes 
available. A number of investigators have shown that even after substance users 
undergo an initial assessment, the likelihood that they will actually enter treatment is 
often less than 50% (Hser et al, 1998; Stark, 1992; Agosti et al, 1991; Ball and Ross, 
1991).  These high rates of ‘pre-treatment attrition’ (Gottheil et al, 1997) are 
problematic as substance users who fail to enter treatment may experience a 
continuation of the problems which spurred the help-seeking activities (Brown et al, 
1989). Waiting list attrition also represents a missed opportunity for treatment 
intervention (Brown et al, 2002) as substance users who do not enter treatment will fail 
to receive any of the benefits of treatment. An American study (Watters and Cheng, 
1991) found that nearly 50% of the out-of-treatment drug users they interviewed said 
they would enter treatment “tomorrow” if a treatment place were available. 
 
Studies on waiting times have largely focused on the relationship between the length of 
the waiting period and the likelihood of treatment entry. Research findings have been 
fairly consistent over several decades. Typically, the longer substance users have to wait 
between initial assessment and the start of formal treatment, the less likely they are to 
follow through with treatment (Hser et al, 1998; Orne and Boswell, 1991). Festinger et 
al (1995) proposed that the first 24-hours after a patient’s initial phone contact is a 
critical period in initiating treatment. They found that of the 235 cocaine users who 
called for an initial treatment appointment at a community out-patient service, 58% did 
not attend the appointment. The greater the delay between the phone-call and scheduled 
appointment the less likely they were to show. The percentage of patients attending the 
initial appointment fell from 83% to 57% in the first 24-hour period following the 
phone contact. Two other studies have shown that waiting periods greater than 7-8 days 
substantially reduced the probability of initial attendance (Hyslop and Kershaw, 
1981;Wanberg and Jones, 1973). Fleming and Lewis (1987) reported that 40% of 
applicants at an out-patient alcohol clinic did not attend when a treatment place became 






Studies which have reduced the length of the waiting period have often been successful 
in increasing attendance rates. Dennis et al (1994) reported an increase in the number of 
patients who kept intake appointments in a methadone programme when the waiting 
period was reduced from 40 days to 14 days. Maddux et al (1995) found a marked 
decrease in pre-treatment attrition when methadone prescribing was started within 24- 
hours of the initial contact with a treatment service compared to the standard 14-days 
waiting period, with 4% of the rapid admission and 26% of the slow admission group 
failing to attend the initial appointment. 
 
A number of explanations for the relationship between attendance and waiting times 
have been suggested. Claus and Kindleberger (2002) and Redko et al (2006) suggested 
that the crisis that precipitated agency contact may have subsided with increasing time 
between initial contact and treatment entry, resulting in substance users feeling less 
need for treatment. Festinger et al (1995) and Woody et al (1975) suggested that a 
patient may have only temporarily overcome internal or external barriers to treatment 
when they first present and the forces to pursue treatment may be quite fragile and time 
limited.  
 
The relationship between the length of waiting time and non-initiation of treatment has 
not been universally detected. Several studies in the UK have failed to demonstrate a 
relationship between the two variables. Donmall et al’s (2005) study of fifteen drug 
treatment agencies found the length of wait between initial referral to the treatment 
services and assessment did not have a significant effect on treatment entry. Georgakis 
(1999) examined 2000 consecutive admissions to a residential detoxification centre 
between 1983 and 1998 and also found no evidence to suggest that people with longer 
waiting times prior to entry were less likely to take up the offer of treatment.  
 
1.5.3     Treatment retention 
 
Stark (1992) stated that “premature termination is one of the greatest problems 
interfering with the effectiveness of substance abuse treatment”.  Retention studies 
typically report high rates of attrition from substance abuse treatment (Joe et al, 1998, 
De Leon et al, 2000b),  with drop-out often occurring within the first few weeks or 





summarise drop-out rates as services and researchers define drop-out in different ways, 
and treatment is based on divergent treatment approaches, studies of drug abuse 
treatment have reported drop-out rates of between 24% and 83% (Gossop et al, 1999; 
Simpson, 1981), and rates of between 18% and 83% for alcohol treatments (Silberfeld 
and Glaser, 1987; Gordis et al, 1981).  
 
Research on the relationship between waiting times and treatment retention is not 
extensive and the studies which do exist have not been consistent in their findings 
(Claus and Kindleberger, 2002; Georgakis, 1999; Addenbrooke and Rathod, 1990).  A 
number of studies have demonstrated a relationship between shorter waiting times and 
longer treatment tenures. Rees et al (1984) found patients at an alcohol treatment unit 
who made 5 or more clinic visits had waited a shorter time (average of 47 days) for their 
first appointment than those who made fewer visits (average of 61 days). An early study 
by Woody et al (1975) compared drug treatment tenures among patients where 
medication was provided 1-3 days after initial assessment or on the same day. 
Decreasing delays at intake significantly increased the retention rate. A greater number 
of patients entering treatment in the rapid-intake group were retained at each monthly 
follow-up for 5 months compared to the longer-intake group. Bell et al (1994) 
investigated the effects of assessment and intake procedures on patients’ performance in 
methadone maintenance treatment in Australia where 89 patients were admitted via a 
rapid-intake procedure (same or second day receipt of methadone) and 74 patients who 
were admitted at a slower rate (first dose 5-8 weeks after applying). Patients who 
underwent prolonged assessment were twice as likely as the rapid-intake group to be 
discharged during the first 400 days of treatment and were five times more likely to 
drop-out without discussion with staff and were notably more likely to use heroin 
during treatment.  
 
High attrition continues to be an important issue for substance abuse treatment 
programmes. A longer stay in treatment is among the few consistent predictors of better 
post-treatment outcomes (Hubbard et al, 2003; Gossop et al, 2001).  A number of 
studies have found that individuals who complete treatment are more likely to abstain 
from alcohol and other drug use and have lower relapse rates and fewer arrests than 
those who drop-out before completing treatment (Stark, 1992; Simpson, 1981). 





have already invested staff time and resources to starting each individual course of 
treatment (Stark, 1992; Deyo and Inui, 1980).  
 
The assumption that an immediate response to substance abusers’ requests for help 
increases the likelihood of retention is not always supported. A number of studies have 
demonstrated that substance users entering treatment after a short delay do not 
necessarily persist with treatment. Addenbrooke and Rathod (1990) studied 130 patients 
at a drug service and found no difference in treatment tenures between those seen within 
seven days of referral or those who had a longer waiting period (mean of 39 days). 
Similarly, studies by Best et al (2002) and Donmall et al (2005) found no relationship 
between patient waiting times prior to treatment entry and retention in treatment three 
and six months after entry.  
 
1.5.4      Behaviour during the waiting period 
 
The literature on the behaviours and functioning of substance users placed on a 
treatment waiting list is limited (Yancovitz et al, 1991; Brown et al, 1989). Several 
studies have shown that a sizeable number of substance users placed on a waiting list 
start making changes in their substance use prior to treatment entry (Redko et al, 2006; 
Moore and Budney, 2002). Tucker (1995) found that nearly 86% of patients awaiting 
entry to alcohol treatment achieved abstinence before intake. Rosengren et al (2000) 
reported that 45% of participants claimed to have stopped substance use, or were 
maintaining abstinence, during an average of twelve days waiting period prior to in-
patient drug and alcohol treatment. In this study the length of time on the waiting list 
was an important contributor to maintenance of sobriety prior to treatment entry. The 
longer the person had to wait, the more difficult sobriety became. A total of 67.7% of 
the patients could maintain abstinence during waits of one week compared to only 
24.9% of those waiting for 18-days or more. 
  
Brown et al (1989) studied 29 waiting list participants who had requested treatment at a 
residential unit in Baltimore for cocaine abuse. Interviews with participants during the 
waiting period found nearly half of all subjects (48.3%) reported some decrease in the 
use of their primary drug subsequent to their registering for treatment. A third also 





application for treatment. Two-thirds of intravenous drug users reported having made 
changes in their behaviours designed to reduce the risk of contracting AIDS and a 
similar proportion reported having sought HIV testing. Being on the waiting list a 
shorter (3 months or less) or  longer (4-6 months) time was not associated with a greater 
or lesser tendency to modify drug-using behaviours, with no difference in the reported 
reductions of drug use among patients with different waiting times prior to entering 
treatment.  
 
Contradictory evidence has been reported by Urschel et al (1991) who found no 
evidence that the drug and alcohol use, or other health problems, of patients awaiting 
treatment entry for cocaine abuse treatment in Philadelphia showed any improvement 
without treatment. Within this study the majority of untreated waiting list patients 
showed significant increases in the severity of their medical, psychiatric, social and drug 
abuse problems over the 4-week waiting period. Forty-eight per cent of the waiting list 
participants reported increases in the severity of drug and alcohol problems, 56% 
reported increased severity of medical problems, 80% reported increased employment 
and support problems and 48% had a greater number of problems in psychiatric, family 
or social adjustment. Less than 60% of the patients who were contacted and told they 
would be eligible for treatment at the end of the 4-week waiting period actually 
accepted treatment.  
 
Brown et al (1989) demonstrated that waiting for long periods without receiving some 
form of treatment was associated with an increase in criminal justice involvement and 
decreased interest in entering treatment. Four of the 13 individuals on the waiting list 
for 4 or more months reported being arrested, whereas none of the 16 subjects on the 
waiting list for 3-months or less reported an arrest. Seven of the 13 subjects waiting 4 or 
more months appeared in court during that period, while only 1 of 16 subjects on the 3-
month waiting list. Six of the 7 individuals who could not be interviewed due to 
incarceration had been on the waiting list 4-months or more. 
 
Adamson and Sellman’s (1998) study of 64 patients awaiting entry to a methadone 
treatment programme in New Zealand found the mean cost of drugs used in the 
preceding 7 days was $882 across all subjects. The mean financial gain from criminal 





property crime and prostitution. An important implication of these findings is that 
untreated opioid users are a substantial financial burden to the community in terms of 
offending and the costs associated with prosecuting the offences. In contrast, removing 
drug users from waiting lists and into interim methadone treatment (without 
counselling) in the US resulted in reduced criminal behaviour (Schwartz et al, 2006) 
and reduced criminal justice costs (Koenig et al, 2005; Zarkin et al, 2005).      
 
Interviews with 52 substance users awaiting entry to either residential or outpatient 
substance abuse services found delayed treatment entry was affected  by other barriers 
to treatment entry which occurred with the passage of time (Redko et al, 2006). During 
the waiting period some substance users found jobs that interfered with treatment entry, 
while others moved away to avoid homelessness or their drug-using social environment. 
Some substance users achieved abstinence during the waiting period and saw this as a 
sign that they did not need treatment and therefore had less interest to enter treatment, 
while many others relapsed to drug use. The substance users’ subjective experiences of 
the passage of time also made waiting particularly difficult, with some describing even 
short waiting periods as “never ending” or “eternal”. 
 
The findings of the small number of studies which have examined the behaviour of 
waiting list participants are consistent on several points. First, the behaviour of users 
awaiting treatment entry does not always remain at the level observed when the person 
first applied for treatment. While some use the time to make changes to their substance 
use, others continue to experience difficulties in functioning or a worsening in their 
overall substance use. Waiting for treatment has been associated with poor levels of 
treatment engagement, patient dissatisfaction, and continued physical, social and 
personal costs (Adamson and Sellman, 1998; Wenger and Rosenbaum, 1994) in a 
number of studies. These costs include physical health risks associated with maintaining 
a substance use habit such as the risk of overdose and the spread of viruses, 
homelessness, crime, incarceration, and the breakdown of families. Untreated substance 
users take up a variety of government interventions and services, including 
hospitalisation and incarceration (Zealberg and Brady, 1999).  Many of the studies 
reviewed highlight the importance of taking advantage of applicants’ initial enthusiasm 
for treatment. For some there appears to be a short ‘window of opportunity’ for 





services will be accepted when they are offered (Brown et al, 2002). The National 
Institute of Drug Abuse’s Principles of Drug Addiction Treatment (NIDA, 1999) states 
“potential treatment applicants can be lost if treatment is not immediately available or 
readily accessible”. While many substance users are ambivalent about seeking treatment 
(Kaplan and Johri, 2000) and have little tolerance for waiting, other substance users will 
be affected by various unintended consequences of waiting time which have been 
shown to be deleterious for treatment entry such as arrest or homelessness (Redko et al, 
2006; Brown et al, 1989).  
 
It may also be the case that the longer that people have to wait for treatment, the less 
effective that treatment will be. Miller (1985) reported that patients receiving treatment 
after a 10-week wait, improved less than patients who received the same treatment 
without having to wait for it. Bell et al (1994) found patients admitted to treatment after 
a prolonged intake procedure lasting 5-8 weeks were more likely to be discharged for 
persistent non-compliance in methadone maintenance treatment compared to patients 
who entered after a rapid assessment procedure with receipt of methadone the same or 
following day.  
 
The research literature presented in the previous section drew attention to some of the 
consequences of delaying access to substance users who request treatment.  While 
substance users wait for treatment their condition remains unaddressed and the 
likelihood of them entering treatment or remaining in treatment declines. The factors 
that may mediate the relationship between waiting times and treatment entry have been 
largely overlooked by researchers. It has been suggested that asking substance users to 
wait before treatment may diminish motivation (Stevens et al, 2008; Schwartz et al, 
2006) and lead to less interest in entering treatment and making changes to substance 
use behaviours. No studies, known to the author, have examined the motivation of 
substance users awaiting treatment entry or how this is related to key treatment events 
such as treatment initiation and clinical variables such as substance use during this 
period. The research programme presented will address this gap in the research 
literature and draw attention to some of the issues surrounding the motivation of heroin 
users awaiting treatment entry and the clinical relevance of this information in the 
treatment of drug abuse.  This thesis proposes that the relationship between outcomes 





the substance users’ motivation for change. The existence of this relationship will be 
examined through two studies in the research programme.   
 
1.6   THE ROLE OF MOTIVATION IN SUBSTANCE ABUSE TREATMENT 
 
This section will present a brief review of the history of motivation within the context of 
substance abuse treatment, with an emphasis on the relationships between patient 
motivation, treatment factors and treatment outcomes.  The second part of this section 
will address some of the possible effects of waiting list participation on patient 
motivation and will conclude with the presentation of the conceptual framework for the 
research programme which will demonstrate how the waiting period and motivation 
may interact to influence treatment entry and substance use over the waiting period. 
 
Motivation is considered to be an important first step towards any action or change in 
behaviour, and has long been regarded as an important factor in the treatment of 
addictive behaviours (Miller, 1985). There is a proliferation of terms used to define 
motivation and many different criteria for assessing motivation which has often led to 
conceptual confusion regarding the concept (Drieschner et al, 2004).  This confusion 
was noted by Rosenbaum and Horowitz (1983) who stated that “definitions of 
motivation are sufficiently fuzzy so that almost any variable can be thought of as 
relevant”. For the purposes of the research programme motivation will be defined as a 
hypothetical construct used to describe the internal or external forces producing the 
initiation, direction, intensity, and persistence of a behaviour (Vallerand and Thill, 
1993).   
 
Historically motivation was often viewed as a static trait or disposition that a patient 
either had or did not have. Low motivation was viewed as deriving from negative 
dispositions such as lack of will power or from ego-defence mechanisms such as denial. 
As one writer noted,  
 
“Notions of moral turpitude and incurability have been linked with problems of 
drug dependence for at least a century. Even now, public and professional 
attitudes toward alcoholism are an amalgam of contrasting, sometimes 





The attitudes toward those who are dependent on opiates are a similar amalgam, 
with the element of moral defect in somewhat greater proportion (Jaffee, 1979). 
 
It was generally assumed that the patient was the most active force in treatment and 
unfavourable treatment outcomes were frequently attributed to low motivation for 
change (Drieschner et al, 2004; Nir and Cutler, 1978; Orford and Hawker, 1974).  This 
conceptualisation of motivation has been criticised because it led to self-fulfilling 
prophecies in which patients felt they were destined to fail and also discouraged 
interventions by the treatment providers to enhance motivation (Miller, 1985).  
 
Over the last few decades there has been a shift in the addiction field's understanding of 
personal change. The revised perspective has moved the focus away from the patient’s 
level of motivation and towards the effects of factors in the environment which may 
influence the individual’s ability to benefit from treatment. This new conceptualisation 
focuses on the multidimensional nature of change and highlights the interactions 
between the individual and the treatment provider in shaping motivation to encourage 
and maintain positive behavioural change (Miller and Sanchez, 1994).  There has been 
substantial interest in understanding the determinants and mechanisms of change within 
the treatment environment which may have a positive influence on patient motivation 
and which in turn may influence treatment outcomes. This interest has been reflected in 
the array of research trials which have included motivation components in their set of 
measures (Project Match Research Group, 1997, Simpson and Joe, 1993).   
 
1.6.1   Motivation and treatment outcomes 
 
A number of studies have shown motivation to be a critical dimension influencing 
whether substance users seek, enter and participate in treatment (Corsi et al, 2007; 
Weisner et al, 2001; DiClemente, 1999; Broome et al, 1999; DiClemente and Scott, 
1997). Pre-treatment motivation has also been found to be a prominent factor in 
predicting treatment outcomes.  Positive relationships between motivation  and patient 
outcomes have been demonstrated across different types of therapeutic settings 
including methadone maintenance programmes (Simpson et al, 1997a) residential 
rehabilitation and drug-free programmes  (Joe et al, 1998) along with  drug in-patient 





Prochaska  et al, 1992). These outcomes have included successful engagement in 
treatment, as measured by session attendance, reductions in substance use and treatment 
retention (Simpson et al, 1997a; De Leon et al, 1994; Simpson and Joe, 1993). The 
relationship between motivation and treatment outcomes has at times been inconsistent 
(Claus and Kindleberger, 2002). A number of studies have found higher motivation at 
treatment entry to be unrelated to either participation in treatment or superior outcomes 
(Rapp et al, 1998; De Leon et al, 1994). The apparently inconsistent findings may be the 
result of differences in how motivation has been defined and measured and the 
examination of the construct in different populations of substance users (Ryan et al, 
1995).  
 
Numerous studies have investigated the factors in the treatment environment which may 
mediate the relationship between a patient’s initial motivation for change and his or her 
treatment outcomes. The role of the therapeutic relationship has received a considerable 
amount of empirical investigation. The therapeutic relationship, also called the helping 
alliance, refers to the relationship between a healthcare professional and a patient 
established during the treatment process and is expressed in, and influenced by, the way 
patients and clinicians communicate. The importance of the therapeutic relationship in 
treatment was highlighted from the results of early studies of alcohol treatments which 
found dramatic differences in the rates of patient drop-out and treatment completion 
among counsellors in the same programme who were using the same counselling 
techniques (e.g. Rosenberg and Raynes, 1973; Raynes and Patch, 1971).  
 
Research has demonstrated that the quality of the relationship between therapist and 
patient is a consistent predictor of treatment engagement (Fiorentine et al, 1999; 
Connors et al, 1997; Simpson et al, 1997b), treatment retention (Fenton et al, 2001; 
Barber et al, 1999), and early improvements in treatment (Simpson et al, 1997b).  A 
small number of studies also found the therapeutic alliance to be related to post-
treatment drug use outcomes in out-patient studies (Joe et al, 200; Hser et al, 1999), 
although a review by Meier et al (2005) found that this relationship is not always 
consistent.  A strong therapeutic relationship is believed to be at the base of effective 
treatment because it promotes the patient’s belief that treatment can help, assists the 
patient change their views on drug use and lifestyle and supports their progress with 





Predictors for the early therapeutic relationship have been found to be related to 
motivation (Connors et al, 2000; Joe et al, 1998). Studies have found that patients with 
greater motivation at the start of treatment are more likely to have a good patient-
counsellor rapport (Joe et al, 1998) and greater reductions in substance use 
(DiClemente, 2007; Simpson et al, 1997b) compared to those with lower motivation.   
Miller and Rollnick (2002) stated that “motivation for change can not only be 
influenced by, but in a very real sense arise from interpersonal context”.  
 
Other factors in the treatment environment have also been found to play a prominent 
role in influencing patient treatment outcomes. For example, numerous studies have 
demonstrated that methadone dose prescribed during treatment has a negative linear 
effect with heroin use and a positive linear effect with treatment retention (Gossop et al, 
2001; Joe et al, 1994; Ward et al, 1994).  Strain et al (1999) found a significantly lower 
rate of opiate-positive urine specimens among patients receiving high-dose methadone 
compared to low-dose methadone, while Kamal et al (2007) found lower doses of 
methadone during treatment were associated with lower rates of opiate abstinence. The 
number of ancillary services (e.g. other medical, legal, employment services) received 
by patients during treatment has been found to related to improvements in treatment 
effectiveness (Simpson et al, 1995; Ball and Ross, 1991).  McLellan et al (1994) found 
that patients who received a broader array and increased frequency of services for their 
alcohol, cocaine and opiate use stayed in treatment longer, and showed fifteen per cent 
better outcomes than patients who did not.  
 
The way in which these treatment factors interact with, or influence, patient motivation 
for change has received little research attention. However, several studies have 
suggested that a patient’s perception and appraisal of the treatment environment may be 
related to motivation which in turn may influence treatment outcomes. Gossop et al 
(2003), for example, found higher levels of motivation were related to programme 
perceptions, and that programme perceptions were predictive of improved heroin use 
outcomes at 1-month and 6-month follow-ups in methadone maintenance programmes.  
Fiorentine et al (1999) also found the perceptions of the utility of treatment and 
ancillary services were related to treatment engagement, although the extent to which 
these appraisals were related to motivation for change was not examined. Specific 





withdrawal symptoms or ancillary services to assist in other problem areas may promote 
confidence in the patient that treatment can help with their problems (De Leon et al, 
1994: Jordan and Oei, 1989) and this confidence may increase motivation for change. 
 
1.6.2    Patient factors and treatment outcome 
 
A number of patient characteristics have also been found to constitute an important 
explanation for treatment effectiveness. Patient characteristics considered to be 
positively related to treatment outcome include a history of previous substance abuse 
treatment (Adamson et al, 2008), being employed (Platt, 1995; McLellan et al, 1994; 
Anglin and Hser, 1990; Hubbard et al, 1989), and the availability of environmental 
resources such as social support (McLellan et al, 1980). Socio-economic status has also 
been previously associated with retention in treatment, while small and varied effects 
have been noted with demographic variables such as relationship status (Stark, 1992). 
Demographic characteristics such as age, race, gender or education do not seem to be 
related to outcomes regardless of the outcome criteria evaluated (McLellan et al, 1994).  
 
Factors associated with less favourable outcomes such as treatment drop-out and relapse 
following treatment include having a more extensive criminal history (De Leon,1984; 
Simpson, 1981), a greater severity of drug dependence (Rounds-Bryant et al, 1999; 
George et al, 1999; McLellan et al, 1994; Anglin and Hser, 1990), stressful life events 
(Finney and Moos, 1984) and more severe psychiatric symptoms and disorders at intake  
(Gossop et al, 2001; McLellan et al, 1996; Carroll et al, 1993), although these results 
may be specific to the programmes being evaluated and the type of patients they serve 
(Stark, 1992).  
 
 
1.6.3   Treatment process models  
 
A number of investigators have proposed treatment process models to account for the 
relationship between motivation and other patient factors, the treatment process and 
treatment outcomes. Joe et al (1994), for example, proposed a treatment process model 
for the Drug Abuse Treatment Outcome Studies (DATOS) to explain the factors 
associated with treatment retention. Their process model is essentially a classification of 





characteristics at admission (e.g. legal pressure, psychological functioning, drug use), 
treatment programme characteristics such as session attributes (frequency of counselling 
session attendance, topics discussed in counselling) and therapeutic involvement 
(rapport, patient confidence that treatment is effective), treatment events and treatment 
readiness. Another model by the same research team (Simpson et al, 2001) attempts to 
depict what actually happens during the different stages of treatment from treatment 
entry to post-treatment care and how these are related to individual factors and factors in 
the treatment environment. The model was developed on studies of methadone 
maintenance involving nearly 3,000 patients in 120 different treatment programmes but 
was found to account for only for a small variance in treatment retention, indicating that 
other factors were more important in explaining outcomes than those included in the 
model. These results show the complexities of examining the relationships between 
motivation, treatment factors and outcomes. Numerous factors are believed to impinge 
upon these relationships, many of which still remain to be identified.  
 
 
1.7    MOTIVATION AND WAITING TIME 
 
While a considerable amount of research has been devoted to treatment process 
components in understanding the relationship between motivation for change and 
treatment outcomes, this has focused predominantly on substance users already engaged 
in treatment (Gossop et al, 2007; Cahill et al, 2003; Simpson and Joe, 1993). Motivation 
has not been systematically examined among substance users placed on a waiting list 
prior to treatment entry. Waiting list participants may not be comparable to treatment 
samples in that they have expressed a desire for treatment but are still exposed to the 
lifestyle and harms associated with on-going substance use. Examination of the 
motivation among this group of substance users may contribute to a greater 
understanding of the short-term effects of being placed on a waiting list such as the 
likelihood of treatment entry and patterns of substance use during this period. 
 
The waiting period is one of the first experiences of the treatment process that many 
substance users will encounter and as such may be a critical stage for shaping the nature 
of the future relationship between the treatment seeker and the treatment service.  A 





often desire an immediate response to their problems (Gariti et al, 1995; Ewalt et al, 
1972).  Although the limited available research is primarily suggestive, it has been 
hypothesised that the inability of a treatment service to meet an individual’s immediate 
needs, by imposing an unexpected or lengthy waiting period, may result in lessened 
confidence in the system to provide the support they require and may diminish 
motivation about changing substance use or entering treatment (Stevens et al, 2008; 
Schwartz et al, 2006). In support of this proposition, Broome et al (1999) found patient 
confidence was higher in out-patient drug-free and out-patient methadone treatment 
when referred services were more readily accessible. An earlier study by Brown et al 
(1989) reported that waiting list participants with varying lengths of delay prior to 
scheduled treatment entry reported a considerable reduction in their interest in receiving 
treatment while waiting for a place to become available. Fiorentine et al (1999) reported 
that the perceived utility of treatment is among one of the strongest predictors of 
treatment engagement and that patients will engage in treatment when they believe 
treatment will address their problems and that they are helpful and worthwhile. Having 
a waiting list is perceived evidence that treatment cannot address their problems at a 
time when they feel most in need of assistance.  
 
1.7.1     Conceptual framework for the research programme 
 
Previous models and frameworks depicting the relationship between patient motivation, 
the treatment environment and outcomes have failed to take into account the waiting 
period prior to treatment entry. There has been an absence of research examining the 
changes in motivation during this period, or how these changing patterns are influenced 
by the length of the waiting period or related to outcomes such as starting treatment or 
making changes to substance use during the waiting period. The thesis hypothesises that 
the relationship between waiting times and outcomes is mediated by motivation to 
change drug use. That is to say, the length of the waiting period influences motivation to 
change drug use which in turn affects the short-term outcomes of successful treatment 
entry and patterns of substance use over the waiting period, thus creating the 
relationship between waiting times, treatment entry and outcomes.  
 
Figure 1.1 depicts the hypothesised directional relationships between the factors 





period. The framework considers both the patient-level (background factors, 
expectations and readiness to change) and treatment level (waiting time) influences on 
the outcomes examined. The central focus of the conceptual framework is the effects of 
the length of the waiting period on readiness to change, and the effects of readiness to 
change on treatment entry and levels of substance use over the waiting period. Although 
patient factors are not of central interest, previous research has shown that certain 
patient characteristics are associated with both treatment entry and motivation to 
change. These factors will be used to examine predictors of changes in readiness over 
the waiting period and predictors of treatment entry at the end of the waiting period. The 
framework also includes the relationship between patient expectations of the length of 
the waiting period and readiness over the waiting period and the association of these 
expectations on the likelihood of treatment entry.   
 
 
Figure 1.1:  Conceptual framework of the proposed relationships between waiting time, 

















Waiting time refers to the total number of days between the initial clinic visit requesting 
treatment and scheduled treatment entry. It is acknowledged that the waiting period may 
also have an influence on longer-term treatment outcomes, although this is beyond the 
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which have shown a relationship between waiting times and time in treatment, although 
such a relationship has not been consistently found as discussed in the earlier Literature 
Review (Donmall et al, 2005; Bell et al, 1994; Rees et al, 1984). 
 
Readiness to change refers to the intrinsic (i.e. originating from within) motivation of 
the patient. It is a concept utilised by the Transtheoretical Model of Motivation 
(Prochaska and DiClemente, 1982) and indicates a willingness or openness to adopt a 
particular behaviour. For the purposes of the research programme readiness to change 
will represent a willingness to change heroin use. Readiness to change and the 
Transtheroretical Model of Motivation will be examined in greater detail in Chapter 2. 
 
The patient characteristics within the framework include age, physical and 
psychological health status, frequency of substance use, severity of dependence for 
heroin use and intravenous heroin use. A number of these factors have been identified in 
previous studies as being related to both treatment entry and levels of motivation.  
(e.g. Austin et al, 2010;  Zule and Desmond, 2000; Hser et al, 1998; Allen, 1994) . It is 
acknowledged that may other patient factors may interact with treatment entry and 
readiness to change though these are beyond the scope of this research programme. 
 
Another element within the conceptual framework represents patient expectations. This 
factor is depicted as being associated with readiness to change drug use and treatment 
entry.  Although there is limited research on patient expectations within the context of 
substance abuse treatment, it has been suggested that the expectations which substance 
users bring with them to the health-care encounter and their subsequent perceptions of 
how these expectations are met may be associated with attrition from the waiting list 
(Meichenbaum and Turk, 1987).  It is hypothesised that this relationship may be 
mediated by motivation. 
 
It is assumed that substance users approach services with different expectations of what 
the treatment process will entail. This may include expectations about the length and 
intensity of treatment, the appropriateness of the treatment service, and the ability and 
efficiency of the service to address their needs. A small number of studies in the field of 
medical treatment have demonstrated that patients also hold expectations about the 





Yarnold (1995) measured the expectations of waiting times to see a doctor among 1,574 
patients in a community hospital in the US. The survey found that when waiting times 
were longer than expected patients were least satisfied, and when actual waiting times 
were shorter than expected they were more satisfied with the quality of care. These 
results are consistent with the Disconfirmation Paradigm (Churchill and Suprenant, 
1982). This states that when there is a gap between performance and expectations, then 
disconfirmation results. According to this paradigm, customer satisfaction is determined 
by the magnitude and direction of the gap between expectations and perceptions of 
performance. Within the field of substance abuse Grant (1997) and Pfeiffer et al (1991) 
found that a lack of confidence in the treatment system, and consequently of an 
expectation that treatment could not help, were significant barriers to treatment entry. 
However, these studies did not assess whether these expectations were predictive of 
treatment entry. It is hypothesised within the research programme that patient 
expectations regarding the length of the waiting period will be negatively associated 
with readiness to change and treatment entry. That is to say, a discrepancy between the 
actual and expected waiting times (i.e. when waiting times are longer than expected) 
will result in reduced levels of readiness  to change and  lower rates of treatment entry 
relative to waiting list participants whose actual waiting times are similar to, or less 
than, their expected waiting times.  
 
Study 1 of this research programme examines the usefulness of a model of motivation - 
the Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES; Miller 
and Tonigan, 1996) - in assessing heroin users’ readiness to change their heroin use at 
separate time points  during a  new episode of outpatient  drug treatment.  If the measure 
is able to detect changes in readiness over time, it will then be used as the measure of 
readiness to change in Study 2 which will examine the relationships between the 
different elements in the conceptual framework.  
 
The conceptual framework will be tested in three stages. First, the relationship between 
the length of the waiting period and readiness to change drug use will be examined. The 
influences of patient factors (e.g. levels of substance use) on the changes in readiness 
will be also examined.  The second stage of testing will address the relationships 
between the two primary variables and outcomes. This will include an examination of  





association between readiness to change and treatment entry. The impact of patient and 
substance use variables on the latter relationship will also be examined. Changes in 
substance use over the waiting period will be examined as a function of the duration of 
the waiting period and as a function of readiness to change. The third stage of the 
testing will examine how patient expectations of the length of the waiting period are 
related to readiness and subsequent treatment entry. 
 
Behaviour has been conceptualised as a process mediated by several interacting factors. 
Exploring how two specific factors - waiting times and readiness to change - are linked, 
and how these factors influence patient behaviours over the waiting period may assist in 
furthering our understanding of elements of the treatment process which in turn may 
promote motivation and behavioural changes among substance users 
 
1.8     OVERVIEW OF THE THESIS 
 
The following overview describes the different chapters and the contribution they make 
towards the overall thesis objectives. 
 
Chapter 2 provides a methodological overview relating to the current research 
programme. This details the research questions to be addressed, the underlying 
theoretical approach employed and some of the broader methodological issues arising 
from the studies. 
 
Chapter 3 presents a Pilot Study which examines whether the chosen measure of 
motivation can detect changes in a small sample of drug users over a six-month 
treatment period. The results of this study will inform the choice of motivation measure 
to be used in Study 2. 
 
Chapter 4 presents the findings of the main waiting list study. It will examine the 
relationship between the waiting period and motivation by randomly allocating 
treatment seekers to a short or more prolonged waiting period prior to treatment entry. 
Changes in motivation will be tracked over the course of the waiting period and the 





substance use will be examined. The design will also allow an examination of the 
treatment seekers who failed to enter treatment after the waiting period.  
 
Chapter 5 presents a general discussion of the findings from the research programme. 
The limitations and implications of the findings are described and conclusions drawn 





























CHAPTER 2:       METHODOLOGY  
 
2.1     INTRODUCTION 
 
Chapter 1 introduced the area of research for this thesis through an examination of the 
published literature relating to treatment waiting times and motivation. The second 
chapter outlines the research objectives and questions which will be addressed within 
the thesis and will provide an overview of the theoretical approaches employed within 
the two studies. Methodological issues which relate to both studies will be discussed 
drawing on examples from the literature.  
 
The issues considered within the next five sections include: 
 
(1) study aims and objectives  
(2) study design 
(3) study sample and setting 
(4) measures used and measurement issues  
(5) overview of data management and statistical procedures 
 
2.2     STUDY AIMS AND OBJECTIVES 
 
This section will introduce the research questions to be explored within the thesis.  
Decisions regarding the research programme were aimed at incorporating the principles 
of good research design to address the key research questions, while remaining 
practically feasible within the available financial and time constraints of the research 
programme.  The challenges of recruiting drug users and conducting longitudinal 
research while working within the context of a busy clinical setting can pose both 
practical and ethical problems. While many of these problems are not insurmountable, 
they need to be carefully and thoughtfully considered while undertaking outcome 
research.  
 
This research programme starts from the premise that motivation to change substance 
use behaviours may be affected by the length of time heroin users are required to wait 





motivation, which in turn may impact on treatment entry and patterns of substance use 
over the waiting period.   
 
As the relationship between waiting times and patient motivation has not been 
previously examined, the research programme will attempt to address some of the gaps 
in the existing knowledge base and redress some of the limitations of previous research 
relating to the impact of treatment waiting times. The first study will pilot the research 
instruments to be used in Study 2.  The second study will use a randomised design to 
examine the research objectives set out below.   
 
The research programme is based around the following four objectives.   
 
Objective 1: To examine the relationship between waiting times and readiness to 
change heroin use. 
 
Objective 1 examines how readiness to change alters over the course of the waiting 
period among a sample of heroin users randomly allocated to two treatment-entry 
conditions which represent short and more prolonged waiting periods. The demographic 
and clinical characteristics which differentiate heroin users who report changes in their 
readiness over the waiting period from those who do not will be also examined. 
 
Hypothesis 1: Heroin users with longer waiting times prior to the start of treatment will 
demonstrate greater reductions in readiness to change than those with shorter waiting 
times.  
 
Hypothesis 2:  Waiting times will be more strongly associated with changes in readiness 
scores over the waiting period than baseline demographic or clinical characteristics. 
 
Objective 2: To examine the relationships between readiness to change, waiting 
times and successful treatment entry.   
  
Objective 2 will examine whether the length of the waiting period prior to scheduled 
treatment entry and/or readiness levels are related to the likelihood of treatment entry 






Hypothesis 3: Longer waiting times will be associated with lower rates of treatment 
entry. 
 
Hypothesis 4:  Readiness to change will be a stronger predictor of treatment entry 
status than demographic or substance use variables. 
 
Objective 3:  To examine the relationships between waiting times, readiness to 
change and substance use. 
 
Objective 3 will examine how substance use behaviours (e.g. frequency of heroin use) 
change over the waiting period and whether this change is related to the length of the 
waiting period and/or to the readiness levels of the waiting list participants.  
 
Hypothesis 5: Longer waiting times will be associated with fewer reductions in 
substance use over the waiting period compared to shorter waiting times.  
 
Hypothesis 6:  Increases in readiness scores over the waiting period will be associated 
with reductions in heroin use over the same period. 
 
Hypothesis 7: Reductions in the frequency of heroin use over the waiting period will be 
associated with high baseline readiness scores. 
 
Objective 4: To examine the relationship between waiting time expectations, 
readiness to change and treatment entry. 
 
Objective 4 will examine the discrepancy between the expected length of the waiting 
period and the actual length of the waiting period. The relationships between this 
discrepancy in waiting times and the likelihood of treatment entry will be examined 
along with the impact of this discrepancy on readiness levels over the waiting period.  
 
Hypothesis 8: Heroin users’ expectations about the length of the waiting period will be 






Hypothesis 9: Heroin users’ expectations about the length of the waiting period will be 
associated with changes in readiness scores over this period.  
 
2.3    RESEARCH DESIGN  
 
The following section will detail the types of research design used within each study to 
address the objectives of the research programme. 
 
2.3.1     Longitudinal cohort design 
 
Both studies in the research programme utilised longitudinal cohort designs to collect 
data on the variables under investigation.  The longitudinal cohort design involves the 
study of the same group of individuals over an extended period of time (Powers and 
Knapp, 1995).  Typically information is collected at the onset of the study and the same 
information is collected repeatedly throughout the length of the study. The two primary 
purposes of this type of research are to describe patterns of change and to describe the 
direction and magnitude of causal relationships between the variables (Menard, 1991).  
The longitudinal design has been used in many large-scale drug abuse outcome studies 
including the Drug Abuse Treatment Outcome Study (DATOS; Simpson et al, 2002), 
and the National Treatment Outcome Research Study (NTORS; Gossop et al, 2001) to 
report changes in substance use, offending behaviour and health variables as a result of 
engagement in different treatment programmes in the UK and US.  Longitudinal studies 
in the field of alcohol use have examined factors such as the consequences of alcohol 
consumption (Cowan et al, 1985) and the prospective evaluation of preventative 
activities (Spooner and Hall, 2002). The major advantage of longitudinal research 
methods is that they enable researchers to study individuals over a period of time which 
may provide valuable information on the behaviours under investigation.  Researchers 
can assess differences between reports of attitudes or behaviours at two or more time 
points by calculating differences between those reports which may allow the researcher 
to identify the antecedent events that lead to given outcome(s).  
 
Participant attrition and financial costs are the biggest challenges associated with 
longitudinal research. Researchers have to maintain contact with, and commitment to, 





money.  At each subsequent wave of questioning some participants may drop-out of the 
study leaving a smaller sample of people to provide usable information at each data 
collection point. Incomplete data can compromise the internal and external validity of 
the results as those who remain in the study may be systematically different to those 
who leave on the variables under investigation (Cook and Campbell, 1979). Some 
investigators have attempted to minimise the problems of successfully locating and 
assessing participants at follow-up assessments by implementing tracking techniques 
(Ribisl et al, 1996; Twitchell, et al, 1992) or predicting contact difficulty on the basis of 
individual characteristics such as age, ethnicity and substance use variables (Bale et al, 
1984; Sobell et al, 1984).  
 
2.3.2     Within-subjects design 
 
Study 1 is a pilot study which used a within-subjects longitudinal design to examine 
whether the chosen measure of motivation for the research programme was able to 
detect changes in readiness over time among a sample of heroin users at the start of a 
new treatment episode. Readiness to change data was collected at three time points over 
a six-month period. The changes in readiness of each patient between these data 
collection points are examined.   
 
These objectives were achieved by utilising a within-subjects (or repeated measures) 
longitudinal design. The within-subjects design makes repeated observations of a single 
group at different points in time, allowing a comparison of changes in these participants 
over time.  By using the same participants at each assessment point smaller samples can 
be used to test the hypotheses under investigation. Also, individual differences between 
participants, such as socio-demographic characteristics and clinical variables, are 
controlled for as they are the same at each assessment point, with each participant acting 
as their own control. A disadvantage associated with the use of within-subjects designs 
include practice effects where participants improve through the repeated administration 
of tests (Forsberg and Goldman, 1987), however, this is more relevant to designs 








2.3.3     Mixed-groups longitudinal design 
 
A mixed-groups design combines the features of the within-subjects and between-
subjects design. Subjects are split into two distinct groups which represents the between 
subjects factor and their behaviour is examined over time at different phases of the 
study, representing the within-subjects factor. The changes which occur are compared 
as function of group membership. Creswell (2009) described this type of design as a 
“useful and effective experimental platform to address more sophisticated types of 
research question”. The main advantage of this type of design is that possible 
interaction effects between the two factors under investigation can be examined. 
 
Study 2 assesses the relationship between waiting times and readiness to change by 
randomly assigning treatment seeking heroin users to one of two treatment-entry 
conditions (short or prolonged waiting period) prior to the start of treatment. A mixed-
group design was used to examine the changes in readiness at two time points (within-
subjects factor) among treatment seekers in the two treatment-entry groups (between-
subjects factor).  Changes in patient readiness and substance use over the waiting period 
and rates of treatment entry were compared as a function of treatment-entry group 
status.  
 
2.3.4   Pilot Studies 
 
A pilot study will be employed in Study 1 to examine the suitability of a measure of 
motivation in detecting changes in motivation over time in a clinical sample of heroin 
users.  The term pilot study is used in two different ways in social science research. It 
can refer to feasibility studies, defined as "small scale versions, or trial runs, done in 
preparation for the major study" (Polit et al, 2001).  A pilot study can also be used to 
pre-test or 'try out' a particular research instrument (Baker, 1994). The use of a pilot 
study in this thesis will involve pre-testing a research instrument to examine the 
suitability of the proposed instrument for examining the research objectives. 
 
Pilot studies are frequently conducted before large-scale quantitative research. A pilot 
study is normally small in comparison with the main experiment and therefore can 





measures. Pilot studies are usually carried out on members of the target population, but 
not on those who will form part of the final sample. This is because it may influence the 
later behaviour of research participants if they have already been involved in the 
research.  Completing a pilot study successfully is not a guarantee of the large-scale 
study being successful. However, the main advantage of conducting a pilot study is to 
reveal potential deficiencies in the design of a proposed experiment or procedure and 
provide advance warning about where the main research project could fail. These 
deficiencies can then be addressed to avoid time and money being wasted on 
inadequately designed large-scale studies.  
 
2. 4    STUDY SAMPLES AND SETTING  
 
2.4.1     Selection of the study samples 
 
In order to apply conclusions drawn from a study to the population the sample is 
designed to reflect, the representativeness of the sample must be ensured. The people 
selected to study must possess similar characteristics as those possessed by the larger 
population of interest. In controlled conditions, participants would be randomly chosen 
so that each person in the population would have an equal chance of selection. This 
way, the results can be reliably projected from the sample to the larger population. 
However, due to the time and resource constraints of many research studies this 
selection process is not always utilised.  
 
The chosen samples for this research programme were two convenience samples of 
heroin users in contact with a single substance abuse treatment service.      
 
     "Researchers often need to select a convenience sample or face the possibility that  
      they will be unable to do the study. Although a sample randomly drawn from  
      the population is more desirable, it usually is better to do a study with a convenience  
      sample than to do no study at all, assuming, of course, that the sample suits the 
      purpose of the study" (Gall et al, 1996). 
 
The problems of the generalisability of the results to a wider population of heroin users 





Study 1 was conducted with a sample of heroin users who were starting a new treatment 
episode at the treatment service. Study 2 was conducted with a sample of heroin users 
requesting a new treatment episode at the point of first contact with the service.  The 
study samples resided in the boroughs of Lambeth and Southwark in South London. 
Lambeth is the largest inner London borough with a resident population of 266,170 
(Office for National Statistics, 2005). The borough has a young age-profile compared 
with the rest of the country (45% of the population is between the ages of 20 and 40 
years). Southwark has a population of approximately 256,000 (ONS, 2005). The 
borough’s population is also a relatively young one, with 53% of the population aged 
between 16-44 years. Both boroughs have an ethnically diverse population. Over 60% 
of the population is white and 25% are of black origin, with other groups making up the 
remaining 15%. In 2004 only 60% of the two boroughs’ working-age population were 
employed, compared to 75% in Great Britain overall. Lambeth and Southwark have 
been described as boroughs with high levels of social deprivation and poor health 
(South London and Maudsley Mental Health NHS Trust, 2005).    
 
2.4.2     Inclusion/exclusion criteria 
 
The aim of the research programme was to examine the relationships between waiting 
times, readiness to change and a number of other patient factors. A number of 
inclusion/exclusion criteria were therefore employed to ensure that the samples 
recruited were appropriate to the research questions posed and would lend themselves to 
fulfilling the main objectives of the research programme. These criteria included: 
 
(1) Contact with the drug treatment service. All participants had to be currently in 
contact with the selected treatment service (the stage of treatment differed within the 
two studies) for a heroin use problem.    
 
(2) Treatment with the service required a classification of substance abuse as defined by 
the Diagnostic and Statistical Manual of Mental Disorders, fourth edition-TR (American 
Psychiatric Association, 2000).  
 
     “A maladaptive pattern of substance use leading to clinically significant impairment  





      month period: recurrent substance use resulting in a failure to fulfil major role  
      obligations at work; school; home; substance use in situations where it was  
      physically hazardous; recurrent substance-related legal problems.” 
 
(3) Satisfactory comprehension and communication. Study participants had to have the 
capacity to consent to study inclusion. Based on British Medical Association and The 
Law Society Assessment of Mental Capacity: Guidance for Doctors and Lawyers 
(2001), the participant needed to understand the facts of the study, to be able to weigh 
up the possible risks and benefits of participation, and to understand the nature and the 
requirements of their involvement in the study. South London has a diverse ethnic 
population, it was therefore necessary that each participant could understand the 
questions in the research interviews and communicate responses.  As there was no 
designated funding for interpreter costs, including patients who could not speak English 
in the studies may have compromised the validity of any findings as there was no 
guarantee that the research questions would be understood.  Heroin users displaying 
learning disabilities, neurological disorders or reported intoxication at assessment were 
also excluded since these factors may have an impact on the comprehension and 
completion of the research interview.  
 
2.4.3     Research Setting   
 
The setting for data collection was a substance abuse out-patient service in the 
Addictions Division of the South London and Maudsley NHS Trust. At the time of the 
studies the Trust provided mental health and substance abuse treatment services to 
people from Croydon, Lambeth, Southwark and Lewisham, and substance abuse 
services in Bexley, Greenwich and Bromley. The Trust also provides specialist 
substance abuse services to people from across the UK.   The majority of substance 
users accessing the treatment service do so through self-referrals. Referrals are also 
received from G.P.s, hospital departments and other treatment services within the 
catchment area. Emergency cases and legal referrals (including Drug Treatment and 
Testing Orders) are generally dealt with by other specialist services within the area. The 
service deals primarily with substance users seeking treatment for opiate, stimulant or 





nurses, drug counsellors, psychiatrists, psychologists, occupational therapists, 
pharmacists, administration staff and a Clinical Nurse Manager.  
 
The treatment service used for data collection for the research programme was selected 
on the grounds of its locality and its capacity to recruit a sufficient numbers of heroin 
users to the study. The service has previously been used in a number of previous 
research studies and the staff and patients were accommodating to research on 
substance-abusing populations. 
 
2.4.4     Treatment programmes 
 
Two different treatment modalities for heroin abusers are delivered within the service. 
These include:  
  
a) Drug maintenance treatment -  These programmes use a long-acting synthetic opiate 
medication, usually methadone or buprenorphine, administered orally for a  sustained 
period at a dosage sufficient to prevent opiate withdrawal, block the effects of illicit 
opiate use, and decrease opiate cravings. At the time of data collection only methadone 
was available within the service for maintenance treatments. 
 
b) Drug detoxification/reduction treatment – Detoxification from opiates and other 
drugs refers to the process “by which the effects of opioid drugs are eliminated from 
dependent opioid users in a safe and effective manner, such that withdrawal symptoms 
are minimized” (National Institute for Health and Clinical Excellence, 2007). The 
process is conducted by administering decreasing doses of a substitute drug, alone or in 
conjunction with other medications, to reduce withdrawal symptoms. The dispensing of 
substitute medication usually takes place at community pharmacies. Methadone is the 
most widely prescribed drug within the clinic, although buprenorphine (Subutex) and 
lofexidine (Britlofex) are also prescribed. The outpatient programmes follow a Harm 









2.4.5     Clinic procedure  
 
Brief Assessment: The treatment service operates an open-access assessment clinic 
which allows treatment seekers to present at the service without a scheduled 
appointment. The Brief Assessment Clinic operates on three afternoons a week. Its 
purpose is to increase the accessibility of the service to treatment seekers, to identify the 
individual’s specific treatment needs and to allocate them to an appropriate service, 
either within the treatment service or elsewhere.  At the initial presentation at the 
service drug users are briefly assessed by a psychiatric nurse or drugs counsellor (key-
worker), to determine the nature of the problem and to provide information on the 
facilities available at the service.  
 
Treatment modality: Allocation to the Methadone Maintenance Clinic (MMC) or 
Community Drug Team (CDT) is based on clinical grounds, on a case-by-case basis, 
from information collected at the Brief Assessment and, where applicable, information 
from the referrer. Clinic allocation is typically decided by the clinical team within 
several days of the Brief Assessment. Approximately 40% of the patients seeking 
treatment for opiate problems are allocated to the MMC and 60% to the CDT, though 
these proportions vary according to the clinical needs of the patients.  
 
Waiting lists: The service operates two separate waiting lists for drug patients based on 
the geographical location of the referral. The service only accepts residents from two 
areas of South London - Southwark and Lambeth. The length of the waiting lists 
fluctuates according to the number of referrals received and current staffing levels. Each 
key-worker is allocated a maximum number of patients to their caseloads. When the 
service has its full complement of staff a higher number of treatment places are 
available than when there are fewer staff employed. 
 
Prioritisation: A prioritisation system for waiting list placement is used within the 
service for patients judged, by the clinical team, to be at ‘high risk’. A variety of clinical 
and social factors are taken into account when deciding on the need for quicker access 
to treatment, these include patients injecting in the groin or neck, pregnant drug users, 






Full Assessment: Once a treatment place becomes available a letter is sent to the patient 
inviting them for a Full Assessment. Full Assessment represents entry into treatment 
after the waiting period. This assessment consists of a more comprehensive examination 
of the problems to be addressed within treatment, personal circumstances and treatment 
goals. The assessment also provides information on the treatment process and the role 
of the patient during treatment. 
 
Dose Assessment: Patients allocated to the CDT or MMC attend a Dose Assessment 
which typically occurs within a week of the Full Assessment appointment, depending 
upon the number of assessment slots available. The purpose of the assessment is to 
establish the patient on a suitable dose of medication to prevent opiate withdrawals and 
to reduce the need to take illicit opiates. Attendance at the clinic is required on three 
consecutive mornings. Patients are requested to abstain from all illicit opiates for 
approximately twelve hours prior to the first day of Dose Assessment to prevent their 
use from interfering with dose titration.   
 
Patients are provided with substitute medication, under medical supervision, during the 
morning of the three days of attendance. Physiological observations (blood pressure, 
pulse, subjective feelings) are monitored and the patient is asked to return within two 
hours for a brief medical check-up and additional medication, if required. Patients are 
typically provided with a low dose of medication which is increased over the three days 
until a stabilising dose is reached. Dose, or type, of medication can be changed at any 
time during treatment by negotiation between the patient and the clinical team. Regular 
treatment monitoring, by urinalysis, checks for the patients’ use of illegal drugs. 
Methadone doses prescribed within the service range from 20mg to 200mg. Figure 2.1 
provides an illustration of the different stages in the treatment access and induction 



























2.5     MEASURES USED AND MEASUREMENT ISSUES 
 
This section will describe the common measurement principles utilised in the research 
programme and the methodological issues considered during the development of the 
two studies. 
 
2.5.1     Structured interviews 
 
Structured interviews were used to collect data on patients’ readiness to change and a 
range of other patient factors relevant to the research questions posed. The relative 
advantages and disadvantages of each type of survey method were considered and the 
selection was influenced by the research questions posed and the resources available to 
examine those questions. The interview protocols used in Study 1 and 2 were designed 
to be administered via face-to-face contact in a clinical setting. Where follow-up 
interviews could not be obtained within the clinical setting, responses relied upon the 
administration of the interview over the phone, or through mail responses. In any 
longitudinal study with substance users it is often challenging to maintain contact with 
an inherently mobile group of research participants.  In the case of outcome evaluation 









illness, moving house, imprisonment, or deciding to withdraw from the study. This 
attrition has implications about the conclusions that can be drawn from the findings. 
This issue will be considered in Chapter 5. 
 
Structured interviews provide a quantitative description of attitudes, behaviours or 
personal characteristics, often about phenomena that are not directly observable 
 (e.g. inner experiences, opinions, values, interests) and takes the form of an ordered 
series of questions or statements. The aim of this approach is to standardise the order in 
which questions are asked of respondents, so the questions are always answered within 
the same context. This is important for minimising the impact of context effects, where 
the answers given to a question can depend on the nature of preceding questions. 
Though context effects can never be avoided it is often desirable to hold them constant 
across all respondents. This also ensures that answers can be reliably aggregated and 
that comparisons can be made with confidence between sample sub-groups or between 
different data collection periods. The choice of answers to the questions is often fixed 
(close-ended) in advance, though open-ended questions can also be included. 
 
Structured interviews can be quick and easy to create, code and interpret, especially if 
closed questions are used. However, the quality and usefulness of the information is 
highly dependent upon the quality of the questions asked.  The format of the interview 
makes it difficult for the researcher to examine complex issues concerning the 
respondents’ beliefs, attitudes and inner experiences in any detail or depth. Even where 
open-ended questions are used, the depth of answers the respondent can provide tend to 
be more limited than with other methods. Also, by designing a list of questions, a 
researcher has effectively decided, in advance of the data collection, the issues they 
consider to be important and unimportant which introduces bias into the selection. 
 
Structured interviews can be administered face-to-face by an interviewer, over the 
telephone or through self-completion. Each method has certain strengths and 









2.5.2      Interviewer-administered face-to-face interviews 
 
Face-to-face interviews refer to the collection of information whereby the interviewer 
asks the respondent a list of pre-determined questions about a carefully selected topic. 
The British Crime Survey (Chivite-Matthews et al, 2005) and National Treatment 
Outcome Research Study (Gossop et al, 2000) collected data via face-to-face 
interviews.  
 
The major advantage of face-to-face interviewing is its adaptability in controlling the 
response situation, scheduling a mutually convenient time and place, and controlling the 
sequence and pacing of the questions asked. The interviewer has the chance to build 
trust and rapport with the respondent which can help achieve and maintain cooperation, 
increase the quality of the data obtained, and makes it possible to obtain information 
that might not have been revealed using other types of data collection methods. 
Response rates can be relatively high in comparison to other methods (Krysan et al, 
1993).  Face-to-face methods allow for a relatively high degree of flexibility in the 
interviewing process – more complex issues can be explored as the interviewer can use 
stimulus material, and probing and prompting to encourage responses can be carried 
out.  
 
The disadvantages of face-to-face data collection are that they are relatively expensive 
and time-consuming to perform particularly among large samples of participants as the 
researcher needs to be present during the delivery of the interview. Face-to-face data 
collection may also be subject to the potential problem of interviewer bias. Each 
interviewer will conduct the interview in a slightly different way and there is the 
possibility that the presence of the researcher may influence the way a respondent  
answers various questions (e.g. embarrassing questions, intimidating interviewer), 
thereby biasing the responses obtained. This is known as the ‘interviewer effect’. To 
minimise the effects of interviewer variance, interviewers are trained to carry out 
interviews according to the instructions provided and to do so in a professional and 








2.5.3     Interviewer-administered telephone interviews 
 
Interview data is sometimes collected from respondents over the telephone. This type of 
data collection has been used by the National Household Survey on Drug Abuse (Office 
of Applied Studies, 1992) in the US and the Alcohol Use Survey (Ministry of Health, 
2007) in New Zealand. The advantages of this interview method are that it can be more 
convenient, and often cheaper, to speak on the phone rather that set up meeting times 
and places. This method allows data to be collected from geographically scattered 
samples more cheaply and quickly than by face-to-face interviewing. In a telephone 
interview some of the benefits of social interaction and the chance to build rapport with 
the respondent may be lost. It can be easier for the respondent to refuse an interview or 
end it prematurely and harder for the interviewer to encourage the respondent to take 
part. Non-coverage of households without telephones is also a concern with this method 
of data collection. 
 
A study comparing the accuracy of data obtained by different survey methods, 
particularly when asking about sensitive issues, found that telephone interviews 
obtained lower levels of substance use data than interviewer-administered surveys 
(Aquilino and Lo Sciuto, 1990).  Data collection employing face-to-face and telephone 
interviews are both susceptible to ‘demand characteristics’ (Orne, 1959) whereby 
participants may be motivated to play the ‘good subject’ and are influenced by their 
perception of why the research is being conducted and the interviewer’s expectations. 
All of these factors may influence the responses provided.  
 
2.5.4     Postal Surveys 
 
Postal surveys are frequently used to obtain information from individuals and groups 
within the general population. They have been previously used to examine 
benzodiazepine use in opiate users (Williams et al, 2005) and alcohol use among the 
unemployed (Hammer, 1992). The main advantages of postal surveys are that they are 
less expensive than face-to-face or telephone interviews as they do not require skilled 
interviewers to conduct and that they have the potential to reach large groups of people. 
Postal surveys are also easy to distribute and analyse (Galpin, 1987).  Respondents can 
complete the questionnaire at their own convenience, answer questions out of order, 





comments. Anonymity and privacy often encourage more candid and honest responses. 
Surveying by mail eradicates the problem of interviewer bias which is sometimes 
introduced when communicating with an interviewer in person or over the telephone.  
 
Disadvantages to this data collection method include the lack of control over who 
completes the questionnaire, which may be someone other than the intended respondent. 
There may also be concerns over the quality of the data received. Incomplete data may 
result from comprehension problems or literacy issues of the respondents. Respondents 
may not answer all the questions or in the way that is required. Also, there are often 
long time delays between the distribution of postal surveys and their return, delaying 
statistical analysis. Postal surveys typically yield the lowest return rates although this 
varies according to the participants surveyed and the subject material sought (Asch et al, 
1997).  
 
2.6     MEASURES USED  
 
The research domains common to both studies were (1) motivation , (2) demographics,  
(3) substance use, (4) severity of substance use dependence and (5) physical and 
psychological health. 
 
2.6.1   Motivation   
 
The primary objective of the research programme is to examine how motivation 
changes over the waiting period in a sample of heroin users. In order to examine this it 
was first necessary to choose a model of motivation and a measure of motivation to 
examine the variables of interest.  
 
In the field of substance-related disorders several perspectives have directed the 
research concerning motivation during the last three decades. The most influential of 
these have included the Social Learning Theory (Bandura, 1977), the Self-determination 
Theory (Deci and Ryan, 1985) and the Transtheoretical Model of Motivation 






The Social Learning Theory (Bandura, 1977) incorporates aspects of behavioural and 
cognitive learning and suggests that a combination of environmental (social) and 
psychological factors influence behaviour. One aspect of the theory asserts that people 
wish to avoid negative consequences while desiring positive results or effects. People 
are more likely to engage in certain behaviours when they believe they are capable of 
executing those behaviours successfully (self-efficacy) and will be more likely to 
engage in that behaviour again. The theory’s concept of self-efficacy has received 
considerable research attention, with a number of studies demonstrating increased self-
efficacy during treatment to be related to reductions in drug (Long et al, 1998) and 
alcohol use (Rounds-Bryant et al, 1997). 
 
One of the strengths of the Social Learning Theory is that it combines several important 
models of learning incorporating cognitive, emotional and social elements. The theory, 
however, has been criticised on the grounds that it is based on the assumption that 
behaviour arises from complex interactions between unobservable variables which 
cannot be assessed (Lee, 1989). Others have asserted that there is ambiguity and lack of 
definition of the concept of self-efficacy (Eastman and Marzillier, 1984). 
 
The Self-determination Theory (Deci and Ryan, 1985) is a general theory of human 
motivation concerned with the development and functioning of the personality within 
social contexts. The theory focuses on the degree to which an individual’s behaviour is 
self-motivated and self-determined. According to the authors, the need for competence, 
autonomy, and relatedness are innate, universal, psychological needs which motivate an 
individual to initiate behaviour. Within the field of substance use the theory has been 
applied to understanding the dynamics of motivation during treatment has been used to 
predict perseverance in treatment (Ryan et al, 1995). Such work has examined the 
association between the treatment environment and patients’ psychological needs and 
how these affect behavioural change.  
 
A major strength of the Self-determination Theory is that it makes distinctions between 
different types of motivation  (e.g. intrinsic and extrinsic) and considers what motivates 
a person at any given time as opposed to treating motivation as a unitary concept which 
focuses on the overall amount of motivation that people have for particular behaviours. 





evidence supporting certain hypotheses within the theory (Reiss, 2005; Lepper et al, 
1996) and the validity of intrinsic and extrinsic motivation (Reiss, 2004). 
 
2.6.2     Transtheoretical Model of Motivation 
 
The Transtheoretical Model of Motivation (Prochaska and DiClemente, 1982)   
describes the process of change underlying attempts to modify problem behaviours. It 
was originally developed as an attempt to integrate different concepts from different 
theoretical models into a single comprehensive framework. According to this model, 
people progress through a series of stages to successful change. The model assumes that 
the stage at which a person is at can be accurately assessed and the success of an 
individual in treatment will depend, in part, upon the stage of change achieved 
(Prochaska and DiClemente, 1992). More success would be expected for those who are 
at the later stages of change. The model was originally applied to populations of 
smokers and has since been applied to behaviours such as substance use, exercise 
behaviour and gambling (Guillot et al, 2004; DiClemente et al, 1999; Norman et al, 
1998). The model incorporates fifteen different theoretical constructs including the 
Stages of Change, Processes of Change, perceived pros and cons of changing and self-
efficacy and temptation. It has been modified several times since its introduction.  
 
The Transtheoretical Model of Motivation (TTM) uses the concept of ‘readiness to 
change’ to represent a more focused view of motivation. Readiness indicates a 
willingness or openness to engage in a particular process or to adopt a particular 
behaviour. It has been conceptualised by some as a combination of the patients 
‘perceived importance of the problem and the confidence in his ability to change’ 
(Miller and Rollnick, 2002).  
 
2.6.3   The Stages of Change 
 
The Stages of Change, often presented as ‘the cycle of change’, represents a 
fundamental dimension of the Transtheoretical Theory that has been adopted by many 
clinicians and researchers as a template through which to view the change process. It 
presents motivational change as an ordered segmented sequence leading from a lack of 





proposes a sequence of five stages involving various kinds of affective, behavioural and 
cognitive appraisal shifts that a person goes through when making behavioural change. 
Each progressive stage is characterised as increased motivation to engage in the process 
of behaviour change (Tierney and McCabe, 2001).  
 
The original Transtheoretical Model proposed four distinct stages (Prochaska and 
DiClemente, 1982). The current model focuses on five stages of change (Prochaska et 
al, 1992). These include:  
 
Precontemplation - during this stage there is no intention to change behaviour. Many 
individuals in this stage are unaware that a problem exists, do not feel that their 
behaviour is a problem for themselves or others and are not interested in any kind of 
help. When precontemplaters present for treatment they often do so because of pressure 
from others. 
 
Contemplation - during this stage people are aware that a problem exists and are aware 
of the consequences of their behaviour. They are thinking about overcoming their 
problem but have not yet made a commitment to take action. During the contemplation 
stage individuals weigh up the pros and cons of the problem and the solutions to the 
problem. Individuals are more open to receiving information about their behaviour and 
reflect on their own feelings and thoughts concerning the behaviour. 
 
Preparation - in the preparation stage people have made a commitment to make a 
change, and may be making small changes in preparation for larger changes in the 
future (e.g. smoking fewer cigarettes each day). 
 
Action - in this stage individuals begin taking direct action to change their behaviour in 
order to overcome their problems. Action involves the most overt behavioural changes, 
involves a variety of different techniques and requires considerable commitment of time 
and energy.  People in this stage also tend to be more open to receiving help and are 






Maintenance – this is the stage at which people work to consolidate the gains attained 
during the Action stage and prevent relapse. This is achieved by avoiding former 
behaviours and maintaining new ones.  
 
According to the model, the majority of people who successfully abandon a behaviour 
do so after cycling through the five stages several times before achieving a stable life- 
style change. Consequently, the model considers relapse to be part of the process of 
change. Studies using the Stages of Change have found that particular stages of change 
are related to greater readiness to change, and  individuals who are in these stages report 
more positive outcomes than other individuals (Smith et al, 1995; Prochaska et al, 1992; 
McConnaughy et al, 1983). Stages of Change have been shown to predict progress in 
treatment such as reductions of substance use (Prochaska et al, 1994; Heather et al, 
1993; Isenhart, 1997), abstinence (Carey et al, 2001) and retention in treatment 
(Mitchell and Angelone, 2006; Simpson and Joe, 1993; Cox and Klinger, 1988). 
 
Early applications of the Stages of Change originally used staging algorithms in which 
each participant was allocated to one of the stages on the basis of responses to 
questionnaire items. More recent studies with drug and alcohol users have employed 
multidimensional questionnaires devised to measure attitudes characteristic of each 
stage. In this approach, each stage is measured by a set of questionnaire items and 
scores are derived by their position on each dimension.  
 
The original paper summarising the TTM (Prochaska and DiClemente, 1982) is one of 
the most widely cited papers in psychological literature. However, while the model 
enjoys popularity in terms of the amount of research literature devoted to it and a large 
following among clinicians, it is not without its problems or critiques. A number of 
commentators have questioned whether the TTM provides a valid description of the 
process of change (Sutton, 2001; Davidson, 2001). Many of the criticisms of the model 
have surrounded the use of the Stages of Change. Evidence for the stages is based on 
clustering of responses to questionnaire items – those believed to be part of one stage 
hold together in cluster analyses far more than those from different stages. However, 
Cooper (1997) states any questionnaire can yield such a structure if the items which 
cluster ask the same questions in different ways. A number of studies have shown a lack 





clusters emerging from statistical analysis of the question responses do not always 
correspond to the supposed stage. Other studies have also reported large correlations 
between adjacent and non-adjacent scales. A particular stage should attempt to capture 
the unique features of the stage (Sutton, 2001), yet these two sets of findings 
demonstrate that the scales are not distinct from each other. 
 
Criticism has also been directed at some of the questions on the staging algorithms 
which assess stage position according to a particular time period (e.g. to be assigned to 
the precontemplation stage individuals must have ‘used unauthorised drugs in the last 
30 days, do not plan to quit in the next 6 months’ whereas to be assigned to the 
contemplation stage individuals are asked whether they have used authorised drugs in 
the last 30 days, plan to quit in the next 6 months but not in the next 30 days’). The 
resulting classification system incorporates a time-element. One of the problems with 
this is that the time periods are arbitrary and individuals in different stages appear to 
differ only in their timing of their intention to change. Using different time periods 
would lead to individuals being assigned to a different stage. From this perspective 
stages are not qualitatively distinct but are arbitrary time segments which may not 
mirror any altered psychological states (West, 2005; Sutton, 2001) DiClemente (2005) 
responded to these criticisms by explaining that making a concept (i.e. Stages of 
Change) operational so that one can assess the phenomena is always arbitrary, and 
simply an attempt to create a dividing line that could be useful in isolating a concept or 
construct – this is true for many new psychological concepts such as depression, 
anxiety, addiction – and there are many ways of operationalising these constructs.  
 
Prochaska and DiClemente (1992) stated that successful recovery from addiction can 
only occur after every stage has been passed through, having found no successful 
changers who have missed a stage. However, there is little empirical evidence to show 
that people progress through the entire stage sequence (Littell and Girvin, 2002; Bunton 
et al, 2000), and evidence suggests that a significant proportion of individuals are not 
assignable to the recognised stages (Kearney et al, 1999; Pierce et al, 1998). These 
findings question whether these stages reflect reality. Prochaska and DiClemente (2005) 
account for such findings, by explaining that stage transitions can be rapid and measures 
taken months apart may miss detecting each transition.  This explanation would be 





capture the moment a stage transition occurred. DiClemente (2005) went on to explain 
that the stages organise tasks into a logical sequence of activities that seem to build 
upon one another. The stages represent tasks that can be accomplished to a greater or 
lesser degree but should not be viewed as boxes from which individuals jump, one to 
the next. 
 
There is a proliferation of instruments which claim to measure stage status yet few 
studies have compared the findings from the use of these different instruments. Farkas 
et al (1996) found that different algorithms used in different measures have produced 
markedly different stage distributions among the samples. The incompatible ways of 
measuring stage status and the lack of standardisation between instruments makes it 
difficult to compare the results from different studies into a coherent body of knowledge 
(Etter, 2005). 
 
There are also a number of omissions to the model. The model does not take into 
account dependence level, withdrawal symptoms or other key determinants of substance 
use such as social factors. The authors were explicit about excluding a social dimension 
to their model, however, many decisions to change are often influenced by social, 
cultural and environmental influences. For example, entry into drug abuse treatment  
may be precipitated by health problems, the drying up of sources of supply, changes in 
social networks, legal or family coercion rather than decisions taken after due 
consideration of the pros and cons of behaviour change as the authors suggest.  
 
Whitelaw’s review of the evidence for the Stages of Change found that only a small 
number of studies using the stages had assessed outcomes. If stages are depicted as 
signposts or progress towards an end goal (e.g. abstinence) then reaching more 
advanced stages should signify greater change in the behaviour (Whitelaw et al, 2000). 
Although a number of studies of smokers and alcohol-dependent patients have found 
that measures of the stages often predict later outcomes (e.g. Hernandez-Avila et al, 
1998; DiClemente and Prochaska, 1998) there has often been a lack of consistency in 
the pattern of results (Littell and Girvin, 2002). Much of the research into outcomes 
using the TTM has been cross-sectional (e.g. Kearney et al, 1999: Jamner et al, 1997), 
thus preventing the assessment of the premise of the model – that change occurs over 





al, 1997; Campbell, 1997) which are likely to be more motivated than random samples, 
and these studies have failed to include control groups.  
 
A number of commentators have also questioned the uncritical use of the model in 
clinical service delivery. The model has been used to guide interventions in a variety of 
problem areas despite the lack of a strong evidence base for stage-matching 
interventions. Interventions based on the model have not been consistently proven to be 
more effective than control interventions or no intervention at all (Riemsma et al, 2003; 
van Sluijs, 2004).  Such practice may mean that patients who are deemed to be in an 
early stage of change may be deprived of effective treatments compared to those 
deemed more ready to change.  
 
The Transtheoretical Model is by far the most prominent model of motivation of 
addictive behaviours among both clinicians and researchers (Sutton, 2001). Despite the 
theoretical and empirical shortcomings of the model, the TTM continues to be an 
important stimulus to theory and practice development. The purpose of the TTM, and 
the research examining the model, has been to enhance our understanding of the process 
of change and to stimulate testable hypotheses that will hopefully lead to enhancements 
of our understanding of complex phenomena such as the change process. As Stockwell 
(1992) states, unlike theories, models can have faults yet still promote understanding 
and discovery.  The Stages of Change provide a useful framework in which to examine 
change or progress in diverse populations, they also avoid overly-simplistic 
classifications of substance abusers as ‘motivated’ or unmotivated’. The model also 
reminds clinicians that substance users vary in their commitment to change, and that 
those in the earlier stages of change will require longer time to progress with changes 
than those in the later stages of change. 
 
The current research programme will select a measure of motivation based on the TTM 
as the Stages of Change dimension  is considered to be a useful method for describing 
the common aspects of patient experiences and recovery. Measures based on the model 
are widely used in the treatment service in which the research progamme is conducted. 
The two studies within the research programme will utilise longitudinal designs to 
assess motivation at several time points among samples of heroin users and will 





reflect the premise of the model – that change occurs over time. In order to avoid some 
of the previously noted criticisms regarding staging algorithms, only multidimensional 
questionnaires will be considered in the choice of the specific measure.  
 
2.6.4     Selecting a measure of motivation  
 
There are a plethora of instruments which aim to assess attitudes and intentions 
characteristic of each of the Stages of Change. The instruments vary in their methods of 
assessment, theoretical underpinnings and their intended populations. Selection of a 
measure of motivation resulted from a combination of consultation with clinicians 
working in drug abuse treatment settings and research into the available, and most 
widely use, measures cited in the substance abuse literature. Once the most widely used 
instruments were identified, the choice of measure was based on a number of factors 
including  administration time and the complexity of administration, previous use on 
drug-using populations and the psychometric properties of the instruments. The 
following commonly used measures were considered: 
 
University of Rhode Island Change Assessment (URICA; McConnaughy et al, 1983): 
The URICA is a 32-item questionnaire designed to measure each stage of change with 
responses recorded on a Likert scale. Cluster analyses of responses on the assessment 
assign people to a stage. Factor analysis of the instrument commonly reveals a four- 
factor structure (DiClemente and Hughes, 1990; McConnaughy et al, 1983), although a 
number of studies have failed to find a consensus on standardised rules for stage 
assignment on the URICA. Attempts to assign stage status have found between two and 
nine identifiable stage profiles rather than the five distinct stages proposed by Prochaska 
and DiClemente (Carney and Kivlahan, 1995; DiClemente and Hughes, 1990).  
 
Due to the problems associated with stage assignment noted in the previous studies the 
URICA was not considered suitable as a measure of motivation for the current research 
programme. Cluster analyses to assign a person to a stage was considered too complex 
for the scope of the research programme and the measure was also considered to be too 
long to administer as it was to be included in a battery of other measures on a structured 





‘problem’, rather than a particular behaviour. As poly-drug use is common among 
substance users engaged in treatment (Marsden et al, 2000), the measure needed to 
focus on their primary substance of abuse (i.e. heroin) independent of other classes of 
drugs.  
 
Readiness to Change Questionnaire (Rollnick et al, 1992): This 12-item measure was 
developed to be used with excessive drinkers to assign them to an optimal form of brief 
intervention according to their stage of change when they presented to a medical setting 
for reasons other than an alcohol problem. Questionnaire items provide scores for three 
scales representing the Stages of Change (Precontemplation, Contemplation and 
Action). The questionnaire allocates individuals to a particular stage on the basis of 
their highest score on the three scales. The measure has satisfactory psychometric 
properties (Rollnick et al, 1992) and predictive validity (Heather et al, 1993). 
 
The Readiness to Change Questionnaire was not considered suitable for use within the 
research programme as a number of studies have found low internal reliability for the 
first two sub-scales which does not support the use of this questionnaire in a treatment 
context (e.g. Gavin et al, 1998). 
 
The Stages of Change, Readiness and Treatment Eagerness Scale (SOCRATES; Miller 
and Tonigan, 1996): The SOCRATES is one of the most widely used instruments for 
measuring motivation to change substance use behaviours. The measure was originally 
designed to assess readiness to change in alcohol abusers and has since been adapted to 
be used with drug users. The latest version of the measure poses nineteen questions 
about drug or alcohol use. Each statement can be endorsed on a five point scale with ‘5’ 
referring to strongly agree and ‘1’ strongly disagree. Despite its intent to represent the 
four original stages of the Transtheoretical model, factor analyses of the measure 
supports three independent scales rather than discrete stages. These scales have been 
named Recognition, Ambivalence and Taking Steps. Its structure of “continuously 
distributed motivational process that may underlie stage of change” (Miller and 
Tonigan, 1996) seeks to avoid some of the criticisms concerning the separate stages of 
change. Similar three factor structures have been reported in other studies using the 





Recognition – reflects the extent to which substance users acknowledge that they are 
experiencing a substance abuse problem and perceive experiencing harm if they do not 
change their behaviour (e.g. ‘I have a serious problem with drugs’).  High scores on this 
scale indicate some openness to reflection, as might be particularly expected in the 
contemplation stage of change. Low scorers deny that substance use is causing them 
serious problems and do not express a desire for change. Seven statements make up the 
Recognition scale. 
 
Ambivalence - is viewed as reflecting the degree of conflict about substance use and 
changing substance use behaviours (e.g. ‘Sometimes I wonder if I am an addict’). High 
scorers say that they sometimes wonder if they are in control of their substance use, are 
taking too many substances and are hurting other people, and/or are addicts. Thus a high 
score reflects a high degree of conflict or uncertainty. Low scorers say that they do not 
wonder whether they use drugs too much, are in control, are hurting others, or are a 
drug addict. Note that a person may score low in Ambivalence either because they 
”know” their drug use is causing problems (high Recognition) or because they “know” 
that they do not have drug use problems (low Recognition). Thus a low Ambivalence 
score should be interpreted in relation to the Recognition score. Four statements make 
up the Ambivalence scale. 
 
Taking Steps – this scale represents the extent to which substance users report they are 
already making changes in their substance use (e.g. ‘I’m not just thinking about 
changing my drug use, I’m already doing something about it’).  High scorers report that 
they are already doing things to make a positive change in their substance use, and may 
have experienced some success in this regard. Change is underway, and they may want 
help to persist or to prevent backsliding. A high score on this scale has been found to be 
predictive of successful change. Low scorers report that they are not currently doing 
things to change their substance use, and have not made such changes recently. Eight 
statements make up the Taking Steps scale.  
 
Scores for the Recognition scale have a possible range of 7-35, for the Ambivalence 
scale a range of 4-20 and for the Taking Steps scale a range of 8-40 (SOCRATES 
scoring sheet, Appendix 9). Individual scores on each scale are ranked as ‘low’, 





interpretative ranges for the scales are based on a large sample of adult men and women 
presenting for treatment of alcohol problems through Project MATCH (Project 
MATCH Research Group, 1993). Miller and Tonigan (1996) reported test-retest 
reliability and internal consistency for these scales. The SOCRATES has also been 
found to correlate with other measures of motivation   (e.g. Mitchell and Angelone, 
2006). 
 
The SOCRATES was chosen as the measure of motivation to be used in the current 
study. This choice was based upon a number of features of the measure. While studies 
on motivation have often been criticised for failing to specify the target behaviour 
(Belding et al, 1995), the SOCRATES allows the specification of  the target goal of 
behaviour change and two separate versions of the measure specifically for drug 
(version 8D) and alcohol (version 8A) abusers exist (Centre on Alcoholism,  Substance 
Abuse and Addictions, CASAA, 1995). The choice of this measure also avoids some of 
the debate concerning whether  motivation, or readiness to change, is best 
conceptualised as a continuum or by discrete stages (Bandura, 1997; Sutton, 1996) as it 
is based on underlying dimensions of motivation derived from factor analysis.  
 
The suitability of the SOCRATES for measuring change among heroin users will be 
examined within the research programme – the measure will first be piloted on a sample 
of heroin users entering substance use treatment. If the SOCRATES is capable of 
detecting changes in readiness over time it will then be used to assess readiness in a 
sample of heroin users awaiting treatment entry. 
 
2.7   Demographics   
 
Five main demographic characteristics were chosen to be included in the two research 
studies. These were - gender, age, ethnicity, employment and relationship status. These 
characteristics were used to – 
 
(a) describe the samples used within the research studies,  
(b) demonstrate that the selected samples are representative of drug-using populations 





(c)  explore the influence of these characteristics on the research questions under 
investigation.  
 
Demographic information was collected as the drug abuse treatment population vary in 
gender, age, ethnicity, employment, relationship status and a number of  other social 
and economic, health and drug-dependence factors (Hubbard et al, 1989).  The literature 
indicates that some of these factors are correlated with motivation (Carpenter et al, 
2002), treatment events including entering treatment (Brady and Ashley, 2005; King, 
2004) and with post-treatment successful outcomes (McLellan et al, 1996; Anglin and 
Hser, 1990).  
 
The categories used for ethnicity and relationship status were drawn from the 2001 UK  
(Office for National Statistics, 2005;Appendix 8). Collection of ethnicity data relied on 
an individuals' self-definition, a method frequently employed for ethnic categorisation 
in the UK.  The ONS classification system used within this thesis included 16 ethnic 
categories and a category for ‘other ethnic groups’ not already included in the list. 
Collection of ethnicity data is important as a number of studies have shown the 
existence of treatment system biases (e.g. ethnic differences between patients and 
providers) and ethnic differences in health beliefs and perceptions about substance use 
problems may hamper treatment access (Farabee et al, 1998; Kaskutas et al, 1997).   
 
2.8   Substance use 
 
Substance use in this research programme was measured using the substance use 
domain of the Maudsley Addiction Profile (MAP; Marsden et al, 1998).The MAP is a 
brief multi-dimensional instrument for assessing treatment outcome for people with 
drug and/or alcohol problems. This measure was chosen because it was designed, and  
is regularly used, within the South London and Maudsley NHS services where the data 
collection for this research programme was conducted. The measure has established 
reliability and validity (Marsden et al, 1998). Assessment of substance use for the 
research programme was limited to alcohol and the following non-prescribed drugs: 
heroin, methadone, crack cocaine and cannabis. For each substance, the subject is asked 
to recall: (i) the total number of days used in the last 30 days; (ii) the typical amount 





intranasal, inhalation or intravenous). This measure was designed to be administered at 
the first contact with the treatment service and at one or more follow-up points.  
 
2.8.1     Measuring substance use  
 
The incidence and frequency of substance use are frequently used outcome measures to 
assess consumption pattern among substance users although both of these factors are 
difficult to measure accurately. The measurement of substance use in social research 
often relies on self-report from substance users (Johnston and O’Malley, 1985; Gawin 
and Kleber, 1984). Self reported substance use is usually reported as the amount of 
substance used (e.g. grammes of heroin), days of use of the substance in a given time 
frame (20 days in the last 30 days) or the amount of money spent on drugs (e.g. £200 
per day). Objective measures of substance use, such as urinalysis and hair sampling, are 
also available but are intrusive for patients and are costly to analyse.  
 
2.8.2     Use of different recall periods 
 
Social research often involves the collection of information about past events and 
behaviours.  It is common for surveys addressing changes in substance use to estimate 
substance use at different time points using a set of recall periods. A recall period refers 
to the collection of data about behaviour within a specific time period which 
participants are asked to recall. The recall periods used are key to ensuring that the full 
scope of the behaviour pattern is captured by the measures used.  Different studies have 
used different recall periods to measure recent substance use. Recall periods typically 
used are substance use in the past 30 days, the past year and lifetime use. The 30-day 
recall period used in the current research programme has been used in a variety of 
research instruments assessing substance use patterns (e.g. Marsden et al, 1998; 
McLellan et al, 1992). Although smaller periods of recall (e.g. past week) are also used 
in substance use research, longer periods are thought to more adequately capture 
substance use which may happen intermittently or less frequently than a week’s recall 








2.9    Severity of substance use dependence 
 
Illicit drug use disorder and dependence were assessed using the Severity of 
Dependence Scale (Gossop et al, 1995). This 5-item scale concerns the psychological 
aspects of dependence specifically related to impaired control over substance use and 
anxiety towards substance use. The scale was selected on the basis that it can be used to 
assess dependence of any illicit drug or alcohol. Studies have reported that the scale has 
good psychometric qualities for heroin, cocaine, amphetamine, benzodiazepine and 
alcohol-using populations (Gossop et al, 2002a; Kaye and Darke, 2002; Ferri et al, 
2000). Each of the five scale items is scored on a 4-point scale (0-3) with endorsements 
for each item ranging between the frequencies of ‘never or almost never’ (0) to ‘always 
or nearly always’ (3). The total score for the scale ranges between 0-15 with higher 
scores representing a higher level of dependence.  
 
2.10     Physical and psychological health  
 
Measures of physical and psychological health functioning were derived from the 
Maudsley Addiction Profile (Marsden et al, 1998). A 10-item physical health symptom 
scale included items assessing the frequency of problems including poor appetite, 
fatigue and muscle pains. A 10-item psychological health symptom scale assessed the 
frequency of feelings such as fearfulness, hopelessness, and loneliness. Patients rated 
the frequency of symptoms on a five-point Likert scale ranging from ‘never experience’ 
(0) to ‘always experience’(4). Each scale was scored by summing the item weights (0-4) 
across the 10-items on each scale; the total can therefore range from 0-40, with higher 














2.11     MEASUREMENT ISSUES 
 
2.11.1     Reliability and validity of self-report data among substance users 
 
The predominant means of obtaining data from substance users on their consumption 
patterns is through self-report (Darke, 1998; Gawin and Kleber, 1984). The primary 
national and international studies that collect information on substance use prevalence 
and trends, such as the National Treatment Outcome Research Study (Gossop et al, 
2001), the Drug Abuse Treatment Outcome Study (Simpson et al, 2002) and The Drug 
Abuse Reporting Program (Hubbard et al, 1989) all employ self report interview 
formats to collect data. Self-report measures can be obtained through various methods 
including self-completion questionnaires and through interviewer-administered 
questionnaires.  
 
The advantages of self-report data are that they give the respondents’ own views, 
perceptions or experiences which are often unobtainable in any other way (Barker, et al, 
2002). Such measures are also relatively easy to administer to large samples, and the 
responses are easily quantifiable and thus can be analysed.  Biochemical markers such 
as urinalysis, saliva tests and radioimmunoassay of hair are sometimes used to collect 
information on substance use but these methods are costly, intrusive and cannot assess 
drug use histories, or the frequency or quantity of drug use over extended periods of 
time (Wolff et al, 1999; Darke, 1998).  
 
Despite the widespread use of self-report measures, concerns about their accuracy in 
describing substance use patterns have been raised for several decades (Skog, 1992; 
Ball, 1967). It is believed that self-report may not accurately reflect substance use for 
several reasons. Respondents may respond in a manner that will be viewed favourably 
by others concerning less socially desirable behaviours, such as intravenous drug use 
and needle sharing (Bardone et al, 2000; Measham et al, 1998), or if there are perceived 
negative consequences associated with reporting certain behaviours such as expulsion 
from treatment programmes which require abstinence (Sherman and Bigelow, 1992; 
Magura et al, 1987). Substance users may unintentionally distort information either due 





judgements over quantities of drugs. Distortion in recall over long periods of time may 
be a threat to reliability of the study results. 
 
Reliability refers to the “…extent to which measures are repeatable by the same 
individual using different measures of the same attribute or by different persons using 
the same measure of the attribute” (Nunnally, 1967). Operationally, reliability refers to 
the "consistency" or "repeatability" of the measure (test scores) over time. The most 
common test of reliability of self-report behaviours is ‘test-retest reliability’ and 
concordance between different interviewers. In test-retest reliability participants are re-
interviewed with the same questions used in the original interview and the correlation 
between the responses is examined (Levy et al, 2004). A number of studies have 
investigated the reliability of self-reported substance use and have found high reliability 
over varying recall periods with treated and untreated substance users (Darke, 1998; 
Adelekan et al, 1996; Ehrman and Robbins, 1994). 
 
Validity refers to the degree to which the questions measure what they claim to. In terms 
of substance use, validity tests whether the measure accurately assesses the actual 
substance consumption of the individual.  A widely used test of validity is ‘concurrent 
validity’ which refers to the degree of agreement between self-report and some other 
current measure of behaviour such as urinalysis (Harrison, 1995) or hair testing 
(Ledgerwood et al, 2008). Self- eported substance use has consistently shown high 
concordance with independent measures of substance use (Adelekan et al, 1996; Bale, 
1979). Routine drugs monitoring through urine samples takes place regularly within the 
treatment service used within this research programme and can be used by the service to 
verify personal reports of drug use.  
 
Toneatto et al (1992) reported that a significant body of literature published over the 
preceding fifteen years demonstrates that adult substance abusers’ self-reports are 
generally accurate, provided that they are conducted in a clinical or research setting, that 
the patient is not under the influence of alcohol and that they are given assurances of 
confidentiality. Despite the limitations of self-report measures, the consistency of the 
findings using different methodologies and in different countries suggests that self-
report measures are sufficiently reliable and valid in providing descriptions of current 





In order to reduce some of the disadvantages associated with self-report data in the 
current research programme assurances of confidentiality were made to each study 
participant. It was made clear to the patient that information would only be discussed 
within the research team and that no information would be passed to the clinical teams 
responsible for their treatment. Participants were assured that no identifying information 
would be entered into the research programme database and that data would be analysed 
by the researcher only. 
 
As well as highlighting problems which may affect the reliability and validity of 
information collected from the heroin users involved in the studies, it may also be 
necessary to question the accuracy of the clinical records used to collect information 
within the two studies. The waiting time for each patient recruited to the two studies 
was retrieved from clinical records held within the treatment service. This information 
could be verified accurately in Study 2 as participants were recruited to the study at the 
start of their waiting period and were re-interviewed around the time of their scheduled 
treatment entry. Waiting time, however, could not be accurately verified in Study 1 as 
the patients were first interviewed by a researcher for the study at the end of the waiting 
period, with no researcher contact prior to this. In these cases, the date of the first 
contact with the treatment service was collected from clinical records completed by the 
key-workers.  There is a possibility that this information may not have been accurately 
recorded, thus affecting the calculation of the waiting period (days between Brief and 
Full Assessment). However, it acknowledged that a degree of human error in 
information reporting may be present in all research and therefore undue concern over 














2.12      OVERVIEW OF DATA MANAGEMENT AND STATISTICAL 
PROCEDURES 
 
2.12.1     Security issues (data protection)  
 
Data protection procedures according to the Kings College London Research Ethics 
Committee (2001) and the Helsinki Declaration of 1983 (World Medical Association, 
1983) were adhered to. Completed interviews and personal locator information were 
anonymised with a numerical identifier and were stored in a locked cupboard at the 
research programme site. An SPSS database containing the numerical identifier and 
corresponding participant name and details was kept on a password-protected computer 
at another location.   
 
2.12.2     Dealing with multiple measures 
 
The research programme involves the testing of multiple comparisons. When multiple 
comparisons are being made within an experiment the probability of observing a 
statistical difference for one of the comparisons increases with the number of 
comparisons being made. A false positive can arise as a result of random variability, 
even when no effect exists (Ludbrook, 1998). Under these circumstances this would 
lead to the rejection of a null hypothesis when it is actually true. This is referred to as a 
‘type 1’ error.  
 
For several decades there has been an on-going discussion about the need and methods 
by which to adjust for multiple comparisons in order to judge the quality of 
experimental research (Feise, 2002; Ludbrook, 1998; Tukey, 1977). Although a number 
of multiple comparison procedures have been developed (e.g.  False discovery rate step 
down procedure, Bonferroni Correction) no consensus on the best procedure exists and 
selection often depends on the requirements of reducing the risk of rejecting a null 
hypothesis while maintaining the likelihood that an experimental effect is detected. 
 
In order to control for the effect of multiple comparisons in the current research 
programme a Bonferroni Correction will be employed. This procedure effectively raises 





simultaneously. The Bonferroni Correction is applied by dividing the alpha level by the 
number of comparisons. (e.g.  if we were examining 5 comparisons, rather than testing 
at the traditional 0.05 alpha level we would test at 0.05/5 = 0.001 level. This would 
ensure that the overall chance of making a type 1 error is still less than 0.05).  
 
Some have argued that the Bonferroni method is too stringent (Feise, 2002) and the 
chances of finding a significant difference between variables become more difficult to 
detect even when differences exist. When working with small samples, reducing the 
alpha value may leave insufficient power to detect differences with small effect sizes. 
This is known as a ‘type 2’ error. This is the error of accepting a null hypothesis when 
the alternative hypothesis is true (failing to observe a difference when in truth there is 
one). For this reason, statistical testing within Study 1 and 2 will reduce the accepted  p- 
value from 0.05 to 0.01. Results with, and without, Bonferroni adjustments will be 
presented. 
 
2.12.3     Missing data 
 
The authors of the SOCRATES (Miller and Tonigan, 1996) provided no instructions as 
to how to deal with incomplete data sets. Due to possible variations between researchers 
conducting the structured interviews and some study participants completing the 
measures by mail there were a number of missing values in the data set. Many statistical 
procedures (e.g. repeated measures t-test) will eliminate an entire observation or case if 
there are any missing data in the defined variables. For this reason when working with 
small sample sizes it is preferable to avoid this. Tabachnick and Fidell (2001) 
recommend substituting the missing value with the group mean.  However, Smeding 
and Inge de Koning (2000) argue that the method of replacing all missing values 
irrespective of its cause is not valid and feasible and must be done with caution. In the 
context of this research programme there were a number of participants with missing 
SOCRATES data on each interview (e.g. baseline and 3-month follow-up), replacing 
this data with the group mean would have provided a profile of responses which would 
not accurately reflect genuine change over time. As there was no pattern to the missing 
data within, or between, participants, those with missing SOCRATES data on any 






2.12.4     Outlier management 
 
The frequencies programme (SPSS Windows, version 16, 2008) was used to identify 
the presence of outliers in the dataset. Outliers are extreme values (those that are 
numerically different) in relation to those observed within the sample as a whole. Any 
statistical test based on sample means and variances can be distorted with the presence 
of outliers, particularly in studies with small sample sizes. Methods for managing 
outliers include recoding the score with the preceding highest value (so that they are 
still extreme but fit within a normal distribution) deleting the extreme cases or, if the 
outliers appear to be part of an overall non-normal distribution, transforming the data 
(e.g. logarithmic transformations) after checking for normality. Transformation is a 
mathematical operation that changes the measurement scale of a variable. For the 
purposes of this research programme two different methods of outlier management were 
utilised - logarithmic transformations and  re-coding of the outliers to the preceding 
highest or lowest value.   
 
2.12.5     Data transformations 
 
The distribution of variables was examined using SPSS frequencies programme to 
generate histograms and to identify skewness and kurtosis. Skewness is a measure of 
the lack of symmetry of a sample distribution. Kurtosis is a measure of whether the data 
are peaked or flat relative to a normal distribution. Tabachnik and Fidell (2001) 
recommend transforming variables where variables are moderately skewed to aid 
interpretation.  Logarithmic and square root data transformations were performed on 
skewed variables to create a more normal distribution. This was to maximise the use of 
parametric tests of analysis. These are detailed in the relevant studies. Statistical 
analyses were performed using SPSS 16 (SPSS, 2008). Statistical tests used within the 
two research studies will be summarised at the beginning of each chapter. 
 
2.13      SUMMARY OF CHAPTER 2  
 
This chapter described some of the broader methodological issues in relation to the 
research programme. The selection of study design and a description of the specific 






CHAPTER 3:    STUDY 1 
 
3.1      INTRODUCTION     
 
The primary purpose of this research programme was to examine the relationship 
between treatment waiting times and readiness to change heroin use and the influence of 
this relationship on treatment entry and substance use over the waiting period. In order 
to reliably examine this relationship readiness will be assessed at the beginning and end 
of waiting periods of different lengths. This section of the thesis reports on a Pilot Study 
assessing whether the chosen measure of motivation - the Stages of Change Readiness 
and Treatment Eagerness Scale (SOCRATES) - was capable of detecting changes  
in readiness over time in heroin users. 
 
Pre-testing of the SOCRATES was necessary as previous research using the measure to 
examine readiness to change has focused primarily on smokers or alcohol-using 
populations (Figlie et al, 2005; Maisto et al, 1999) and has relied upon a static concept 
of motivation. Within these studies, motivation is usually assessed at the start of 
treatment, and is used to predict future outcomes such as abstinence and treatment 
retention (Miller, 1985).  This static measurement of motivation has been criticised 
because it ignores the premise of the Transtheoretical Model on which the measure is 
based – that people change their behaviour over time through a series of stages that 
represent progressively greater commitments to change. This Pilot Study assesses 
readiness to change at three different points in a sample of heroin users at the start of a 
new treatment episode, and three and six months later.  
 
3.2      RESEARCH OBJECTIVES 
 
The four objectives of the Pilot Study are - 
 
1. To examine whether the SOCRATES can detect statistically significant changes in 
readiness over time among a sample of heroin users. These results will determine 
whether it is feasible to proceed with the use of the SOCRATES in the second study 






2.  To pre-test a set of research measures on the structured interview to be used in Study 
2. This will include collecting information from study participants regarding the 
content, wording and the ordering of the questions on the interview schedule.  
 
3. To check that the investigator was sufficiently skilled in administering the interview 
schedule. 
 
4.  To conduct a preliminary examination of the relationship between the length of the 
waiting period and readiness to change. It is expected that heroin users who experience 
long waiting periods prior to the start of treatment will have lower levels of readiness at 
the beginning of treatment relative to those heroin users who experience shorter delays. 
 
3.3     METHOD    
 
3.3.1     Study design   
 
A within-subjects repeated measures longitudinal cohort design was used to assess 
readiness to change at three time points in order to examine the direction and magnitude 
of change in a sample of heroin users at the start of a new treatment episode at a 
community out-patient treatment service. Structured interviews were conducted with 
patients after their first clinical appointment at the service after waiting periods of 
varying lengths, and three and six months later. The readiness of all patients was 
examined regardless of their treatment status (in treatment/out of treatment) at the time 
of the follow-up interviews. Patient records were used to provide information on the 
length of the waiting period prior to treatment entry in order to examine the relationship 
between treatment waiting times and readiness to change.  Data for this study were 
collected in connection to a larger study investigating the early impact of treatment for 
substance abusers, details of which are reported in Best et al (2002) (Appendix 10) . 
 
3.3.2     Study sample 
 
The sample for the current study comprised forty individuals attending a statutory 
substance abuse treatment service in South London for the treatment of heroin use.  The 





programmes primarily for individuals seeking help with opiate problems. Details on the 
treatment service, the process of treatment access and induction within the service is 
presented in Chapter 2. Access to treatment includes a Brief Assessment conducted with 
a psychiatric nurse or drug counsellor through an open-access clinic, followed by 
allocation to a clinical team within the service.  Heroin users are typically placed on a 
waiting list operated by each clinic until a treatment slot becomes available. Treatment 
entry after the waiting period begins with a Full Assessment with a member of the 
relevant clinical team to assess current substance use. This is followed by a three-day 
Dose Assessment procedure to establish a therapeutic dose of methadone.  
 
3.3.3     Inclusion/exclusion criteria   
 
Full details of the inclusion criteria for the current study are presented in Chapter 2 and  
include: (1) individuals attending the treatment service for their first clinical 
appointment of a new treatment episode, (2) heroin use in the 30 days prior to the first 
clinical appointment, (3) aged between 18 and 65 years, (4) a diagnosis of  heroin 
dependence, (5) fluent in the English language.  
 
3.3.4      Measures 
 
Two structured interviews were developed to assess a number of measures considered 
relevant to testing the research programme hypotheses examined in the main waiting list 
study (Study 2). The interviews in the Pilot Study were designed to obtain baseline data 
at the start of treatment and follow-up data three and six months after this time. The first 
interview collected baseline data on demographic characteristics including gender, age, 
relationship status, ethnicity and employment. Information on readiness to change, 
substance use, patterns of dependence, health risk behaviours and physical and 
psychological health in the 30-days prior to the interview were collected on the intake 










3.3.5     Ethical approval 
 
Ethical approval for the study was granted by the South London and Maudsley NHS 
Trust Ethical Committee (Study No. 036/98) in 1998. The study was carried out in 
accordance with of the Declaration of Helsinki (World Medical Association, 1983) for 
experiments involving humans. Data was collected from the treatment service over a 
14-month period. 
 
3.3.6     Procedure 
 
The researcher liaised with the clinical teams on a weekly basis to establish when a 
patient with a heroin use problem was assigned a place at the service. Clinical notes 
were reviewed for eligibility against inclusion and exclusion criteria, and for evidence 
of the capacity to provide informed consent. The researcher then sought confirmation 
from the responsible key-worker that the patient was well enough to participate in the 
research. Consecutive admissions of patients eligible for participation in the study were 
approached directly by the researcher after their first clinical appointment at the 
treatment service. This was typically after the final day of Dose Assessment.  
 
The researcher explained the purpose of the study and the data collection procedures to 
each identified heroin user and provided them with an information sheet (Appendix 1).  
If the patient agreed to participate in the study they were asked to read and sign a 
consent form. They were informed that trial participation was voluntary and refusal 
would not affect the treatment they received. The intake research interview (Appendix 
2) was conducted immediately following study recruitment, or if this was not 
convenient for the patient an appointment was made to conduct the interview within the 
following few days. Patient recruitment and the administration of the structured 
interviews were carried out by an experienced researcher trained in the administration of 










3.3.7     Conducting the research interview 
 
The intake interview was conducted in a private room within the treatment service and 
lasted approximately forty minutes.  The interview began with the researcher explaining 
the purpose of the study again. The interview was delivered in a fixed order, 
commencing with demographic characteristics, followed by physical and psychological 
health, the substance use assessment, health risk behaviours, Severity of Dependence 
scale and the SOCRATES.  Information collected on the intake interview referred to 
behaviours in the previous 30 days (e.g. ‘how many days in the last 30 have you used 
heroin?’).  Patients were offered a £10 voucher to recompense them for their time and 
their assistance.  
 
Details concerning the waiting period of each patient was collected from clinical notes 
kept within the treatment service. Waiting time was defined by the clinic, and for the 
purposes of this research programme, as the number of days between accessing 
treatment (attending Brief Assessment) and treatment entry (Full Assessment). 
 
All study participants were contacted 3 months (3-month interview) and 6 months  
(6-month interview, Appendix 3) after the intake research interview. The same 
structured interview was conducted at two follow-up points. Research measures used 
within the follow-up interviews covered the 30-day period prior to the 3- and 6-month 
interviews. Follow-up interviews were sought regardless of whether the study 
participant was still engaged in treatment at each follow-up point. The same researcher 
conducted all follow-up interviews. These follow-up interviews were conducted face-to-
face in the treatment clinic or at a mutually agreed public meeting place. When a 
research interview was conducted outside of the clinical environment two researchers 
were present. If the patient could not be contacted within several weeks of the 3-month 











3.3.8     Participation rates   
  
A total of 77 treatment patients eligible for study participation were approached. These 
patients met inclusion criteria based on information gathered from their clinical notes 
and from the clinical teams. Of these 77 patients, 9 refused consent and 3 who had 
agreed to participate failed to attend the intake interview. Attempts to contact these 
patients were unsuccessful and they did not return to the service for treatment.  It was 
not possible to evaluate whether those who refused to participate in the study were 
systematically different from those who agreed to participate. Sixty-five patients were 
successfully recruited to the study (Figure 3.1). 
 
At the 3-month interview 49 (75.4%) patients completed an interview. Sixteen (24.6%) 
patients could not be interviewed in the time-frame for this follow-up due to difficulties 
locating them. At the third follow-up point, 41(63.1%) patients were interviewed. This 
included 3 patients who could not be contacted at the 3-month follow-up but were 
successfully located at the 6-month interview point.  A further 8 (12.3%) patients could 
not be contacted for the 6-month follow-up interview. 
 
Only patients who completed all three research interviews were included in the analysis. 
As the authors of the measure provided no information on how to deal with missing 
data, patients with missing SOCRATES data on any of the interviews were excluded 
from the analyses. At the 3-month interview 1 patient had missing SOCRATES data. 
Data is presented on the 40 patients with complete SOCRATES data on all three 
interviews.  
 
At the 3-month interview 85.0% (n=34) of the sample who were included in the final 
study analyses were still engaged in treatment and 15.0% (n=6) were no longer in 
treatment (1 had completed treatment, 1 had been discharged from the service on 
disciplinary grounds, 4 had left against medical advice). At the 6-month follow-up 
77.5% (n=31) were still in treatment. A total of 7.5% (n=3) had dropped out of 
treatment between the 3- and 6-month interviews (3 had left against medical advice), 
while another 7.5% (n=3) who had dropped out by the time of the 3-month interview 
had returned to treatment by the time of the 6-month interview (these 3 patients had left 










                                                                                                             
 

















3.3.9     Assessment intervals  
 
Patients were initially interviewed (intake interview) on a mean of 1.5 (s.d. 1.4) days 
after their first clinical appointment at the treatment service. The 3-month follow-up 
interview was conducted a mean interval of 100.8 days (s.d. 23.0) later. The 6-month 





Assessed for eligibility (n=77) 
Excluded (n=12): 
 Refused to participate (n=9) 
 Failed to attend the interview (n=3) 
 
Completed the interview (n=65) 
 
Completed the interview (n=49) 
Lost to contact (n=16) 
Completed the interview (n=41) 
Lost to contact (n=8)  
Analysed (n=40) 
Excluded from the analysis: 
Did not complete all 3interviews (n=24) 





3.3.10    Statistical analysis 
 
Data were analysed using SPSS version 16 (SPSS, 2008). The frequencies programme 
was used to check for the presence of outliers and a normal distribution among the 
variables. All variables were screened for skewness and kurtosis following initial 
screening using histograms and basic computation as specified by Tabachnick and 
Fidell (2001).  
 
These tests identified that the readiness scale scores and the frequency of substance use 
were not normally distributed.  Logarithmic data transformations were performed on the 
skewed variables prior to analysis to create a more normal distribution, thereby 
maximising the use of parametric tests of analysis. One outlier was identified within the 
waiting time variable – a waiting time of 110 days. As the outlier appeared to be part of 
an overall non-normal distribution of waiting times, this variable was also transformed 
logarithmically. This method of outlier management preserved the natural distribution 
of waiting times which occurred under normal clinical practice within the treatment 
service. 
 
First, descriptive statistics were used to characterise the study sample, readiness scale 
scores and waiting times at the start of treatment. Pearson’s correlations for parametric 
data and Spearman’s correlations for non-parametric data were computed to assess the 
degree of association between readiness scale scores, waiting times and demographic 
and clinical characteristics of the sample. Repeated measures analyses of variance were 
used to examine changes in readiness between the three time points. 
 
Since a number of multiple comparisons were conducted within the analyses, the 
Bonferroni Correction procedure was applied to control for the inflation of type 1 errors.  
This was set at an alpha level of 0.01. Test results before and after adjustment with the 
Bonferroni procedure will be presented. The advantages and disadvantages of adjusting 









3.3.11     Waiting times 
 
The waiting period between Brief Assessment and Full Assessment was calculated for 
all patients included in the study. The mean waiting time between Brief Assessment and 
Full Assessment was 38.8 days (s.d. 22.9; CI=31.4 - 46.1), with a median of 36 days. 
The distribution of waiting times of the sample is presented in Figure 3.2.  
 
 
Figure 3.2: Waiting time (days) between Brief Assessment and Full Assessment 
 




























The sample was comprised of 40 patients attending the service for the treatment of  
heroin dependence. The total sample had a mean age of 35.2 years (s.d.8.5; range 22-53 





majority of the sample were white-British (85.0%; n=34). A further 2.5% (n=1) 
classified themselves as ‘Black Other’, 10.0% (n=4) were white European and 2.5% 
(n=1) were Irish.  Of the 37 patients who reported their employment status, the majority 
(73.0%; n=27) were unemployed or in receipt of long-term sickness benefits and 27.0% 
(n=10) were in paid part- or full-time employment.  At the time of the intake research 
interview 8 patients (20.0%) reported that they were currently in a relationship and 32 




The study participants reported using heroin on a mean of 25.4 days (s.d.7.9) in the 
previous 30 days (range of 2-30 days) with 26 (65.0%) patients reporting daily heroin 
use. Patients reported consuming a mean of 0.6g of heroin (s.d.0.4) on a typical using 
day. The mean duration of heroin use in the sample was 3 years (s.d.3.8) with a range of 
3 months to 15 years. The mean age of onset of heroin use was 21.7 years (s.d.6.9) with 
a range between the ages of 13 and 41 years.  
 
Cannabis was the second most frequently reported drug used, with 25 patients 
(n=62.5%) using on a mean of 5.9 (s.d. 3.1) days in the previous 30 days. More than a 
third of the sample reported the use of crack cocaine (n=15; 37.5%) and 21 (52.5%) 
patients had used non-prescribed methadone in the previous 30 days.  The majority of 
the sample (n=36; 90.0%) reported the use of more than one illicit drug, with a mean of 
3.3 (s.d.1.4) types of drugs consumed. This figure ranged from 2 to 7 types of drugs 
consumed. Twenty-five (62.5%) patients reported that they had previously injected 
drugs, with 21 (52.5%) injecting in the preceding 30 days. Eighteen (45.0%) of those 
using intravenously reported doing so every day.  Eight (20.0%) patients reported 
sharing injecting equipment in the previous 30 days. Fifteen (49.2%) patients reported a 
previous drug overdose, with 8 (20.0%) reporting between 2-4 previous overdoses. 
 
Half the sample (n=20; 50.0%) reported  alcohol use on 15.2 days (s.d.11.5) in the 
previous 30 days with a mean of 6.2 units (s.d.4.3)  consumed per day. This ranged 
between 1.5 units to 18 units per day.  Six (15.0%) reported daily alcohol use. Eleven 
patients (27.5%) reported engaging in heavy drinking (defined as consuming 6 or more 





Treatment for substance use 
 
Twenty-nine (72.5%) patients reported having previous experience of substance abuse 
treatment. A total of 33 (82.5%) patients had previously received treatment for their 
heroin use, 4 (10.0%) for methadone use, 1 (2.5%) for benzodiazepine use and 1 (2.5%) 
for crack cocaine use. Previous treatment for alcohol problems were reported by 1 
(2.5%) patient. 
 
Severity of Dependence 
 
Severity of Dependence was ascertained for heroin use at intake. The mean Severity of 
Dependence Scales (SDS) score was 11.9 (s.d.2.5) with a range of 7-15 (possible 
range=0-15). This mean score indicates that a proportion of the sample was 
experiencing a high level of heroin dependence. 
 
Physical and psychological health  
 
The patients demonstrated a mean physical health score of 17.9 (s.d.6.0) at treatment 
intake with a range between 6 and 31 (possible range = 0 - 40). The mean psychological 
health score was 18.3 (s.d.6.3) with a range between 1- 40. These results indicate that 
the patients were experiencing a number of physical and psychological health problems, 
but in the majority of cases these symptoms were not experienced on a regular basis. 
 
Readiness to change substance use behaviour 
 
Readiness to change scores assessed at the intake interview are presented in Table 3.1. 
The Recognition scale at intake had a mean score of 30.4 (s.d. 3.6), the Ambivalence 
scale had a mean score of 15.4 (s.d. 2.2) and the Taking Steps scale had a mean score of 
32.6 (s.d. 4.7).  Miller and Tonigan (1996) provided interpretative ranges (‘profiles’) for 
the scale scores based on 1,726 adults presenting for the treatment of alcohol problems 
in Project MATCH (Project MATCH Research Group, 1993). According to these 
ranges, the mean scores for all three readiness scales fall into the ‘medium’ range 
relative to people already presenting for alcohol treatment. This profile on the 





fully recognise that they have a heroin use problem. For the other two scales, the 
‘medium’ range represents a middle ground between wondering and not wondering if 
their heroin use is having an effect on themselves and others (Ambivalence scale) and  
making some positive changes in their heroin use, or expressing intentions to do so 
(Taking Steps scale). 
       







Mean scale score (s.d) 30.4 (3.6) 15.4 (2.2) 32.6 (4.7) 
Confidence Interval (95%) (29.2, 31.6) (14.7, 16.8) (31.1, 34.4) 
Median  30 15 32 
Range  21-35 10-20 18-40 
Possible ranges: Recognition 7 to 35, Ambivalence 4 to 20, and Taking Steps 8 to 40. 
       
 
       Statistically significant positive correlations were found between the three readiness 
scales. The Recognition scale was positively correlated with the Ambivalence scale  
      (r = 0.56, p<0.01) and the Taking Steps scale (r = 0.74, p<0.01).  The Ambivalence 
scale was positively correlated with the Taking Steps scale (r = 0.45, p<0.01). The 
implications of these correlations will be addressed in Chapter 5. 
 
To demonstrate the variability of scores within the sample all patients were grouped into 
three profiles based on their readiness scale scores at treatment intake. This provided 
groups of ‘high’, ‘medium’ and ‘low’ profiles. The figures presented in Table 3.2 
demonstrate that nearly 60.0% of the sample had a Recognition score in the ‘high’ range 
indicating acknowledgement of their heroin use problems, while over a quarter (27.5%) 
of the sample were unaware that they had a heroin use problem. The remaining 15.0% 
of the sample had a score falling in the ‘medium’ range. 
      
On the Ambivalence scale 60.0 % of the sample obtained scores within the ‘medium’ 
profile, 25.0% had ‘high’ scores which suggests uncertainty about changing their heroin 
use and 15.0% of the sample had ‘low’ Ambivalence scores which implies that they do 





have a problem or because they know that they have a problem and so do not need to 
wonder, Miller and Tonigan, 1996).  
 
Table 3.2: Number of patients in each readiness profile at intake 







Recognition 23(57.5) 6(15.0) 11(27.5) 
Ambivalence 10(25.0) 24(60.0) 6(15.0) 
Taking Steps 9(22.5) 18(45.0) 13(32.5) 
      Recognition: High ≥35, medium 31-34, Low ≤30,   Ambivalence: High ≥17,  Medium 14-16,  Low ≤ 13, 
       Taking Steps: High ≥36, Medium 31-35, Low ≤30. 
   
 
The distribution of patient scores on the Taking Steps were more evenly distributed 
within the three readiness profiles than scores on the Recognition and Ambivalence 
scales. While 32.5% reported little activity, or intentions, to change their heroin use 
(‘low’ range), 22.5% endorsed a high number of intentions and behaviours designed to 
change (‘high’ range) and 45.0% of patients reported some activity to change 
(‘medium’ range). 
       
      3.4     RESULTS 
 
Preliminary analyses were conducted to examine the relationships between a number of 
demographic and substance use variables and readiness to change assessed at treatment 
intake. These results are presented in Table 3.3 and 3.4. Pearson’s and Spearman’s 
correlations failed to reveal any statistically significant relationships between gender, 














Table 3.3: Correlations between readiness to change scores and demographic 
characteristics at intake  
 







Age      -0.07    (0.68) -0.04    (0.98) -0.23   (0.19) 
Physical health *  -0.09    (0.58) 0.03     (0.86) 0.01   (0.94) 
Psychological health -0.06    (0.71)    -0.22     (0.18)   -0.10    (0.52) 
Gender -0.03    (0.85) -0.07    (0.68)  0.05    (0.77) 
Employment status -0.05    (0.77)  0.02    (0.89) -0.11   (0.52) 
Relationship status    -0.23    (0.19)  -0.33     (0.07) -0.19    (0.28) 
*Physical and psychological health scores range from 0-40, with higher scores indicating a greater 
number of symptoms. 
 
Only one of the substance use variables assessed at treatment intake showed a 
significant correlation with readiness scores. The Severity of Dependence Scale (SDS) 
for heroin use was positively correlated with the Ambivalence scores (r = 0.39, p<0.05), 
although this relationship failed to reach statistical significance once the Bonferroni 
Correction was applied. These results suggest that patients with more severe heroin use 
problems have greater conflict about changing their heroin use.  
 
Table 3.4:  Correlations between readiness scores and substance use variables assessed 
at intake 
 







Frequency of heroin use  0.02   (0.89) -0.21  (0.19)  -0.07   (0.65) 
Quantity of heroin use  0.17   (0.31) -0.18  (0.27) 0.04    (0.52) 
Frequency of alcohol use -0.02  (0.92) -0.12  (0.46) -0.14    (0.40) 
Quantity of alcohol  0.08   (0.73)  0.18    (0.45) 0.06    (0.80) 
Frequency of crack cocaine use  0.89   (0.59) -0.14   (0.38) -0.09    (0.60) 
Quantity of crack cocaine use -0.19  (0.51) -0.11  (0.71)  0.13     (0.67) 
Heroin SDS*  0.11   (0.51)    0.39  (0.02) -0.08    (0.65) 
*SDS (Severity of Dependence Scale) scores range between 0-15 with higher scores representing greater 







3.4.1    Changes in readiness over time 
 
In order to examine whether the SOCRATES could detect changes in readiness over 
time, changes in readiness scores between treatment intake and the 3-month and  6-
month follow-up interviews were examined. Repeated measures analyses of variance 
showed a statistically significant reduction in Recognition scores (F = 10.32, p<0.01) 
between the intake and 3-month interview. A reduction in Ambivalence scores during 
this period (F = 5.65, p<0.05) was also observed although this was not significant once 
the Bonferroni Correction was applied.  No statistically significant changes on the 
Recognition or Taking Steps scales were found. Similarly, there were no significant 
changes on any of the three readiness scales between the 3-month and 6-month 
interviews, with scores remaining relatively static between these points (Table 3.5).  
 
The magnitude of change on the readiness scales between the interviews can be 
determined by the effect size. At the 3-month follow-up small effect sizes were shown 
on all three scales: Recognition  scale (0.3), Taking Steps scale (0.1), Ambivalence 
scale (0.2) according to Cohen’s d (Cohen, 1992)1. Calculations for effect sizes showed 
no notable differences between the readiness scores between the 3- and 6-month 
interviews. 
 












months, F (p) 
Change 
3/6 months, 
F  (p) 
Recognition 
 
30.4(3.6) 28.3(4.2) 27.7(4.5) 10.32 (0.01)* 1.08  (0.31) 
Ambivalence 15.4(2.2) 14.3(2.6) 14.6(2.8) 5.65  (0.03) 
 
0.41  (0.52) 
Taking Steps 32.6(4.7) 31.5(4.3) 32.3(4.4) 2.56  (0.12) 1.18   (0.28) 





                                            
1Cohen’s d where 0.2 represents a small effect size, 0.5 a medium effect size and 0.8 a large effect size 








It was expected that scores on the Recognition scale would increase by the 3-month 
interview point, the absence of the predicted change therefore warranted further 
examination of the variables. Changes in readiness have been assessed using the group 
mean which masks both the variability of the direction of change in scores (e.g. that 
some may increase their score while others may reduce scores between the interview 
points) and also the amount of change among individuals. Table 3.6 shows the number 
of patients who increased their scores, whose scores remained static and whose scores 
decreased between the intake and 3-month follow-up on the three readiness scales. 
 
Table 3.6: Changes in readiness scores between the intake and 3-month interviews 






Recognition 11(27.5) 4(10.0) 25(62.5) 
Ambivalence 8(20.0) 4(10.0) 28(70.0) 
Taking Steps 15(37.5) 8(20.0) 17(42.5) 
 
 
Case-by-case analysis revealed that while many patients (62.5%) decreased their 
Recognition scores between the intake and 3-month interview, over a quarter (27.5%) of 
increased their scores and 10.0% of the sample’s scores did not change between the two 
interview points. On the Ambivalence scale the greatest proportion of patients (70.0%) 
decreased their scores, 10.0% did not change their scores and 20.0% increased their 
scores between the interviews. On the Taking Steps scale 42.5% of the patients 
decreased their scores, 20.0% did not change their scores and 37.5% increased their 
Taking Steps scores at follow-up. 
 
An examination of changes in readiness scores between the 3- and 6-month interviews 
indicated that over half the patients (52.5%) showed a reduction in their Recognition 
scores, 22.5% remained static and 25.0% increased their scores. On the Ambivalence 
scale 47.5% of patients decreased their score, 22.5% remained static and 30.0% 





during this period 32.5% of the patients decreased their scores, 27.5% were unchanged 
and 40.0% increased their score. These figures are presented in Table 3.7. 
 
Table 3.7: Changes in readiness scores between the 3-month and 6-month interviews 






Recognition 10(25.0) 9(22.5) 21(52.5) 
Ambivalence 12(30.0) 9(22.5) 19(47.5) 
Taking Steps 16(40.0) 11(27.5) 13(32.5) 
 
It must be noted that follow-up data was collected regardless of whether the patient was 
still engaged in treatment at the 3-month and 6-month follow-up points. The effect of 
the patients’ treatment status on the study results will be addressed in the study 
discussion section. 
 
3.4.2     Waiting times and readiness to change 
 
A preliminary examination of the relationship between the length of the waiting period 
prior to treatment entry and readiness scores was conducted. Previous analyses 
examining the relationships between readiness scale scores and clinical characteristics 
of the sample revealed a positive correlation between the Ambivalence scale and the 
Severity of Dependence Scale scores. In order to control for the possible confounding 
effects of the severity of heroin dependence of the sample on the results, this variable 
was controlled for in the following analyses. 
 
Pearson’s correlational analyses revealed a positive association between scores on the 
Ambivalence scale and the number of days waited prior to treatment entry (r = 0.31,  
p = 0.05), although this failed to reach statistical significance once the Bonferroni 
Correction was applied. This result demonstrates that patients with longer waiting times 
reported greater conflict about reducing their heroin use (or those with shorter waiting 
times reported less conflict about changing their heroin use). No significant associations 
were found between waiting times and patient scores on the Recognition or Taking 






Table 3.8: Correlational analyses between readiness scores at intake and waiting time 








Waiting time (days)  -0.17 (0.29) 0.31 (0.05) -0.02 (0.92) 
 
 
These analyses were repeated to examine the possible associations between the length 
of the waiting period and readiness scale scores at the 3- and 6-month follow-up 
interviews. No statistically significant associations between waiting time and readiness 
scores at the follow-up points were found (Tables 3.9 and 3.10). 
 
Table 3.9: Correlational analyses between readiness scores at 3 months and waiting time 








Waiting time (days)  -0.12(0.45) -0.11(0.52) 0.11(0.50) 
 
 
Table 3.10: Correlational analyses between readiness scores at 6 months and waiting 
time 
























3.4.3   Summary of Study 1 findings 
 
• The SOCRATES revealed a reduction in patient scores on the Recognition and 
Ambivalence scales between the intake and 3-month interviews. 
 
• SOCRATES scores remained relatively static between the 3- and 6-month 
interviews.  
  
• A positive correlation was found between intake Ambivalence scores and 
waiting time, demonstrating that patients with longer waiting times reported 
greater conflict around reducing their heroin use (non-significant after 
Bonferroni Correction).  
 
• No associations were found between waiting times and the Recognition or 

































3.5      DISCUSSION 
   
 
This section of thesis discusses the findings from the analyses of Study 1. It will report 
on the utility of the SOCRATES in assessing readiness to change over time, and the 
preliminary examination of the relationship between waiting times and readiness to 
change heroin use. 
 
 
3.5.1   Readiness to change at treatment entry 
 
According to the readiness profiles suggested by Miller and Tonigan (1996), mean 
readiness scores of patients entering treatment fell within the ‘medium’ profile on the 
Recognition, Ambivalence and Taking Steps scales relative to alcohol users entering 
treatment in the Project MATCH samples (Project Match Research Group, 1993). The 
mean  readiness profiles reported in the current study are comparable with those 
obtained by Gossop et al (2007) among a sample of drug users starting a new treatment 
episode at residential and community treatment settings in the UK.  
 
The Recognition scores in the current study demonstrate that while a proportion of the 
heroin users entering treatment are able to acknowledge that they have a heroin use 
problem, others deny that their heroin use is causing  them serious problems and do not 
express a desire for change. While medium, or low, Recognition may be expected 
among heroin users mandated into treatment by the courts, it is less expected among 
voluntary participants at the start of treatment. Such a finding suggests that treatment 
entry may not be entirely voluntary among a proportion of the sample and that coercion 
to enter treatment may have originated from other sources such as pressure from the 
workplace, social networks and welfare services. This lack of recognition of their heroin 
use problems may be related to the concept of denial, a common characteristic among 
drug users (Li et al, 2011; Rapp et al, 2006).  Denial has been defined as a person's way 
of coping with a painful situation. By denying the existence of a problem, a person does 
not have to deal with it or assume any responsibility for it. Some of the heroin users 
may not fully recognise that they have a drug use problem as they believe they are still 
able to function effectively in some areas of their lives, or because they have avoided 






The trend in scores on the Ambivalence scale implies that patients are experiencing 
some uncertainty and conflict about their heroin use. Ambivalence has been described 
as a natural part of the process of change (Miller and Rollnick, 2002; Prochaska and 
DiClemente, 1992) and represents conflicting intentions, with individuals weighing up 
the pros and cons of changing their drug use. At the start of treatment many patients 
may have some desire to cut back or stop their drug use, but the temptation to continue 
may also be very strong because of their psychological or physical dependence to 
heroin. Initiating change is often associated with the fear of failing which many 
contribute to their ambivalence about change. This may also be confounded by the 
feelings of trepidation treatment seekers may experience about being in a new 
environment and exposing their problems to a drugs counsellor. 
 
Nearly half of the sample reported Taking Steps scores in the ‘medium’ profile at 
intake. This indicates that a proportion of the sample are preparing, or starting, to make 
some changes in their heroin use, such as cutting down the frequency or quantity of 
their use. The fact that many are able to make changes prior to treatment is a positive 
finding. However, a proportion of the sample reported little activity to change their 
behaviour. Reducing heroin use may be too difficult for some without the assistance of 
formal treatment. Others may not see the need to initiate change prior to treatment as 
they know they will soon be in receipt of substitute medication which they anticipate 
will make changing their heroin use easier.    
 
Case-by-case analyses found substantial variability in readiness profiles 
(high/medium/low) at treatment entry. Over half of the sample scored within the ‘high’ 
range on the Recognition scale, 25.0% per cent scored ‘high’ on the Ambivalence scale 
and 22.5%  ‘high’ on the Taking Steps  scale. A further 27.5% scored ‘low’ on the 
Recognition scale, 15.0% ‘low’ on the Ambivalence scale  and 32.5% of the sample 
scored ‘low’ on the Taking Steps scale. The variability in readiness scores among the 
sample at the start of treatment highlights the importance of recognising that drug users 
enter treatment with different levels of motivation. This supports previous research 
which has demonstrated that those who express an interest in treatment may not all be 
highly motivated to change their drug use (Battjes et al, 1999). Although this may seem 
contradictory, a number of investigators have highlighted the distinction between 





conceptualised as a combination of the individual’s perceived importance of the 
problem and confidence in their ability to change. Readiness for treatment focuses on 
motivation to seek help, preparedness to engage in treatment activities and how they 
impact on the individual’s attendance, compliance and outcome. Substance users may 
participate in treatment but may not be ready to take action to change their behaviour. 
Measures which have assessed readiness to change along with readiness for treatment 
among alcohol-dependent outpatients found a number of  patients scored high on 
readiness for treatment and low on readiness for change and vice versa (DiClemente, 
1999).  
 
3.5.2   Changes in readiness over time 
 
Given that the Transtheoretical Model aims to depict the process of how people change 
over time, it is important that the model demonstrates actual changes in readiness rather 
than inferring changes from the behaviours it is intended to predict, such as levels of 
substance use or treatment retention (Cahill et al, 2003; Miller, 1985). The use of the 
Pilot Study in the research programme was to test the capability of the SOCRATES in 
detecting change in readiness over time among heroin users in order to reliably assess 
the relationships between readiness to change and waiting times examined in Study 2. 
The current study compared readiness scores of heroin users at three time points in 
order to examine changes in readiness during a six-month period following treatment 
entry. Statistically significant reductions on the Recognition and Ambivalence scales 
between treatment entry and the three-month follow-up were found, while scale scores 
remained relatively unchanged between the three and six-month follow-up interviews.  
There were no statistically significant changes on the Taking Steps scale at either of the 
follow-up periods. 
 
Although the reduction in Recognition scores over the first three-month period  may be 
evidence that the treatment programme did not heighten heroin users’ awareness of their 
problems, it may alternatively suggest that there is less of a problem requiring  
recognition as time goes by, especially as improvements in heroin use are made. Factors 
in the treatment environment, such as the receipt of substitute medication and 
therapeutic involvement, as discussed in the Literature Review, may have led to 





problem to recognise. Even if actual changes in heroin use had not yet been made, the 
patients have still experienced some of the benefits of exposure to treatment, such as the 
stabilising effect that treatment provides for many. A reduction in Recognition over 
time may alternatively suggest that the heroin users do not perceive their problems to be 
as serious as when they entered treatment because of the circumstances surrounding 
their treatment seeking. Previous research has found that drug users often present to 
treatment during a period of crisis (Prochaska et al, 1992; Weisner, 1990)  
(e.g. financial, health or relationship problems) when they feel a pressing need for help 
with their problems.  It may be that this crisis subsides during the passage of time, 
altering their perception and awareness of their problems or their need to change.  
 
The reported reductions in Ambivalence scores in the first three months appears to be a 
positive finding, with heroin users experiencing less conflict and uncertainty about their 
heroin  use as time goes by.  One of the roles of counselling during treatment is to assist 
the patient to reduce the conflict associated with changing their drug use (Miller and 
Rollnick, 2002).  After three months of therapeutic engagement patients may have 
already weighed up the pros and cons of their heroin use and have decided that their 
desire for change is greater than their desire to continue using drugs. Experiencing 
positive changes to their heroin use through the treatment process may also assist in 
reducing this conflict. 
 
The absence of statistically significant changes on the Taking Steps scale at the three-
month follow-up indicates that heroin users are not engaging in more behaviours 
designed to change their heroin use than those reported at the start of treatment. This is 
an unexpected finding but may suggest that once heroin users have made substantial 
improvements in their heroin use, they may not believe that further action on their part 
is necessary. Although the SOCRATES was originally developed on alcohol in-patient 
samples, it fails to recognise that attending treatment is an action engaged in to change 
drug use. Each time a drug user attends a counselling session or consumes substitute 
medication they are making a conscious decision to change their heroin use. Failure to 
address action associated with attending treatment may represent an omission of the 
SOCRATES. However, others have suggested that the assessment of motivation may be 
confounded when medication is prescribed, as much of the activity associated with 





Such a contention would question the relevance of the use SOCRATES for treatment 
samples in receipt of substitute medication. It remains to be determined whether the 
same change processes occur in drug users who use pharmacological agents to alter 
their drug use as those who change without such assistance. Further research would be 
useful to determine the extent to which heroin users receiving substitute medication 
perceive themselves as actively involved in the change process. 
 
The absence of changes in readiness between the three- and six-month interviews  may 
demonstrate that once patients are successfully engaged  in treatment, motivation to 
change ceases to be an important factor in the process of recovery. It may be that 
motivation is only important during the early stages of change where will power and 
determination are required. What happens during treatment, such as therapeutic 
relationships formed and substitute medication prescribed, may be more important than 
motivation to change.  Changes in readiness at three months but an absence of changes 
after this period may be a reflection of the early improvements made to heroin use.  A 
number of previous studies have found substantial improvements in substance use are 
made within the first few months of treatment (Strang et al, 1997). Strain et al (1993), 
for example, found that the most marked reductions in drug use and other problem 
behaviours tended to occur within the first month of treatment, with problem levels 
remaining relatively unchanged during the subsequent four months.  Cacciola et al 
(1998) also reported significant improvement in a number of outcome areas after two 
months with no further improvements between three and seven months. As the 
relationship between readiness to change and substance use outcomes was not assessed 
within the current study it is not possible to determine whether the changes in readiness 
were associated with corresponding changes to heroin use.  The absence of changes in 
readiness after three months may alternatively indicate that motivation for change 
naturally plateaus after a period of time regardless of treatment involvement.  
 
It must be noted that a number of patients included in the study analyses were not 
engaged in treatment for the entire duration of the study period. A total of eight patients 
dropped out of treatment during the study period and one completed treatment. A 
further three patients dropped-out of treatment prior to the three-month interview but 
returned by the six-month interview. The majority of patients who dropped out of 





statistical analyses on, or compare with patients who remained in treatment for the 
duration of the study, it must be acknowledged that the reasons for changes in readiness 
among patients who dropped out of treatment may be different to those engaged in 
treatment. Reductions on the Recognition scale among patients who discontinued 
treatment may be due to them feeling that they do not have a heroin use problem serious 
enough to warrant treatment. Reductions on the Recognition scale may also be related 
to reductions on the Ambivalence scale. The authors of the SOCRATES state “that a 
person  may score low in Ambivalence either because they ”know” their drug use is 
causing problems (high Recognition) or because they “know” that they do not have drug 
use problems (low Recognition).  Lowered Recognition and lowered Ambivalence  in 
the current sample may indicate that  the sample know that they do not have drug use 
problems, whether this is due to changes already  made in drug use or to a lack of 
awareness of their problems is unknown. Further qualitative assessment would be useful 
to clarify how patients feel about their drug problems. This aspect of the SOCRATES 
will be discussed in Chapter 5. 
 
Examination of sub-groups representing different patterns of change in readiness at 
follow-up revealed that while over 70.0% of the sample reduced or did not change their 
Recognition scores between the intake and three-month interview, nearly 30.0% 
increased their scores. A similar pattern of changes emerged on the Ambivalence scale, 
with the greatest proportion of patients decreasing (70.0%) or maintaining (10.0%) their 
scores and 20.0% increasing their scores. On the Taking Steps scale over 60.0% of 
patients decreased or did not change their scores, and nearly 40.0% increased their 
scores at follow-up.  Variability in the direction of change was also observed between 
the three- and six-month interviews. This pattern of change over time, with some 
patients’ scores increasing and some decreasing on the different dimensions of 
readiness, is supported by previous studies which have found motivation levels are 
likely to fluctuate over time, and that motivation for change may decrease in some over 
the course of treatment (Hiller et al, 2002; Norman et al, 1998).  
 
3.5.3   Waiting times and readiness to change 
 
An examination of the waiting times of the sample found wide variations in the length 





of 38.3 days to start treatment, although 40.0% of the sample waited considerably 
longer than this, up to a maximum of 110 days.  A preliminary investigation of the 
relationship between the length of the waiting period and readiness scores revealed a 
positive association between waiting times and Ambivalence scores, although this 
association failed to reach significance once the Bonferroni Correction was applied to 
deal with the testing of multiple measures. No associations were found between waiting 
times and scores on the Recognition and Taking Steps scales.  
 
This positive association between waiting times and Ambivalence scores indicates that 
longer delays for treatment are related to greater conflict and uncertainty about changing 
heroin use. High scorers on the Ambivalence scale, according to the authors of the 
SOCRATES, say that they sometimes wonder if they are in control of their substance 
use, are taking too many substances and are hurting other people, and /or are addicts. 
Lengthier waiting periods may provide the patients with greater time to question the 
pros and cons of their drug use and potential behaviour change, and they may decide 
that they do not have a problem great enough to warrant change.  These explanations are 
speculative as the retrospective design of the study did not permit an examination of 
how readiness changed over the waiting period and whether these levels of 
Ambivalence were present prior to treatment entry. Also, the results are drawn from 
correlational data and so have to be regarded as weak as it cannot be concluded that one 
variable causes a change in another. The correlation found may be due to the influences 
of  ‘other’ variables. There may be a number of other factors present during the waiting 
period, or within the patient (e.g. substance use variables, availability of social support) 
which impacts on  readiness assessed at treatment intake. 
 
The absence of significant associations between waiting times and two of the three 
readiness scales demonstrates that the length of the waiting period had little impact on 
problem recognition or on the activity concerned with changing heroin use, at least 
when assessed by the SOCRATES. The absence of significant relationships may 
suggest that the heroin users who successfully entered treatment after the waiting period 
possess certain individual characteristics which make them tolerant of the wait for 
treatment regardless of their motivation levels, or the length of delay. Further research 
examining a greater range of individual or clinical variables is necessary to identify 





The absence of significant relationships between waiting times and the Recognition or 
Ambivalence scales may alternatively suggest that the SOCRATES is not capable of 
detecting subtle relationships between the variables under investigation. The 
SOCRATES was originally developed to be used on alcohol in-patient samples and 
therefore may not be sensitive enough to fully capture all the aspects of motivation 
among drug users. Further studies examining the use of the SOCRATES among drug 
use samples is therefore needed to test such a proposition.  
 
The Pilot Study was also employed to test a number of other research measures to be 
used in Study 2. Pre-testing assessed the acceptability of the structured interview to the 
patient group and provided the researcher with an opportunity to practice administering 
the interview schedule. During and after the interview the patients were asked to 
comment on the length and the content of the interview, including any questions which 
they found difficult to understand. Piloting identified some items on the interview which 
needed to be slightly revised. For example, several participants commented that the 
interview appeared to repeat questions which they had previously answered. This 
problem was removed by changes to the sequence of the interview questions, with 
questions pertaining to similar areas (e.g. Drug Use Grid and Severity of Dependence 
Scale) grouped together to provide a more logical flow and enable the patients to see 
that the questions asked about different aspects of the same subject area. The majority 
of the sample concluded that the length of the interview was an appropriate duration. 
Overall the interview appeared to be acceptable to the sample of treatment patients.  
 
 
3.5.4   Summary of Study 1 
 
Although the SOCRATES has  previously been used on drug samples (e.g. Gossop et al, 
2007; Burrow-Sanchez and Lundberg, 2007), no studies, known to the author, have 
examined readiness at more than one time point to assess how readiness alters over time 
or in response to different situations such as treatment involvement. The results reported 
fulfilled the main objective of the Pilot Study which was to assess whether the 
SOCRATES could detect changes in readiness over time within a sample of heroin 
users seeking treatment. Although the observed changes in readiness were not large in 
magnitude, the SOCRATES identified statistically significant changes on the 





findings demonstrate that people with drug problems who seek or participate in 
treatment differ significantly in their levels of readiness to change and that this 
readiness changes over time and in different directions. 
 
The preliminary investigation of the relationship between treatment waiting times and 
readiness to change found that longer waiting periods were associated with increased 
Ambivalence scores, although no relationships were evident on the Recognition or 
Taking Steps scales.  The findings of the current study are insufficient to provide 
conclusions concerning the impact of waiting times on readiness to change heroin use.  
The limitations of the current study and the clinical implications of the findings will be 
addressed in Chapter 5.  
 
This study assessed the readiness to change of a group of heroin users starting a new 
treatment episode. Heroin users assigned to the waiting list but who failed to enter 
treatment once a place became available were not included in the sample. Heroin users 
who successfully enter treatment may be different from those who do not enter 
treatment on a number of dimensions, including readiness to change.  This design 
omission will be addressed within the second study which will assess the relationship 
between the length of the waiting period and readiness to change in a sample of heroin 
users assigned to a waiting list prior to entering treatment. The study will utilise a larger 
sample of heroin users and prospectively examine changes in readiness between the 
start and end of the waiting period. These changes in readiness will be examined as a 
function of the length of the waiting period. As the study specifically examines the 
waiting period, heroin users who successfully enter treatment at the end of the waiting 
period and those who fail to enter treatment will be included in the study to provide a 












CHAPTER 4:      STUDY 2 
 
 
4.1     INTRODUCTION  
 
The research literature concerning substance abuse treatment waiting times has 
primarily focused on the relationship between waiting times and treatment entry, with 
studies generally finding that attendance rates decline as waiting time increases (Rees 
and Farmer, 1985; Leigh et al, 1984).  As outlined in Chapter 1, it has been suggested 
that asking substance users to wait before entering treatment may diminish motivation 
(Stevens et al, 2008; Schwartz et al, 2006) which may lead to less interest in entering 
treatment and making changes to substance use behaviours. Despite its potential clinical 
utility, there is a paucity of research which examines the motivation of heroin users 
awaiting treatment entry, or the relationship of motivation during the waiting period to 
key treatment events such as treatment entry, or to clinical variables such as substance 
use during this period. 
 
Identifying factors that affect an individual’s motivation is an important goal in 
substance abuse treatment research and can help guide the development of more 
targeted substance abuse interventions. Understanding how motivation changes among 
heroin users seeking treatment, and how this is related to treatment characteristics such 
as waiting times, is of clinical value as many treatment characteristics are amenable to 
change. If reducing treatment waiting times would serve to maintain or strengthen 
patients’ readiness to change their drug use then this is clearly an important first step in 
encouraging substance users to engage in treatment and ultimately increase the 
effectiveness of treatment.  
 
The pilot study afforded a preliminary examination of readiness to change in a small 
sample of heroin users in the first few months of treatment, after naturally occurring 
waiting times. The design of the study only permitted a retrospective analysis of the 
relationship between waiting times and readiness to change, and only among those 
heroin users who successfully entered treatment after the waiting period.  The study 
failed to find strong support for a relationship between waiting times and readiness to 
change. Study 2 focuses on heroin users awaiting entry into methadone treatment. It 





entry (short waiting period/prolonged waiting period) and changes in readiness over the 
waiting period. The study also examines whether these variables are associated with the 
likelihood of treatment entry after the waiting period and changes in substance use 
during this time.  
 
4.2     RESEARCH QUESTIONS AND OBJECTIVES 
 
The following section will describe the objectives of Study 2. 
 
The conceptual framework for this study was presented in Chapter 1 and is based on the 
hypothesis that the relationship between treatment waiting times and the likelihood of 
treatment entry is mediated by readiness to change heroin use. It is proposed that 
lengthy waiting periods between initial requests for treatment and scheduled treatment 
entry will result in diminished readiness to change, and that these reductions will be 
related to lower rates of treatment entry and fewer changes in patterns of patients’ 
substance use over this period. This study will examine the different proposed 
relationships within the conceptual framework.  
 
Objective 1: To examine the relationship between waiting times and readiness to 
change heroin use. 
 
Objective 1 examines how readiness to change alters over the course of the waiting 
period among a sample of heroin users randomly allocated to two treatment-entry 
conditions which represent short and more prolonged waiting periods. The demographic 
and clinical characteristics which differentiate heroin users who report changes in their 
readiness over the waiting period from those who do not will be also examined. 
 
Hypothesis 1: Heroin users with longer waiting times prior to the start of treatment will 
demonstrate greater reductions in readiness to change than those with shorter waiting 
times.  
 
Hypothesis 2:  Waiting times will be more strongly associated with changes in readiness 






Objective 2: To examine the relationships between readiness to change, waiting 
times and successful treatment entry.   
  
Objective 2 will examine whether the length of the waiting period prior to scheduled 
treatment entry and/or readiness levels are related to the likelihood of treatment entry 
once a treatment place becomes available. 
 
Hypothesis 3: Longer waiting times will be associated with lower rates of treatment 
entry. 
 
Hypothesis 4:  Readiness to change will be a stronger predictor of treatment entry 
status than demographic or substance use variables. 
 
Objective 3:  To examine the relationships between waiting times, readiness to 
change and substance use. 
 
Objective 3 will examine how substance use behaviours (e.g. frequency of heroin use) 
change over the waiting period and whether this change is related to the length of the 
waiting period and/or to the readiness levels of the waiting list participants.  
 
Hypothesis 5: Longer waiting times will be associated with fewer reductions in 
substance use over the waiting period compared to shorter waiting times.  
 
Hypothesis 6:  Increases in readiness scores over the waiting period will be associated 
with a reduction in heroin use over the same period. 
 
Hypothesis 7: Reductions in the frequency of heroin use over the waiting period will be 
associated with high baseline readiness scores. 
 
Objective 4: To examine the relationship between waiting time expectations, 
readiness to change and treatment entry. 
 
Objective 4 will examine the discrepancy between the expected length of the waiting 





discrepancy in waiting times and the likelihood of treatment entry will be examined 
along with the impact of this discrepancy on readiness levels over the waiting period.  
 
Hypothesis 8: Heroin users’ expectations about the length of the waiting period will be 
associated with the likelihood of treatment entry.   
 
Hypothesis 9: Heroin users’ expectations about the length of the waiting period will be 
associated with changes in readiness scores over this period.  
 
4.3     METHOD 
 
4.3.1     Study design 
 
A prospective mixed-groups longitudinal design was chosen for the second study. The 
design utilises two treatment-entry conditions to assess the relationships between 
waiting times, readiness to change and a number of patient factors. Study participants 
were randomly assigned to a short (Accelerated treatment-entry) or more prolonged 
(Standard treatment-entry) waiting period prior to the start of treatment. Readiness to 
change scores at the start and end of the waiting period were compared within, and 
between, the two treatment-entry groups to assess whether readiness levels change 
according to the length of the waiting period experienced.   
 
Data for the study was collected as part of a larger study examining waiting times as 
part of a Drug Misuse Research Initiative funded by the Department of Health 
(described in more detail in Ridge et al, 2002, Appendix 10).  The larger study followed 
a sample of 182 heroin users through the waiting period and focused on the effects of 
treatment delay on the likelihood of treatment entry after the waiting period, treatment 
retention and patient behaviours (e.g. substance use, offending) over this time. The 
purpose of this study was to consider the potential benefit of reducing waiting times in 
UK drug treatment services. The current study focuses specifically on the waiting 
period prior to treatment entry and will not involve the treatment phase.  
 
As the larger waiting list study focused on the relationship between the length of the 





design to allocate study participants to a short or more prolonged waiting period prior to 
the start of treatment. The purpose of the random allocation was to ensure that patient 
factors (e.g. gender, levels of heroin use) were balanced between the two treatment- 
entry groups so that differences in the outcomes observed between the groups were the 
result of the study conditions and not individual differences between the participants.  
 
It was decided to compare patients who received expedited treatment entry 
approximately 14 days after their first clinical presentation at the service, with patients 
whose treatment was offered after a delayed period under the normal waiting list 
conditions operating within the treatment service. The choice of the 14-day waiting 
period was partly based on two previous studies which found that waiting periods of 2 
weeks or less were associated with increased attendance rates. Dennis et al (1994) 
reported an increase in the number of patients that kept intake appointments in a 
methadone programme when the waiting period was reduced from 40 days to 14 days, 
while Fleming and Lewis (1987) reported that waiting time of more than 2 weeks 
increased non-attendance at an out-patient alcohol clinic. Although a number of earlier 
studies with out-patient samples reported that waiting periods greater than eight days 
reduced the probability of initial attendance (Hyslop and Kershaw, 1981; Wanberg and 
Jones, 1973) the treatment service used in the current study insisted that a 2-week 
period after the initial assessment was required for clinical information to be collected 
from referrers and clinical decisions to be made about treatment provided within the 
service.  
 
4.3.2    Power calculation to determine sample size 
 
As there are no previous published studies assessing the relationship between waiting 
times and changes in motivation, a small effect size (0.3) was selected to test the main 
study hypothesis predicting greater changes in readiness among the Accelerated group 
relative to the Standard group. Entering this effect size into a statistical software 
programme (GPower), indicated that a sample size of at least 72 participants would be 
required to demonstrate differences in treatment-entry group means at follow-up. Test 
significance = 0.05, groups = 2, number of repetitions = 2 with 80% power. It was 
anticipated that a number of participants would have incomplete SOCRATES data or 





recruited to the larger cohort study, and who fulfilled the inclusion criteria for statistical 
analyses, were included in the current study. 
  
4.3.3     Sample 
 
The sample for the current study comprised 133 treatment seekers attending an initial 
assessment at the community drug treatment service which forms part of the Addictions 
Directorate of the South London and Maudsley NHS Trust. A total of 49 patients 
recruited to the larger study did not meet the inclusion criteria for the current study (see 
Figure 4.1). As detailed in Chapter 2, the drug clinics within the service provide 
community-based reduction and maintenance programmes primarily for individuals 
seeking help for opiate dependence and provides substitute and maintenance prescribing 
and counselling following a Harm Reduction Model. The recruited sample were all 
seeking treatment for heroin dependence problems over a 19-month period.   
 
4.3.4     Inclusion/exclusion criteria 
 
Inclusion criteria for the current study included –  
 
 (1) Heroin users presenting to the service with a primary heroin dependence problem 
requesting out-patient treatment, 
(2) Heroin users reporting heroin use in the 30 days prior to first contact with the clinic,  
(3) Heroin users aged between 18 and 65 years, and  
(4) Heroin users fluent in the English language.  
 
Exclusion criteria for the study included – 
 
(1) Heroin users who were currently prescribed substitute medication from another 
source (e.g. G.P.s) at the time of initial assessment at the treatment service. Many local 
G.P.s and other services provide short-term substitute prescriptions to heroin users until 
they can be accepted into formal treatment programmes. These individuals were 
excluded from the study to prevent the possible confounding influence of substitute 
medication on substance use behaviours and the likelihood of treatment entry after the 





(2) Heroin users considered to be of greater risk from the harms associated with heroin 
use were prioritised by the service to receive speedier access to treatment. These 
included pregnant drug users, drug users recently released from prison, sex workers, and 
those with risky injecting practices (e.g injecting in the groin or neck). These 
individuals were excluded from the study as random allocation to a treatment entry 
group was not possible. 
 (3) Heroin users identified as having learning disabilities, neurological disorders or 
reported intoxication at initial assessment by the treating clinicians were excluded from 
the study since all of these were likely to have an impact on heroin users’ 
comprehension and completion of the research interview.  The impact of these 
exclusion criteria on the results of the study will be addressed in Chapter 5.  
 
4.3.5     Measures    
 
Instrument development  
 
 
A comprehensive set of data collection instruments was used to gather information for 
the 30-day period prior to the baseline interview. Key domains of behaviour taken from 
the Maudsley Addiction Profile (MAP; Marsden et al, 1998) included the assessment of  
substance use, physical and psychological health functioning, severity of substance use 
dependence and health risk behaviours. The Stages of Change, Readiness and Treatment 
Eagerness Scale (SOCRATES; Miller and Tonigan, 1996) was used to assess readiness 
to change heroin use among the sample. Details of these measures can be found in 
Chapter 2. As no instructions on to how to deal with incomplete SOCRATES data sets 
was provided by the authors, only participants who completed the measure without 
















4.3.6     Research interviews 
 
 
Baseline interview   
 
In addition to the measures detailed above, further questions were used to collect 
demographic information (age, gender, accommodation, ethnicity and employment 
details). All information in the baseline interview referred to behaviours (e.g. substance 
use) during the previous 30 days. Participants were also questioned on how long they 
expected to wait for their treatment to start. Detailed locator information was also 
recorded at the baseline interview to ensure the collection of reliable follow-up data.  
This included both participant and next-of-kin details (Appendix 5). 
 
Follow-up interview  
 
The second structured research interview (Appendix 6) used the same measures as the 
baseline interview.  Information in the follow-up interview concerned behaviours in the 
period between baseline interview and the date of scheduled treatment entry (start and 
end of the waiting period). Among the Accelerated treatment-entry group, the follow-up 
interview was conducted approximately 14 days after the baseline interview. Among the 
Standard group, this period varied according to the length of the waiting period.  
 
‘Lost-to treatment’ interview  
 
Study participants who failed to attend the Full Assessment appointment (and thus did 
not enter treatment) after the waiting period were located, where possible, and 
interviewed. The Lost-to-treatment interview assessed substance use, severity of drug 
dependence, physical and psychological health and readiness to change for the period of 
time since the last research interview was conducted. Additional items were included to 
assess heroin users’ reasons for not starting treatment and an assessment of their future 
plans for reducing substance use (Appendix 7).  
 
Lost-to-treatment interviews took place in locations mutually convenient to the 
participant and researcher (e.g. treatment service, patients’ homes, local cafe). When the 





always present. For safety reasons, someone associated with the project was informed 
where the staff were going and when they expected to return. Several attempts to 
contact waiting list participants who failed to attend their Full Assessment were made. 




4.3.7     Piloting the research interview 
 
 
The structured interview to be used in the current study was piloted on a sample of 40 
heroin users starting a new treatment episode within the same service used for the 
current study data collection. The purpose of the Pilot Study, detailed in Chapter 3, was 
to examine whether the chosen measure of motivation (SOCRATES) was capable of 
detecting changes in readiness over time in a sample of heroin users and also assessed 
the acceptability of the structured interview to the patient group.   The SOCRATES was 
administered at three separate time points in a 6-month period after treatment entry. The 
results demonstrated that changes in readiness could be detected on the Recognition and 
Ambivalence scales over the first 3-month period studied.  These results fulfilled the 
main acceptability criteria set within the Pilot Study and was therefore chosen as the 
measure of motivation for the current study. Piloting of the structured interview also 
indicated that the instrument was acceptable to the patient group in terms of the content 
and duration of the interview. 
 
4.3.8     Procedure 
 
The process of clinical assessment and treatment entry used within the service is 
detailed in Chapter 2. In summary, a heroin user attends the walk-in drug clinic and is 
assessed (Brief Assessment) by a drug counsellor or psychiatric nurse (key-worker). 
They are then referred to the appropriate clinic either within the treatment service 
(reduction or maintenance programmes) or to another more appropriate service to 
address their needs. Within the treatment service heroin users are placed on a waiting 
list until a treatment slot becomes available. At this point they are invited to the service 
for another, more detailed, clinical assessment (Full Assessment). This represents the 
start of treatment. Within a few days of this assessment they attend a three-day Dose 





Once engaged in treatment the heroin users receive weekly or fortnightly counselling 
sessions with a key-worker and are monitored with routine urinalysis to test for the 
presence of illicit drugs. 
 
4.3.9   Participant recruitment 
 
 
Heroin users presenting to the clinic and who fulfilled the inclusion criteria (as 
confirmed with the key-worker who conducted the initial clinical assessment) were 
approached by a researcher after the Brief Assessment and invited to participate in the 
study. Written informed consent was obtained from each heroin user who agreed to 
participate after the aims of the study and the data collection procedures had been fully 
explained (Appendix 4). They were informed that study participation was voluntary and 
refusal would not affect the treatment they received. Patients who had literacy problems 
had the study aims and objectives fully explained to them by a researcher.  
 
4.3.10     Conducting the research interview 
 
Each study participant was interviewed by an independent researcher not associated 
with the provision of treatment. Each structured interview lasted approximately forty 
minutes. The same researcher also conducted all follow-up interviews. A baseline 
interview was conducted with each participant after their initial clinical assessment at 
the treatment service (Brief Assessment). After this interview participants were 
randomly assigned to one of two treatment-entry groups (Standard or Accelerated) 
which will be detailed in the following section. Study participants who entered 
treatment at the end of the waiting period were interviewed for a second time (follow-up 
interview) straight after their Full Assessment appointment. If this was not possible, an 
appointment was made with them to complete the research interview within the 
following few days. Study participants who failed to attend the Full Assessment 










4.3.11     Randomisation of the heroin users to the treatment-entry groups 
 
All participants were randomly allocated to a treatment-entry group after the baseline 
interview had been conducted. The randomisation procedure was conducted by a 
researcher not involved in the study or with the clinical teams within the treatment 
service. The randomisation was achieved by generating random number lists on a 
computer using SPPS version 16. The randomisation was conducted in blocks to arrive 
at equal numbers of study participants in each treatment-entry group. The randomisation 
was conducted for the larger study cohort (n=182) which generated two groups of 91 
participants. 
 
The study participants were informed of their treatment-entry group allocation within 
several days of the first structured interview by a letter sent to their current address. 
Allocation concealment was not possible after the baseline interview as individuals 
randomised to the Accelerated treatment-entry group would be invited for a Full 
Assessment within 2 weeks of the baseline interview. No deviations from the 
randomised allocation occurred throughout the course of the study. 
 
Accelerated treatment-entry group: Participants randomised to the Accelerated group 
were sent a letter with a date for a Full Assessment appointment within several days of 
their initial presentation at the service. The Full Assessment appointment was scheduled 
approximately 2 weeks after their initial presentation at the service. The follow-up 
research interview was conducted after the Full Assessment appointment. This 
interview was designed to measure behaviours over the short waiting period prior to the 
start of treatment.  
 
Standard treatment-entry group: Participants randomised to the Standard group were 
placed on the clinic waiting list after the Brief Assessment and waited for a treatment 
slot to become available as would occur under normal conditions within the clinic. The 
Standard group were offered a Full Assessment appointment date as soon as a treatment 
place became available. This was typically between 4 and 12 weeks after the Brief 








4.3.12     Participation rates 
 
During the 19-month study recruitment period a total of 380 heroin users accessed the 
clinic. Of these, 93(24.5%) were prioritised by the clinic to receive fast-track treatment 
entry (pregnant drug users, sex-workers, those with risky injecting practices, recent 
release from prison) and 47 (12.4%) were currently prescribed substitute medication 
from another source. Both of these groups were excluded from the study. A further 58 
(15.3%) heroin users refused to participate in the study at the time of recruitment. A 
total of 182 heroin users were successfully recruited to the larger cohort waiting list 
study funded by the Department of Health.  
 
For the present study, 133 participants who completed both baseline and follow-up 
interviews or Lost-to-treatment interviews (among those who failed to enter treatment) 
and who had complete data on the SOCRATES were included in the study sample. This 
consisted of 51 participants randomised to the Standard group and 82 to the Accelerated 
group. A flow diagram of participant progress through the phases of the study is 
presented in Figure 4.1. 
 
Although all heroin users seeking treatment at the service were approached, the majority 
of those consenting to study participation were allocated to the methadone reduction 
programme (n=128) after their initial clinical assessment rather than to the methadone 
maintenance programme (n=5). The reason for the discrepancy in programme allocation 
is unclear but may be the result of the prioritisation system existing within the service 
for heroin users at higher risk of drug-related harms (e.g. risky injecting practices, 
recent release from prison). It may be the case that the clinical teams felt that the needs 





















                                                                                                             
 

































Assessed for eligibility (n=380) 
Excluded (n=198) 
-Prioritised to receive fast-
track treatment entry (n=93) 
-Prescribed substitute 
medication from another 
source (n=47) 




Completed (n=73)  
Did not complete (n=18) 
Lost to treatment interview: 
Completed (n=13) 
Did not complete (n=6) 
 
Completed baseline interview and 
either follow-up interview or ost to 
treatment interview (n=86) 
 
Excluded: 
Incomplete SOCRATES data (n=4) 
 




Allocated to intervention 
Accelerated treatment-entry group 
(n=91) 
Allocated to intervention 




Did not complete (n=44) 
Lost to treatment interview: 
Completed (n=12) 
Did not complete (n=33) 
 
Completed baseline interview and 
either follow-up interview or lost to 
treatment interview (n=59) 
 
Excluded: 
Incomplete SOCRATES data (n=8) 
 





4.3.13     Data analysis  
 
Data were analysed using SPSS version 16. All variables were screened for skewness 
and kurtosis following initial screening using scatterplots and basic computation as 
specified by Tabachnick and Fidell (2001). Heroin frequency assessed at the baseline 
interview failed tests of normal distribution (skewness = -2.14, kurtosis = 2.25) and the 
Kolmogorov-Smirnov test confirmed the data were not normally distributed (p<0.001).  
Frequency of non-prescribed methadone use at baseline was also not normally 
distributed (skewness = 2.53, kurtosis = 2.38, Kolmogorov-Smirnov <0.001). 
Logarithmic transformations reduced the skew of the distribution for non-prescribed 
methadone and heroin frequency, with a better approximation to the normality  
requirements of the statistical procedures employed. Raw scores are presented in all 
tables to aid interpretation.  
 
Demographic and substance use characteristics of the study participants randomised to 
the Accelerated and Standard treatment-entry groups were compared with independent 
t-tests and chi-square tests. The distribution of waiting times experienced by each group 
is displayed in graphs. 
 
Repeated measures analysis of variance compared changes in readiness over the waiting 
period (start of the waiting period/end of the waiting period) of the Standard and 
Accelerated treatment-entry groups. This allowed an examination of the actual change 
in readiness according to the length of the waiting period. Chi-square analyses 
compared the direction of changes in readiness (increased/ decreased/ stayed the same). 
GLM multivariate analysis of variance examined patient and clinical factors which 
differentiated heroin users who made changes in readiness over the waiting period to 
those who did not. Data  reported as ‘follow-up’ combines information collected from 
the participants entering treatment after the waiting period (follow-up interview) and 
information collected from those who failed to enter treatment  (Lost-to-treatment 
interview). 
 
Chi-square analysis was used to compare the treatment entry rates of the Standard and 
Accelerated treatment-entry groups and independent t-tests examined the likelihood of 





and substance use variables associated with treatment entry was performed using chi-
square tests for categorical data and independent t-tests for continuous variables. 
Variables significant at the bi-variate level were entered into separate logistic regression 
analyses to examine the variables which predicted treatment entry.  
 
Repeated measures analysis of variance compared changes in substance use over the 
waiting period (start of the waiting period/end of the waiting period) of the Standard 
and Accelerated treatment-entry groups. This allowed an examination of the actual 
change in substance use according to the length of the waiting period. Chi-square 
analyses compared the direction of changes in substance use (increased/ decreased/ 
stayed the same). GLM repeated measures analysis of variance assessed the relationship 
between changes in readiness levels over the waiting period as a function of heroin 
frequency change groups (increased/ stayed the same/ decreased the frequency of heroin 
use) and GLM multivariate analysis of variance examined the patient and substance use 
factors which differentiated heroin users who made changes to their substance use over 
the waiting period to those who did not. 
 
Follow-up interviews recorded information for the period between the two research 
interviews. This period was variable within and between the two treatment-entry 
groups. In order to make meaningful comparisons between the Standard and 
Accelerated groups, the frequency of substance use data (number of days used since the 
previous interview) were converted into ‘days of use per week since the last interview’. 
Less than 18.0% of the sample reported the use of benzodiazepines, cocaine powder or 
amphetamines. These drugs will be excluded from the analyses. 
 
Independent t-tests were used to compare the actual waiting times of those who entered 
treatment and those who did not according to the four expected waiting time categories 
of different durations. Analyses of variance (ANOVA) were conducted to assess 
whether demographic and substance use characteristics assessed at the baseline 
interview were associated with expectations of waiting time. GLM repeated measures of 
analysis compared the changes in readiness over the waiting period according to the 






As a result of the need to conduct multiple comparisons for a number of measures, the 
Bonferroni Correction procedure was applied to control for the inflation of type 1 error 
rates. This was set at an alpha level of 0.01. Test results before and after adjustment 
with the Bonferroni method are presented. The advantages and disadvantages of 
adjusting the alpha level are discussed in Chapter 2. 
 
The intake characteristics and waiting times of the present study sample (n=133) and of 
the remaining participants from the larger waiting list study cohort (n=49) were 
compared using logistic regression to see the extent to which the two study samples 
differed.  Variables included in the analysis were: gender, age, frequency of heroin, 
non-prescribed methadone and crack cocaine use, injecting status, physical and 
psychological health scores. This model was significant (χ2= 26.93, p<0.01). The two 
groups differed on two variables. Heroin users from the larger cohort had higher 
physical health scores (18.1 vs 15.9; Wald= 5.39, p<0.05) and experienced a longer 
waiting period (47 days, s.d.= 24.5) compared to the study sample (30.8 days, s.d.24.9; 
Wald =14.32, p<0.01). 
 
4.3.14     Characteristics of the study sample 
 
A preliminary analysis of the data was conducted to describe the sample and compare 
the characteristics of participants randomised to the Standard and Accelerated 
treatment-entry groups. Chi-square tests were used to compare differences for 
categorical variables and independent t-tests for continuous variables. The results are 
presented in Tables 4.1 and 4.2. 
 
Approximately three-quarters (75.9%) of the sample was male and 60.9% described 
themselves as ‘White British’. The ages of the sample ranged from 19-54 years with a 
mean of 33.3 years (s.d. 7.9) Almost half of the sample had a partner (48.9%) and  
22.6% had worked in the 30 days prior to seeking treatment at the service. Almost half 
(47.4%) had previously been imprisoned and a third (33.8%) reported committing a 
crime in the previous 30-day period.  Study participants reported heroin use on a mean 
of 6.1 days per week (s.d.2.0).  A total of 63.2% of the sample reported crack cocaine 
use, 31.6% reported the use of non-prescribed methadone, 55.6% reported cannabis use 





sample reported current intravenous use of at least one drug and 69.2% of the sample 
had at least one previous episode of heroin treatment. 
 
 
Table 4.1:  Baseline demographic characteristics of the full sample and the treatment-
entry groups 
 







Age 33.3(s.d.7.9) 32.1(s.d.7.2) 33.3(s.d.8.2) 0.96(0.34) 
Gender:    male 101(75.9%) 60(46.2%) 61(49.4%) 0.15(0.71) 
Ethnicity: 
                White British 
                 European 
                 Black British 
                 African 
                 Asian 
                 Mixed 




























Employed 30(22.6%) 14(18.2%) 18(22.2%) 0.40(0.56) 
Current partner 65(48.9%) 39(50.6%) 38(46.9%) 0.22(0.75) 
Previous imprisonment 63(47.4%) 30(39.0%) 42(51.9%) 2.65(0.11) 
Crime (last 30 days) 45(33.8%) 28(36.4%) 30(37.0%) 0.01(1.00) 
Physical health* 15.9(s.d.7.7) 15.4(s.d.7.5) 16.9(s.d.7.9) 1.24(0.22) 
Psychological health 16.8(s.d.8.4) 14.2(s.d.7.6) 5.2( s.d.8.5) 1.20(0.18) 
*Physical and psychological health status assessed by the MAP. Scores range from 0-40 where higher 
scores represent a greater frequency of symptoms 
 
 
The random assignment to the Standard and Accelerated groups produced two groups 
that closely resembled each other on demographic and clinical variables collected at the 
baseline interview. The Standard and Accelerated groups were comparable on ethnicity, 
gender, age, physical and psychological health, relationship status, crime and previous 
imprisonment (Table 4.1). The two groups reported similar substance use frequencies, 















Table 4.2: Baseline clinical characteristics of the full sample and the treatment-entry 
groups 
 







Heroin frequency* 6.1(s.d.2.0) 6.2(s.d.1.9) 6.0(s.d.1.9) 0.61(0.54) 
Methadone use 42(31.6%) 15(29.4%) 27(32.9%) 0.18(0.67) 
Methadone frequency 3.6(s.d.5.2) 3.8(s.d.5.0) 3.5(s.d.5.1) 0.21(0.30) 
Crack cocaine use 84(63.2%) 33(64.7%) 51(62.2%) 0.85(0.77) 
Crack cocaine  
frequency 
2.0(s.d.1.1) 2.3(s.d.1.2) 1.8(s.d.1.4) 1.30(0.19) 
Alcohol frequency 1.7(s.d.1.1) 1.9(s.d.1.3) 1.5(s.d.0.9) 1.02(0.31) 
Cannabis use 74 (55.6%) 27(52.9%) 47 (57.3%) 0.24(0.38) 
Heroin quantity 0.5(s.d.0.4) 0.5(s.d.0.41) 0.5(s.d.0.4) 0.22(0.83) 
Crack cocaine 
quantity 
0.3(s.d.0.2) 0.3(s.d.0.2) 0.3(s.d.0.1) 0.30(0.76) 
Alcohol use 72(54.1%) 27(52.9%) 45(54.9%) 0.05(0.49) 
Alcohol quantity 3.8(s.d.2.1) 3.9(s.d.1.7) 4.0(s.d.2.0) 0.39(0.72) 
IV drug use 60(45.1%) 37(48.1%) 38(46.9%) 0.02(1.00) 
Previous heroin 
treatment 
92(69.2%) 52(67.5%) 59(72.8%) 0.53(0.49) 
Heroin SDS** 11.2(s.d.2.9) 11.0(s.d.2.7) 11.3(s.d.2.7) 0.51(0.61) 
*Frequency of substance use refers to days per week   ** SDS (Severity of Dependence Scale) scores 
range between 0-15 with higher scores representing greater severity of heroin use. 
 
 
4.3.15     Length of the waiting period prior to scheduled treatment entry 
 
 
The mean waiting times of the full sample and the Standard and Accelerated groups 
were examined.  The full sample waited a mean of 31.2 days (s.d. 26.0) between first 
contact with the treatment service and the scheduled treatment entry (range of 6 -116 
days).  Examining the treatment-entry groups separately, the Standard group waited a 
mean of 58.5 days (s.d. 23.4, range of 22-116 days) and the Accelerated group waited a 
mean of 14.2 days (s.d. 2.11, range of 6-21 days). Figure 4.2 and 4.3 displays the 
waiting times of study participants randomised to the Standard and Accelerated 
treatment-entry groups. Appendix 12 shows the frequency of individual waiting times 
of the two groups. The waiting times of the Standard group and the Accelerated group 









Figure 4.2: Waiting time between first presentation at the treatment service and time of 




Figure 4.3. Waiting time between first presentation at the treatment service and time of 





Examination of the distribution of waiting times revealed 4 outliers: 105,106,108 and 
116 days. One method for managing outliers is to replace the extreme scores with the 
preceding highest value (Tabachnick and Fidell, 2001). This value was 96 days. With 
the outliers removed the full sample waited a mean of 30.8 days (s.d.24.9) with a range 





removed) the Standard group waited a mean of 57.5 days (s.d.21.4, range of 22-96 days) 
and the Accelerated group waited a mean of 14.2 days (s.d.2.11, range of 6-21 days). 
 
 
4.3.16     Readiness to change at the baseline interview 
 
 
Table 4.3 displays the readiness to change scores of the full sample at the baseline 
interview. According to the interpretive ranges2 suggested by Miller and Tonigan 
(1996) the mean sample score on the Recognition scale was categorised as ‘low’ (mean 
of 30.4, s.d.3.4). The mean score on the Ambivalence scale (14.4, s.d.2.4) was classified 
as ‘medium’ and the mean score on the Taking Steps scale as ‘low’ (29.5, s.d.5.9).  
 









Mean scale score (sd) 30.4 (s.d.3.4) 14.4 (s.d.2.4) 29.5 (s.d.5.9) 
Confidence Interval (95%) (29.8, 30.9) (14.0, 14.8) (28.5, 30.5) 
Median  30 15 30 
Range  21-35 9-20 10-40 
Possible scale ranges: Recognition 7-35, Ambivalence 4-20, Taking Steps 8-40. 
 
Statistically significant positive correlations were found between the Recognition and 
the Ambivalence scale scores (r = 0.43, p<0.01) and also between the Recognition and 
the Taking Steps scale scores (r = 0.32, p<0.05).  There was no statistically significant 
correlations between the Ambivalence and Taking Steps scales (r = 0.17, p = 0.22). The 
implications of these correlations will be addressed in Chapter 5. Independent t-tests 
failed to detect any differences between the readiness scale scores of the Standard and 






                                            
2 Interpretive ranges are based on a sample of 1,726 adult men and women presenting for treatment for 
alcohol problems through Project MATCH (Project MATCH Research Group, 1993). Interpretive ranges 





Table 4.4:  Baseline readiness scale scores of the Standard and Accelerated groups  
 Standard 
mean score (s.d) 
Accelerated 
mean score (s.d) 
t 
(st/ac) 
p CI (95%) 
Recognition 30.2(3.6) 30.5(3.2) 0.50 0.62 -1.48, 0.88 
Ambivalence 14.3(2.6) 14.5(2.3) 0.38 0.71 -1.01, 0.69 
Taking Steps 29.2(6.1) 29.8(5.6) 0.56 0.58 -2.62, 1.46 
Possible scale ranges: Recognition 7-35, Ambivalence 4-20, Taking Steps 8-40. 
 
4.4   RESULTS 
 
4.4.1   Changes in readiness over the waiting period    
 
Hypothesis 1: Heroin users with longer waiting times prior to the start of treatment will 
demonstrate greater reductions in readiness to change than those with shorter waiting 
times.  
 
Changes in readiness between the baseline interview and the follow-up interview (time 
of scheduled treatment entry) were examined using GLM repeated measures analysis of 
variance with the two interview points (baseline/follow-up) as the within-subjects factor 
and the treatment-entry group (Standard/Accelerated) as the between-subjects factor. 
These results are presented in Table 4.5. 
 
Recognition scale: The mean scores of the Standard and Accelerated treatment-entry 
groups remained relatively static between the baseline and follow-up interviews  
(F =2.38, d.f. = 1,131, p = 0.44) and no statistically significant interaction effects were 
found between group randomisation and changes in Recognition scores over time 













Table 4.5: Mean readiness to change scores at baseline and follow-up interviews 

























30.2(3.3) 29.4(3.9) 30.5(3.2) 30.3(3.4) 2.38 1.26 
Ambivalence 14.3(2.6) 13.7(2.7) 14.5(2.3) 10.7(2.7) 69.42** 14.70* 
Taking Steps 29.2(6.1) 28.8(6.0) 29.8(5.6) 23.1(4.7) 47.15** 9.26** 
Possible scale ranges: Recognition 7-35, Ambivalence 4-20, Taking Steps 8-40. *p<0.01, **p<0.001 
 
Ambivalence scale: Both treatment-entry groups reported a mean reduction in 
Ambivalence scores between baseline and follow-up interviews (F = 69.42, d.f. = 1,131, 
p<0.001) with a statistically significant interaction effect between group randomisation 
and changes on the Ambivalence scale (F =14.70, d.f. = 1,131, p<0.01). The 
Accelerated group reported a greater reduction in scores compared to the Standard 
group.  
 
Taking Steps scale: Overall there was a reduction in scores on the Taking Steps scale 
between the baseline and follow-up interviews (F = 47.15, d.f =1,131, p<0.001). A 
significant interaction effect between treatment-entry group and changes on the scale 
over time was found (F = 9.26, d.f =1,131, p<0.001). The Accelerated group reported 
greater reductions in scores on the Taking Steps scale compared to the Standard group.  
 
In terms of effect size (Cohen’s d), the Standard treatment-entry group reported small 
reductions on the Recognition scale (0.3) and the Ambivalence scale (0.3) and no 
notable differences for scores on the Taking Steps scale (0.1). Within the Accelerated 
treatment-entry group no notable differences were found on the Recognition scale while 
large reductions were found on the Ambivalence (0.9) and Taking Steps (0.9) scales. 
 
To summarise these findings, in terms of group means, the shorter waiting periods of 
the Accelerated group were associated with reduced scores on the Ambivalence and 





periods experienced by the Standard group were not associated with changes on any of 




The purpose of the randomisation to the Standard and Accelerated treatment-entry 
groups was to create two groups with distinctively different waiting periods in order to 
compare the effects of these waiting periods on readiness to change. Due to some small 
variations in the waiting times of the Accelerated group, 20 waiting list participants 
experienced waiting times above 14 days, up to a maximum of 21 days (Appendix 11). 
Due to the naturally occurring waiting times of the Standard group, 3 waiting list 
participants waited a shorter duration than that which was expected (30 days or less, 
Appendix 10). 
 
In order to minimise the impact of these waiting time anomalies within the statistical 
analyses, the relationship between waiting times and readiness scores was re-analysed 
with waiting time as a continuous variable (i.e. number of days waited for scheduled 
treatment entry) rather than a dichotomous variable (Standard/Accelerated treatment- 
entry groups).  A change variable was also created for each readiness scale (readiness at 
baseline - readiness at follow-up). 
 
It was also considered that managing outliers (those with waits more than 96 days days) 
in the waiting time variable with the mean substitution method may not have provided a 
true representation of the more prolonged waiting periods experienced by the heroin 
users. This method substitutes the longest waiting times experienced with a shorter 
waiting time to fit in with the normal distribution of waiting times within the sample. It 
was decided to logarithmically transform the waiting time variable in order to maintain 
the full waiting time data while at the same time stabilising the variance of the sample. 
Logarithmic transformations use the natural logs of the values of the analyses, rather 
than the original raw values and are commonly used for positive data. Box-plot analysis 
showed that this method successfully managed the outlying waiting time values. All 






Table 4.6 present the results of the correlational analyses between readiness change 
scores between baseline and follow-up interviews and waiting time (days). Using a 
different method to examine the relationship between waiting times and changes in 
readiness over the waiting period did not reveal a different pattern of results to that 
reported for the separate Standard/Accelerated waiting times. Statistically significant 
positive correlations were found between the Ambivalence change score variable  
(r = 0.43, p<0.001) and Taking Steps change score variable (r = 0.39, p<0.001). No 
statistically significant correlation was found between waiting times and changes on the 
Recognition scale over the waiting period. 
 
Table 4.6: Change in readiness scores between baseline and follow-up correlated with 








Waiting time (days) -0.10(0.26) 0.43(0.001) 0.39(0.001) 
 
4.4.2    Changes in readiness scores at a case-by-case level 
 
Inspection of readiness scores over the waiting period at a case-by-case level revealed 
variations in the pattern of changes between the baseline and follow-up interviews 
among the sample. The data was reanalysed to obtain three subgroups – (1) participants 
whose readiness scores decreased, (2) participants whose scores increased, and  
(3) participants whose scores did not change over the waiting period. Tables 4.7 to 4.9 
display the number of waiting list participants whose readiness scores increased, 
decreased or stayed the same between baseline and follow-up interviews on each scale.  
 
Recognition scale: The greatest proportion of the Standard (52.9%) and the Accelerated 
groups (41.5%) showed a reduction in Recognition scores between the baseline and 
follow-up interviews. Nearly a third of the Standard group (31.4%) and the Accelerated 
group (37.8%) increased their Recognition scores and a small proportion from each 
group did not change their scores (Standard =15.7%; Accelerated = 20.7%).Chi-square 
analysis found no statistically significant differences in the pattern of changes between 






Table 4.7: Changes in Recognition scores between baseline and follow-up interviews 





     
increased 16(31.4) 31(37.8) 1.70 0.43 
stayed the same 8(15.7) 17(20.7) 
decreased 27(52.9) 34(41.5) 
 
Ambivalence scale: The majority of the Accelerated group (85.4%) reported reductions 
on the Ambivalence scale between baseline and follow-up interviews. Only a small 
proportion of the Accelerated group increased their scores (4.9%) or maintained their 
scores (9.8%) between the interview points. Within the Standard group, 43.1% 
decreased their Ambivalence scores, 33.3% increased their scores and 23.5% did not 
change their scores between the interviews. Chi-square analysis indicated statistically 
significant differences in the proportions of the Standard and Accelerated group that 
changed their scores between the baseline and follow-up interviews (χ2 = 28.20, 
p<0.001) (Table 4.8). 
 
Table 4.8: Changes in Ambivalence scores between baseline and follow-up interviews 





     
increased 17(33.3) 4(4.9) 28.20 0.001 
stayed the same 12(23.5) 8(9.8) 
decreased 22(43.1) 70(85.4) 
 
Taking Steps: The majority (86.6%) of the Accelerated group reported decreasing their 
Taking Steps scores over the waiting period, 7.3% increased their scores and 6.1% 
maintained their scores between the interviews. Within the Standard group 45.1% 
decreased their Taking Steps scores, 45.1% increased their scores and a further 9.8% 
maintained their scores between the two interview points. There was a statistically 
significant difference between the proportions of the Standard and Accelerated groups 








Table 4.9: Changes in Taking Steps scores between baseline and follow-up interviews 





     
increased 23(45.1) 6(7.3) 28.82 0.001 
stayed the same 5(9.8) 5(6.1) 
decreased 23(45.1) 71(86.6) 
 
4.4.3     Changes in readiness according to baseline readiness scores 
 
Hypothesis 2:  Waiting times will be more strongly associated with changes in readiness 
scores over the waiting period than baseline demographic or clinical characteristics. 
 
Two sets of analyses were performed to examine the relative association of a range of 
patient characteristics within the sample on the changes in readiness scores reported in 
the previous analyses. First of all analysis of variance (ANOVA) examined the direction 
of change in readiness scores (increased/ decreased/ stayed the same) between the  
baseline and follow-up interviews according to baseline readiness levels. Post-hoc 
paired comparisons between the change groups were assessed by Scheffe tests (for 
unequal sample sizes).  
 
Figure 4.4 demonstrates that heroin users whose Recognition scores decreased over the 
waiting period had significantly higher baseline Recognition scores (31.8, s.d.3.3) 
compared to those whose scores increased (28.4, s.d.3.3) or stayed the same between the 























Heroin users whose Ambivalence scores decreased over the waiting period had 
significantly higher baseline Ambivalence scores (15.0, s.d.2.0) compared to those 
whose scores increased (12.7, s.d.1.8) or remained stable at follow-up (13.6, s.d.1.0; 
d.f.= 2,130, F = 9.72, p<0.001)  (Figure 4.5). 
 
 











Waiting list participants whose Taking Steps scores decreased over the waiting period 
had the highest baseline Taking Steps scores (29.9, s.d.4.07) compared to those whose 
scores increased over the waiting period (25.7, s.d.6.07) or remained the same (26.9, 
s.d.3.7). The baseline Taking Steps scores of the three change groups were significantly 
different (F =12.35, d.f = 2,130, p<0.001) (Figure 4.6). 
 
Figure 4.6: Change in Taking Steps scores over the waiting period in relation to baseline  




The same pattern of results was found on each of the readiness scales. Heroin users with 
the lowest baseline readiness scores increased their scores over the waiting period, and 
those with the highest baseline readiness scores decreased their scores over the same 
period.  
 
In order to assess whether any patient characteristics were associated with the direction 
of change in readiness scores over the waiting period GLM multivariate analyses of 
variance (MANOVA) were conducted. Patient characteristics were entered as the 
dependent variables and the direction of change (increased/ decreased/ stayed the same) 
was entered as the grouping variable. Continuous variables included in the analysis 
were age, physical and psychological health scores and Severity of Dependence Scale 
for heroin use assessed at the baseline interview. Waiting time prior to scheduled 
treatment entry (number of days) was also included in the analysis. Post-hoc paired 





square tests assessed the association between categorical variables (gender, 
employment, relationship and injecting status) and the direction of change in readiness 
scores (increased/ decreased/ stayed the same). 
 
The MANOVA for the Recognition scale was not statistically significant  
(F = 1.26, p = 0.26). However, univariate F tests indicated that physical health status  
(F = 3.88, p<0.05) and psychological health status (F = 4.12, p<0.05) were significantly 
related to Recognition scale change status. Heroin users who increased their 
Recognition scores over the waiting period reported significantly higher mean physical 
health scores and psychological health scores than those whose scores decreased or did 
not change over the waiting period (Table 4.10).  
 
The length of the waiting period was not associated with the direction of change in the 
readiness scores over this period, supporting the earlier findings when mean changes 
over the waiting period on the Recognition scale were analysed.  There was a trend for 
heroin users whose scores increased to be older, although this did not reach statistical 
significance in univariate F-tests.  
 
Table 4.10: Associations between baseline demographic and clinical characteristics and 












Physical health score 18.3(7.6) 13.6(7.5) 14.9(7.5) 3.88 0.02 
Psychological health score 19.6(9.5) 14.7(6.7) 15.4(7.7) 4.12 0.02 
 
 
Chi-square analysis revealed differences in the proportion of men and women in the 
Recognition change groups (F = 6.41, p<0.05), with a greater proportion of women 
increasing their Recognition scores over the waiting period compared to men (53.1% 
versus 29.7%). Employment status, relationship status and injecting status did not differ 
between the three groups.  
 
The MANOVA was repeated using the same baseline characteristics and change status 





scale was statistically significant (F = 2.45, p = 0.01). Waiting time was the only 
significant variable in the model. Heroin users whose Ambivalence score increased over 
the waiting period waited twice as long for treatment entry (49.8 days, s.d.24.9) as those 
whose scores decreased (24.0 days, s.d.21.8).  
 
The MANOVA for the Taking Steps scale was also significant (F = 13.70, p<0.001) and 
showed the same pattern of results. Waiting time was the only significant variable in the 
model. Heroin users whose Taking Steps scores increased over the waiting period 
waited twice as long (48.7, s.d.26.5) for treatment entry as those whose scores decreased 
(23.8, s.d.20.8). Chi-square analyses did not find any statistically significant differences 
between the Ambivalence and Taking Steps change status groups for gender, 
employment, relationship, or injecting status.  
 
Hypothesis 2 predicted that waiting times would be more strongly associated with 
changes in readiness than baseline demographic or clinical characteristics. The results 
for the Ambivalence and Taking Steps scales support this hypothesis. Waiting time was 
the only variable to be significantly associated with readiness change status. Longer 
waiting times were associated with increased scores in the Ambivalence and Taking 
Steps scales. Waiting time was not associated with change status on the Recognition 
scale. Physical health and psychological health were more strongly associated with 
change status on this scale. 
 
4.4.4    Waiting times and treatment entry 
 
Hypothesis 3: Longer waiting times will be associated with lower rates of treatment 
entry. 
 
Of the 133 heroin users who applied for treatment, 108 (81.2%) entered treatment after 
the waiting period and 25 (18.8%) did not. Of the 108 who entered treatment 39 
(76.5%) had been randomised to the Standard group and 69 (84.1%) to the Accelerated 
group after the baseline research interview. The difference in treatment entry rates 





An independent t-test revealed that the heroin users who did not enter treatment 
experienced a longer delay (days waited) than those who entered treatment, although 
this failed to reach statistical significance (35.8 days compared to 30.1 days; t = 0.30,  
p = 0.76). When the waiting times of the Standard and Accelerated groups were 
examined separately, those who entered treatment did not experience a significantly 
shorter or longer wait compared to those who did not enter treatment (Table 4.11). 
 





mean wait (days/s.d) 
Did not enter 
treatment 
mean wait (days/s.d) 
t p 
Full sample 30.1(25.9) 35.8(26.6) 0.30 0.76 
Standard group 58.3 (24.5) 58.9(20.5) 0.35 0.73 
Accelerated group 14.1(2.1) 14.5(1.9) 0.74 0.46 
 
 
The waiting times of the Standard group ranged from 22-116 days (without the outliers 
removed).  In order to more adequately examine the relationship between waiting times 
and treatment entry, the number of days waited by study participants in the Standard 
group was divided into two groups by a median split of 47 days. Chi-square tests 
showed that there was no difference in treatment entry rates of those who waited less 
than 47 days or more than 47 days to enter treatment  (χ2 = 0.01, p = 0.94).  
 
The hypothesis that longer waiting times would be associated with lower rates of 
treatment entry was not supported. Similar proportions of the Standard and Accelerated 
groups entered treatment after the waiting period. Examining waiting times as a 












4.4.5     Readiness to change and treatment entry 
 
Hypothesis 4:  Readiness to change will be a stronger predictor of treatment entry 
status than demographic or substance use variables. 
 
Chi-square analyses and independent t-tests were conducted to assess the relationship 
between treatment entry status (entered treatment/did not enter treatment) and a number 
of demographic, substance use and readiness to change variables. These results are 
presented in Tables 4.12 and 4.13. 
 
Table 4.12:  Baseline descriptive data for individual characteristics associated with 





Did not enter 
treatment 
(n=25) 
χ2 /t p 
Age 33yrs (s.d.8.1) 32.7yrs (s.d.7.4) 0.37 0.71 
Gender :         male 






Ethnicity*      white 









Physical health scores** 16.2 (s.d.7.3) 14.4 (s.d.9.2) 1.02 0.31 
Psychological health scores 16.7 (s.d.8.1) 17.1 (s.d.9.7) 0.23 0.82 
Relationship status: partner 54(50.0%) 54 (50.0%) 0.29 0.58 
Employed 25(23.1%) 5 (20.0%) 0.12 0.73 
*Due to the small number of heroin users in the different ethnic categories, these were combined into 
white/non-white categories. **Physical and psychological health status. Scores range from 0-40 where 
higher scores represent a greater frequency of symptoms 
 
Only one characteristic assessed at baseline was found to be associated with treatment 
entry – frequency of crack cocaine use was higher among heroin users who did not enter 
treatment compared to those who entered treatment (3.1 versus 1.6 days per week; 






                                            





Table 4.13:  Baseline descriptive data for readiness to change and substance use 









Recognition 30.4(s.d.3.3) 30.0 (s.d.3.7) 0.53 0.60 
Ambivalence 14.3(s.d.2.4) 14.9 (s.d.2.4) 1.08 0.28 
Taking Steps 29.2(s.d.6.0) 31.0 (s.d.4.6) 1.45 0.15 
Heroin frequency*  6.0(s.d.2.0) 6.2  (s.d.1.9) 0.38 0.71 
Non-prescribed methadone 
frequency 
0.8(s.d.1.8) 1.1  (s.d.2.3) 0.17 0.45 
Crack cocaine frequency  1.6(s.d.1.2) 3.1  (s.d.2.2) 2.23 0.03 
Cannabis frequency 1.8(s.d.1.0) 2.0  (s.d.1.3) 0.29 0.78 
Alcohol frequency 1.7(s.d.1.1) 1.7  (s.d.1.0) 0.01 0.99 
Intravenous drug use 46 (42.6%) 14 (56%) 1.47 0.23 
Heroin SDS** 11.3(s.d.2.9) 10.5(s.d.3.1) 1.17 0.24 
*Substance use frequency refers to days per week ** Severity of Dependence Scale scores range between 




The previous analyses demonstrated that only one baseline characteristic was 
significantly associated with treatment entry status.  The analyses were repeated to 
examine the relationship between treatment entry status and patient characteristics 
assessed at the time of scheduled treatment entry. These results are presented in Table 
4.14. 
 
Four variables assessed at the time of scheduled treatment entry were associated with 
treatment entry.  Frequency of heroin use was higher among those who did not enter 
treatment (5.0 versus 3.2 days per week; t = 2.09, p<0.05)4. Frequency of crack cocaine 
was also higher among heroin users who did not enter treatment (3.2 versus 1.1 days per 
week: t = 3.05, p<0.01). Recognition scores were higher among those who entered 
treatment (30.4 versus 28.2; t = 2.06, p<0.05) 5 and Ambivalence scores were lower 
among those who entered treatment (11.5 versus 13.6; t = 3.27, p = 0.001). Results 
adjusted with the Bonferroni Correction found only Ambivalence scores and frequency 
                                            
 





of crack cocaine, assessed at time of scheduled treatment entry, were significantly 
associated with treatment entry status. 
 
Table 4.14: Readiness to change and substance use variables assessed at follow-up  
 Entered treatment 
(n=108) 
Did not enter 
treatment (n=25) 
χ2/t p 
Recognition 30.4(s.d.3.1) 28.2 (s.d.5.0) 2.06 0.04 
Ambivalence 11.5(s.d.3.0) 13.6 (s.d.3.0) 3.27 0.001*** 
Taking Steps 24.9 (s.d.5.9) 27.0 (s.d.5.7) 1.65 0.10 
Heroin frequency* 3.2(s.d.2.8) 5.0 (s.d.2.7) 2.09 0.04 
Non-prescribed 
methadone frequency 0.75(s.d.2.0) 0.46(s.d.1.5) 
0.62 0.54 
Crack cocaine frequency 1.1(s.d.1.0) 3.2 (s.d.2.8) 3.05 0.005*** 
Cannabis frequency 1.8(s.d.1.0) 1.2(s.d.0.8) 0.91 0.37 
Alcohol frequency 1.7(s.d.1.1) 1.9(s.d.0.9) 0.47 0.64 
Intravenous drug use 46(42.6%) 14(56.0%) 0.33 0.56 
Heroin SDS** 11.3(2.9) 10.5(3.1) 1.17 0.24 
*Substance use frequency refers to days per week. ** Severity of Dependence Scale scores range between 




The likelihood of treatment entry was also assessed according to the direction of change 
on each of the readiness scales over the waiting period (increased/ stayed the same/ 
decreased readiness scores).  Treatment entry status was not significantly associated 
with changes on the readiness scales over the waiting period (Recognition  
χ2 = 4.27, p = 0.12; Ambivalence χ2 = 3.35, p = 0.19; Taking Steps χ2 = 4.31, p = 0.12). 
Changes in heroin use between baseline and treatment entry (increased/ stayed the 
same/ decreased frequency of heroin use) were also not significantly related to treatment 
entry status (χ2 =1.45, p = 0.49). 
 
4.4.6     Modelling predictors of treatment entry  
 
Logistic regression procedures (using a backward elimination method) were conducted 
to identify the possible predictors of treatment entry.  Measures included in the logistic 
regression were those variables statistically significant (p<0.05) in the bi-variate 
analyses (crack cocaine frequency at baseline, Recognition and Ambivalence scores, 
heroin frequency and crack cocaine frequency at the time of scheduled treatment entry). 





Pearson correlations showed that the Recognition scores and Ambivalence scores were 
positively correlated (r = 0.1, p<0.05), however as this was only a modest correlation 
both variables were included in the logistic regression analysis.  Frequency of crack 
cocaine use assessed at baseline and at treatment entry were highly correlated, (r = 0.7, 
p<0.001).  Frequency of crack cocaine assessed at the time of treatment was chosen to 
be included in the analysis. These variables were entered as predictors of the 
dichotomous outcome variables - entered treatment and did not enter treatment. 
 
Table 4.15: Variables in the final model of the logistic regression analysis predicting 
treatment entry status 
 
Independent variables in the 
final model 
B Wald p Odds Ratio 
(Exp)B 
95% C.I 
Ambivalence -0.42 12.21 0.001 0.65 0.52,0.83 
Recognition 0.35 14.90 0.001 1.41 0.89,1.69 
Frequency of crack cocaine -0.36 12.77 0.001 0.70 0.57,0.85 
 
The final model was statistically significant (χ2 =39.58, d.f. = 3, p<0.001). The logistic 
regression indicated that Recognition scores (p<0.001), Ambivalence scores (p<0.001) 
and frequency of crack cocaine use (p<0.001) assessed at the time of treatment entry 
were all significant variables in the final model predicting treatment entry status (see 
Table 4.15). However, the model predicted only 8.0% of the variance in treatment entry 
status. Frequency of heroin use assessed at treatment entry was not a significant 
predictor of treatment entry status.  
 
A negative Beta value suggests that the Ambivalence scale scores and the frequency of 
crack cocaine use were lower among heroin users who entered treatment and higher 
among those who did not enter treatment. A positive Beta value suggests that 
Recognition scores were higher among waiting list participants who entered treatment 
compared to those who did not enter treatment. 
These findings support the hypothesis that higher readiness to change, and specifically 
the Ambivalence and Recognition dimensions, is a stronger predictor of treatment entry 
status than any of the demographic or substance use variables examined. The one 






which was also found to be a statistically significant predictor of treatment entry within 
the sample, with lower scores reported among those who entered treatment after the 
waiting period. 
 
4.4.7   Treatment-entry group and substance use 
 
Hypothesis 5: Longer waiting times will be associated with fewer reductions in 
substance use over the waiting period, compared to shorter waiting times.  
 
Changes in the frequency of heroin, non-prescribed methadone, crack cocaine, cannabis 
and alcohol use between the baseline and follow-up interviews were examined using 
GLM repeated measures analysis of variance. The two interview points 
(baseline/follow-up) were the within-subjects factor and treatment-entry group 
(Standard/Accelerated) was the between-subjects factor. The changes in the frequencies 
of these five substances are displayed as main effects in Table 4.16.  
 
A statistically significant interaction effect was found between changes in the frequency 
of heroin use and treatment-entry group (F = 0.93, p<0.05). The Standard group 
reported reductions in the frequency of heroin use over the waiting period, although 
there was no change over this period among the Accelerated group. Statistically 
significant increases in the frequency of non-prescribed methadone use were found 
within the Standard and Accelerated groups (F = 7.69, p<0.01) although these changes 
did not differ between the two groups. Small, but statistically significant, reductions in 
the frequency of crack cocaine use over the waiting period were also reported (F = 5.23, 
p<0.05), which did not differ between the two groups. There were no significant 
changes in the frequency of cannabis and alcohol use over the waiting period.    
 
These results do not support the hypothesis that longer waiting times will be associated 
with fewer reductions in substance use over the waiting period relative to shorter 
waiting times. The Standard group reported the greatest reductions in the frequency of 
heroin use over the waiting period. Changes reported for the other substances did not 





                Table 4.16.   Changes in the frequency of substance use (days per week) between baseline and follow-up interviews  




















Effect     
sizes 
(Cohen’s d) 




0.5(0.8) 0.8(1.9) 0.2 0.5(0.8) 0.9(1.9) 0.4 7.69*** 0.09 
Crack cocaine 1.9(2.5) 1.3(2.2) 0.4 1.8(2.6) 1.7(2.5) 0.7 5.23** 0.15 
Cannabis 1.5(2.4) 1.5(2.6) 0 2.0(2.7) 1.8(2.6) 0.4 0.49 0.64 
Alcohol 1.9(2.8) 2.0(2.8) 0 1.6(2.6) 1.5(2.5) 0 0.09 0.88 




In order to further explore the relationship between waiting times and changes in 
substance use levels these variables were re-analysed using a continuous waiting time 
variable (number of days waited) and a change variable for each substance  (substance 
use at baseline - substance use at follow-up).  Correlational analyses were conducted 
assessing the relationship between waiting times and the change in the frequency of 
substance use over the waiting period. This method of analysis avoided some of 
problems associated with the distribution of waiting times of the two treatment-entry 
groups mentioned earlier. The results are presented in Table 4.17.  
 
Table 4.17:  Correlational analyses between waiting times and change in the frequency 
of substance use over the waiting period. 
 
Frequency of substance use  r (sig) 
Heroin  -0.04(0.69) 
Non-prescribed methadone -0.07(0.45) 
Crack cocaine -0.16(0.06) 
Cannabis 0.06 (0.44) 
Alcohol 0.08(0.39) 
 
This method of examining changes in the frequency of substance use over the waiting 
period failed to reveal any significant relationships between the variables. The 
association between cra ck cocaine use and waiting time approached statistical 
significance (r = -0.16, p= 0.06).  
 
4.4.8     Changes in substance use at a case-by-case level 
 
The previous results are useful in demonstrating group changes in substance use, but 
they fail to show the variability of changes within the two treatment-entry groups. 
Examining substance use at a case-by-case level indicated a wide variation in the 
direction of changes reported by the sample. Chi-square analyses examining changes in 
the frequency of substance use (increased/ decreased/ stayed the same) between baseline 





Heroin frequency: The majority of the sample reported no change in the frequency of 
heroin use between the baseline and follow-up interviews (Standard =58.8%; 
Accelerated =57.3%). The results also showed that approximately a quarter (22.0%) of 
the Accelerated group and a third (35.3%) of the Standard group made reductions in the 
frequency of their heroin use over the waiting period while 5.9% of the Standard and 
20.7% of the Accelerated group reported increasing the frequency of their heroin use 
over this period.  Chi-square analysis found a statistically significant difference in the 
proportion of substance users in the Standard and Accelerated groups who made 
changes in heroin use over the waiting period (χ2 = 6.69, p<0.05)6 (Table 4.18). 
 
Table 4.18: Changes in heroin frequency between baseline and follow-up  





     
decreased 18(35.3) 18(22.0) 6.69 0.04 
stayed the same 30(58.8) 47(57.3) 
increased 3(5.9) 17(20.7) 
 
 
Non-prescribed methadone frequency: Among the waiting list participants who reported 
non-prescribed methadone use at baseline, approximately 60.0% of both treatment-entry 
groups reported no change the frequency of use between the interviews. Reductions in 
the frequency of non-prescribed methadone use were reported by 15.7% of the Standard 
group and 24.4% of the Accelerated group and increased use was reported by 23.5% of 
the Standard group and 17.1% of the Accelerated group between the interviews (Table 
4.19). 
 
Table 4.19: Changes in non-prescribed methadone frequency between baseline and 
follow-up  
 





     
decreased 8 (15.7) 20(24.4) 1.83 0.40 
stayed the same 31(60.8) 48(58.5) 
increased 12(23.5) 14(17.1) 
                                            





Crack cocaine frequency: Among the crack cocaine users, 41.2% of the Standard and 
46.3% of the Accelerated group maintained the frequency of use between the baseline 
and follow-up interviews. Reductions in the frequency of crack cocaine use were 
reported by 41.2% of the Standard and 30.5% of the Accelerated group and the 
remaining 17.6% of the Standard and 23.2% of the Accelerated group reported 
increasing the frequency of use (Table 4.20). 
 
Table 4.20: Changes in crack cocaine frequency between baseline and follow-up 





     
decreased 21 (41.2) 25(30.5) 1.68 0.43 
stayed the same 21 (41.2) 38(46.3) 
increased 9(17.6) 19(23.2) 
 
Cannabis frequency: Among the cannabis users, 50.0% of the Standard group and 
56.2% of the Accelerated group reported the same frequency of use at the baseline and 
follow-up interviews. Reductions in the frequency of cannabis use were reported by 
32.0% of the Standard group and 27.5% of the Accelerated group, and 18.0% of the 
Standard and 27.5% of the Accelerated reported increasing the frequency of their 
cannabis use at follow-up (Table 4.21). 
 
Table 4.21: Changes in cannabis frequency between baseline and follow-up  





     
decreased 16(32.0) 22(27.5) 0.49 0.78 
stayed the same 25(50.0) 45(56.2) 
increased 9(18.0) 22(27.5) 
 
Alcohol frequency: Among the heroin users reporting alcohol use at baseline, over half 
of both treatment-entry groups maintained the frequency of their use between the 
interviews. Less than a fifth of the Standard (11.8%) and Accelerated (19.5%) groups 
reported reductions in the frequency of alcohol use, and the remaining 29.4% of the 
Standard and 25.6% of the Accelerated group reported increasing their use over the 





Table 4.22: Changes in alcohol frequency between baseline and follow-up  





     
decreased 6 (11.8) 16(19.5) 0.10 0.49 
stayed the same 30 (58.8) 45(54.9) 
increased 15(29.4) 21(25.6) 
 
There were no statistically significant differences in the proportion of heroin users who 
changed the frequency of non-prescribed methadone use (χ2 = 1.83, p = 0.04), crack 
cocaine use (χ2 =1.68, p = 0.43), cannabis (χ2 = 0.49, p = 0.78) or alcohol use  
(χ2 = 0.10, p = 0.49) over the waiting period. 
 
A number of heroin users also reported achieving abstinence during the waiting period. 
While 4 (3.0%) patients reported stopping heroin use, 19 (45.2%) patients reported 
abstinence from non-prescribed methadone, 22 (26.2%) abstinence from crack cocaine, 
23 (31.1%) abstinence from cannabis and 17 (23.6%) abstained from alcohol. There 
were no statistically significant associations between treatment-entry group and 
abstinence of heroin use (χ2 = 0.70, p = 0.43), non-prescribed methadone use (χ2 = 0.67, 
p = 0.40), crack cocaine use (χ2 = 4.00, p = 0.14), cannabis (χ2 = 0.35, p = 0.56) or 
alcohol use (χ2 = 0.65, p = 0.42).  
 
Analyses of changes in substance use at a case-by-case level over the waiting period 
found that members of the Standard group reported greater reductions in the frequency 
of heroin, crack cocaine and cannabis use compared to the Accelerated group, although 
change in the frequency of heroin use over the waiting period was the only relationship 
to be statistically significant. The Accelerated group reported greater reductions in 
alcohol and non-prescribed methadone use although this was not significantly related to 
treatment-entry group. These findings fail to support the hypothesis that longer waiting 
times will be associated with fewer reductions in substance use over the waiting period 









4.4.9   Readiness to change and heroin use    
 
Hypothesis 6: Increases in readiness scores over the waiting period will be associated 
with reductions in heroin use.  
 
In order to examine whether changes in readiness scores over the waiting period were 
associated with changes in the frequency of heroin use over the same period GLM 
repeated measures analysis of variance were performed on each of the three readiness 
scales. Readiness scores at the two interview points (baseline/follow-up) were the 
within-subjects factor and changes in the frequency of heroin use over the waiting 
period (increased/ stayed the same/ decreased) were the between subjects factors. Post-
hoc paired comparisons between the change-groups were assessed by Scheffe tests (for 
unequal sample sizes). The results of the analyses are presented in Tables 4.23 - 4.25   
 
The analyses revealed no statistically significant changes on the Recognition scale 
between baseline and follow-up interviews (F = 0.01, d.f. =1,131, p = 0.92) and no 
interaction effects were found between these variables (F = 2.09, d.f.=1,131, p<0.13) 
(Table 4.23). 
 
Table 4.23: The relationship between Recognition scale scores and change in the 













F for change 
by group (p) 
 
Increase in frequency of 
heroin use 
28.3(4.1) 29.6(4.1) 0.01(0.92) 2.09 (0.13) 
No change in frequency of 
heroin use 
30.9(3.0) 30.5(3.3) 




On the Ambivalence scale, statistically significant main effects were found for mean 
scores between baseline and follow-up, with scores decreasing within each change 
group (F = 60.32, df =1,131, p = 0.001), although no interaction effect was found 
between these Ambivalence scores and the change groups (F =1.05, d.f. 1,115, p = 0.35) 





Table 4.24: Relationship between Ambivalence scale scores and change in the 








F for change 
(p) 
F for change 
by group(p) 
 
Increase in frequency of 
heroin use 
14.1(1.9) 10.4(2.9) 60.32(0.001) 1.05(0.35) 
No change in the 
frequency of heroin use 
14.5(2.4) 12.1(2.8) 
Decrease in frequency 
of heroin use 
14.1(2.9) 11.1(4.0) 
 
The same pattern of results was found on the Taking Steps scale, with a main effect for 
changes in Taking Steps scores over time (F = 37.39, d.f.=1,131, p = 0.001), although 
these scores were not associated with heroin frequency change group  
(F = 1.64, d.f.=1,131,p = 0.20) (Table 4.25). 
 
Table 4.25: Relationship between Taking Steps scale scores and change in the 









F for change 
(p) 
 
F for change 
by group (p) 
 
Increase in frequency of 
heroin use 
30.1(4.5) 23.1(4.7) 37.39(0.001) 1.64(0.20) 
No change in the 
frequency of heroin use 
28.6(6.8) 24.7(6.3) 
Decrease in the frequency 
of heroin use 
30.5(4.4) 27.3(5.1) 
 
Together these results demonstrate that changes in readiness scores over the waiting 
period were not related to changes in the frequency of heroin use over the same period. 
The next section will assess whether other patient factors were related to changes in 











4.4.10    Changes in heroin use and baseline readiness scores 
 
Hypothesis 7:  Reductions in the frequency of heroin use over the waiting period will be 
associated with high baseline readiness scores. 
 
In order to examine whether reductions in the frequency of heroin use were associated 
with baseline readiness scores, multiple analysis of variance (MANOVA) were 
conducted using heroin change status (increased/ stayed the same/ decreased over the 
waiting period) as the independent variable and readiness scores (Recognition, 
Ambivalence, Taking Steps), waiting time (number of days waited) and patient factors 
(frequency of heroin use, physical health status and psychological health status assessed 
at baseline) as the dependent variables. 
 
Table 4.26 displays the MANOVA results. The model of the MANOVA was 
statistically significant (F = 1.71, d.f. = 7,124, p<0.001).  Frequency of heroin use, 
Recognition scores assessed at baseline and waiting time were associated with heroin 
frequency change status. Post hoc analyses showed significant differences between the 
subgroups (increased/ decreased /stayed the same) on the three variables significant on 
the MANOVA. 
 
Table 4.26: Variables significant in the MANOVA assessing the association between 
baseline patient factors and frequency of heroin change status  
 
 Change in heroin frequency F p 
Increased 
mean (s.d.) 
Stayed the same 





3.2(0.4) 6.7(0.2) 6.1(0.3) 42.55 0.001* 
Recognition 28.6(0.8) 30.9(0.4) 30.1(0.6) 3.94 0.02* 
Waiting time 18.1(5.6) 34.5(2.7) 28.8(4.3) 3.61 0.03* 
* Post Hoc analysis indicated statistically significant differences between the groups 
 
 
Waiting list participants whose frequency of heroin use did not change between the 
interviews had the highest baseline Recognition scores (30.9, s.d.0.4), the highest 





s.d.2.7) compared to participants whose heroin use increased or decreased  over the 
waiting period. 
 
Waiting list participants who increased the frequency of heroin use had the lowest 
baseline Recognition scores (28.6, s.d.0.8), the shortest waiting times of the three 
subgroups (18.1 days, s.d.5.6) and the lowest baseline heroin frequency (3.2 days,  
s.d 0.4) compared to those heroin users whose heroin use decreased or remained at the 
same level over time. 
 
The results of the MANOVA support the hypothesis stating that reductions in the 
frequency of heroin use over the waiting period will be associated with high baseline 
readiness scores, to an extent. While reductions in the frequency of heroin use were 
associated with high baseline Recognition scores, waiting list participants whose 
frequency of heroin use did not change over the waiting period had the highest baseline 
Recognition scores. Changes in the frequency of heroin use over the waiting period 
were not associated with baseline Ambivalence or Taking Steps scale scores. 
 
4.4.11   Waiting time expectations and treatment entry 
 
Hypothesis 8: Heroin users’ expectations about the length of the waiting period will be 
associated with the likelihood of treatment entry.   
 
The baseline research interview asked the full sample (n=133) how long they expected 
to wait for treatment to start. The mean waiting times of the heroin users who entered 
treatment and those who did not are presented in Table 4.27 within the categories of 
their expected waiting times. Among the participants who expected to wait a week for 
treatment to start, average waiting times were 26.3 days (s.d.26.5) for those who entered 
treatment and 40.6 days (s.d.40.1) for those who did not. Participants who entered 
treatment and expected to wait between 1 and 4 weeks actually waited a mean of 26.9 
days (s.d.21.7), while those who did not enter treatment waited 35.0 days (s.d.23.2). 
Although waiting times of those who did not enter treatment exceeded the waiting times 
of those who did enter treatment in the 1 week and 1-4 week expected waiting time 






Table 4.27:  Actual waiting times (days) of the substance users who entered treatment 




Entered treatment  
 
mean wait (s.d.) 
Did not enter 
treatment  
mean wait (s.d.) 
t p 
1 week 26.3   (26.5) 40.6   (40.1) 0.89 0.39 
1-4 weeks 26.9   (21.7) 35.0   (23.2) 1.28 0.21 
1-2 months 35.1   (29.6) 31.0   (29.4) 0.22 0.83 
More than 2 months 47.3   (43.7) -   
Don’t know 38.5   (32.8) 37.5   (33.2) 0.41 0.97 
 
 
Participants who entered treatment and who expected to wait between 1 and 2 months 
for treatment to start waited 35.1 days (s.d.29.6) and those who did not enter waited 31 
days (s.d.29.4). None of the heroin users who failed to enter treatment expected to wait 
more than 2 months. Those who entered treatment and expected to wait more than 2 
months actually waited for 47.3 days (s.d.43.7). Participants who responded that they 
did not know how long they would be expected to wait and entered treatment actually 
waited 38.5 days (s.d.32.8) and those who did not enter treatment waited 37.5 days 
 (s.d.33.2). The difference in waiting times of the initiators and non-initiators who 
expected to wait 1-2 months (t = 0.22, p = 0.83) and those who did not know how long 
they were going to wait (t = 0.41, p = 0.97) were not statistically significant. 
 
Within the full sample, 40.9% (n=54) of the study participants accurately matched the 
expected waiting time categories to their actual waiting times. For 22.0% (n=29) of the 
sample the actual waiting times were less than expected, and for 37.1% (n=49) the 
actual waiting times were longer than they expected.   
 
Among the study participants who did not enter treatment, 56.0% (n=14) experienced 
waiting times which were greater than their expected waits. Half of these (n=7) 
participants endorsed being unhappy with the delay for treatment in the Lost-to-
treatment interview. Of the remaining 11(44.0%) study participants who did not enter 
treatment (actual waiting time matched their expected waiting time = 7, actual waiting 
time was less than the expected waiting time = 4) none reported being unhappy with the 
delay for treatment. 
 
In order to examine the relationship between waiting time expectations and the 





entry status and the three categories representing the degree of concordance between 
expected and actual waiting times  (Table 4.28). The results showed a trend for heroin 
users who did not enter treatment to be more likely to have actual waiting times greater 
than their expected waiting times, although this was not statistically significant  
(χ2 = 4.72, p = 0.09). 
 








Matched actual and 
expected waiting time 
47(43.9) 7(28.0) 4.72 0.09 
Actual waiting time less 
than expected waiting time 
25(23.4) 4(16.0) 
Actual waiting time more 
than expected waiting time 
35(32.0) 14(56.0) 
 
4.4.12     Factors associated with expected waiting times 
 
In order to examine if any demographic or substance use characteristics assessed at 
baseline interview were associated with waiting time expectations, analysis of variance 
(ANOVA)  for continuous variables (with Scheffe post-hoc comparisons) and chi-
square analyses  for categorical variables were performed.  The results are presented in 
Table 4.29. Age was the only characteristic which significantly differed between the 
expected waiting time categories. The older waiting list participants (mean of 35.9 
years; s.d.7.8) expected to wait the shortest amount of time for treatment to begin (1 
week) and the youngest participants (mean of 31.9 years; s.d.7.7) expected to wait 
between 1- 4 weeks for treatment to begin (F = 2.95, p<0.05).  The number of previous 
heroin treatments, Severity of Dependence Scale score for heroin use, gender, ethnic 
status, physical or psychological health status or readiness to change scores assessed at 
the start of the waiting period were not related to waiting time expectations.  
  
                      
 
 
                     Table 4.29: Analysis of variance for demographic, readiness and substance use characteristics (baseline) and expected waiting times 
 
 1 week 1-4 weeks 1-2 months More than 2 months F/χ2 p 
Age 35.9(s.d.7.8) 31.9(s.d.7.7) 32.3(s.d.8.0) 32.5(s.d.6.2) 2.95 0.02 
Number of previous heroin 
treatments 
2.5  (s.d.2.2) 1.3  (s.d.1.1) 1.7  (s.d.3.0) 1.3  (s.d.0.5) 1.40 0.24 
Severity of Dependence* 11.8(s.d.2.6) 10.9 (s.d.2.6) 11.5(s.d.3.8) 8.8  (s.d.2.2) 1.19 0.32 
Gender: male 13   (12.9%) 58    (57.4%) 14   (13.9%) 3    (3.0%) 3.92 0.42 
Ethnic status: white 14   (13.9%) 55    (54.5%) 19   (18.8%) 3    (3.7%) 1.62 0.80 
Physical health score** 15.6(s.d.9.5) 15.4(s.d.7.4) 16.8(s.d.6.8) 17.8(s.d.7.0) 0.20 0.94 
Psychological health score 17.2(s.d.8.8) 16.1(s.d.8.0) 16.9(s.d.9.5) 15.0(s.d.5.0) 0.53 0.72 
Recognition 31.2(s.d.3.5) 30.3(s.d.3.4) 30.6(s.d3.2) 28.8(s.d1.7) 0.63 0.64 
Ambivalence 15.3(s.d.1.7) 14.2(s.d.2.5) 14.7(s.d.2.2) 12.3(s.d.1.7) 2.31 0.07 
Taking Steps 28.5(s.d.6.5) 29.7(s.d.6.1) 31.0(s.d.4.9) 28.0(s.d.7.0) 0.92 0.45 
                         *Severity of dependence where higher scores indicate a greater severity of substance use  **Physical and psychological      
                           health status assessed by the MAP.  Scores range from 0-40 where higher scores represent a greater frequency of  
                           symptoms 
  
4.4.13   Readiness to change and waiting time expectations 
 
Hypothesis 9: Heroin users’ expectations about the length of the waiting period will be 
associated with changes in readiness scores over this period.  
 
GLM repeated measures analyses of variance were performed on each of the three 
readiness scales according to waiting time expectation group. Readiness scores at the 
two interview points (baseline/follow-up) were the within-subjects factor and the 
expected waiting time categories were the between-subjects factors. Post-hoc paired 
comparisons between the change groups were assessed by Scheffe tests (for unequal 
sample sizes). The results of the analyses are presented in Tables 4.30 - 4.32. 
 
There were no statistically significant main effects (F = 0.72, d.f. 1,129, p = 0.40) or 
interaction effects (F = 0.31, d.f. 1,129, p = 0.73) between waiting time expectation 
group and changes in Recognition scores over the waiting period. The pattern of 
changes on the Recognition scale did not vary according to the degree of concordance 
between expected and actual waiting times (Table 4.30).  
 
Table 4.30: Relationship between Recognition scores and waiting time expectation 
categories 
 







F for change 
by group (p) 
Matched actual and 
expected waiting time 
30.2(3.3) 30.2(3.4) 0.72(0.40) 0.31(0.73) 
Actual waiting time less 
than expected waiting time 
30.2(3.4) 29.9(3.2) 
Actual waiting time more 
than expected waiting time 
30.7(3.6) 30.1(4.0) 
 
Analysis of changes on the Ambivalence scale revealed statistically significant changes 
in scores over time (F = 70.09, d.f. 1,129, p = 0.001) and interaction effects between 
these changes and the waiting time expectation group (F = 4.94, d.f. 1,129, p<0.01) 
(Table 4.31). Post-hoc tests showed a significant difference between changes on the 
Ambivalence scale among  participants whose expected and actual waiting times were 
the same and participants whose expected waiting times were more than their actual 





whose actual waiting times were more than their expected waiting times and 
participants whose actual waiting times were less than their expected waiting times 
(p<0.05). 
 









F for change 
(p) 
F for change 
by group 
(p) 
Matched actual and 
expected waiting time 
14.4(2.4) 10.4(2.7) 71.94(0.001) 4.94(0.009) 
Actual waiting time less 
than expected waiting time 
13.6(2.4) 11.4(2.4) 
Actual waiting time more 
than expected waiting time 
14.7(2.5) 13.0(3.2) 
 
Analysis of changes on the Taking Steps scores over the waiting period revealed 
statistically significant main effects (F = 42.80, d.f. 1,129, p = 0.001) and significant 
interaction effects between changes in scale scores and waiting time expectation group 
(F = 6.45, d.f. 1,129, p<0.01) (Table 4.32). Although post-hoc tests failed to reveal any 
significant differences between the changes on the Taking Steps scales within the three 
waiting time categories, the table demonstrates that those participants whose expected 
and actual waiting times matched showed the greatest reduction in scores over the 
waiting period, compared to those participants whose expected and actual waiting times 
did not match.   
 









F for change F for change 
by group 
Matched actual and 
expected waiting time 
29.8(5.6) 23.3(6.2) 51.94(0.001) 6.45(0.002) 
Actual waiting time less 
than expected waiting time 
28.2(6.2) 24.4(6.4) 
Actual waiting time more 









4.4.14     Summary of Study 2 findings  
  
• Longer waiting periods were not associated with reductions in readiness to 
change. The shorter waiting times of the Accelerated group were related to 
reductions on the Ambivalence and Taking Steps scales. 
 
• Waiting time was more strongly associated with changes on the Ambivalence 
and Taking Steps scores over the waiting period compared to other patient 
characteristics within the sample. Heroin users whose scale scores increased 
experienced longer delays than those whose scores remained static or decreased 
during this time. Physical and psychological health scores associated with 
increases on the Recognition scale but waiting time was not. 
 
• Longer waiting times were not associated with lower rates of treatment entry. 
Similar proportions of the Standard and Accelerated groups successfully entered 
treatment.  
 
• Lower Ambivalence scores and higher Recognition scores (assessed at treatment 
entry) were associated with treatment entry. A lower frequency of crack cocaine 
use at treatment entry was also found to be predictive of entering treatment 
within the sample. 
 
• Longer waiting times were not associated with fewer reductions in substance use 
over the waiting period. The Standard group reported the greatest reductions in 
the frequency of heroin use over the waiting period. Changes in the frequency of 
the other substances used did not differ between the treatment-entry groups. 
 
• Changes in readiness scores over the waiting period were not related to changes 
in the frequency of heroin use over the same period.  
 
• Reductions in the frequency of heroin use over the waiting period were 
associated with higher baseline readiness scores, although study participants 
whose frequency of heroin use did not change between the interviews had the 






• Heroin users’ expectations about the length of the waiting period were not 
associated with the likelihood of treatment entry.  
 
• Waiting time expectations were associated with readiness change scores over the 
waiting period.  The greatest reductions in Ambivalence and Taking Steps 

































4.5     DISCUSSION 
 
The purpose of Study 2 was to explore the pre-treatment period of a sample of heroin 
users awaiting entry into methadone treatment, focusing on the potential interactions 
between waiting periods of different durations, changes in readiness, treatment entry 
and patterns of substance use over the waiting period. The Discussion will review the 
findings of the different relationships examined within Study 2. The position of these 
findings within the conceptual framework will be examined within Chapter 5. 
  
4.5.1     Length of the waiting period prior to treatment entry   
 
The study reported wide variations in the length of time heroin users were required to 
wait to enter treatment under the normal clinical procedures operating within the 
treatment service. The Standard group experienced a mean waiting time of 58 days, 
which ranged between a minimum of 22 days and a maximum of 116 days. Variability 
in waiting times within individual treatment services (Donmall et al, 2005) and between 
treatment services (Luty, 2002; Stewart et al, 2000) have been reported elsewhere and 
may be a common feature of drug service provision in some areas of the country. This 
variability has been attributed to a variety of factors including the level of demand for 
drug services and the capacity of the service to treat drug abusers (Brown et al, 2002). 
These in turn are affected by economic and political factors such as staffing levels, 
efficiency with which services are delivered and treatment length. Regardless of the 
reasons for the delays in service provision, reports of lengthy waiting times clearly 
demonstrate that there is a disparity between supply and demand for substance abuse 
treatment. 
 
4.5.2     Distribution of readiness to change scores 
 
 
According to the interpretive ranges suggested by Miller and Tonigan (1996), the 
greatest proportion of the sample requested treatment with ‘low’ Recognition of their 
problem (42.9%), ‘medium’ Ambivalence (45.9%) and ‘low’ Taking Steps to change 
their behaviour (53.4%). Scores reported for the Recognition and Ambivalence scales 
are largely consistent with those described for drug users by Burrow-Sanchez and 





among waiting list participants with drug and alcohol problems, although the Taking 
Steps scores in the current sample are lower than those reported in the earlier study.  
The readiness scores in the current sample suggest that many of the heroin users may 
not be highly motivated to change their heroin use, not recognising that they have a 
problem or currently making positive changes to address their heroin use. Although it 
would be assumed that heroin users seeking treatment would have a desire to change 
their drug use, this is not always the case. Motivation for treatment is not synonymous 
with motivation for changing substance use as discussed in Chapter 3. Many substance 
users seek treatment for reasons other than reducing substance use such as pressure 




4.5.3    Changes in readiness over the waiting period 
 
 
The first hypothesis predicted that heroin users with longer waiting times would show 
greater reductions in readiness over the waiting period compared to those with shorter 
waiting times. This hypothesis was not supported, no statistically significant changes in 
readiness were found within the Standard group.  However, reductions in Ambivalence 
and Taking Steps scores between the start and end of the waiting period were reported 
among the Accelerated group. The reductions on the Ambivalence and Taking Steps 
scales suggests that heroin users with short waiting periods are experiencing more 
willingness to change (reduced Ambivalence) characterised by less conflict and 
uncertainty about changing their drug use, but less propensity to take action (lower 
Taking Steps). The responsiveness of the treatment service, as represented by expedited 
treatment entry, may have reduced the feelings of uncertainty that change was needed in 
their lives and triggered greater a commitment to the change process. The finding that 
many waiting list participants report that they are doing less to change their heroin use 
at the end of the waiting period relative to the start of the waiting period may suggest 
that they do not feel the need to change their heroin use when they know that substitute 
medication will soon be prescribed. This may reflect the difficulty previously 
experienced in reducing drug use without the help of substitute medication.  
 
The absence of statistically significant changes within the Standard group may suggest 





waiting period as reported among the Accelerated group) were not sustained over longer 
delays. The design of the study does not allow us to directly test whether short-term 
changes in readiness among the Standard group return to baseline levels by the end of 
the waiting period. The findings suggest that a more prolonged wait does not have a 
deleterious effect on readiness to change in the current study - delays of more than two 
weeks were not associated with motivational decrements, at least in terms of the mean 
readiness scores examined.  
 
The waiting period was not associated with changes on the Recognition scale in either 
treatment-entry group. This may suggest that problem recognition may have prompted 
treatment seeking but failed to be heightened once requests for treatment had been 
made. Alternatively, the absence of changes on the Recognition scale may suggest that 
the SOCRATES is not sensitive enough to detect subtle differences in readiness over 
time on this dimension. Zhang et al (2004), in a study of readiness to change among a 
sample of alcoholic patients with severe mental illness, also reported that the 
Recognition subscale appeared to be less sensitive for differentiating variability of 
readiness to change than the other subscales. 
 
Case-by-case analyses revealed a greater variability in the changes on the readiness 
scales over the waiting period than those represented by group means.  Fifty per cent of 
the Standard group and over forty per cent of the Accelerated group reported a reduction 
in Recognition scores.  Over thirty per cent of the Standard group increased their 
Ambivalence scores, compared to only five per cent of the Accelerated group.  Nearly 
ninety per cent of the Accelerated group decreased their Taking Steps scores, as did 
almost half of the Standard group.  Comparisons of changes between the treatment-
entry groups found greater reductions in Ambivalence and Taking Steps scores among 
the Accelerated group compared to the Standard group, thus supporting the mean results 
presented earlier. These figures show that waiting for treatment, regardless of its length, 
was associated with reductions in readiness to change for many waiting list participants. 
The reduction in Recognition scores among the Accelerated group suggests that even a 
two-week waiting period can lead some to question whether they have a heroin use 
problem. The reductions on the Recognition and Taking Steps scales may be associated 
with the factors which prompted treatment seeking in the first place. Research has found 





DiClemente, 1999). These crises may have been resolved during the waiting period and 
their motivation to change may return to pre-crisis levels when a change seemed less 
important. 
 
Analyses assessing baseline readiness and the direction of change in readiness scores 
found that participants reporting reductions on all three scales had higher baseline 
readiness scores, and those reporting increases in readiness had significantly lower 
baseline readiness scores. This pattern of results may suggest that those with higher 
readiness to change  may experience frustration and disappointment when their 
expectations for starting treatment promptly are not met. This may serve to reduce their 
readiness to change over time. Conversely, the passage of time prior to treatment entry, 
regardless of the duration, appeared to have a positive effect on those with lower 
baseline readiness, acting as a catalyst for positive action. This pattern of results was 
consistent within the Standard and Accelerated treatment-entry groups. Previous 
research has recommended that substance users with low motivation at the beginning of 
treatment should be identified in order for motivation enhancements to be implemented 
(Prochaska and DiClemente, 2005). The present results suggest the opposite to be true – 
waiting list participants with higher readiness to change early in the treatment process 
are more vulnerable to a loss of motivation and therefore may need to be targeted during 
the waiting period and offered interventions to maintain, or enhance, their initial 
motivation for change. 
 
Hypothesis 2 predicted that waiting times would be more strongly associated with 
changes in readiness over the waiting period compared to patient characteristics. This 
hypothesis was supported with respect to changes on the Ambivalence and Taking Steps 
scales, although not for changes on the Recognition scale. Multivariate analyses 
demonstrated that waiting time was the only factor to predict changes to scores on the 
Ambivalence and Taking Steps scales over time. Waiting list participants whose 
Ambivalence and Taking Steps increased over the waiting period scores waited twice as 
long for treatment entry as those whose scores decreased over the waiting period. 
Increases on the Ambivalence scale may suggest that longer waits were associated with 
heightened conflict and uncertainty about changing heroin use. Those with longer 
waiting times may have more time to think about their problems and consider whether 





Taking Steps scale and hence greater reported action or intentions to act. This finding is 
encouraging and suggests that delays to enter treatment can be associated with 
behaviours intended to make positive changes in drug use, at least among some heroin 
users. Physical and psychological health variables and severity of heroin dependence 
did not differ across the change groups on the Ambivalence or Taking Steps scales 
showing that these factors were not important in influencing changes in readiness. The 
absence of statistically significant associations between patient characteristics and 
readiness change patterns parallels previous research in which individual characteristics 
have been weak or inconsistent predictors of motivation (Ryan et al, 1995). This may 
suggest that an individual’s attitude to change (i.e. whether they desire change) is more 
important than any of the individual characteristics which they present to treatment 
with.  
 
In contrast to the results for the Ambivalence and Taking Steps scales, increases on the 
Recognition scale over the waiting period were associated with higher baseline physical 
and psychological health scores (at the univariate level), although waiting time was not. 
This finding may suggest that recognition of heroin use problems may have been 
prompted by physical or psychological health problems. Relationships between 
motivation and health status have been reported in a number of previous studies of 
substance users (Nwakeze et al, 2002; De Leon et al, 2000a; Melnick, 1999).  However, 
these relationships are often complex, depending on the types and severity of the 
variables examined. For example, psychological problems such as depression and 
anxiety may be related to a lack of insight of current problems which may make it 
difficult for drug users to perceive their health deterioration and hence the need for 
change.   
 
4.5.4     Rates of treatment entry 
 
The study found that approximately twenty per cent of the sample failed to enter 
treatment when a place became available. Although this figure is lower than pre-
admission attrition rates reported in other studies of drug users (Hser et al, 1998; Ball 
and Ross, 1991; Stark et al, 1990), it still represents a substantial proportion of heroin 





substance use, improvements in health and reduced offending (Gossop et al, 2002b; 
Hall et al, 1998).  
 
The hypothesis predicting that longer waiting times would be associated with lower 
rates of treatment entry was not supported, with a similar proportion of the Standard and 
Accelerated groups entering treatment. Even when the variable waiting times of the 
Standard group were examined separately, no statistically significant relationships 
between the length of the delay and treatment entry were found. This finding contradicts 
a number of studies which have demonstrated that attendance decreases as waiting 
periods increase in both drug and alcohol samples (Maddux et al, 1995; Dennis et al, 
1994; Fleming and Lewis, 1987).  The current findings are, however, consistent with a 
small number of studies where waiting times have not been associated with treatment 
entry (Donmall et al, 2005; Eriksen, 1986).   
 
A possible explanation of the absence of a relationship between waiting times and 
treatment entry may be that the two-week waiting period of the Accelerated group was 
not sufficiently short enough to satisfy heroin users’ need for help and promote 
treatment entry. Previous research in alcohol treatment settings have reported that 
waiting periods greater than 7-8 days substantially reduced the chances of initial 
attendance at services (Hyslop and Kershaw, 1981; Wanberg and Jones, 1973) and 
some studies have shown that patients scheduled for assessment after 24-hours of their 
first contact are less likely to show for intake interview compared to those scheduled on 
the same day (Festinger et al, 1995; Stark, 1992, Woody et al, 1975). Earlier treatment 
entry for the Accelerated group may have produced a different pattern of results.  
 
4.5.5     Predictors of treatment entry   
 
Readiness to change assessed at the beginning of the waiting period was not related to 
the likelihood of treatment entry, although readiness to change assessed at the time of 
scheduled treatment entry was. Higher Recognition scores and lower Ambivalence 
scores were reported among heroin users who successfully entered treatment compared 
to those who failed to attend. Previous research has shown that recognition of 
substance-related problems, defined with different measures, is a key step in treatment 





investigators have found that many substance abusers will fail to recognise, deny or 
minimise their problems and will be unmotivated to seek help until their substance 
abuse reaches an advanced stage or overwhelming problems are experienced in several 
areas of their lives (Zhang et al, 2004; Lorch and Dukes, 1989).  Lower Ambivalence 
scores among those who entered treatment may demonstrate that these heroin users have 
already weighed up the pros and cons of behaviour change and decided that change is 
warranted. 
 
The positive associations between treatment entry and readiness to change assessed at 
the end of the waiting period, yet an absence of associations between the variables when 
readiness is assessed at the start of the waiting period, highlights the complexities of 
examining readiness which is temporally distant for the events it may be associated 
with. Relating SOCRATES scores to future events or behaviour (e.g. treatment entry 
three months after assessment) assumes that readiness is static. The current study has 
found that readiness is not a fixed phenomenon but is subject to change over time. It 
may therefore be unrealistic to expect treatment entry to be related to readiness which 
has changed since it was originally assessed. It may be that readiness is only associated 
with events and patient behaviours which occur temporally close to its assessment.  The 
proposition that the SOCRATES may be less predictive over longer periods may help to 
explain the lack of associations between outcomes (e.g. reduction in drug use) and 
readiness assessed at treatment entry reported in a number or studies using the measure 
(Gossop et al, 2007; Rapp et al, 1998).   
 
The Taking Steps scale was not related to treatment entry, although it must be noted that 
the scale reflects readiness for, or action towards, changing heroin use and not 
motivation for treatment.  However, entering treatment is in itself an action designed to 
reduce drug use, this may suggest that the Taking Steps scale does not reflect the range 
of actions which drug users may employ to change their drug use.  
 
Unadjusted bi-variate analyses also indicated that the frequency of crack cocaine and 
the frequency of heroin use assessed at the time of scheduled treatment entry were 
higher among those who failed to enter treatment. The higher frequency of crack 
cocaine and heroin use may suggest that these study participants are either  too 





that treatment would be able to address their problems. Crack cocaine use has 
previously been found to reduce the likelihood of treatment entry among heroin users 
(Booth et al, 2003) and may be mediated by the concomitant problems associated with 
crack cocaine use such as greater risk-taking behaviours, criminality and psychiatric 
distress (Grella et al, 1995).  
 
In the multivariate analyses, higher Recognition scores and lower levels of crack 
cocaine use were the only significant predictors of treatment entry, although these 
variables did not explain a great deal of variance in treatment entry status. It is likely 
that characteristics not examined within this study are more important in encouraging 
treatment entry. The quality of the initial assessment interview, for example, has been 
noted by number of investigators as influential in treatment entry (Hyams et al, 1996; 
Miller, 1985). This issue will be addressed in Chapter 5. The results indicate that heroin 
users with more severe substance abuse problems may need to be targeted early on in 
the treatment process to be provided with expedited entry into treatment, interim 
methadone prescribing or additional support during the waiting period to ensure that 
they successfully enter treatment and receive the help they require.   
 
It is also interesting to note from the results that the frequency of non-prescribed 
methadone use was higher among waiting list participants who entered treatment than 
those who did not, although this difference failed to reach statistical significance. This 
finding may show that heroin users who successfully enter treatment are self-medicating 
with non-prescribed methadone during the waiting period  in an attempt to begin to 
make changes in their heroin use prior to being prescribed methadone by the treatment 
service. This speculation is supported by the finding that the mean frequency of heroin 
use of those who enter treatment falls by approximately fifty per cent of the baseline 
levels.  
 
In summary, the hypothesis stating that higher readiness at the end of the waiting period 
would be associated with a greater likelihood of treatment entry than demographic or 
substance use variables, was partly supported.  Recognition assessed at the end of the 
waiting period was the only scale to successfully predict treatment entry, in addition to 
the frequency of crack cocaine use. While many studies examining predictors of 





beginning of the waiting period), these results highlight the importance of assessing 
individual characteristics at different stages of the treatment process. Certain 
characteristics (e.g. substance use, readiness to change) may be subject to change, 
particularly when more prolonged waiting periods are experienced.  
 
4.5.6     Changes in substance use over the waiting period    
 
Hypothesis 5 predicted that longer waiting times would be associated with fewer 
reductions in substance use over the waiting period relative to shorter waiting times. 
The findings of the current study do not support this hypothesis.  The longer waiting 
periods of the Standard group were in fact associated with a greater tendency to reduce 
the mean frequency of heroin use.  These reported reductions within the Standard group 
may suggest that heroin users start making efforts to reduce their primary drug in 
preparation for treatment when lengthier waiting periods are experienced. This may also 
be associated with the factors which prompted treatment seeking such a health or 
financial concerns necessitating the need to reduce heroin use over time. While 
reductions in substance use prior to treatment have been reported previously (Rosengren 
et al, 2000; Tucker, 1995),  the study findings contrast those of Brown et al (1989) who 
reported that the length of the waiting list was not associated with any greater or lesser 
tendency to change drug using behaviours. The absence of group changes among the 
Accelerated group may demonstrate that heroin users who know they are soon to start 
treatment may not see the need to initiate changes when substitute prescribing will soon 
begin.  
 
Analyses of heroin outcomes at a case-by-case level revealed that a quarter of the 
sample (27.1%) decreased their baseline heroin use, over half (57.9%) maintained their 
baseline levels and 15.0% increased their use. Variations in the patterns of substance 
use over time have been reported in previous studies of waiting list participants 
(Donmall et al, 2005: Best et al, 2001; Brown et al, 1989) and demonstrate that delay 
for treatment has different effects on different substance users. Such a finding highlights 
the need for tailored interventions for some heroin users to counteract the negative 






A small number of study participants reported achieving abstinence over the waiting 
period. The rates of abstinence did not differ between the two treatment-entry groups in 
the current study. This finding contrasts those of Rosengren et al (2000) who reported 
that abstinence became more difficult to sustain with longer waiting periods. However, 
the results presented in the current study only included heroin users who successfully 
made changes in heroin use during the waiting period, it is not possible to assess how 
many attempted to change but failed in their attempts.  
 
These findings suggest that although the waiting period (regardless of its length) is 
characterised by a continuation of heroin use at the same level as that reported at the 
initial presentation for treatment for many, it is reasonable to expect some to begin 
making changes to their  heroin use prior to treatment entry, particularly when longer 
waiting periods are experienced. The need to maintain a drug habit during the waiting 
period and the continuing exposure to drug-using networks may make efforts to make 
positive change in heroin use difficult for some.  
 
Although only a small number of study participants reported increasing their heroin use 
over the waiting period, this is still a matter of concern due to the risks of accidental 
overdose, needle sharing and other consequences of heroin use (DeGennaro and Zeitz, 
2009; Hoffman et al, 2008). The increase in heroin use reported by twenty per cent of 
the Accelerated group may represent a last binge of heroin, either because they are 
entering treatment and know they will not be using heroin again, or because they have 
quantities of heroin which need to be consumed. Associations with drug-using networks 
may also encourage additional heroin use prior to treatment entry. Some treatment- 
seekers may feel that they have eliminate contact with such networks to promote their 
recovery and so spend additional time with them, and hence consume more drugs, prior 
to treatment.  
 
Outcome response profiles relating to changes in the direction of heroin frequency over 
the waiting period found that heroin users who reduced the frequency of their heroin use 
had higher baseline heroin use (mean of 6.2 days use per week) and heroin users who 
increased their heroin use had the lowest baseline use (mean of 3.2 days per week). 
These findings contrast those of previous research which has shown that individuals 





reductions in their use (Gossop et al, 2003).  While these results are puzzling, they offer 
insights into the complexities of changes in heroin use which occur during treatment 
waiting periods. It may be that study participants with more severe heroin use problems 
sought treatment for financial reasons in that they could not longer afford to consume 
heroin at their usual levels, or that health factors or family conflict prompted the desire 
for change.  
 
A large proportion of the sample reported using a range of different substances at the 
time of treatment seeking. Over half the sample reported the use of cannabis and 
alcohol, a third reported the use of non-prescribed methadone and over sixty per cent of 
the current sample reported the use of crack cocaine. Poly-drug use among treatment- 
seeking heroin users is common (Marsden et al, 2000) and high prevalence rates of 
crack cocaine use have been documented in methadone patients both before admission 
and during treatment (Gossop et al, 2003; Grella et al, 1995). Ball and Ross (1991), for 
example, reported pre-treatment cocaine use in half of all methadone clinic admissions 
studied.  Crack cocaine use has been found to be a significant problem in terms of 
treatment prognosis with patients typically spending less time in treatment than patients 
not using cocaine (Rowan-Szal et al, 2000). Cocaine-using methadone patients also 
have higher rates of criminal involvement (Hall, et al, 1993), and have been reported to 
have more anti-social personality disorders and a greater risk of HIV infection than non-
cocaine users (Grella et al, 1995). 
 
Change profiles for substances other than heroin, found that the majority of heroin users 
reporting the use of non-prescribed methadone, crack cocaine and alcohol at baseline 
maintained the frequency of use at the same level over the waiting period although there 
was considerable variation in the patterns of changes in substance use during this 
period. None of these changes were associated with treatment-entry group membership. 
Between 15.0-30.0% of the sample reported increasing the frequency of at least one 
substance, other than heroin, over this period. Small, but statistically significant, 
reductions in the frequency of crack cocaine and non-prescribed methadone use were 
found over the waiting period within both treatment-entry groups. Nearly half (45.2%) 
of the non-prescribed methadone users reported abstinence from the drug at follow-up. 
Although it can be assumed that heroin use prompted the sample to seek treatment, a 





substances, particularly other opiates. No statistically significant changes in cannabis or 
alcohol use were reported over the waiting period. These may be substances which 
participants feel are less important to change in the short-term or the long-term.  
 
4.5.7    Changes in heroin frequency and readiness to change 
 
Hypothesis 6 predicted that increases in readiness scores over the waiting period would 
be associated with reductions in heroin use. In order to avoid problems with assessing 
the heroin use outcomes temporally distant from readiness as noted earlier, the current 
study assessed changes in heroin use over the waiting period as a function of changes in 
readiness over the same period. This choice of analysis failed to find any statistically 
significant relationship between the direction of change in heroin frequency 
(increased/remained the same/decreased) and changes in readiness on any of the three 
scales. This finding supports a number of previous studies which have failed to find a 
relationship motivation and substance use outcomes (Gossop et al, 2007; Rapp et al, 
1998). The absence of a significant relationship between the variables may be 
associated with problems with the SOCRATES. The scale measures attitudes and stated 
intentions to change, however, several investigators have noted that stated intentions do 
not always  translate  into actual behavioural changes (Gossop et al, 2003). The measure 
may not therefore be appropriate for predicting outcomes. 
 
Although there was no evidence of an association between changes in readiness and 
changes in heroin use over the waiting period, separate analyses found associations 
between baseline readiness and changes in heroin use. Reductions in the frequency of 
heroin use over the waiting period were associated with high baseline Recognition 
scores, thus supporting Hypothesis 7 which predicted that reductions in the frequency of 
heroin use over the waiting period would be associated with high baseline readiness 
scores. However, multivariate analyses revealed it was the waiting list participants 
whose frequency of heroin use did not change between the interviews who had the 
highest baseline Recognition scores. Changes in the frequency of heroin use over the 
waiting period were not associated with baseline Ambivalence and Taking Steps scores. 
This pattern of results is difficult to explain, but may suggest that high problem 
recognition may be an important factor in the ability to maintain the frequency of heroin 





heroin use. Those with more severe heroin use problems may recognise that they have a 
serious problem but may find it too difficult to make changes without the assistance of a 
formal treatment programme. Heroin users with lower baseline Recognition, on the 
other hand, may not fully realise that their heroin use is problematic because of its less 
frequent use, and not yet feel the need to change their behaviour.  Relationships between 
problem recognition and substance use variables (frequency of heroin use, severity of 
dependence) have been reported in previous studies (Bell et al, 2005; Rapp et al, 2003) 
and have also been found to be an important factor in predicting treatment entry among 
drug and alcohol users (Finney and Moos, 1995; Pfeiffer et al, 1991). No relationships 
were found between baseline Ambivalence and Taking Steps scores and changes in 
heroin use over the waiting period.  
 
Bi-variate analyses found that a greater proportion of women reported increasing their 
Recognition scores over the waiting period compared to men. Previous research has 
reported that gender differences in problem recognition, with females less open to 
acknowledging that their problems are related to substance use than males (Mangrum et 
al, 2006; Thom, 1987). However, the current study may show that taking an initial step 
towards change by seeking treatment, or making arrangements for childcare provision 
during treatment, may serve to enhance problem recognition to a greater extent in 
women than their male counterparts. This explanation is speculative as reports of gender 
evaluations in substance abuse literature are rarely made (Toneatto et al, 1992) often 
due to the small number of women in formal treatment programmes (Moras, 1998).  
 
4.5.8        Waiting time expectations  
 
The study found participants’ expectations regarding waiting times were variable, with 
some expecting to wait a week for treatment and others expecting to wait up to two 
months. The degree of discrepancy between expected and actual waiting times was not 
related to treatment entry. Heroin users’ whose expected waiting times were longer than 
their actual waiting times were just as likely to enter treatment as those  participants 
whose expected waiting times matched their actual waiting times, or were less than their 
actual waiting times. However, there was a non-significant trend for those whose actual 
waiting times exceeded their expected waiting times to be less likely to enter treatment. 





The absence of a significant relationship between actual and expected waiting times 
within the current study conflicts with the findings of Thompson and Yarnold (1995) 
reported in the Literature Review, who found that patients were least satisfied with their 
care when waiting time was longer than they expected in medical settings. The results 
also fail to support the Disconfirmation Paradigm which states that customer 
satisfaction is determined by the magnitude and direction of the gap between 
expectations and perceptions of performance (Churchill and Suprenant, 1982). 
However, it must be noted that actual satisfaction with waiting times was not measured 
within the current study but implied from successful treatment entry. Satisfaction with a 
service may not be accurately reflected in the activity of entering treatment. Also, 
previous research was based upon general medical patients who may not be comparable 
to patients with heroin use problems. It is also not possible to determine whether the 
waiting list participants had been given any information about the length of the waiting 
period during the Brief Assessment, prior to the first research interview, which may 
have informed their waiting time expectations.  
 
Although it was expected that individual and clinical factors, such as previous treatment 
experiences, would be related to waiting time expectations, in fact only age was a 
significant contributory factor. Older heroin users expected to wait the shortest amount 
of time (1 week) for treatment to start. While this finding is difficult to explain, the 
question ‘how long do you expect to wait to start treatment’ may have been answered 
according to the desires of starting treatment rather than actual expectations.  Older 
heroin users may have reached a time in their life when finances and relationships have 
become more important than taking drugs and hence may be more committed to 
entering treatment and changing their drug use behaviours.  
 
Hypothesis 9 predicted that changes in readiness over the waiting period would be 
associated with the degree of discrepancy between patients’ expected and actual waiting 
times. Analyses supported this prediction and demonstrated that waiting list participants 
whose expected and actual waiting times were closely matched reported the greatest 
reductions in Ambivalence and Taking Steps scores over the waiting period compared 
to those participants whose expected waiting times were less than or more than their 
actual waits. Reductions on the Taking Steps scales among this sub-group of patients 





genuine research finding.  During the recruitment phase of the study patients were 
informed that they had a chance of receiving quicker access to treatment. Some of the 
study participants may have used this information to inform their expectations on 
waiting times and then coincidentally may have been randomised to the Accelerated 
group, thus fulfilling their expectations. Examination of the expected waiting times of 
the patients within this sub-group may shed more light on this finding. If the waiting list 
participants expected to enter treatment quickly they may have felt that action to change 
their heroin use was necessary when substitute prescribing would soon begin. 
 
The reduction in Ambivalence scores among waiting list participants whose expected 
and actual waiting times corresponded is a positive finding and suggests that conflict 
and uncertainty are reduced when the service received is in line with the patient’s 
expectations. Although waiting time expectations have not been previously researched 
within substance abuse populations, these findings suggest that meeting patient 
expectations regarding the length of the waiting period may promote a positive image of 
the service and engender trust and confidence in the patient that the service is a useful 
resource, responsive to their needs and which can assist them to make positive changes 
to their drug use. This may in turn enhance motivation for change.   
 
Motivation has been related to compliance with treatment, treatment retention and drug 
use outcomes in a number of studies as presented in the Literature Review. A small 
number of studies have also shown that patient’s pre-treatment expectations may have 
an impact on treatment outcomes. For example, a qualitative study examining 
participation in drug treatment suggested that a close matching of user expectations of 
the service with actual services provided encouraged compliance with treatment (Neale, 
1998). In a recent study by Kuusisto et al (2011), patients’ pre-treatment expectations 
regarding participation in a Twelve-Step programme were related to treatment retention 
and treatment effectiveness in terms of percent days abstinent at follow-up.  
The relationships between patient expectations and outcomes reported in these studies 
may be mediated by patient motivation. It may be that a close matching of patient 
expectations and reality enhances motivation to change. Such findings offer the 
potential for treatment providers to enhance motivation during the waiting list by 
managing patient expectations of waiting times. This could be achieved by discussing 





treatment waiting times. These recommendations will be discussed in greater detail in 
Chapter 5. 
 
It must be noted that this study focused explicitly on the independent variables of  
waiting time expectations, readiness to change and treatment entry, no covariates were 
examined. It has been suggested that patient expectations regarding treatment may be 
influenced by the complexity of the patient’s substance use problem, the more complex 
the problem, the greater the discrepancy between the patient’s expectations and the 
treatment received (Kuusisto et al, 2011). The inclusion of substance use variables in 
future research examining the factors associated with patient expectations is therefore 
recommended to provide a clearer picture of the respective relationships. 
 
 
4.6     Conclusions to Study 2  
 
Study 2 permitted an examination of the time-sensitive relationships between readiness 
to change drug use and treatment waiting times. For a large proportion of the waiting 
list participants, waiting for treatment, regardless of the length of the waiting period  
was associated with reduced readiness to change. However, different patterns of change 
were observed within the sample which demonstrates that people respond differently to 
waiting for treatment and maintaining motivation over time may be just as important as 
generating it in the first place. 
 
Contrary to expectations, longer waiting times were not associated with lower rates of 
treatment entry or to fewer reductions in substance use over the waiting period relative 
to shorter waiting times.  Readiness scores at the end of the waiting period were 
associated with treatment entry but were not associated with changes in heroin use over 
the waiting period. Heroin users’ expectations about the length of the waiting period 
were not associated with the likelihood of treatment entry but were associated with 
readiness change scores over the waiting period. The clinical implications of these 
findings will be discussed in Chapter 5. 
 
Further research is needed to understand how treatment seekers respond to waiting 
periods and to more adequately explore how motivation changes as a function of 





behaviours, as well as the nature of impediments to these changes such as waiting times, 
is important in developing interventions to help promote successful behaviour change. 
For example, if future research provides supportive evidence of a detrimental effect of 
waiting times on patient motivation, then efforts could be focused on assisting the 
individual to maintain or enhance their initial motivation for change. This may serve to 
prevent the ramifications of poor motivation such as treatment attrition and non-




























CHAPTER 5:      DISCUSSION  
 
This final chapter assesses the extent to which the research programme has answered 
the research questions posed and its contribution to furthering our understanding of 
readiness to change and the effects of treatment waiting times. Consideration is given to 
the use of SOCRATES within the research programme and to a number of limitations of 
the findings of the research studies.  This chapter will also discuss the clinical 
implications for the treatment of drug users and suggest recommendations on how 
treatment might be tailored to better meet the needs of drug users awaiting treatment 
entry. 
 
5.1     OVERVIEW OF THE RESEARCH PROGRAMME 
 
Waiting times have been identified as a potential barrier to treatment access among 
substance users (Neale et al, 2007). Little, however, is known about the nature of its 
effects on the motivation of drug users awaiting treatment entry. The main focus of the 
research programme was to examine the relationship between waiting times and 
readiness to change among heroin users requesting methadone out-patient treatment and 
how this relationship impacts on patient behaviour and treatment entry. The first study 
piloted the Stages of Change, Readiness and Treatment Eagerness Scale (SOCRATES) 
on a treatment population in order to examine its utility in detecting changes in 
readiness over time. The second study randomly assigned treatment seekers to waiting 
periods of different lengths (short or prolonged waits) and assessed changes in readiness 
over the course of the waiting period. The likelihood of treatment entry, patterns of 
substance use over the waiting period and patient expectations were examined as a 













5.2   DISCUSSION OF THE FINDINGS 
 
5.2.1    The waiting period and readiness to change 
 
While many studies have assessed the motivation of substance-using populations, few 
studies have examined how motivation changes over time or how these changes are 
related to factors in the treatment environment. No studies, known to the author, have 
systematically examined motivation among heroin users placed on a waiting list prior to 
treatment entry or how the length of the waiting period is related to the changes in 
motivation which may occur during this period.  
 
Study 1 examined the relationship between readiness to change and waiting times 
retrospectively in a sample of heroin users at the point of treatment entry after a variable 
waiting period.   The Ambivalence scale was the only dimension found to be associated 
with waiting times, with longer waiting times positively associated with greater conflict 
around changing drug use (or that shorter waiting times are associated with less 
conflict).  No relationship was found between the length of the waiting period and the 
Recognition or Taking Steps scale scores. While the design of Study 1 does not allow us 
to assess whether the scale scores altered over the course of the waiting period, the 
results may indicate that longer waiting periods provide the heroin users with greater 
time to reflect on their drug use and question the implications of behaviour change 
leading to uncertainty and conflict about such behaviour. 
 
Assessment of readiness among Study 1 participants found they entered treatment with 
‘medium’ Recognition scores, ‘medium’ Ambivalence scores and ‘medium’ Taking 
Steps scores according to Miller and Tonigan’s (1996) interpretative ranges. A closer 
inspection of the scale scores revealed considerable variability among the heroin users, 
with some denying, and others acknowledging, that they have a heroin use problem, 
with some experiencing uncertainty about changing their heroin use, while others do 
not, and with some making efforts to change their drug use, while  others reported little 
activity in this area. 
 
Among the waiting list participants in Study 2, the greatest proportion of the sample 





problem, ‘medium’ Ambivalence and ‘low’ Taking Steps to change their behaviour. 
While considerable variation in the changes in readiness scores were observed over the 
waiting period, group means revealed that those heroin users scheduled to enter 
treatment after a short delay (Accelerated group) reported reductions in both Taking 
Steps scores and Ambivalence scores. Waiting list participants entering treatment after a 
prolonged delay (Standard group) reported no statistically significant changes on these 
scales. Further analyses revealed heroin users whose Ambivalence scores decreased 
over the waiting period waited a significantly shorter period (24 days) than those whose 
scores increased (50 days). Similarly, heroin users whose Taking Steps scores decreased 
over the waiting period waited less time (24 days) than those who scores increased (49 
days).  
 
Study of the sub-groups representing changing patterns of readiness over the waiting 
period (increased, decreased or stayed the same) revealed that a sizeable proportion of 
both treatment-entry groups reported reductions on all three readiness scales between 
the start and end of the waiting period, a smaller proportion reported increases in 
readiness for change and some reported no changes between the two interviews.  These 
patterns of changes over the waiting period, with some heroin users increasing, and 
some decreasing their scores on the three scales are consistent with a ‘spiral model of 
change’ proposed by Prochaska and DiClemente (1982). A number of other 
investigators have commented on the dynamic nature of motivation that can fluctuate 
over time and in relation to different situations (Vallerand and Thill, 1993;Reeve, 1992; 
Rosenbaum and Horowitz, 1983). However, it is not known whether these fluctuations 
in readiness may occur naturally, regardless of waiting list participation. Examining 
how readiness changes over time among heroin users with no current intentions of 
seeking treatment would allow further exploration of this contention.  
 
The reduction in readiness scores among the Accelerated group demonstrates that 
changes can occur over relatively short waiting periods. The reductions on the 
Ambivalence and Taking Steps scales suggests that heroin users with short waiting 
periods are experiencing more willingness to change (reduced Ambivalence), but less 
propensity to take action (lower Taking Steps). Reductions on the Ambivalence scale 
may suggest that waiting list participants experienced less uncertainty and conflict 





However, this same knowledge appears to have diminished their efforts to make 
changes to their heroin use. While this finding is difficult to explain, waiting list 
participants with short waiting periods may not perceive the need to change their drug 
use behaviour when they will soon receive substitute medication to replace their heroin 
use.  
 
Although there is a paucity of research assessing changes in SOCRATES scores over 
time, reductions on the Ambivalence scale were also found in a study of treatment- 
resistant substance users who later presented for treatment (Daugherty et al, 2000). 
However, in contrast to the current study, Daugherty and colleagues found a reduction 
in Recognition scores and increases in scores on the Taking Steps scale.  Although this 
study examined readiness among alcohol users in the period prior to treatment seeking 
and so is not entirely comparable to a waiting list sample of heroin users, it supports the 
findings that changes in readiness occur over short periods of time.  
 
It was predicted that longer waiting periods would be associated with greater reductions 
in readiness scores over this period. The absence of statistically significant changes in 
readiness scores within the Standard group was somewhat unexpected and difficult to 
explain. The results may be taken to show that long waiting periods do not appear to 
have a significant effect on patient readiness. Waiting list participants may feel that they 
will not be able to make changes to their drug use without the assistance of treatment 
and it is therefore unnecessary to experience conflict about making changes when 
change is in the future. This may suggest that many heroin users have more important 
short-term priorities than their thoughts and activities regarding change, such as 
procuring and taking drugs. The reductions in Ambivalence may support this contention 
– when they know that treatment entry is close, waiting list participants begin to 
contemplate change. 
 
Study 2 collected readiness data at the beginning and end of the waiting period.  It is not 
known whether readiness levels fluctuated to a greater extent than that represented in 
the mean score analyses within the Standard group. Readiness assessed at the end of the 
waiting period may have returned to the level reported when they first presented to 





of the waiting period, rather than just at the beginning and end, may present a clearer 
picture of the changes which occur within this group.  
 
The absence of changes on the Recognition scale over the waiting period within both 
treatment-entry groups may demonstrate that this dimension is more stable over time 
and less subject to external influences such as waiting time than the other dimensions. It 
may alternatively suggest that this dimension is more important for initiating the desire 
for change and promoting treatment seeking but less involved in the actual change 
process than previously assumed. If this is the case, then the Recognition scale of the 
SOCRATES may not adequately reflect the factors involved in the change process. 
 
It must be noted that the SOCRATES asks about current motivational attitude about 
making changes to drug use. Within Study 2, the SOCRATES was initially 
administered after the first clinical contact with the service, immediately after the 
treatment seekers were informed that a waiting period was inevitable. Information that 
they would not receive immediate help may have disappointed many, or roused doubts 
about changing their drug use, which may in turn have affected their responses to 
statements on the measure. Scores on the SOCRATES in this instance may not have 
accurately reflected the readiness of the participants. Such a contention highlights the 
importance of taking the timing and contextual factors surrounding the administration of 
the SOCRATES into account. Although Prochaska and DiClemente were explicit about 
leaving contextual factors out of the Transtheoretical Model, it is likely that motivation 
is affected by events and emotions surrounding its use.  
 
Although the association between waiting times and Ambivalence is not particularly 
strong within Study 1, and is based on correlational analyses, it serves to corroborate the 
findings of Study 2 and may suggest that this dimension of readiness is affected by 
waiting periods prior to treatment entry to a greater extent than the other dimensions.  
These findings may highlight the need for treatment services to identify and address 
ambivalence for change among treatment seekers at their first clinical contact and at 
other times during the waiting period when lengthier waits are necessary.  
 
 It is interesting to note, although perhaps not surprising, that the Recognition and 





higher than those reported among the waiting list sample at the start of the waiting 
period in Study 2. Study 1 included only those treatment seekers who successfully 
entered treatment after the waiting period. These patients had already endured a waiting 
period of up to three months and several assessment procedures prior to treatment entry.  
It may be the case that only the more motivated treatment-seeking heroin users were 
able tolerate the delay for treatment entry and thus were included in the study sample.  
Treatment seekers with lower levels of motivation may not have been able to tolerate 
the wait, failed to enter treatment, and were therefore not included in the study. The 
heroin users in Study 2, on the other hand, were recruited to the study at the beginning 
of the waiting period and therefore included those who would go on to successfully 
enter treatment and also those who would not. Some of these treatment seekers may 
have presented to treatment during a period of crisis or may have been coerced into 
treatment by others and may not be as committed to alter their drug use or entering 
treatment at this point in time.  
 
The findings reported support the first stage of the conceptual framework presented in 
Chapter 1 which depicted a relationship between waiting times and readiness to change.   
The research programme demonstrated that waiting for treatment is associated with 
changes in readiness in a large proportion of the sample, although unexpectedly, shorter 
waiting times were associated with a greater reduction in readiness over time relative to 
longer waiting periods. These findings demonstrate the transient nature of readiness to 
change, and suggest that treatment services should take advantage of treatment 
applicants’ initial desire for change when they first present for treatment. Although 
readiness for change was not particularly high among the waiting list participants at the 
first presentation at the service, the passage of time, even when this was only a short 
period, reduced patients’ recognition of their problems and their propensity for action 
designed to change their drug use. Case-by-case analyses revealed that people 
experience the waiting period very differently. More research is required to examine 
how waiting times and readiness to change interact among treatment seekers assigned to 









5.2.2     Waiting time and treatment entry 
 
The length of the waiting period in Study 2 was not related to treatment entry, with 
similar proportions of the Standard and Accelerated groups starting treatment. While 
these findings are consistent with a small number of studies which have also failed to 
find an association between waiting times and treatment initiation (Donmall et al, 2005; 
Eriksen, 1986), they contradict a larger body of research which has demonstrated that 
the longer substance users have to wait the less likely they are to enter treatment (Hser 
et al, 1998; Leigh et al, 1984; Raynes and Warren, 1971). Differences in the findings of 
the current study and previous studies may be a result of the different ways waiting 
times have been defined and measured. The current study defined waiting times as the 
period between the first presentation at the service and the start of treatment (Best et al, 
2002; Hser et al, 1998; Orne and Boswell, 1991). Some of the previous studies have 
defined waiting times as the amount of time between initial client referral and first 
clinical assessment at the treatment service (Festinger et al, 1996; Gariti et al, 1995; 
Wanberg and Jones, 1973). These periods of time may have different meanings to 
treatment seekers. For example, substance users who seek referral from a G.P. will have 
to initiate the forces which prompted initial treatment seeking a second time when a 
clinical assessment at a treatment service is provided, which may prove to be too 
difficult for some.  
 
The conceptual framework for the research programme was based on the premise that 
readiness to change mediates the relationship between waiting times and treatment entry 
which has been frequently reported in the substance abuse literature. The absence of an 
association within Study 2 largely invalidates the conceptual framework and the role of 
readiness to change in mediating the specified outcome. However, it must be noted that 
the waiting time of those who entered treatment was shorter than those who did not 
enter treatment, although this difference did not reach statistical significance. This may 
suggests that the size of the study sample, and the resulting discriminatory power of the 
statistical tests employed, may have contributed to the absence of significant 
associations between the variables under investigation. This will be addressed further in 
the reflections on the research programme section. The absence of a significant 
relationship between waiting times and treatment entry may have also have arisen from 





seekers need for treatment and initiating change.  The relationships between waiting 
times and a second outcome measure (changes in substance use) will be discussed in 
Section 5.2.4. 
 
5.2.3   Readiness to change and treatment entry 
 
Higher Recognition scores and lower Ambivalence scores, assessed at the end of the 
waiting period, were associated with treatment entry, although only Recognition scores 
remained a significant predictor of treatment entry status in multivariate analyses.  
Supportive evidence for the role of Recognition in treatment entry is provided by a 
number of studies which have found problem recognition, assessed with a variety of 
measures, was one of the most influential factors in initiating the treatment process 
entry (Tsogia et al, 2001; Jordan and Oei, 1989). Without high problem recognition 
heroin users may fail to see the extent of their heroin use problem and hence the need 
for treatment. Recognition (and frequency of crack cocaine use) accounted for only a 
small amount of variability in treatment entry in Study 2. Other factors not assessed 
within the study are likely to impact on the likelihood of treatment entry. 
 
The relationship between treatment entry and lower Ambivalence found in the bi-variate 
analyses suggest that heroin users are less likely to enter treatment when they are 
experiencing a high degree of conflict about changing drug use. As the Ambivalence 
scale represents the weighing up of the pros and cons of behaviour change, not entering 
treatment may reflect the perceived advantages of continued heroin use outweighing the 
advantages of changing heroin use. However, it must be noted that this Ambivalence 
was recorded after they had missed their Full Assessment appointment. The reported 
conflict may have arisen from failing to enter treatment when a place became available 
and hence missing an opportunity for change. The collection of qualitative information 
from waiting list participants about their feeling towards change would help to clarify 
the relationship between readiness and treatment entry. 
 
While readiness assessed at the end of the waiting period was associated with treatment 
entry, readiness assessed at the start of the waiting period was not. This finding 
highlights the importance of the timing of the assessment of readiness, or other 





and outcomes. As noted in Study 2, readiness is subject to change over time and in 
some instances readiness and outcomes are only related when they are assessed 
temporally close to each other. The conceptual framework predicted a relationship 
between readiness and treatment entry. The existence of this path has been partly 
supported by the statistical analyses, although only when readiness was assessed at the 
same time as treatment entry.  
 
5.2.4     Waiting times and substance use 
 
Previous waiting list research has generated minimal data on the behaviours of 
substance users during the period between treatment seeking and treatment entry.  
The study sample demonstrated variations in the patterns of heroin use over the waiting 
period. While over half of both treatment-entry groups reported no changes in their 
heroin use over the waiting period, twenty per cent of the Accelerated group and six per 
cent of the Standard group reported increasing their heroin use, and thirty-five percent 
of the Standard group and twenty-two per cent reported decreasing their heroin use. 
While these findings show that the waiting period, regardless of its length, is not 
characterised by a deterioration of drug use as reported in some previous studies (e.g. 
Urschel et al, 1991), it does show that a large proportion of waiting list participants are 
still exposed to the problems which prompted their initial treatment seeking efforts. 
Stability of drug use over the waiting period should therefore not be seen as a positive 
finding. While it is promising to see that a proportion of the waiting list participants do 
start to make changes to their heroin use during the waiting period, the finding that a 
proportion of the Accelerated group increased their heroin use over the two-week 
waiting period is a matter of concern due to the risks of accidental overdose and risk-
taking behaviours associated with excessive heroin use (Darke et al, 2006). Increases in 
heroin use over the waiting period may reflect a perceived final heroin binge prior to 
entering treatment, either because the treatment seekers believe they will no longer use 
heroin once substitute prescribing begins or because they possess quantities of heroin 
which they feel need to be used  prior to quitting drugs.  This increased heroin use over 
the waiting period may make the treatment induction phase more difficult when heroin 






Study 2 predicted that longer delays would be associated with fewer reductions in 
substance use, however, this association was not detected. Comparison of the mean 
changes in the frequency of heroin use between the treatment-entry groups found that 
the longer waiting periods of the Standard group were in fact associated with reductions 
in the frequency of heroin use over the course of the waiting period, while the frequency 
of heroin use was unchanged within the Accelerated group. The reasons that prompted 
treatment seeking (e.g. financial or health reasons) may have necessitated the need to 
reduce heroin use on their own when treatment entry was not imminent within the 
Standard group. The absence of reported reductions in the Accelerated group may be 
due to heroin users anticipating that heroin use will reduce with the aid of substitute 
prescribing within a short period of time.   
 
Analysis of the use of other substances over the waiting period found the greatest 
proportion of both treatment-entry groups reported maintaining the frequency of non-
prescribed methadone, crack cocaine, cannabis and alcohol use over the waiting period. 
There was no difference in the reported changes between the Standard and Accelerated 
groups. Lack of changes in substances other than heroin may demonstrate that treatment 
seekers do not feel that their use of other substances is problematic and therefore do not 
need to change them. Pre-admission use of one or more illicit drugs in addition to 
heroin have been reported in large proportions of methadone patients (Dunteman et al, 
1992; Hubbard et al, 1989) and continued drug use during methadone treatment has 
been reported in up to seventy per cent of patients (Best et al, 2000; Belding et al, 1998; 
Sunjic and Howard, 1996). Those patients who continue to use other drugs during 
treatment have been reported to have generally poorer treatment outcomes than those 
who abuse only heroin (Weiss et al, 1988). This poly-drug use prior to, and during, 
treatment is also a matter of concern as multiple drug use has been related to heroin 
overdose (Darke et al, 1996) and HIV-transmission risk (Grella et al, 1995).  
 
The relationship between waiting times and substance use supports the conceptual 
framework for the research programme, although the relationship between the two 
variables was not in the predicted direction. Longer waiting periods were associated 
with reductions in heroin use, while the frequency of heroin use remained largely 





period did not significantly impact on the levels of the other substances consumed by 
the study participants. 
 
5.2.5    Readiness to change and substance use 
 
Changes in heroin use over the waiting period were not associated with changes on any 
of the three readiness scales. Although this is an unexpected finding, it corroborates a 
number of other studies which have also failed to detect relationships between 
motivation and substance outcomes (Gossop et al, 2007; Rapp et al, 1998). While it was 
assumed that the absence of findings within these previous studies was the result of 
assessing motivation at a temporally distant time to the assessment of substance 
outcomes, using change measures for heroin use and readiness levels also failed to 
detect a relationship between the variables. The SOCRATES assesses self-reported 
intentions and behaviours. The observation that these do not correspond to actual 
substance use in this research programme may demonstrate the inconsistent nature of 
the stated intentions and behaviours concerned with making changes. Callaghan et al 
(2007) stated that “a central and defining feature of addiction is the disjunction between 
consciously expressed intentions or attitudes and corresponding addiction behaviours”.  
 
An examination of the relationship between heroin use over the waiting period and 
baseline readiness scores found reductions in the frequency of heroin use were 
associated with higher baseline Recognition, Ambivalence and Taking Steps scores. 
It appears that those with greater problem recognition, higher ambivalence about change 
and those who take action to change their heroin use are more likely to report changes to 
their heroin use over the waiting period. This readiness may have prompted treatment 
seeking and it appears that in this instance high Taking Steps scores are translating into 
behaviour (i.e. reductions in heroin use). Waiting list participants who increased their 
heroin use over the waiting period reported lower baseline readiness scores on all three 
scales. Increased heroin use among waiting list participants with lower problem 
recognition, less conflict about their drug use and who are not engaging in activities to 
change drug use, may represent a final binge prior the anticipated reduction in heroin 
use when treatment begins A lack of insight into their heroin use problems may prevent 






The presence of a relationship between baseline readiness levels and changes in heroin 
use over the waiting period, but an absence of a relationship between changes in 
readiness and changes in heroin use over the same period, is quite difficult to explain. 
The findings may suggest that the readiness which prompted the initial treatment 
seeking is the most powerful predictor of change, while the changing patterns of 
readiness observed over the waiting period are less influential in promoting change.  
However, it must be noted that the assessment of readiness at the end of the waiting 
period represents readiness at a particular moment in time. These readiness levels may 
reflect feelings about entering treatment or failing to enter treatment. Assessing 
readiness levels at other time points during the waiting period may demonstrate a 
different pattern to those when assessment is only at the start and end of the waiting 
period. 
 
This pattern of results contrasts the earlier findings which demonstrated that baseline 
readiness had no impact on treatment entry, while readiness assessed at treatment entry 
was related to successful treatment entry. Readiness appears to have a differential effect 
on the specified outcomes and it appears that the timing of the assessment of readiness 
is important in detecting relationships between the variables. This may once again 
reflect the transient nature of readiness over time.  
 
The relationship between changes in heroin use and baseline readiness scores may be 
taken as evidence that the SOCRATES is capable of predicting future outcomes. Those 
associated with the Transtheoretical Model have been reluctant to suggest that the 
model has significant predictive power, particularly when only the Stages of Change 
element of the model is used (Velicer et al, 1996). However, many still believe that the 
model has predictive power and given that the model claims to contribute to the 
understanding of behavioural change some believe that this is not an unreasonable 
expectation (e.g. Whitelaw et al, 2000).  Previous research has produced mixed results 
regarding the predictive utility of the SOCRATES (Chavez et al, 2003; Daugherty et al, 
2000), with some studies reporting that readiness for change did not predict less 
frequent use of illicit opiates one year after treatment intake (Gossop et al, 2007) or 
alcohol use among alcohol patients over time (Hewes and Janikowski, 1998; Campbell, 
1997). Inconsistencies in the predictive value of other stage-based measures have also 





The conceptual framework proposed that the relationship between waiting times and 
substance use outcomes would be mediated by readiness to change, that is, the length of 
the waiting time would influence changes in readiness over the waiting period and these 
changes would in turn influence patterns of substance use over this time. According to 
this pathway, a relationship between substance use and readiness to change cannot be 
confirmed. Although Study 2 found that baseline readiness levels were related to 
changes in heroin use over the waiting period, this is not how the framework presented 
the proposed relationship. 
 
5.2.6     Waiting time expectations, readiness to change and treatment entry 
 
There has been an absence of research examining the expectations which substance 
users hold regarding the length of the waiting period or how these expectations are 
related to readiness to change drug use. It was predicted that waiting list participants 
who experienced waiting times longer than they expected would be less likely to enter 
treatment, and also that this group would demonstrate reductions in motivation over the 
waiting period. The study demonstrated that treatment seekers do hold expectations 
about the length of the waiting period which they may be expected to endure, although 
the discrepancy between heroin users’ actual waiting times and expected waiting times 
was not related to treatment entry. Heroin users whose actual waiting times were longer 
than they expected were no less likely to enter treatment than those whose actual 
waiting times were similar, or shorter, than they expected. 
 
Expectations of the length of the waiting period were found to be related to changes in 
readiness over the waiting period. The greatest reductions in Ambivalence scores were 
reported among waiting list participants whose expected waiting times matched their 
actual waiting times. This group also reported the greatest reduction in Taking Steps 
scores over the waiting period. The reduction in Ambivalence scores is a positive 
finding and highlights the importance of treatment services meeting patient expectations 
in order to encourage motivation. Meeting patient expectations may contribute to a 
positive appraisal of the service and give patients confidence in the capability of the 
service to assist them in their change process. Reductions on the Taking Steps scale 
among patients whose expected and actual waiting times matched, demonstrates that 





drug use. These heroin users may have felt that their previous efforts to change drug use 
were no longer necessary when substitute prescribing was soon to begin.    
While much remains to be determined regarding the association between waiting time 
expectations, patient motivation and treatment entry, further research is needed to 
examine the source of patient expectations and how these can be modified by treatment 
providers to reduce unrealistic expectations and the disappointment that ensues when 
expectations are not met. If a relationship exists between pre-treatment waiting time 
expectations and motivation, then influencing patient expectations by making them 
more compatible with treatment reality should be made part of the treatment provision. 
This could be achieved by providing treatment seekers with accurate information about 
the length of the wait prior to treatment at the initial contact with the treatment service.  
 
The conceptual framework proposed relationships between waiting times expectations, 
readiness to change and treatment entry. Although a relationship was found between 
waiting time expectations and readiness to change over the waiting period, the absence 
of a relationship between waiting time expectations and treatment entry fails to support 
the meditational role of readiness within the proposed pathway. 
 
5.2.7     Summary of the conceptual framework results 
 
Study 2 tested  a conceptual framework to account for the relationships between waiting 
times, readiness to change, treatment entry and changes in patterns of substance use. 
The study hypothesised a mediational role for readiness to change in the relationship 
between waiting times and outcomes previously reported in the substance abuse 
literature. In order to examine whether readiness to change was a mediator between the 
waiting times and outcomes the presence or absence of the various paths in the mediator 
model were tested.  
 
The first part of the framework assessed the relationship of the independent variable 
(waiting time) on the mediator variable (readiness to change). The presence of this path 
was supported – a relationship was found between the length of the waiting period 
(short or long wait) and changes in readiness over this time. The mediator variable 
(motivation) should also affect the dependent variable(s) (treatment entry and changes 





detected, although no associations were found for the relationship between motivation 
and changes in heroin use. The third path in the framework should see an effect of the 
independent variable (waiting time) on the dependent variable (treatment entry) when 
the mediator variable (motivation) is excluded. No relationship was detected between 
waiting times and treatment entry, although a relationship was detected between waiting 
times and substance use. Examination of the path between expectations, readiness and 
treatment entry found that waiting time expectations were related to readiness to 
change, but were not related to treatment entry. A limited number of patient factors 
were associated with some of the variables assessed. 
 
Although a number of paths within the framework were supported, the absence of other 
paths between the variables means that a mediational role for readiness cannot be 
confirmed. The length of the waiting period was related to changes in readiness over 
this period, but this relationship does not appear to influence the specified outcomes. 
While both waiting times and readiness were associated with outcomes, they were not 
associated with the same outcomes – waiting time was related to changes in heroin use, 
but was not related to treatment entry, while readiness to change was associated with 
treatment entry and waiting time expectations but was not related to changes in 
substance use. The pattern of results from the testing of the different pathways within 
the conceptual framework is quite complex. The absence of the predicted relationship 
between waiting times and treatment entry was unexpected and may reflect problems 
with the size of the sample in Study 2. This problem may have impacted on the other 
relationships examined and will be discussed in the next section. Further testing is 
required to clarify the nature of these relationships.  
 
 
5.3    REFLECTIONS ON THE RESEARCH PROGRAMME 
 
This section of the Discussion reflects on the design and data collection process of the 
research programme. It will examine some of problems associated with the research 
which may have contributed to the unexpected findings, or the absence of expected 
findings, and will make suggestions regarding improvements which could have been 







5.3.1   Constraints of the Department of Health Study 
 
While the larger cohort waiting list study discussed in Chapter 4 provided an 
opportunity for the current research programme to be conducted and served to guide the 
approaches and measures employed, it also imposed a number of constraints and 
limitations which may have compromised the findings of Study 2.       
 
Prior to the commissioning of the larger cohort study there were concerns surrounding 
the existence of extensive waiting times in drug treatment services in the UK. Given the 
social costs and individual impairment associated with heroin use, the Department of 
Health wanted to increase the number of drug users in treatment. One way to achieve 
this was to reduce the length of drug treatment waiting lists and increase the number of 
drug users each service could see. The main aim of the larger cohort study was to assess 
the impact of reducing the length of waiting times prior to treatment entry on the 
likelihood of entering treatment once a place became available and successfully 
retaining patients in treatment. Randomisation of treatment seekers to either a short or a 
more prolonged waiting period was considered to improve upon the design of previous 
waiting list studies by randomly distributing individual and substance use characteristics 
between the groups so that such differences would not impact on the relationships 
examined. 
 
Sixty-eight per cent of the 182 heroin users recruited to the larger cohort study  
(91 in each treatment-entry group) started treatment after the waiting period, with a 
greater proportion of the Accelerated group entering treatment compared to the 
Standard group (77.0% versus 59.0%).  An examination of the patient characteristics at 
the first research interview revealed that patients who failed to start treatment were 
more likely to use crack cocaine, and use it more frequently, than those patients who 
successfully entered treatment.  All patients who successfully started treatment were 
followed up at three-monthly intervals over the course of a year. Slightly fewer patients 
from the Accelerated group were retained in treatment at each follow-up period, 
although the difference between the groups was not statistically significant. 
Randomisation to the Accelerated group was associated with fewer patients using drugs 
and patients using smaller quantities of drugs, while randomisation to the Standard 





period. A large proportion of the Standard group who did not start treatment cited the 
waiting list as a factor in their non-return. This was not cited by any of the Accelerated 
group who failed to enter treatment. In summary, the larger cohort study found that 
reducing delays prior to treatment was associated with successful treatment entry, 
although it did not improve treatment retention. The Executive Summary of the larger 
cohort study can be found in Appendix 11. 
 
The significant relationship found between rates of treatment entry and the length of the 
waiting period in the larger cohort study contradicts the results of Study 2 which failed 
to demonstrate the effectiveness of Accelerated treatment entry, in terms of enhanced 
treatment initiation rates, relative to Standard treatment entry.  Even when the waiting 
period was analysed as a continuous variable rather than the dichotomous variable 
(short or prolonged waiting periods) no relationship was found. The sample size of the 
two studies was the only factor which differentiated them, with Study 2 comprising 
forty-nine fewer participants than the larger cohort study. As Study 2 required 
motivation data at two data collection points, only study participants who could be 
located and interviewed at follow-up study were included in the analyses. Attrition from 
the waiting list and difficulty contacting study participants resulted in a smaller sample 
than that which was available at recruitment. The impact of this was not fully realised 
until statistical analysis for the research programme began. As the main objective of the 
larger cohort study was to assess rates of treatment entry, obtaining follow-up data was 
not such a priority. Treatment entry data was available within the treatment service for 
all 182 study participants, thus providing a larger sample size to examine the main 
research objective. It therefore seems likely that the waiting time intervention was 
effective in Study 2 but that the study sample was too small to establish the efficacy 
statistically. Recruitment numbers were based on the requirements of the larger cohort 
study and there was no possibility of collecting more data at the end of the recruitment 
period for the purposes of the current research programme.  Although the size of the 
sample in Study 2 met the sample size calculation requirement, this calculation was 
based on the testing of the study hypothesis predicting greater changes in readiness 
among the Accelerated group relative to the Standard group. It now seems likely that 
this sample size was insufficient to detect differences in the rates of treatment entry 






The research programme also failed to find a statistically significant relationship 
between waiting time expectations and treatment entry, however analysis of this 
relationship in the larger cohort study found that waiting list participants whose waiting 
times were the same as or less than they expected were more likely to enter treatment 
than those participants whose waiting time was longer than they expected. Future 
research would be wise to perform sample size calculations on each of the hypotheses 
tested and employ larger sample sizes to minimise the power problems associated with 
patient attrition. The collection of better contact details at recruitment may also assist in 
improved follow-up rates. This will be discussed in greater detail in the 
Recommendations for future research section.  
 
5.3.2     Reliance on quantitative data 
 
A further constraint of the larger cohort study was the reliance on quantitative data 
collection. Although this was imperative for the collection of data regarding substance 
use, offending behaviour and health and psychological functioning over the waiting 
period, it prevented the examination of other factors which may be relevant for 
examining the relationship between waiting times and motivation to change. As this 
relationship has not been previously examined, qualitative research that explores the 
patients’ understanding of what motivates them  to seek treatment, and questions 
concerning the experience of waiting for treatment, would have added value to the 
research findings. By designing a set of questions for the study we had in effect decided 
in advance of data collection what issues were important. While this was acceptable for 
the larger cohort, it limited the information available for the thesis.  
 
Inadequate planning prior to the design of the research interview, and a focus on the 
needs of the larger cohort study rather than those of the research programme, meant that 
the opportunity to access novel information was lost. The perspective of substance users 
remains largely ignored in research conducted in treatment services (Carlson, 2006; 
Tsogia et al, 2001), although researchers have noted that “patient perspectives on 
treatment may have a role in treatment outcomes and should be explored as a dimension 
of the treatment process” (Lee et al, 2007). The perspectives and opinions of drug users  
would  offer an intimate understanding of how shorter  waiting times are received and 





5.3.3     The measurement of motivation 
 
Although the SOCRATES fulfilled its intended purpose - to detect changes in readiness 
over time - some of the findings were difficult to explain. The use of a second measure 
of motivation may have proved useful to validate the findings. However, the inclusion 
of a second measure of motivation would have been problematic as other measures are 
based on different dimensions of the construct making comparisons between the two 
sets of results difficult. 
 
Other problems with the research design such as the use of the Standard and 
Accelerated treatment-entry groups and the length of the waiting periods within these 
groups also raised issues which had not been anticipated. These will be discussed in the 
Limitations section.    
 
5.4     THE USE OF THE SOCRATES IN THE RESEARCH PROGRAMME  
 
The SOCRATES is the one of the most widely used instruments for measuring 
readiness to change, and while it has been extensively used with substance users, only a 
small number of studies have used  it to assess changes in motivation over time.  The 
absence of such longitudinal data necessitated piloting the instrument using repeated 
administrations to ensure it was capable of detecting changes in readiness over time in 
heroin users.  
 
5.4.1   Applicability of the SOCRATES to drug users and waiting list participants 
 
The main strength of the SOCRATES in this research programme was its capability in 
detecting changes in readiness over time in study participants assigned to a waiting list 
and also to those entering and participating in methadone treatment.  In the Pilot Study 
changes in readiness were observed on all three scales between treatment intake and the 
three- and six-month follow-up points, and statistically significant changes were found 
on the Recognition and Ambivalence scales between intake and the three-month follow-
up interview. In Study 2, changes were also observed on all three scales over both short 





recorded for the Ambivalence and Taking Steps scale scores over a two-week waiting 
period.  
 
A number of commentators have suggested that because the SOCRATES was 
developed on an in-patient alcohol treatment sample it may not be sensitive enough to 
fully capture aspects of motivation among drug users. However, evidence for this 
proposition within the current research programme is lacking.  The SOCRATES could 
detect changes in readiness in drug-using populations and readiness was also found to 
be related to treatment entry and changes in heroin use within this population over the 
waiting period.  An absence of reported mean changes on the Taking Steps scale 
reported in Study 1, and on the Recognition scale within Study 2, may be seen to 
demonstrate that the measure may not be sensitive to detect subtle differences on this 
dimension among heroin users. However, it is likely that these findings reflect problems 
associated with using mean scores to assess change as case-by-case analyses in both 
studies revealed changes in scale scores over time. An absence of  statistically 
significant relationships between certain dimensions of readiness and some of the 
variables examined may be the result of inadequate sample sizes rather than the measure 
not being relevant to drug-using populations. This problem will be discussed in greater 
detail in Section 5.5.2. Burrow-Sanchez and Lunberg (2007) conducted the only 
previous study, known to the author, which assessed motivation among drug users 
assigned to a waiting list. Findings from the analysis of the factor structure of the 
SOCRATES on waiting list participants also demonstrated that the measure can be 
useful with samples of adults waiting for treatment for which alcohol is not the primary 
drug of abuse.  
 
The research programme suffers from the fact that few studies have examined changes 
in readiness over time which meant that the findings could not be adequately placed in 
the context of previous research. However, the use of the SOCRATES in this research 
programme provided a meaningful way to segment the process of change into separate 
dimensions and increase our understanding of motivation as a multi-faceted concept.  
The findings support additional exploration and evaluation of the measure to assess 
change in heroin users and in waiting list participants, and other research that explores 






Despite the strength of the SOCRATES in measuring changes in readiness over time, 
the research programme has drawn attention to a number of problems with the measure. 
 
5.4.2     Problems with the interpretive ranges 
 
The interpretative ranges provided by the authors of the SOCRATES are based upon 
mean readiness scores collected from a large sample of alcohol users starting treatment 
as part of Project MATCH research trial (Project MATCH Research Group, 1993).  
Mean scores obtained in other studies using the measure are interpreted relative to this 
sample of substance users. It may therefore be necessary to question the applicability of 
these interpretive ranges for drug-using populations or for waiting list participants.  The 
current research programme has shown that readiness scores of waiting list participants 
are somewhat lower than the readiness scores of heroin users entering treatment. As 
previously mentioned, it may be expected that heroin users who have successfully 
tolerated the waiting period may represent a more motivated group than those who have 
only just requested treatment. Although this contention does not detract from the 
usefulness of the measure in assessing readiness to change, additional research using the 
measure on different samples of waiting list participants and on drug users entering 
treatment would be useful to generate a different set of interpretive ranges for these 
specific groups and would offer additional information regarding the utility of this 
measure in these populations. 
 
5.4.3    The Ambivalence scale 
 
The interpretation of scores on the Ambivalence scale was problematic within the 
current research programme. Miller and Tonigan stated that ‘low’ Ambivalence should 
be interpreted in relation to the interpretive range of the Recognition scale. While this 
may be possible when administering the SOCRATES to a single subject (i.e. in a 
clinical setting), using it on study data sets proved to be less practical. Within the 
current research programme splitting the samples into sub-groups with low 
Ambivalence and high Recognition or low Ambivalence and low Recognition in order 
to interpret their readiness for change, would have reduced the sample sizes, 
compromising the chances of obtaining statistically significant  relationships between 





suitable to use in clinical settings as opposed to research studies testing the relationship 
between multiple variables.  Although several studies (e.g. Burrow-Sanchez and 
Lunberg, 2007; Chavez et al, 2003) have examined the factor structure of the three 
readiness scales, and many have used it to predict future treatment outcomes, none have 
attempted to provide additional descriptive information about the three scales.  Greater 
clarification concerning the Ambivalence scale would aid with the interpretation of 
changes observed on this scale over time and the interpretation of relationships between 
the Ambivalence scale and the variables examined. 
  
5.4.4    Collinearity of the SOCRATES scales 
 
The positive correlations found between the Recognition and Ambivalence scores at the 
first research interview in both studies, may be taken to demonstrate that the study 
participants responded similarly to items on these two scales. This finding may suggest 
that the scales are not distinct dimensions of readiness to change. Although several 
studies have assessed the factor structure of the SOCRATES among drug users and 
waiting list participants (Burrow-Sanchez and Lundberg, 2007; Daugherty, 2000), the 
three-dimensional structure proposed by Miller and Tonigan (1996) has not always been 
found.  Although the Taking Steps scale has frequently been identified, support for the 
Ambivalence and Recognition scales has not been consistent (Gossop et al, 2007; Figlie 
et al, 2005; Zhang et al, 2004) and the two scales have sometimes been combined into a 
single factor called ‘AmRec’ (Figlie et al, 2005; Maisto et al, 1999). Results regarding 
the scales should therefore be interpreted cautiously. However, it must be noted that the 
Recognition and Taking Steps scales in the current research programme also showed 
positive correlations in both studies and the Taking Steps and Ambivalence scales were 
positively correlated in Study 1. Collinearity of all three scales may therefore suggest an 
overlap of some of the factors within each dimension, which may present a problem in 
interpreting the results. These findings highlight the difficulties of measuring different 
dimensions of the same concept and while this may call for a revision of some of the 
statements on the SOCRATES, it may be necessary to consider whether different 








5.4.5   Omissions of the SOCRATES  
 
The research programme noted a number of omissions on the SOCRATES, particularly 
on the Taking Steps scale. Statements on the Taking Steps scale fail to recognise that 
seeking, entering, or participating in treatment are actions designed to change drug use. 
The absence of changes on the Taking Steps scale in Study 1 may be taken to 
demonstrate that the treatment participants were engaging in the same level of activities 
to change their heroin use as those reported at treatment entry.  Similarly, the 
Accelerated group in Study 2 reported reductions in mean Taking Steps scores 
demonstrating that they were engaging in fewer behaviours to change their heroin use 
than that reported at the first contact with the service. As the scale does not contain 
specific statements regarding attempts to enter treatment or activities engaged in within 
the treatment setting, the findings may not accurately represent the activities of the 
study participants. The findings on the Taking Steps scale should therefore be 
interpreted cautiously. Findings regarding this scale should be viewed as a product of 
the statements posed on the scale by the authors rather than actions designed to change 
drug use.  
 
5.4.6    Missing data 
 
The lack of instructions from the authors on how to deal with patients with missing 
SOCRATES scores meant that a small number of study participants were excluded from 
the analyses, thereby reducing the sample size of both studies and potentially 
constraining the ability to examine some of the variables under investigation reliably. 
There are several methods in empirical research to deal with missing data. One 
frequently used method involves substituting the missing value with the group mean, as 
recommended by Tabachnick and Fidell (2001). As some patients in the research 
programme had missing data at two interview points, mean substitution in these 
instances would have failed to show the true nature of changes in motivation over time 
and distorted the results. The provision of instructions from the authors on how to deal 
effectively with missing data on the measure is therefore recommended. 
 
It must be noted that this research programme focused on only one component of the 





including the Processes of Change, are believed to be responsible for movement through 
the Stages of Change (and hence changes of the SOCRATES scale scores). The absence 
of significant results on some of the variables considered within this research 
programme, and within other research studies, may be the result of failing to utilise all 
the elements of the model.  
 
Assessment of motivation presents a significant challenge and there is clearly much 
more to learn about the process of change and how individuals go about creating and 
stabilising a new behaviour and abandoning an old one. Intrinsic (e.g. internal thoughts 
and feelings) and extrinsic (e.g. coercion from others) factors are all believed to 
contribute to a person’s motivation to implement behavioural change. Although it 
would be impossible to capture all of these aspects of change in one measure, the 
SOCRATES has proved useful within this research programme to indicate where a 
person is in his change process at different points in the process of seeking and 
participating in treatment. Whether the three dimensions of readiness accurately reflect 
the change process is open to debate. 
 
5.5     OPERATIONAL AND DESIGN LIMITATIONS 
 
The study has a number of limitations which need to be addressed. 
 
5.5.1     Generalisability of the findings 
 
There are some limitations to the generalisability of the study findings as a result the 
systems operating within the treatment service where the research programme was 
conducted, the exclusion criteria set within the studies, and the populations assessed. 
Conducting research in a clinical setting required a flexible approach to work around the 
policies already in operation within the service. These service policies had a significant 
impact on the scope of recruitment to the study. For example, as the service already 
operated a priority system according to which heroin users with severe and more 
pressing needs would have expedited entry to treatment, a large number of treatment 
seekers at the service could not be randomised to a treatment-entry group in Study 2 and 
therefore had to be excluded from study participation. Heroin users recruited to the 





The results therefore cannot be generalised to those with more severe substance use 
problems or more pressing needs such as recent release from prison or pregnant drug 
users.  
 
The study also set a number of exclusion criteria which may also limit the 
generalisability of the results. These criteria included the exclusion of intoxicated 
people, those who had inadequate language and comprehension, and those with learning 
disabilities and neurological problems. These factors were assessed by clinicians at the 
first clinical assessment at the service, so it not known how many were excluded from 
the study. While it was considered that these factors may have affected the 
comprehension of the research interview, it may also have produced a sample of heroin 
users with less severe substance use and other problems which may not adequately 
represent heroin users presenting to treatment.   
 
It must also be noted that the data was collected from two convenience samples 
accessing treatment at the same out-patient service within South London. The sample 
may therefore not generalise well to populations at other services or in other 
geographical locations to those reported in the current research programme.  For 
example, the service may have certain features that are not shared by other services, 
such as the assessment procedures conducted (e.g. Brief Assessment, Full Assessment, 
Dose Assessment) which may have had an impact on treatment entry rates or the 
motivation of the heroin users involved in the study.  
 
5.5.2     Response rates 
 
One of the challenges facing researchers conducting longitudinal outcome studies is 
successfully locating participants for follow-up assessments (Twitchell et al, 1992). 
This is particularly true when conducting investigations with substance abuse 
populations, as the chaotic and sometimes transient lifestyle of these individuals can 
impede the researcher’s ability to maintain contact over extended periods of time. The 
large number of participants who failed to enter treatment and could not be successfully 
re-interviewed in Study 2, particularly within the Standard group, led to insufficient 
statistical power to reliably detect differences between the two treatment-entry groups 





Follow-up rates vary greatly by study (Ribisl et al, 1996; Capaldi and Patterson, 1987) 
and there is much discussion about how much attrition is acceptable without biasing the 
study. A number of researchers concluded that there is no absolute answer to this since 
much depends on the topic of research and the design and nature of the survey (Hedeker 
et al, 1999; Foster and Bickman, 1996). Researchers have examined the nature of the 
possible bias that attrition might cause in the interpretation of study findings (Brown et 
al, 1989; Cook and Campbell, 1979). Incomplete data can compromise the validity of 
the study, as difficult to locate participants may have differed from other participants 
with regards to their substance use, motivation, or level of functioning at follow-up. A 
number of investigators have found that participants who were easier to locate had 
lower substance use at follow-up (Walton et al, 1998; Moos and Bliss, 1978). Brown et 
al (1989) noted that participants included in waiting list studies are those that are 
contactable during the follow up period, it may that these patients were doing relatively 
well and that any harmful effects of not entering  treatment may have been greater for 
those who were not contactable.  
 
5.5.3    Waiting times 
 
The purpose of the design of Study 2 was to produce two groups of treatment seekers 
with distinctively different waiting periods in order to compare the impact of these 
waiting periods on patient motivation.  Unfortunately this objective was not achieved, 
with a small proportion of the two groups experiencing waiting periods which were not 
dissimilar to each other. The waiting period of the Accelerated group varied from the 
intended 14 days, up to a maximum of 21 days. These variations occurred when waiting 
list participants failed to attend the Full Assessment appointment at the clinic, 
necessitating rescheduling of the appointment. Fluctuations in staffing levels during the 
study recruitment period and fluctuations in the number of heroin users requesting 
treatment during this time also resulted in a small number of the Standard group 
experiencing very short waiting periods - 3 patients waited less than 30 days to enter 
treatment. The similar waiting periods in the two treatment-entry groups may have 
constrained the ability to detect differences between the groups.  This problem was 
resolved by explorative statistical analyses where a number of participants in each group 
were excluded from some of the analyses. However, it is noted that reducing the sample 





treatment-entry groups being detected.  Unfortunately this is one of the drawbacks to 
working in a clinical setting where the length of the waiting period is influenced by a 
number of factors beyond the control of the research team.  
 
5.5.4     Factors not assessed within the research programme  
 
Modern conceptualisations view motivation as arising from the interplay between the 
individual and the service, rather than simply as an intrinsic property of the individual. 
It is therefore reasonable to expect that other factors, not considered in the research 
programme, were involved in the process of change. A major limitation of the research 
programme is that motivation was assessed in isolation from other factors. In Study 1 
treatment variables were not collected and therefore not included in the analyses. 
Changes in readiness observed at the follow-up periods may have been influenced by a 
number of factors in the treatment environment. It would have been interesting to assess 
the effect of the therapeutic relationship between patients and clinicians on motivation, 
or the impact of methadone dose on patient motivation for change as detailed in the 
Literature Review.   
 
Study 2 failed to take into account the initial contact between the treatment seekers and 
the treatment service which may have played a vital role in framing the experience of 
the treatment seeker and may have influenced motivation and subsequent behaviour 
such as entering treatment. Although the amount of contact with the treatment service 
among treatment seekers placed on a waiting list is minimal, recent research suggests 
that many treatment seekers know (explicitly or otherwise) very early on in the 
treatment process whether or not they are ready to engage with a service (Stanick et al, 
2008). Participants in Study 2 had an initial clinical assessment within the drug service 
prior to being placed on a waiting list, the effect of the intake facilities, the intake 
interview, the early therapeutic relationships and the patients’ appraisal of the service 
may all have influenced their motivation and their choice to enter treatment after the 
waiting period.  
 
The effect of the initial clinical contact on patient behaviour has not been extensively 
studied, although a qualitative study of applications to a substance abuse treatment 





admissions processes with the overwhelming amount of paperwork required to meet 
regulatory requirements. They also commented on a lack of privacy and confidentiality 
in the waiting rooms at the intake facilities.  
 
Just as the quality of the therapeutic relationship established during treatment is a 
significant predictor of substance abuse outcomes, including treatment engagement and 
retention withindifferent treatment programmes (Meier et al, 2005; Fiorentine et al, 
1999; Simpson et al, 1997b), a patient’s first contact with a treatment service may 
influence the nature of the therapeutic relationship that ensues and also be related to 
subsequent treatment uptake. Hyams et al (1996), for example, looked at the impact of 
patient satisfaction on engagement in alcohol treatment after an initial assessment. 
Patients who reported a positive therapeutic experience with the worker were much 
more likely to engage in treatment. Patients were more likely to engage if they felt 
“liked” by the worker and if they felt the worker “understood” how they felt. Patients 
were less likely to engage if they felt “criticised” or if they felt the therapist was not 
genuine and “acting a part”. Miller (1985) also found that satisfaction with aspects of 
the doctor-patient relationship during the initial service visit was related to treatment 
uptake. Priebe and McCabe (2008) have suggested that there may need to be a minimal 
threshold in the therapeutic relationship to motivate the patient to engage with a 
clinician and his or her service. If the relationship is too poor, the patient may not turn 
up for another appointment and refuse further contact.  
 
The studies also suffered from the fact that a limited range of patient factors were 
analysed. Individuals with heroin use problems are a diverse population with differing 
levels of drug-related problems, and varying levels of capabilities and resources to cope 
with these problems.  The regression model predicting treatment entry in Study 2 
accounted for only 8.0% of the variance in treatment entry status. Clearly other 
variables were important in encouraging or preventing treatment entry and also in 
changing readiness scores over the waiting period. The choice of patient factors was 
based on those used in previous research, however, the use of these factors failed to 
generate new findings within the field of research. Inclusion of a greater number of 







5.5.5     Reliance on self report data 
 
The study relied entirely on self-reported data. Such data are subject to problems 
associated with memory recall and social desirability, and thus it was not possible to 
verify the reliability and validity of the information collected. The drug and alcohol 
measures used in the research programme were not supported by more objective 
measures of substance use such as urinalysis, therefore under- or over-reporting of 
substance use may have occurred. Also, some of the heroin users may not have been 
truthful in their responses on the SOCRATES due to a strong desire for social approval. 
 
The use of self-report is a limitation common to many research studies conducted with 
substance use populations and it is assumed that the same under or over-reporting would 
have occurred at all data collection points, negating any potential problems. To 
minimise the problems of mis-reporting, patient confidentiality was assured at each 
structured-interview session. Despite these concerns, studies have generally found self-
report of substance use to be reliable over varying recall periods (Darke, 1998; 
Adelekan et al, 1996). 
 
5.6     CLINICAL IMPLICATIONS OF THE RESEARCH FINDINGS  
 
The findings from this study point to several areas of potential improvements in service 
delivery.  
 
5.6.1    The assessment of motivation     
 
The findings demonstrate that heroin users seek and enter treatment with varying levels 
of readiness to change, and many may not be highly motivated to change their heroin 
use. Low Recognition and low Taking Steps scores reported at the start of the waiting 
period in Study 2 suggest that clinicians must not assume that individuals who express 
interest in treatment are highly motivated to change their substance use behaviours 
(Battjes et al, 1999). Low motivation may not always be obvious to clinicians and many 
heroin users may be unable to adequately articulate their attitudes and intentions for 






The research programme also demonstrated that readiness to change is a dynamic 
process that varies over time. Reductions in readiness were observed over relatively 
short waiting periods among the Accelerated group within the waiting list sample and 
among heroin users engaged in treatment. These findings highlight the importance of 
assessing motivation at different stages of the waiting period and during the treatment 
process. Recognising that differences in readiness and motivation exist among treatment 
seekers, and that motivation changes over time, and in response to different situations, 
is of practical importance for treatment services to ensure that support is provided to 
those who most need it.  
 
5.6.2     Motivational interventions 
 
The research literature indicates that motivation can be developed or discouraged by the 
treatment agency (Miller et al, 2002; Fiorentine et al, 1999). The findings that readiness 
to change can deteriorate over a two-week waiting period, and that heroin users with 
higher Recognition and lower Ambivalence scores were more likely to enter treatment, 
suggests a need to implement techniques and interventions to address patients’ 
motivational needs at different points during the waiting period and also during the 
treatment process. As noted by Brown and Miller (1993), “the central task of drug 
treatment should be to heighten the motivation of patients, with particular attention on 
individuals who are ambivalent or even negative about being there”. 
 
A motivational intervention is clinical strategy designed to enhance motivation to 
change. Motivational interventions employed prior to treatment are designed to assist in 
modifying substance users’ attitudes towards treatment and can help develop behaviours 
that are predictive of treatment engagement. Although several motivational 
interventions have been developed, none have received greater empirical support than 
Motivational Interviewing (Miller and Rollnick, 2002).  Motivational Interviewing is a 
therapeutic style intended to help clinicians work with patients to address their 
ambivalence, to modify unrealistic treatment expectations and enhance patients self-
efficacy prior to, or during treatment. Principles utilised in motivational interviewing 
include empathy towards the patient, supporting self-efficacy, avoiding arguments and 
highlighting the disadvantages of continuing their behaviour and advantages of 





problem alcohol drinkers in the early stages (precontemplation and contemplation) of 
readiness for change.  
 
Motivational interviewing has been associated with a variety of successful outcomes, 
including the facilitation of referrals to treatment, reduction or termination of substance 
use, and increased participation in and compliance with specialised treatments. These 
outcomes been reported among severely substance-dependent populations (Saunders et 
al, 1995), dual diagnosis patients (Swanson et al, 1999),  polydrug-abusing adolescents, 
and heroin and marijuana users (Stephens et al, 2000; Bien et al, 1993; Brown and 
Miller, 1993). A review of eleven clinical trials of Motivational Interviewing concluded 
that this method is a "useful clinical intervention...and appears to be an effective, 
efficient, and adaptive therapeutic style worthy of further development, application, and 
research" (Noonan and Moyers, 1997). Other studies have shown brief interventions 
using Motivational Interviewing to be more effective than no treatment, or being placed 
on a waiting list, and promote similar outcomes as some more extensive types of care 
(Noonan and Moyers, 1997; Bien et al, 1993). 
 
The NTA has recognised the importance of interventions to enhance motivation during 
the waiting period (NTA, Making the system work - Summary guidance on managing 
and reducing waiting times for specialist drug treatment services in England, 2002) in 
order to prepare drug users for structured treatment, with suggestions of developing an 
additional structured treatment modality if the effectiveness of motivational 
interventions in relation to treatment outcomes can be demonstrated. Additional 
research on motivational interventions is needed to establish which elements of the 
interventions are most useful for promoting motivation. The effectiveness and cost-
effectiveness of motivational interventions in relation to other established and more 
extensive substance abuse treatments should also be examined.  
 
5.6.3     Maintaining contact during the waiting period   
  
The finding that twenty per cent of the waiting list sample did not initiate treatment 
when a place became available may suggest that greater efforts by the treatment service 
to promote treatment entry are required. Although this study did not collect data about 





period, information provided by clinical staff suggests that no contact usually occurs 
until a treatment place becomes available. Interviews in Donmall et al’s (2005) study of 
treatment waiting times found drug users were critical about the lack of contact during 
the waiting period, with some reporting that they would have appreciated a day- or 
drop-in service while waiting.  Brown et al (1989) suggested that a lack of contact 
results in a loss of confidence in the service’s ability to cater for substance users’ needs. 
 
Initiatives which permit services to maintain contact with treatment-seekers during the 
waiting period would serve several purposes. These may include updating the patients 
on their waiting list status, to provide interim support to enable patients to reduce heroin 
use-related risks while awaiting treatment, to enhance motivation as a precursor to 
entering treatment, to ensure the retention of individuals on the waiting list, to ascertain 
if the patients still require treatment or have sought help elsewhere, and to prepare 
patients for the induction phase of treatment. This contact would allow services to be 
seen as a useful resource for the patient. Although such approaches may not always be 
feasible due to the extra resources required to deliver this type of patient management, 
the adoption of some of the techniques may prove beneficial in improving attendance. 
The NTA (2002) recommended interim contacts during the waiting period such as 
providing patients with estimations of treatment entry dates and then contacting them 
prior to the appointment to arrange a mutually convenient slot. Whether such strategies 
have been adopted by services is unknown. 
 
It has been suggested that commencing induction procedures soon after the first contact 
between the patient and the service, prior to treatment entry, may allow services to be 
seen as a meaningful resource to the patient.  This could take the form of role inductions 
which would function to clarifying roles, allay concerns, correct misconceptions and 
provide the patient with a better understanding of the treatment process. Such efforts 
appear to be particularly appropriate for substance users who have no previous 
treatment experience and who will often express numerous fears such as failing in 
treatment (Cunningham et al, 1993; Oppenheimer et al, 1988; Sheehan et al, 1986).  
 
Although role inductions have not been extensively evaluated, Zweben and Li (1981) 





to treatment in an outpatient substance abuse clinic were more likely to remain for the 
initial four sessions of treatment than were those who did not receive role inductions.  
When a treatment place becomes available more assertive efforts should be extended to 
contact and engage patients in treatment. Some heroin users may have obstacles such as 
psychiatric instability or homelessness which may need to be treated more flexibly than 
is typically the case to encourage patients to attend treatment. Reminder telephone calls 
or letters before the first scheduled session have been shown to improve attendance 
rates across several mental health sectors, including alcohol treatments (Donohue, et al, 
1998), particularly when appointments are scheduled soon after referral (Gariti et al, 
1995). Contacts adopting a more personal approach have demonstrated superior results 
than less personal methods (Stark, 1992; Nirenburg et al, 1980).  
 
5.6.4     Addressing patient expectations 
 
Treatment services may need to address the expectations that drug users bring with 
them to the health care encounter. Interviews with heroin users at the start of the waiting 
period in Study 2 indicated that over half of the sample expected to wait less than four 
weeks to enter treatment. The mean waiting time for the Standard treatment-entry group 
was eight weeks, with a number waiting up to sixteen weeks to be offered a treatment 
place. The discrepancy between expected and actual waiting times observed in Study 2 
suggests that treatment services need to review their communication strategies and 
provide clearer information regarding the length of the waiting list in order to promote 
realistic expectations of treatment entry and to fully engage with patients early in the 
treatment process. During the initial contact between the treatment seeker and treatment 
service, clinicians should explore patient’s expectations about the length of the waiting 
period and educate them about treatment. This may help to bring the expectations of the 
substance user in line with the realities of treatment and reduces the probability of 
treatment not living up to their expectations. Previous research has demonstrated that 
treatment retention is positively related to clients’ expectations of treatment (Zweben 









5.6.5     Reduction of waiting times 
 
The difficulties of engaging drug users effectively in treatment, regardless of their level 
of motivation, is compounded when services are limited or rationed by the use of 
waiting lists. Although the statistical analyses failed to show a relationship between 
waiting times and treatment entry, the waiting period was still a period of attrition for 
approximately twenty per cent of the sample who requested treatment. The waiting 
period was also characterised by a reduction in motivation on a number of dimensions 
on the SOCRATES, regardless of the duration of the wait. These findings suggests that 
even a two-week waiting period was a sufficient length to rouse second thoughts in a 
number of heroin users about changing their drug use or for wanting treatment, or for 
other events to occur which prevented them from entering treatment.  
 
Although many heroin users reported reducing, or maintaining, the frequency of their 
heroin use over the waiting period, and a small number reported a deterioration in their 
heroin use, the waiting period still represents a period of risk, and the costs of continued 
drug abuse to society must not be underestimated. The consequences of untreated drug 
abuse includes homelessness (Adamson and Sellman, 1998) health risks including 
needle sharing, overdose (Chen and Lin, 2009) and disease transmission (Wenger and 
Rosenbaum, 1994), along with the long-term problems associated with heroin use such 
as liver damage, cardiovascular disease and clogging of the blood vessels (Hoffman et 
al, 2008; Buckland et al, 2008). Untreated drug use also poses extensive costs to health 
and social services and to the law enforcement agencies (Zealberg and Brady, 1999; 
Bushnell and Bakker, 1997). The impact of crimes committed by drug users to 
individuals, families and communities (Gordon et al, 2006) is also a significant concern. 
Such findings suggest that a reduction or elimination of waiting times would be an 
important step in reducing the harms associated with untreated drug abuse for both the 
individual and society.  
 
Since the inception of this research programme there has been increased attention to the 
issues of waiting times in drug abuse treatment settings by the Department of Health 
and the NTA. The Updated Drug Strategy of 2002 set the target to double the number of 
people in treatment by 2008 and called for "maximum waiting times from referral to 





G.P. prescribing and three weeks for all other forms of treatment" by 2004 (Home 
Office, 2002). There was a trebling of Government investment in specialist drug 
treatment from £142m in 2001/2 to £385m in 2006/7. Increases in funding have 
expanded the workforce with an extra 4000 drug treatment workers in post nationally in 
September 2005 compared to March 2002. This in turn reduced waiting times and 
consequently increased the number of problematic drug users accessing services.  
 
“Access to, and the capacity of, substance misuse services has improved dramatically                          
in recent years. Around 160,000 people joined treatment programmes in 2004/2005 
compared with 85,000 in 1998/1999, a rise of 89 per cent. Government investment 
has triggered a significant expansion in services that has cut waiting times down 
from an average of 9.1 weeks in December 2001 to 2.4 weeks in September 2005” 
(Healthcare Commission, 2006). 
 
While reductions in waiting times and increases in the capacity of services can only be 
viewed as a positive step, these measures of success need to be contextualised with 
information relating to treatment retention and the outcomes of individuals leaving 
treatment services. National figures suggest that many drug users drop out of treatment 
long before treatment is complete, with 34% dropping out before significant benefits 
can be realised (NTA, 2005).  Additional attention to treatment attrition is therefore 
warranted. 
 
5.6.6     Interim drug clinics   
 
If a reduction in waiting times is not possible, then the implementation of interim 
methadone prescribing until a formal treatment place becomes available would address 
the immediate needs of the treatment seekers. Such prescribing would serve to reduce 
the harms associated with procuring and taking heroin and prepare heroin users for 
formal treatment which may have the potential to reduce attrition over the waiting 
period. Interim methadone maintenance has been tested as a rapid-intake alternative for 
heroin addicts waiting for treatment. Such interim clinics provide limited services to 
heroin users including supervised daily dosing with methadone, physical examinations 
and education, but do not provide counselling or social services support which are 





York in an attempt to halt the spread of HIV. Schwartz et al (2006) compared interim 
maintenance treatment to a waiting list condition at an opioid treatment programme and 
found sustained benefits of interim treatment ten months after enrolment in terms of 
increased treatment entry and reduced heroin use and criminal behaviour compared to 
patients on a waiting list with no interim contacts. Seventy-six percent of study 
participants receiving interim methadone entered comprehensive treatment within four 
months, compared with only 21 percent of the control group.  
 
Despite the success of interim services they have been prohibited in the US 
even as a preliminary to full-service programmes as federal regulations requires 
counselling and other supports for opiate users provided with methadone. In the UK, 
general practitioners, in certain areas, provide interim prescribing prior to formal 
treatment (Donmall et al, 2005), although there is a lack of information about the  
prevalence of such practice or the effectiveness of this prescribing in terms of 
promoting entry into formal treatment programmes.   
 
5.7     RESEARCH RECOMMENDATIONS 
 
Based on the results of this research, a number of areas for future research can be 
identified. 
 
5.7.1     Additional research on waiting list samples 
 
Additional research on the effects of waiting list participation is warranted. Specifically, 
there is a lack of qualitative studies that focus exclusively on the experience of waiting 
for treatment or the effects of the waiting period on treatment entry or on the motivation 
of substance users during this period. Information from such research could contribute 
in various ways to the field of drug abuse such as assisting clinicians to predict who is 
more likely to enter treatment after the waiting period and direct additional support such 









5.7.2    Additional research on the SOCRATES 
 
Although the SOCRATES has been used in treatment populations and out-of-treatment 
substance users, it has only been used to assess the readiness to change in one previous 
study of waiting list participants (Burrow-Sanchez and Lundberg, 2007).  Additional 
research is required to determine whether this measure, or other measures of motivation, 
is appropriate for use with waiting list participants. There may also be a need to develop 
specific items or measures to use specifically with waiting list samples. For example, as 
noted earlier, the statements on the Taking Steps scale of the SOCRATES fail to 
recognise that seeking treatment is an action designed to change drug use.  The content 
of the SOCRATES reflect the behaviours which the authors of the SOCRATES 
believed were important in the process of change among alcohol users at the point of 
treatment entry and thus included in the measure. Different statements may be required 
to reflect the intentions, attitudes and behaviours of treatment seekers awaiting 
treatment entry.  
 
5.7.3     Attrition   
 
More research needs to be conducted to address the pre-intake drop-out problem. Since 
participation in treatment has been associated with a range of positive outcomes in 
terms of reduction in substance use and offending, research into interventions that 
encourage initiation after the waiting period should be paramount. A number of studies 
support the idea that pre-treatment interventions may be effective in facilitating 
treatment entry for substance users (Marlatt et al, 1997), although more research is 
needed to evaluate which strategies, or combinations of strategies, are most effective. 
Further research would be useful to identify the most appropriate stage at which service 
enhancements are most likely to increase the likelihood of entering treatment. Service 
providers could audit non-attendance patterns to identify indicators of non-attendance 
among the population which they serve. 
 
Further study on research attrition is also needed. The current study demonstrated that 
tracking drug users in longitudinal research is challenging and obtaining high follow-up 
rates is a difficult and resource-intensive task. Research attrition is a concern among 





ability of the study findings to provide accurate generalisations to the larger population. 
The findings recommend that additional time and resources are permitted for tracking 
activities in longitudinal research and also that additional research on methods to locate 
difficult-to-contact study participants is undertaken. While the current study used  next-
of-kin details to seek participants who could not be contacted through conventional 
methods, these contacts conferred no additional benefit in locating the study 
participants.  Future longitudinal research should consider the use of other contacts such 
as G.P.s or sites where unemployed substance users collect their benefits, with the prior 
consent of the participant, to gain contact with study participants.  Identification of 
baseline characteristics associated with attrition and difficult-to-locate participants 
would also allow the targeting of study resources towards those participants who are 
most likely to elude contact (Hansten et al, 2000).   
 
5.8     CONCLUDING COMMENTS  
 
The purpose of this research programme was to determine the extent and nature of the 
relationship between waiting times to enter drug abuse treatment and motivation to 
change heroin use. The effect of treatment waiting times on substance users’ motivation 
to change their substance use is a largely undocumented area and no previous studies, 
known to the author, has tracked the motivation of waiting list participants over the 
course of the waiting period, or have related the changes in motivation to treatment 
events or patient behaviours. Although the research programme failed to show that 
readiness to change mediates the relationship between treatment waiting times and 
outcomes during this period, a number of relationships between the variables were 
found providing useful and relevant information about the motivation of waiting list 
participants and more importantly to the changes in motivation during this period.  
 
The research programme found varying patterns of change in readiness over the course 
of the waiting period and during a six-month treatment period, demonstrating that 
people respond differently to the delay for treatment and to treatment participation.  
Although this research programme had the advantage of longitudinal outcomes and 
examined a number of relationships which have not previously been addressed within 
the substance abuse research literature, problems with sample sizes, the design of Study 





the scope of the research programme to adequately examine some of the variables of 
interest. More detailed and comprehensive studies of the motivation of waiting list 
participants and the relationship of motivation and waiting times are recommended. 
Such research may be important for promoting a greater understanding of the treatment 
entry process and the ways in which treatment systems can increase their 
responsiveness to substance abusers. 
 
The longitudinal use of the SOCRATES in detecting changes in readiness over time 
adds to the small body of research which has directly examined the use of the 
Transtheoretical Model in assessing changes in readiness over time, rather than inferring 
readiness or motivation from changes in behaviour. The research programme has shown 
that intentions and behaviours reported on the SOCRATES do not always translate into 
observable behaviours. It is therefore recommended that future research examines 
motivation and outcomes separately and does not assume that the two are always 
related.  
 
Motivation is still an elusive concept and it is likely that a complex interaction of factors 
is associated with a heroin user’s decision to change heroin use behaviours and 
participate in treatment. While readiness to change may represent an important 
component of the change process, researchers have stated that it should be 
conceptualised as a multi-dimensional construct with multiple determinants. A better 
understanding of some of the determinants of change, including treatment waiting 
times, can help to identify key influences that enhance motivation. Such an 
understanding may lead to the development of effective strategies to encourage drug 
users who make contact with treatment services to return and stay for a sufficiently 
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Treatment Outcome Study 
Intake Interview 
Community Drug /Alcohol Team 
 





We are recruiting alcohol and drug users to a research project being conducted at 
Marina House. The project is trying to find out about your substance use, your health 
and your spending habits during your time in treatment. 
 
If you choose to take part in the study we would like you to complete a questionnaire 
(with the help of a researcher) today and another questionnaire in three months time and 
one in six months time. Each questionnaire will take about 40 minutes to complete. 
Each questionnaire will be completed at the treatment service or at a venue that is 
convenient to you. If you drop out of treatment we would also like to conduct a 
questionnaire with you for the project. 
 
Choosing to take part in the project is entirely up to you and you are free to stop 
completing the questionnaires any time during the project.  
 
Any information you provide will be kept in the strictest confidence and will not be 













SECTION A: DEMOGRAPHICS 
 
1.Community Alcohol Team               Community Drug Team   
 
2.Respondent code                                          3.Keyworker  
 
4.Gender                                                    5. Ethnicity (code)  
 
6.Age                                                               7.Date 
 
 
8.Which treatment service are you attending? 
 CDT CAT MMC 
Date of admission/start of treatment     
Number of times attending per 
week 
   
 
9. How many nights have you spent in each of the following places in the last 30 days? 
 
Own or relative’s home         Prison/Detention                                    
 
On the street                                               Hotel/ Temp. Accommodation 
 
Friends/other people’s home                      Hospital/Treatment Centre     
 
10. In the last 30 days have you been mainly in 
 
Full-time work                  
                                             
Part-time work                                                  Unemployed 
 

























Section B: Physical and Psychological Health  
 
Physical health in the last month 
 
11. How often in the last month have you experienced the following? 
 Never  Rarely Sometimes Often Always 
Poor appetite       
Tiredness / fatigue      
Nausea      
Stomach pains      
Difficulty breathing      
Chest pains      
Joint / bone pain      
Muscle pain      
Numbness/tingling      
Tremors (shakes)      
 
 
Psychological health in the last month 
 
12. How often in the last month have you experienced the following? 
 Never  Rarely Sometimes Often Always 
Feeling tense or keyed up      
Suddenly scared for no reason      
Feeling fearful/afraid      
Nervousness or shakiness inside      
Spells of panic or terror      
Feeling hopeless about the future      
Feelings of worthlessness      
Feeling no interest in things      
Feeling lonely      






SECTION C: DRUG & ALCOHOL USE  
 
13. In the last 30 days, can you tell me how often you have used the following 













Age of first 
treatment 
Heroin            
                g 
   
Methadone                      
                    
                     
              ml   
   
Other opiates                      
 
             mg  
   
Benzodiazepines                     
 
             mg            
   
Crack cocaine                         
                                      
                g                                  
  
Cocaine powder                         
                                        
                g 
  
Amphetamines   
               g 
   
Cigarettes   
 
 
Cannabis          
                            oz/joints 
  
Alcohol                






14. Can you tell me which drugs/alcohol you have taken over the last 3 days 
 





Day 1 (today)  
 
   
Day 2 (yesterday)  
 
   
Day 3 (day before)  
 
   
 
15. CAGE drinking questionnaire 
 Yes No 
Have you ever felt you ought to cut down on your 
drinking? 
  
Have people annoyed you by criticising your drinking?   
Have you ever felt bad or guilty about your drinking?   
Have you ever had a drink first thing in the morning to 
steady your nerves or to get rid of a hangover? 
  
 
16. Over the last year, did you ever think that your heroin/alcohol use was out of control 
Never or almost 
never 
Sometimes Often Always or nearly 
always 
    
 
17. Over the last year did the prospect of not taking heroin/alcohol make you very 
anxious or worried? 
Never or almost 
never 
Sometimes Often Always or nearly 
always 
    
 
18. Did you worry about your heroin/alcohol  use over the last year? 
Never or almost 
never 
Sometimes Often Always or nearly 
always 







19. Did you wish you could stop taking heroin/alcohol over the last year? 
Never or almost 
never 
Sometimes Often Always or nearly 
always 
    
 
20. How difficult would you find it to stop, or go without heroin/alcohol ? 
Easy Fairly Difficult Very Difficult Impossible 
    
 
Section D: Injecting and Risk Behaviour 
 
If you have not injected drugs in the last 30 days please skip to Q26 
 
21. When did you last inject ?  _______________   days 
22. In which part of the body do you usually inject?  ________________________ 
23. How many times in the last 30 days have you used a need after someone else? 
 
Never                                                           3-5 times 
 
Once                                                             6-10 times 
 
Twice                                                            more than 10 times 
 
24. In the last 30 days how often have you injected alone? 
Never Rarely Sometimes often Always 
     
 
25. When injecting how often do you drink alcohol? 
Never Rarely Sometimes often Always 
     
 
26. In the last 30 days how many overdoses have you had?      
27. In the last 30 days how many overdoses have you witnessed?                               













SECTION E: PERSONAL ALCOHOL/DRUG USE QUESTIONNAIRE 
(SOCRATES) 
  







29. I really want to make changes in my 
drug/alcohol use 
     
30. Sometimes I wonder if I am an 
addict/alcoholic 
     
31. If I don’t change my drug/alcohol use 
soon, my problems are going to get worse 
     
32. I have already started making some 
changes in my drug/alcohol use 
     
33. I was using too much at one time, but I’ve 
managed to change my drug/alcohol use 
     
34. Sometimes I wonder if my drug/alcohol 
use is hurting other people 
     
35. I have a drug/alcohol problem      
36. I’m not just thinking about changing my 
drug/alcohol use, I’m already doing 
something about it 
     
37. I have already changed my drug/alcohol 
use, and I am looking for ways to keep from 
slipping back to my old pattern 
     
38. I have a serious problem with 
drugs/alcohol 
     
39. Sometimes I wonder if I am in control of 
my  drug/alcohol use 
     
40. My drug/alcohol use is causing a lot of 
harm 
     
41. I am actively doing things now to cut 
down or stop drug/alcohol use 
     
42. I want help to keep from going back to the 
drug/alcohol/alcohol use problems that I had 
before 
     
43. I know that I have a drug/alcohol use 
problem 
     
44. There are times when I wonder if I  take 
drugs/alcohol too much 
     
45. I am an drug addict/alcoholic      
46.I am working hard to change my 
drug/alcohol use 
     
47.I have made some changes in my 
drug/alcohol use, and I want some help to 
keep me from going back to the way I used to 
use 





SECTION F: SOCIAL FUNCTIONING 
 
48. How many members of your family have you seen in the last 30 days? 
49. How many immediate family members do you have? 
 
50. How many members of your family have drug problems? 
none one a few most all 
     
 
51.    How many members of your family have alcohol problems? 
none one a few most all 
     
 
52. If you are currently in a relationship, how often in the last 30 days has your partner 
 Never Rarely Sometimes Often Always 
Complained about your 
drinking/drug use? 
     
Tried to stop you from having a 
drink/drugs? 
      
Refused to talk to you because 
you have been drinking/using? 
     
Threatened to leave you because 
of your drinking/using? 
     
Had to put you to bed after you 
had been drinking/using? 
     
Refused to have sex with you 
because of drinking/using? 
     
Have you shouted at him/her 
when you have been 
drinking/using? 
     
Have you injured him/her after 
you have been drinking/using? 
     
Have you been legally separated 
from your spouse? 












53. If you have children who you are regularly in contact with how often in the last 30 
days have they 
 Never Rarely Sometimes Often Always 
Criticised your drinking/using      
Tried to stop you from having a 
drink/drugs 
      
Have you had rows with your children 
about drinking/using 
     
Do your children tend to avoid you 
when you have been drinking/using 
     
 
54. If you have been employed in last 30 days how often have you 
 Never Rarely Sometimes Often Always 
Found your work less interesting than 
you used to?  
     
Been unable to arrive on time for 
work due to your drinking/using? 
      
Missed a whole day after a 
drinking/using session? 
     
Been less able to do your job because 
of your drinking/using? 
     
Had any formal warnings from your 
employers? 
     
Been suspended or dismissed from 
work? 
     
Had any accidents at work after 
drinking/using? 
     
Has anyone at work complained about 
you being late or absent? 
     
 
SECTION G. TREATMENT PERCEPTIONS 
55. Please indicate whether you agree or disagree with the following statements 
I came into treatment/ I chose 
to start treatment... 
Stron. 
Disag. 
Disagree Undecided Agree Stron. 
agree 
to please my family      
to please my children      
to please my  partner      
through my own choice      
because of legal problems      
because of health 
concerns(specify) 
     
because of work reasons      
because I was fed up of using      






SECTION H. INVOLVEMENT WITH OTHER SERVICES/SUPPORT 
SYSTEMS    
 
56. In the last 30 days have you accessed any other treatment services?        yes         no  
57. Which services have you attended and how useful did you find them? 
 
 How useful/helpful did 
you find them? 













Day programme        
Street agencies        
Drop-in services        
GP        
In-patient detox        
Residential rehab        
Counselling 
service 
       
Other        
 
 
SECTION I: SOURCES OF INCOME 
 
58. Are you currently in any form of employment?       Yes                           No      
 
59. What kind of work do you do, how many hours per week do you work and what is 
your salary? 
 
 Type of work Hours Salary 
Full-time    
Part-time    






























60. Which benefits are you claiming, how long have you been claiming them, how often 
do you get paid and how much money do you receive per week? 







    
Income support     
Housing benefit     
Incapacity/sickness 
benefit 
    
Child benefit     
Disability allowance     
Other(specify)     
 
61. Do you use any of the following methods to raise money (in the last 30 days)? 
 use No. of times in 
the last 30 days 
Amount earned 
per week 
Selling the big issue    
Begging    
Gambling    
Pawning own belongings    
Pawning someone else’s belongings    
Prostitution    
 
 How much in the last 30 days 
Money from siblings/family/friends  
Covenants  
Interest from savings  
Family inheritance  
 
SECTION J.  SPENDING 
 
62. Do you pay rent/mortgage where you live?           Yes          No     if No skip to Q.66 
 
63. Over the last 30 days have you kept up to date with you rent/mortgage ?  
              Yes                      No 
 
















65. How much do they cost per week? 
 Amount per week? Amount paid by benefits? 
Rent    
Mortgage   
 
Household bills: 
66. In the last 30 days have you paid any household bills?    Yes                No 
 If no, amount owed If yes, amount spent per week 
Electricity   
Gas   
Water rates   
Council tax   
T.V. License   
Telephone   
Bank loans/money lenders   
Rental costs ( TV)   
 
67. How many times per week do you go food shopping and how much do you spend 
on food (in the last 30 days)? 
 Number of times per week Amount spent per week 
Supermarket   
Market   
Take-away   
Restaurants   
Local shop/garage   
 
68. Do you spend money on any of the following (in the last 30 days)? 
 Number of times per week Amount spent per week 
Public transport   
Petrol   
Laundrette   
Crèche/nursery   









Time of interview :     3 month                           6 month    
 3 month 6 month 
In treatment    
Out of treatment    
 
SECTION A:  
 
1.Community Alcohol Team                Community Drug Team   
 




5.Which treatment service are you attending? 
 
 CDT CAT MMC 
Number of times attending per 
week 
   
 
6. If no longer in Maudsley treatment services..... 
 
Since the previous interview have you attended any inpatient or out-patient services at 
the Royal Bethlem and Maudsley Trust? 
 Out-patient services In-patient services 




On how many occasions?       
When did you last attend?       
Did you complete the 
programme? 
      
Date of discharge?       
Self/disciplinary/medical?       
For how long were you 
abstinent after you left? 














7. How many nights have you spent in each of the following places in the previous  
30 days ? 
Own or relative’s home        Prison/Detention                                    
On the street                                              Hotel/ Temp. Accommodation 
Friends/other people’s home                     Hospital/Treatment Centre     
 
8. In the previous 30 days have you been mainly in 
Full-time work                              Part-time work                                                   
Unemployed 
In Education                                                         Sickness Benefit 
 
Section B: Physical and Psychological Health  
 
Physical health in the last month 
 
9. How often in the last 30 days have you experienced the following? 
 Never  Rarely Sometimes Often Always 
Poor appetite       
Tiredness / fatigue      
Nausea      
Stomach pains      
Difficulty breathing      
Chest pains      
Joint / bone pain      
Muscle pain      
Numbness/tingling      






















Psychological health in the last month 
10. How often in the last 30 days have you experienced the following? 
 Never  Rarely Sometimes Often Always 
Feeling tense or keyed up      
Suddenly scared for no reason      
Feeling fearful/afraid      
Nervousness or shakiness inside      
Spells of panic or terror      
Feeling hopeless about the future      
Feelings of worthlessness      
Feeling no interest in things      
Feeling lonely      
Thoughts of ending your life      
 
SECTION C: DRUG & ALCOHOL USE  
11. In the last 30 days, can you tell me how often you have used the following 












Age of first 
treatment 
Heroin                      g    
Methadone                                  ml      
Other opiates                    mg     
Benzodiazepines                    mg              
Crack cocaine                                      
                    g                                                           
  
Cocaine powder                                                                                 
                    g 
 
Amphetamines                      g    
Cigarettes    
Cannabis                              oz/joints   
Alcohol                 







12. Can you tell me which drugs/alcohol you have taken over the last 3 days 





Day 1 (today)  
 
   
Day 2 (yesterday)  
 
   
Day 3 (day before)  
 
   
 
13. CAGE drinking questionnaire: In the last 30 days 
 Yes No 
Have you ever felt you ought to cut down on your 
drinking? 
  
Have people annoyed you by criticising your drinking?   
Have you ever felt bad or guilty about your drinking?   
Have you ever had a drink first thing in the morning to 
steady your nerves or to get rid of a hangover? 
  
 
Section D: Injecting and Risk Behaviour 
 
If you have not injected drugs in the last 30 days please skip to Q18 
 
14. When did you last inject ?  _______________   days  ago 
 
15. In which part of the body do you usually inject?  ________________________ 
 
16. How many times in the last 30 days have you used a need after someone else? 
 
Never                                                          3-5 times 
 
Once                                                            6-10 times 
 










17. In the last 30 days how often have you injected alone? 
 
Never Rarely Sometimes Often Always 
     
 
 
18. In the last 30 days how many overdoses have you had? 
19. In the last 30 days how many overdoses have you witnessed?                               

































SECTION E: PERSONAL ALCOHOL/DRUG USE QUESTIONNAIRE 
(SOCRATES) 






21. I really want to make changes in my 
drug/alcohol use 
     
22. Sometimes I wonder if I am an 
addict/alcoholic 
     
23. If I don’t change my drug/alcohol use 
soon, my problems are going to get worse 
     
24. I have already started making some 
changes in my drug/alcohol use 
     
25. I was using too much at one time, but 
I’ve managed to change my drug/alcohol 
use 
     
26. Sometimes I wonder if my 
drug/alcohol use is hurting other people 
     
27. I have a drug/alcohol problem      
28. I’m not just thinking about changing 
my drug/alcohol use, I’m already doing 
something about it 
     
29. I have already changed my 
drug/alcohol use, and I am looking for 
ways to keep from slipping back to my old 
pattern 
     
30. I have a serious problem with 
drugs/alcohol 
     
31. Sometimes I wonder if I am in control 
of my  drug/alcohol use 
     
32. My drug/alcohol use is causing a lot of 
harm 
     
33. I am actively doing things now to cut 
down or stop drug/alcohol use 
     
34. I want help to keep from going back to 
the drug/alcohol/alcohol use problems that 
I had before 
     
35. I know that I have a drug/alcohol use 
problem 
     
36. There are times when I wonder if I  
take drugs/alcohol too much 
     
37. I am an drug addict/alcoholic      
38.I am working hard to change my 
drug/alcohol use 
     
39.I have made some changes in my 
drug/alcohol use, and I want some help to 
keep me from going back to the way I used 
to use 





SECTION F: SOCIAL FUNCTIONING 
 
40. How many members of your family have you seen in the last 30 days? 
 
41. If you are currently in a relationship, how often in the last 30 days has your partner 
 
 Never Rarely Sometimes Often Always 
Complained about your 
drinking/drug use? 
     
Tried to stop you from having  a 
drink/drugs? 
      
Refused to talk to you because 
you have been drinking/using? 
     
Threatened to leave you because 
of your drinking/using? 
     
Had to put you to bed after you 
had been drinking/using? 
     
Refused to have sex with you 
because of drinking/using? 
     
Have you shouted at him/her 
when you have been 
drinking/using? 
     
Have you injured him/her after 
you have been drinking/using? 
     
Have you been legally separated 
from your spouse? 
     
 
 
42. If you have children who you are regularly in contact with how often in the last 30 
days have they 
 
 Never Rarely Sometimes Often Always 
Criticised your drinking/using      
Tried to stop you from having a 
drink/drugs 
      
Have you had rows with your 
children about drinking/using 
     
Do your children tend to avoid 
you when you have been 
drinking/using 









43. If you have been employed in last 30 days how often have you 
 
 Never Rarely Sometimes Often Always 
Found your work less interesting 
than you used to?  
     
Been unable to arrive on time for 
work due to your drinking/using? 
      
Missed a whole day after a 
drinking/using session? 
     
Been less able to do your job 
because of your drinking/using? 
     
Had any formal warnings from 
your employers? 
     
Been suspended or dismissed 
from work? 
     
Had any accidents at work after 
drinking/using? 
     
Has anyone at work complained 
about you being late or absent? 
     
 
SECTION G. INVOLVEMENT WITH OTHER SERVICES/SUPPORT 
SYSTEMS    
44. Since the previous research interview have you accessed any other treatment 
services?                                 
                                Yes          No                     If No, skip to Q 46 
 
45. Which services have you attended and how useful did you find them? 
 
 How useful/helpful did 
you find them? 














Day programme        
Street agencies        
Drop-in services        
GP        
In-patient detox        
Residential 
rehab 
       
Counselling 
service 
       






SECTION H: REASONS FOR DROPPING OUT OF TREATMENT 
 
IF YOU ARE STILL ENGAGED IN TREATMENT PLEASE SKIP TO Q.50 
 
46. Can you tell me how much you agree/disagree with the following statement as 
reasons why you dropped out of treatment at Marina House 
 Stron. 
Disag. 
Disagree Undecided Agree Stron. 
agree 
I moved out of the catchment 
area 
     
I was dissatisfied with my 
key-worker 
     
I relapsed      
I entered another treatment 
service 
     
I was dissatisfied with the 
lack of progress 
     
Withdrawals were too severe 
 
     
I was craving alcohol/drugs 
too much 
     
I did not feel I was ready for 
that level of commitment 
     
 The type of treatment was 
not suitable for my needs 
     
I sorted out my alcohol/drug 
problem myself 
     
Other reason(specify)      
  
47. Do you have any intention of re-entering treatment?                          Yes          No   
 
48. Do you have any intention of re-entering another treatment service?  Yes         No 







49. If Yes, when do you think you will re-enter treatment? 









     
 
 
SECTION I. TREATMENT PERCEPTIONS 
 
If you are no longer in treatment please skip to Q.51 
 
50. Please indicate whether you agree or disagree with the following statements 




Disagree Undecided Agree Stron. 
agree 
to please my family      
to please my children      
to please my  partner      
through my own choice      
because of legal problems      
because of health concerns 
(specify) 
     
because of work reasons      
because I was fed up of using      
other reasons   
(specify)  
     
 
SECTION J: SOURCES OF INCOME 
 
51. Are you currently in any form of employment?    Yes               No      
 
52. What kind of work do you do, how many hours per week do you work and what is 
your salary ? 
 
 Type of work Hours Salary 
Full-time    
Part-time    







53. Which benefits are you claiming, how long have you been claiming them, how often 
do you get paid and how much money do you receive per week? 
 







    
Income support     
Housing benefit     
Incapacity/sickness 
benefit 
    
Child benefit     
Disability allowance     
Other(specify)     
 
54. Have you used any of the following methods to raise money in the last 30 days? 
 use No. of times in 




Selling the big issue    
Begging    
Gambling    
Pawning own belongings    
Pawning someone else’s belongings    
Prostitution    
 
 
 How much in the last 30 days 
Money from siblings/family/friends  
Covenants  
Interest from savings  








SECTION K:  SPENDING 
 
55. Do you pay rent/mortgage where you live? Yes            No             if No skip to Q.59 
 
56. Over the last 30 days have you kept up to date with you rent/mortgage? Yes         No 
 
57. If No, how much do you owe?    
 
58. How much do they cost per week? 
 Amount per week? Amount paid by benefits? 
Rent    
Mortgage   
 
Household bills: 
59. In the last 30 day have you paid any household bills?  Yes                No    
 If no, amount owed If yes, amount spent per week 
Electricity   
Gas   
Water rates   
Council tax   
T.V. License   
Telephone   
Bank loans/money lenders   
Rental costs ( TV)   
 
60. How many times per week do you go food shopping and how much do you spend 
on food (in the last 30 days)? 
 Number of times per week Amount spent per week 
Supermarket   
Market   
Take-away   
Restaurants   
Local shop/garage   
 
61. Do you spend money on any of the following (in the last 30 days)? 
 Number of times per week Amount spent per week 
Public transport   
Petrol   
Laundrette   
Crèche/nursery   
Other (specify)   














We are carrying out a research project of opiate users waiting to receive detoxification 
treatment at Marina House. We would like to find out what clients do during their wait 
for treatment and the effectiveness of the treatment you receive. We are interested in 
your drug use, your health, your reasons for seeking treatment and what you expect to 
gain from treatment. 
 
People who present themselves at Brief Assessment clinic will be randomly split into 
two groups. One group will receive fast-track treatment and the other group will receive 
treatment after the normal waiting period. Clients in both groups will receive exactly the 
same treatment. 
 
Your participation in the project will involve answering three 40-minute questionnaires 
over the next two months. Interviews will be conducted after brief assessment, two 
weeks after initial contact and approximately 6 weeks later. These interviews will take 
place in person or on the telephone. 
 
If you decide not to take up the offer of treatment at Marina House or drop out of 
treatment we would also like to interview you for the project. 
 
Any information you provide will be kept in the strictest confidence and will not be 













DEPARTMENT OF HEALTH 
WAITING LIST STUDY 
 
BASELINE INTERVIEW (BRIEF ASSESSMENT) 
 
 
Section A: Demographic 
 
Client name  
Client code  
Date  
Sex  
Age   



















treatment     
centre 
Other 
       
 
 
2. In the last month for how many days (from 0 to 30) were you : 
 
 In full-time 
work 











Section B : Drug and Alcohol Use 
 
1. Drug & alcohol use in the previous month 
 
a. In the last 30 days, can you tell me how often you have used the following 























Age of first 
treatment 
Heroin            
               
       grams 
    
Methadone 
                      
  
 
      
              ml   
    





     
 
             mg  






                                 
             
             mg 
   
Crack cocaine           
        grams                                  
    
Cocaine powder                  
        grams 
    
Amphetamines          grams     
Cigarettes       
Cannabis                                
                     oz/joints 
   
Alcohol                                          
                           units 
   







2. Drug and alcohol dependence 
 
a. Over the last year, did you ever think that your ...........  use was out of control 
  
 Never or 
almost never 
Sometimes Often Always or nearly 
always 
Heroin     
Methadone     
Benzodiazepines     
Crack Cocaine     
Cocaine powder     
Cannabis      
Cigarettes      
Alcohol     
 
 b. Over the last year did the prospect of not taking .......... make you very anxious or 
worried? 
 Never or 
almost never 
Sometimes Often Always or nearly 
always 
Heroin     
Methadone     
Benzodiazepines     
Crack Cocaine     
Cocaine powder     
Cannabis     
Cigarettes     











c. Did you worry about your ...........  use over the last year? 
 Never or 
almost never 
Sometimes Often Always or nearly 
always 
Heroin     
Methadone     
Benzodiazepines     
Crack Cocaine     
Cocaine powder     
Cannabis     
Cigarettes     
Alcohol     
 
d. Did you wish you could stop taking ............ over the last year? 
 Never or 
almost never 
Sometimes Often Always or nearly 
always 
Heroin     
Methadone     
Benzodiazepines     
Crack Cocaine     
Cocaine powder     
Cannabis     
Cigarettes     
Alcohol     
 








Heroin     
Methadone     
Benzodiazepines     
Crack Cocaine     
Cocaine powder     
Cannabis     
Cigarettes     





Section C: Overdose 
1. Have you had a drugs in the last 30 
days (if no, skip to Q.2) 
YES NO 
a. How many overdoses have you had in 
the last 30 days 
 




c. Which drugs did you take on the day of 
the last overdose 
 




e. How was the overdose resolved  
 




2. Have you witnessed a drugs overdose 
in the last 30 days 
YES NO 
a. How many overdoses have you 
witnessed in the last 30 days 
 
b. How many of these overdoses proved 
fatal 
 
c. Dates of the witnessed overdoses in the 
last 30 days 
  
 
d. Which drugs do you know were taken 
on the day of the last overdose 
 
e. How was the overdose resolved  
 
f. What did you do  
 







Section D: Injecting Behaviour 
 
1. When did you last inject ?  _______________   days/ mths ago 
 
2. Have you ever used a syringe that has been cleaned after someone else has used it?
      
       Yes    No  If YES how often?  _______Why?______________________ 
                                                                             
                                      Mainly with:( partner/other)   
   
                                      Only with: (partner/other)   
 
3. Have you ever used a syringe that has not been cleaned after someone else has used 
    it?   
 
       Yes     No  If YES how often? _____________   
                                     Why?________________________ 
 
                                      Mainly with: (partner/other)  
   
                                      Only with: (partner/other) 
 
















 Section E : Treatment History 
1  Alcohol  Drug Other  
Mental 
Health 
a How many times have you attended 
in-patient treatment? 
   
b How many times have you attended 
for out-patient treatment? 
   




















































h Were you abstinent after his 
treatment? 


















Section F : Personal Alcohol / Drug Use Questionnaire (SOCRATES) 
 






1 I really want to make changes in 
my drug use 
    
2 Sometimes I wonder if I am an 
addict 
    
3 If I don’t change my drug use 
soon, my problems are going to 
get worse 
    
4 I have already started making 
some changes in my drug use 
    
5 I was using too much at one 
time, but I’ve managed to change 
my drug use 
    
6 Sometimes I wonder if my drug 
use is hurting other people 
    
7 I have a drug problem     
8 I’m not just thinking about 
changing my drug use, I’m 
already doing something about it 
    
9 I have already changed my drug 
use, and I am looking for ways to 
keep from slipping back to my 
old pattern 
    
10 I have a serious problem with 
drugs 
    
11 Sometimes I wonder if I am in 
control of my  drug use 
    
12 My drug use is causing a lot of 
harm 
    
13 I am actively doing things now to 
cut down or stop drug use 
    
14 I want help to keep from going 
back to the drug use problems 
that I had before 
    
15 I know that I have a drug use 
problem 
    
16 There are times when I wonder if 
I  take drugs too much 
    
17 I am an drug addict     
18 I am working hard to change my 
drug use 
    
19 I have made some changes in my 
drug use, and I want some help 
to keep me from going back to 
the way I used to use 







Section G : Psychological and Physical Health 
 
1. Health in the last month 
How often in the last month have you experienced the following? 
  
 Never  Rarely Sometimes Often Always 
Poor appetite       
Tiredness / fatigue      
Nausea      
Stomach pains      
Difficulty breathing      
Chest pains      
Joint / bone pain      
Muscle pain      
Numbness/tingling      
Tremors (shakes)      
 
 
2. Psychological health in the last month 
How often in the last month have you experienced the following? 
 
 Never  Rarely Sometimes Often Always 
Feeling tense or keyed up      
Suddenly scared for no reason      
Feeling fearful/afraid      
Nervousness or shakiness inside      
Spells of panic or terror      
Feeling hopeless about the future      
Feelings of worthlessness      
Feeling no interest in things      
Feeling lonely      






Section H : Treatment Perceptions/ Assessment Perceptions 
 
1. Please tell me to what extent you agree or disagree with each of the following   




Disagree Undecided Agree Strongly 
agree 
to please my family      
to please my children      
to please my  partner      
through my own choice      
because of legal problems      
because of health concerns 
(specify) 
     
because of work reasons      
because I was fed up of using      
other reasons   
(specify)  
     
 
2. 
a.  When did you decide to seek treatment for your drug use? _____________________ 
b. If applicable: 
    Why have you waited so long before coming to Marina House since deciding to seek      
    treatment? 
______________________________________________________________________ 
 













Section I : Social Functioning 
 
1. Do you currently have a partner?               Yes                    No 
                                                              If YES for how  long ?________________ 
 
2. Have you got family contact?                            Yes                    No 
 
3. Do you have any children?                                Yes                    No 
     
    How many of these children live with you? ________________________________ 
 
4. How many members of your family are you in contact with? __________________ 
 
5. Partner’s drug and alcohol use         
Is your partner Yes No 
a. Currently in treatment   
b. Currently using but not in treatment   
c. Has used but no longer uses   
d. Never used   
 
6.    How many members of your family have drug problems? 
none one a few most all 
     
 
7.    How many members of your family have alcohol problems? 
none one a few most all 
     
 
8.  How much time do you spend in the company of people with drug problems?     
no time less than once a 
week 
at least once a 
week 
most days every day 
     





How does this impact on your drug use? ______________________________________ 
 
9.  How much time do you spend in the company of people with alcohol problems? 
 
no time less than once a 
week 
at least once a 
week 
most days every day 
     
 
How many days in the last 90 days? _______________ 
 
Section J: Criminal and Drug History 
 
1. Have you ever been involved in any criminal activity?   Yes         No      
            
2. Have you ever been in prison?    Yes     How many times? ______ 
                                                                                      No   
3. Age of first imprisonment?                                             __________ 
 




















5. Have you committed any of the following in the last 30 days? 














How often have you 
done it to pay for 
drugs 
Drug selling       
Drug Running      
Other drug offence      
 
Shoplifting      
Burglary        
Robbery      
Receiving /  
Handling stolen 
goods 
     
 
Car crimes       
Theft       
Violent crimes      
Drunk and 
disorderly 
     
Criminal damage      
Fare evasion      
Driving offences      
Fraud      
 
6. This section is about contact with the criminal justice system in the last 3 months 
 












a. Policecustody      
b. Court      
c. Prison      
d. Arrest 
referral 
     
e. DTTO      
f. CARATS      






Section K: Treatment Perceptions 
 








1. It was easy to find where 
Marina House was located 
     
2.The facilities at Marina House 
were clean/hygienic 
     
3. The layout/structure of 
Marina House was off-putting 
     
4. I was kept waiting too long in 
Marina House before being seen 
for brief assessment 
     
(specify time)___________________________________________________________ 
5. How did you find out about Marina House?_________________________________ 
 








1. I felt that the brief 
assessment was too intrusive 
     
2. I felt the brief assessment 
got to the route of my problems 
     
3. The brief assessment took 
too long to conduct 
     
4.I understand what is going to 
happen to me after brief 
assessment 
     
(please specify) _________________________________________________________ 










1. My assessor was 
sympathetic towards me 
     
2.My assessor appeared 
suitably experienced to carry 
out the brief assessment 
     
3.My assessor understood my 
problems 
     
4. I feel that the assessor would 
be competent at helping me 
with my problems 

















1. The reception staff were 
friendly towards me 
     
2. The other clients in the 
clinic were off-putting/ 
intimidating to me 
     
 










1. I am confident that this is 
the right place for my 
treatment 
     
2. I feel that my treatment 
needs will be met at Marina 
House 
     
3. I expect to be abstinent from 
drugs as soon as I start 
treatment at Marina House 
     
4. I am worried that all of my 
needs will not be addressed 
     
 
5. How long do you expect to be in treatment at Marina House? 
 
  1 month 1 – 3 months  3 – 6 months    6 – 12 months  More than 1 year 
     
 
6. How long do you think it will be until you are abstinent from drugs? 
 
1 month 1 – 3 months 3 – 6 months 6 – 12 months More than 1 year 
     
 
7. What do you feel are your chances of successfully quitting drugs? 
 
Very Unlikely Unlikely Undecided/ 
unsure 
Likely Very likely 
     
 
8. How long do you expect to wait for your treatment to start? 
         1 week       1 – 4 weeks     1 -2 months More than 2 months 






DEPARTMENT OF HEALTH 
WAITING LIST STUDY 
FULL ASSESSMENT (treatment entry) 
 
Section A: Demographic 
 
Client name  
Client code  
Date  
Date of full assessment  
Dates of dose assessment  
First appt. date  
Date of FA interview  Days in-between  
No. of days in treatment/ 
till treatment starts 
 
 











treatment    
centre 
Other 
       
 
 
2. Since the last interview (_____days) how many days were you : 
 In full-time 
work 




      
 
3. Is your address the same as when you first initiated contact with the clinic?   




4.Will entering treatment influence your ability to – 
 YES NO N/A 
a. Work/attend college    
b. Look after children    
c. Look after other dependent 
relatives 





Section B : Drug and Alcohol Use 
 
1. Drug & alcohol use since last interview 
 
Since your last interview (____days) can you tell me how often you have used the 














Main route  
of ingestion 
Heroin                                 
                   
          grams  
Methadone 
                      
  
 
     
                ml  
 
Other opiates   
 
    






                                 
              mg 
Crack cocaine                  
          grams                                  
 
Cocaine powder                 
          grams 
 
Amphetamines    
          grams 
 
Cigarettes    
Cannabis           oz/joints 
Alcohol                 units 







2. Prescribed drug use 
 
i. Any change in prescription drug use since your last interview?      Yes    No 
Drug Source Time on 
script 
Amount Has this 
changed 




    
Diazepam 
 
     
Other 
Benzodiazepines 
     
Buprenorphine 
 
     
Dihydrocodeine 
 
     
Anti-depressants 
(specify) 
     
Other 
(specify) 
     
 




Disagree Undecided Agree Strongly 
agree 
a. The prescription I receive  is 
not adequate for removing 
withdrawal symptoms 
     
b. I am experiencing cravings 
on the medication I receive 
     
c. The medication provided is 
adequate in providing stability 
for my drug use 





3. Drug and Alcohol Dependence  
 
a. Since the last research interview, did you ever think that your ........... use was out of 
control?  
 Never or 
almost never 
Sometimes Often Always or nearly 
always 
Heroin     
Methadone     
Benzodiazepines     
Crack Cocaine     
Cocaine powder     
Cannabis      
Cigarettes      
Alcohol     
  
b. Did the prospect of not taking ....... make you very anxious or worried since the last 
interview ? 
 Never or 
almost never 
Sometimes Often Always or nearly 
always 
Heroin     
Methadone     
Benzodiazepines     
Crack Cocaine     
Cocaine powder     
Cannabis     
Cigarettes     











c. Did you worry about your ...........  use since the last interview? 
 Never or 
almost never 
Sometimes Often Always or nearly 
always 
Heroin     
Methadone     
Benzodiazepines     
Crack Cocaine     
Cocaine powder     
Cannabis     
Cigarettes     
Alcohol     
 
d. Did you wish you could stop taking ............ since the last interview? 
 Never or 
almost never 
Sometimes Often Always or nearly 
always 
Heroin     
Methadone     
Benzodiazepines     
Crack Cocaine     
Cocaine powder     
Cannabis     
Cigarettes     
Alcohol     
 








Heroin     
Methadone     
Benzodiazepines     
Crack Cocaine     
Cocaine powder     
Cannabis     
Cigarettes     





Section C: Overdose 
 
1. Have you had a drugs overdose since 
the last interview (if no, skip to Q.2) 
YES NO 
a. How many overdoses have you had 
since the last interview 
 




c. Which drugs did you take on the day of 
the last overdose 
 





e. How was the overdose resolved  
 
 




2. Have you witnessed a drugs overdose 
since the last interview (if no skip to 
section D) 
YES NO 
a. How many overdoses have you 
witnessed since the last interview 
 




c. Dates of the witnessed overdoses since 
the last interview 
  
 
d. Which drugs do you know were taken 
on the day of the last overdose 
 
e. How was the overdose resolved  
 
 
f. What did you do  
 
 












Section D: Injecting Behaviour 
 
1. When did you last inject?  ______________ days/months ago 
 
2. Have you used a syringe that has been cleaned after someone else has used it since 
the last interview?      
          
                        No   Yes  If YES how often? _______________ 
                      Why? _______________________________________ 
          
                        Mainly with:(partner/other)   
   
                        Only with:(partner/other)   
 
3. Have you used a syringe that has not been cleaned after someone else has used it 
since the last interview?    
    
                          No      Yes   If YES how often? ________________ 
                        Why? ________________________________________ 
                            
                          Mainly with:(partner/other) 
  
                          Only with:(partner/other)  
 
Section E : Hepatitis and HIV Status 
 
1. Have you been tested for any of the following since the last interview? 





If NO what would 
you anticipate that 
you are 
(+ve, -ve, don’t 
know) 
Hepatitis C     
Hepatitis B     





Section F: Personal Alcohol / Drug Use Questionnaire (SOCRATES) 
  







1 I really want to make changes in 
my drug use 
     
2 Sometimes I wonder if I am an 
addict 
     
3 If I don’t change my drug use 
soon, my problems are going to 
get worse 
     
4 I have already started making 
some changes in my drug use 
     
5 I was using too much at one 
time, but I’ve managed to change 
my drug use 
     
6 Sometimes I wonder if my drug 
use is hurting other people 
     
7 I have a serious problem with 
drugs 
     
8 I’m not just thinking about 
changing my drug use, I’m 
already doing something about it 
     
9 I have already changed my drug 
use, and I am looking for ways to 
keep from slipping back to my 
old pattern 
     
10 I used to have a problem with 
drugs but not any more 
     
11 Sometimes I wonder if I am in 
control of my  drug use 
     
12 My drug use is causing a lot of 
harm 
     
13 I am actively doing things now to 
cut down or stop drug use 
     
14 I want help to keep from going 
back to the drug use problems 
that I had before 
     
15 I know that I have a drug use 
problem 
     
16 There are times when I wonder if 
I  take drugs too much 
     
17 I am an drug addict      
18 I am working hard to change my 
drug use 
     
19 I have made some changes in my 
drug use, and I want some help 
to keep me from going back to 
the way I used to use 







Section G : Psychological and Physical Health 
 
1.Health since last interview 
How often since the last interview have you experienced the following? 
 
 
 Never  Rarely Sometimes Often Always 
Poor appetite       
Tiredness / fatigue      
Nausea      
Stomach pains      
Difficulty breathing      
Chest pains      
Joint / bone pain      
Muscle pain      
Numbness/tingling      
Tremors (shakes)      
 
2. Psychological health since last interview 
 
How often since the last interview have you experienced the following? 
 
 Never  Rarely Sometimes Often Always 
Feeling tense or keyed up      
Suddenly scared for no reason      
Feeling fearful/afraid      
Nervousness or shakiness inside      
Spells of panic or terror      
Feeling hopeless about the future      
Feelings of worthlessness      
Feeling no interest in things      
Feeling lonely      





3.Have you had any of the following at Marina House or elsewhere since brief 
assessment? 
 
 Yes No What were they? Have you benefited 
from them? 
Health assessment     
Psychiatric 
assessment 
    
Health intervention     
Psychiatric 
intervention 
    
 


























Section H :  Treatment Preparations 
 
1. Have you been receiving support from anyone with regards to your drug problem 





























YES     NO 






YES  NO 
           
a. Partner           
b. Parents           
c. Children           
d. Other family 
members 
          
e. Using friends           
f. Non-using friends           
g. G.P.           
h. Social services           
i. Voluntary 
agencies 
          
j. Helplines           
k. A&E           
l. AA/NA           
m. Other services 
(specify) 
















Disagree Undecided Agree Strongly 
agree 
a. I have stopped using and do 
not intend to use again  
     
b. I have gradually reduced 
my drug  use  
     
c. I have made no changes in 
my drug use  
     
d. I will have one last binge 
before stopping my  drug use  
     
e. I have increased my drug 
use 
     
f. I will consider stopping my 
drug use 
     
g. I have unsuccessfully tried 
to reduce my drug use 
     
 










a. I have been seeking 
support from my non-
using friends 
      
b. I have reduced 
contact with my dealer 
      
c. I have reduced 
contact with my drug-
using friends 














4. Have you been given advice about any of the following during your visits to the 
clinic? 
 





a. HIV awareness/testing     
b. Sterilising equipment     
c. Hep B/ C testing     
d. Hep B immunisation      
e. Advice on safe use      
f. Advice on managing treatment     
g. Information on other services 
available 
    
h. Clear guidelines about treatment     
i. Encouragement about reducing drug 
use 
    
j. Leaflets on clinic services     
k. Clear treatment plan     
l. Treatment contract     
m. Primary healthcare advice     
n. Overdose prevention     
 
 
5.To what extent do you agree or disagree with each of the following 
 




Disagree Undecided Agree Strongl
y agree 
to please my family      
to please my children      
to please my partner      
through my own choice      
because of legal problems      
because of health concerns 
(specify) 
     
because of work reasons      
because I was fed up of using      







6.Since the last interview how the following factors changed? 
 





a. Finances     
b. Debt     
c. Relationship with parents     
d. Relationship with partner     
e. Relationship with dependent children     
f. Relationship with non-using friends     
g. Relationship with using friends     
h. Relationship with neighbours     
i. Housing     
j. Confidence     
k. Assertiveness     
l. Employment     
m. Health problems     
n. Crime      
 
7. Have you experienced any of the following feelings about treatment since the last 
interview?               
 Strongly  
disagree 
Disagree Undecided Agree Strongly 
agree 
a. I do not think I am motivated 
enough 
     
b. I do not really want to stop using      
c. I do not think this is the right 
treatment for   me 
     
d. I am not ready to detox      
e. Even if I detox I doubt if I will 
stay clean 
     
f. I am more committed to 
treatment 
     






8. Have you tried to arrange rehabilitation once your treatment at Marina House 
finishes?                                         Yes      No    
 
a. What action have you taken?_________________________________________ 
 
b. What has been the outcome of this action?______________________________ 
 
Section I : Social Functioning 
 
1. How much time have you spent in the company of people with other drug users since 
the last research interview?   
                             
No time Less than once a 
week 
At least once a 
week 
Most days Every day 
     
 How many days in the last  __________ days?  ___________ 
 How does this impact on your drug use? ____________________________________ 
   
2. How much time have you spent in the company of people with alcohol problems 
since   your last interview? 
 
No time Less than once a 
week 
At least once a  
week 
Most days Every day 
     
 













3. How does your social life affect your drug use? 
 
 yes no 
a. Partner uses   
b. Partner deals   
c. Most friends use   
d. A few friends use   
e. Parents use   
f. Most neighbours use   
 
4. Has the drinking or drug use of those around you changed since you started coming 
to Marina House? 
 
 Increased Decreased No change 
 alcohol drugs alcohol drugs alcohol drugs 
a. Partner       
b. Using friends       
c. Non-using friends       
d. Family members       
 
5.Have you been in any fights/arguments with partner/children/friends since brief 
assessment?                Yes      No 
      















Section J  : Criminal and Drug History 
1. Have you committed any crimes since the last interview?           Yes   No 
 
2. Have you committed any of the following since the last interview? 












How often have you 
done it to pay for 
drugs 
 
Drug selling       
Drug running      
Other drug offence      
 
Shoplifting      
Burglary        
Robbery      
Receiving /  
Handling stolen 
goods 
     
 
Car crimes       
Theft       
Violent crimes      
Drunk and 
disorderly 
     
Criminal damage      
Fare evasion      
Driving offences      
Fraud      
 
2. This section is about contact with the criminal justice system since the last 
interview? 
 
 Have you had 
contact 






a. Police custody     
b. Court     
c. Prison     
d. Arrest referral     
e. DTTO     
f. CARATS     








SECTION K: TREATMENT PERCEPTIONS 
 








1. I felt that I had a good 
relationship with my  
assessor  
     
2. I would not  like to get my 
assessor for my key-worker 
     
3. My assessor understood 
my problems 
     
4. I do not think my assessor 
would be competent at 
helping me with my 
problems 
     
 








1. I do not feel comfortable 
coming to Marina House 
     
2. I  was treated with respect 
by the reception staff 
     
3. I found full assessment 
disturbing 
     
4. I feel I have been made to 
jump through too many 
hoops 
     
5. I have found the delays 
frustrating 
     
6. I have found the 
assessments intrusive 
     
7. There have been too many 
stages to go through before 
entering treatment 
     
8. I made a mistake choosing 
Marina House as my 
treatment venue 






















1. I am confident that Marina 
House is the right place for my 
treatment 
     
2. I feel that my treatment 
needs will be met at Marina 
House 
     
3. I expect to be abstinent from 
drugs within 6 months of 
entering treatment at Marina 
House 
     
4. I am worried that all of my 
needs will not be addressed 
     
 
 
5.How long do you expect to be in treatment at Marina House? 
 
  1 month 1 – 3 months  3 – 6 months    6 – 12 months  More than 1 year 
     
 
6. How long do you think it will be until you are abstinent from all drugs? 
 
1 month 1 – 3 months 3 – 6 months 6 – 12 months More than 1 year 
     
 
7. What do you feel are your chances of successfully quitting drugs? 
 
Very Unlikely Unlikely Undecided/ 
unsure 
Likely Very likely 
     
 
8. Why did you choose community detox for your treatment needs rather than other 
forms of treatment (e.g inpatient detox) ? 
______________________________________________________________________ 
 
9.To what extent has your motivation to quit drugs changed since your last interview? 
 
Increased 
 a lot 
Increased  
a little 
















DEPARTMENT OF HEALTH 





Section A: Demographic 
 
Client name  
Client code  
Date  
Date of last contact with the clinic  
Date of last contact with researcher  
 
 











Hospital/treatment    
centre 
Other 
       
 
 
2. Since the last interview ( _____days) how many days were you : 




Unemployed In Education Sickness Benefit 











Section B : Drug and Alcohol Use 
 
1. Drug & alcohol use since last interview 
 
Since the last interview (_____days) can you tell me how often you have used the 












Main route  
of ingestion 
Heroin                          
        grams  
 
Methadone 
                     
  
 
                   
              ml 
 





                        
                   







                                 
                       
             mg 
 
Crack cocaine              
         grams                                  
 
Cocaine powder            grams  
Amphetamines           grams  
Cigarettes    
Cannabis          oz/joints 
Alcohol               units 












2. Drug and Alcohol Dependence  
 
a. Since your  last  interview, how often did you think that your ........... use was out of 
control 
 
 Never or 
almost never 
Sometimes Often Always or nearly 
always 
Heroin     
Methadone     
Benzodiazepines     
Crack Cocaine     
Cocaine powder     
Cannabis      
Cigarettes      
Alcohol     
  
b. Did the prospect of not taking .......... make you very anxious or worried since your 
last  interview ? 
 
 Never or 
almost never 
Sometimes Often Always or nearly 
always 
Heroin     
Methadone     
Benzodiazepines     
Crack Cocaine     
Cocaine powder     
Cannabis     
Cigarettes     









c. Did you worry about your ...........  use since your last  interview? 
 Never or 
almost never 
Sometimes Often Always or nearly 
always 
Heroin     
Methadone     
Benzodiazepines     
Crack Cocaine     
Cocaine powder     
Cannabis     
Cigarettes     
Alcohol     
 
d. Did you wish you could stop taking ............ since your last interview? 
 Never or 
almost never 
Sometimes Often Always or nearly 
always 
Heroin     
Methadone     
Benzodiazepines     
Crack Cocaine     
Cocaine powder     
Cannabis     
Cigarettes     
Alcohol     
 









Heroin     
Methadone     
Benzodiazepines     
Crack Cocaine     
Cocaine powder     
Cannabis     
Cigarettes     











Section C: Overdose 
 
1. Have you had a drugs overdose since 
the last interview (if no, skip to Q.2) 
YES NO 
a. How many overdoses have you had 
since the last interview 
 




c. Which drugs did you take on the day of 
the last overdose 
 





e. How was the overdose resolved  
 
 




2. Have you witnessed a drugs overdose 
since the last interview 
YES NO 
a. How many overdoses have you 
witnessed since the last interview 
 
b. Dates of the witnessed overdoses since 
the last interview 
  
 
c. Which drugs do you know were taken 
on the day of the last overdose 
 
d. How was the overdose resolved  
 
 
e. What did you do  
 
 















Section D: Injecting Behaviour 
 
1. When did you last inject?     __________________  days/months ago 
 
2. Have you used a syringe that has been cleaned after someone else since the last 
interview?      
             No   Yes  If YES how often? ______________________________ 
                                                     
                                                    Why ? _______________________________________ 
                       
                         Mainly with:(partner/other)   
   
                         Only with:(partner/other)   
 
 
3. Have you used a syringe that has not been cleaned after someone else since the last 
interview?    
    
                          No     Yes   If YES how often? ______________________________ 
                                                       
                                                      Why? ______________________________________ 
                         
                          Mainly with:(partner/other) 
  














Section E: Personal Alcohol / Drug Use Questionnaire (SOCRATES) 
 






1 I really want to make changes in 
my drug use 
     
2 Sometimes I wonder if I am an 
addict 
     
3 If I don’t change my drug use 
soon, my problems are going to 
get worse 
     
4 I have already started making 
some changes in my drug use 
     
5 I was using too much at one 
time, but I’ve managed to change 
my drug use 
     
6 Sometimes I wonder if my drug 
use is hurting other people 
     
7 I have a drug problem      
8 I’m not just thinking about 
changing my drug use, I’m 
already doing something about it 
     
9 I have already changed my drug 
use, and I am looking for ways to 
keep from slipping back to my 
old pattern 
     
10 I have a serious problem with 
drugs 
     
11 Sometimes I wonder if I am in 
control of my  drug use 
     
12 My drug use is causing a lot of 
harm 
     
13 I am actively doing things now to 
cut down or stop drug use 
     
14 I want help to keep from going 
back to the drug use problems 
that I had before 
     
15 I know that I have a drug use 
problem 
     
16 There are times when I wonder if 
I  take drugs too much 
     
17 I am an drug addict      
18 I am working hard to change my 
drug use 
     
19 I have made some changes in my 
drug use, and I want some help 
to keep me from going back to 
the way I used to use 







Section F : Psychological and Physical Health 
 
1.Health since the last interview 
How often since the last interview have you experienced the following? 
 
 Never  Rarely Sometimes Often Always 
Poor appetite       
Tiredness / fatigue      
Nausea      
Stomach pains      
Difficulty breathing      
Chest pains      
Joint / bone pain      
Muscle pain      
Numbness/tingling      
Tremors (shakes)      
 
2.Psychological health since the last interview 
How often since the last interview have you experienced the following? 
 
 Never  Rarely Sometimes Often Always 
Feeling tense or keyed up      
Suddenly scared for no reason      
Feeling fearful/afraid      
Nervousness or shakiness inside      
Spells of panic or terror      
Feeling hopeless about the future      
Feelings of worthlessness      
Feeling no interest in things      
Feeling lonely      







Section G :  Dropping out  
1.Reasons for not starting treatment? 
 










a. I felt I was not making any progress in reducing my 
drug use 
     
b. I was experiencing withdrawals I could not cope with       
c. I could not control my drug use      
d. I am not ready for treatment       
e. Unhappy with brief assessment       
f. Unhappy with full assessment       
g. Unhappy with the treatment offered 
(specify)  
     
h. Not the right type of treatment for my needs      
i. Dissatisfied with the range of treatment options offered      
j. I felt I could complete detox without assistance      
k. I needed urgent in-patient detox      
l. Dissatisfaction with dispensing/prescribing (delete)      
m. I did  not get on with my key worker       
n. My keyworker was not supportive      
o. Transferred by Marina House to another service  
(specify) 
     
p. Moved out of the area      
q. Preferred other treatment offered elsewhere       
r. Court/legal problems 
( specify) 
     
s. Attending treatment was interfering with my 
employment/training/education responsibilities  (delete) 
     
t. Discharged from treatment      
u. I could not make the appointments      
v .I did not like the structure of the clinic      
w. Unhappy with the delay for treatment stating      
x. Other patients made me feel uncomfortable      
y. Other reason 
(specify) 
     
 
I was discharged from treatment because -  
 
 Yes No 
a. Failure to keep appointments   
b. Continued use of illegal/illicit drug   
c. Conflicts with staff   





2.   Have you been in contact with any other individuals or agencies concerning drug 














the support you 
receive 
1. G.P      
2. Drug treatment service      
3. Voluntary agencies      
4. Helplines      
5. A & E      
6. Hospital detox      
7.Mental health/Dual 
diagnosis 
     
8. AA/NA      
9.Other 
 (specify) 
     
 
 
3. Did you experience any of the following feelings about coming into treatment? 
                    
 Strongly 
disagree 
Disagree Undecided Agree  Strongly 
agree 
a. I did not think I was motivated 
enough 
     
b. I did not really want to stop using      
c. I did not think Marina House was 
the right treatment venue for me 
     
d. I was not ready to detox      
e. Even if I detoxed I did not think I 
would  stay clean 
     
f.  I was committed to the treatment       
g. I was uncertain what I wanted      
 
Section H : Social Functioning 
 
1.How much time have you spent in the company of people with drug problems since 
the last interview? 
 
How many days in the last _______ days ? ____________________________________ 







2.  How much time have you spent in the company of people with alcohol problems 
since the   last interview? 
None A few days At least once 
 a week 
Most days Every day 
     
 
3. How does your social life affect your drug use? 
 Yes No 
a. Partner uses   
b. Partner deals   
c. Most friends use   
d. A few friends use   
e. Parents use   
f. Other members of household use   
g. Most neighbours use   
 
4. Has the drinking or drug use of those around you changed since you started coming 
to Marina House? 
 Increased Decreased No change 
 alcohol drugs alcohol drugs alcohol drugs 
a. Partner       
b. Using friends       
c.Non-using friends       
d. Family members       
 
5.How have your friends’/partner’s drug use influenced your decision to drop-out of 
treatment? 
 Yes No 
a. Temptation too hard to resist when people around me are using   
b. Pressure to resume drug use from others   
c. Given drugs by partner/friend   







Section I : Criminal and drug history 
 
1. Have you committed any crimes since the last interview?           Yes           No 
 
2. Have you committed any of the following since the last interview? 
 











How often have 
you done it to pay 
for drugs 
Drug selling       
Drug running      
Other drug offence      
 
Shoplifting      
Burglary        
Robbery      
Receiving /  
Handling stolen 
goods 
     
 
Car crimes       
Theft       
Violent crimes      
Drunk and 
disorderly 
     
Criminal damage      
Fare evasion      
Driving offences      
Fraud      
 
3. This section is about contact with the criminal justice system since the last interview 
 








a. Police custody     
b. Court     
c. Prison     
d. Arrest referral     
e. DTTO     
f. CARATS     



















1. I did not feel comfortable 
coming to Marina House 
     
2. I  was treated with respect 
by the reception staff 
     
3. I  found one-to-one 
sessions with my key worker 
disturbing 
     
4. I felt I was made to jump 
through too may hoops at 
Marina House 
     
5. I  found the delays 
frustrating 
     
6. I  found the assessments 
intrusive 
     
7. There were too many 
stages to go through before 
receiving treatment 
     
8. I made a mistake choosing 
Marina House as my 
treatment venue 










1. I felt that I have a good 
relationship with my  key 
worker 
     
2. My key worker understood 
what I was going through 
     
3. I did not think my key 
worker was experienced 
enough to help 
     
4. I did not have enough 
contact with my key worker 
     
5. I would have liked more 
assistance from my key 
worker 
     
6. My key worker provided 
sufficient support me while I 
was in contact with the clinic 
     
7. My key worker has not 
been available when I needed 
to contact him/her 





1. What do you feel are your chances of successfully quitting drugs now you have left 
treatment? 
Very Unlikely Unlikely Undecided/ 
unsure 
Likely Very likely 
     
 
2..To what extent has your motivation to quit drugs changed since your initial clinic 
contact? 
Increased 
 a lot 
Increased  
a little 






     
 
3. When did you first decide to leave treatment?_______________________________ 
 
4.. Were there any specific events which made you want to leave treatment at this time? 
______________________________________________________________________ 
 
5.How are you planning to manage your drug use now you have left treatment? 
 Strongly 
disagree 
Disagree Undecided Agree Strongly 
agree 
a. I have stopped using and do 
not intend to use again  
     
b. I have gradually reduced my 
drug  use   
     
c. I have made no changes in my 
drug use of  
     
d. I will have one last binge 
before stopping my drug use 
     
e. I have increased my drug use        
f. I will consider stopping my 
drug use 
     
g. I have unsuccessfully tried to 
reduce my drug use 
     
 
6.What did you want from treatment that you did not receive?____________________ 
 








a. I would be willing to try 
treatment at Marina House again 
     
b. I would be willing to try drug 
treatment at a different  venue 
     
c. I will try to stop using at home      
d. I would need in-patient detox      
e. My experiences at  Marina 
House have put me off drug 
treatment 
     












White and Black Caribbean 
White and Black African 
White and Asian 
Other Mixed 









Chinese or Other Ethnic Group 
Chinese 


















SOCRATES Scoring Form – 19 items Version  8.0 
 
Recognition                               Ambivalence  Taking Steps 
 
    1 -------------  2 ---------------   4 --------------- 
    3 -------------        5 ---------------                                                     
               6 --------------- 
    7 -------------                       8 ---------------                                                                
                       9 --------------- 
    10 ------------                      11---------------                         13 -------------- 
    12 ------------                                             14-------------- 
 
    15 ------------             16 --------------   18 -------------- 
    17 ------------        19 -------------- 
 
 
TOTALS   Re ------------          Am ---------------                   TS -------------- 
 
Possible 
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